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Summary 
Depression is one of the most prevalent human diseases, and causes high disability and mortality, 
both alone and in association with several other diseases with which it is highly co-morbid. Depression 
is a heterogeneous neuropsychiatric disorder with core symptoms of depressed mood, loss of 
interest/pleasure and fatigue, and a broad range of additional symptoms. 
Human clinical and experimental studies demonstrate associations between environmental 
stress, the inflammatory system and depression. This evidence has led to the inflammation hypothesis 
of depression, which postulates that peripheral and central immuno-inflammation is increased by 
stress and induces neurobiological changes leading to depression. To test this hypothesis, animal 
models would be essential, but only if these are valid, meaning that they must comprise human-
relevant components in terms of: (1) an environmental manipulation that causes psychosocial stress 
and induces (2) behavioural effects that are relevant to depression psychopathologies and are 
underlain by (3) inflammatory-neurobiological effects that are relevant to depression aetio-
pathophysiology. This PhD thesis presents such a valid mouse model, constituting psychosocial stress 
in the form of chronic social defeat (CSD) – and behavioural changes in the form of increased fear of 
aversive events, generalised helplessness and fatigue. Subsequent identification of physiological and 
cortico-limbic transcriptome-expression characteristics of the model put the focus on immuno-
inflammation-dopamine (DA) dysfunction as a major depression aetio-pathophysiology and treatment 
target. 
 Depression aetiology is proposed to include an important genetic component in the form of 
polymorphisms that predispose to depression aetio-pathophysiology in response to environmental 
stressors. The best-studied gene-environment interaction is that of individuals with genotype-
dependent low serotonin (5-HT) transporter (5-HTT) function exhibiting increased depression 
prevalence if they experienced psychosocial stress during development (but not adulthood). In 
adulthood, low 5-HTT function is associated with increased immune resilience. Using a 5-HTT 
knockout mouse strain, interaction between 5-HTT genotype (heterozygous knockout vs. wildtype) and 
adulthood CSD was studied in terms of fear learning, peripheral immune response and brain 5-HT and 
DA activity. Relative to wildtype mice, heterozygous 5-HTT-control mice exhibited increased 5-HT and 
DA activity in the nucleus accumbens, with no effect of CSD. Heterozygous 5-HTT knockout inferred 
resilience against CSD in terms of attenuated fear and immuno-inflammation responses, providing 
evidence that the increased immune resilience associated with low 5-HTT function could extend to 
depression resilience in adulthood. 
In terms of antidepressant treatment, recent evidence indicates that a single, low-dose 
infusion of racemic (RS-)ketamine exerts a rapid, sustained anti-depressant effect in otherwise 
treatment-resistant depressed patients. Stimulated by this, several mouse studies have reported that 
acute low-dose RS-ketamine exerts antidepressant effects in screening tests such as the forced swim 
test (FST). A study was conducted comparing effects of RS- and the more potent S-ketamine at low- 
and high-dose in the FST and on prefrontal cortex (PFC) glutamate release. Only low-dose RS-
ketamine was effective in the FST and this effect, in contrast to a common assumption, was not 
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underlain by increased PFC glutamate release, which occurred with high-dose ketamine only. This 
evidence has important implications for the future development of antidepressant treatments based on 
ketamine’s mechanism of action. 
By combining environmental, genetic and pharmacological approaches to the translational 
study of depression psychopathology, aetio-pathophysiology and psychopharmacology, this PhD 
thesis presents several significant advances in (1) understanding of depression aetio-pathophysiology 
and (2) identification of novel antidepressant mechanisms-of-action. 
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Zusammenfassung 
Die Depression ist eine der häufigsten Krankheiten und führt oft zu Arbeitsunfähigkeit, Komorbidität 
und Tod. Neben den Hauptsymptomen depressive Stimmung, Interessensverlust und gesteigerter 
Ermüdbarkeit  treten verschiedene zusätzliche Symptome auf, die Depression zu einer heterogenen 
neuropsychiatrischen Erkrankung machen. 
Klinische und experimentelle Studien haben Zusammenhänge zwischen Umweltbelastung, 
Entzündungsreaktion und Depression aufgezeigt. Diesen Befunden liegt die Entzündungshypothese 
der Depression zu Grunde: Stress erhöht entzündungsstimulierende Reaktionen im Blut und Gehirn 
und dies verursacht wiederum neurobiologische Veränderungen, die die Erkrankung auslösen. Um 
solche Hypothesen zu testen, sind aussagekräftige Tiermodelle essentiell, welche aus drei der 
Depression analogen Komponenten bestehen müssen. (1) Ursache: Umweltbelastungen, die 
psychosozialen Stress herbeiführen; (2) Auswirkung: Verhaltensänderungen, die relevant zu den 
Psychopathologien der Depression sind; und (3) Mechanismus: neurobiologische 
Entzündungsreaktionen ähnlich zur Ätio-Pathophysiologie von depressiven Patienten. Diese 
Dissertation präsentiert ein valides Tiermodell bestehend aus einer Manipulation mit psychosozialem 
Stress, genannt „Chronic Social Defeat“ (CSD), und den daraus resultierenden Verhaltensänderungen 
in Form von erhöhter Furcht gegenüber aversiven Ereignissen, generalisierter Hilflosigkeit und 
gesteigerter Ermüdbarkeit. Zusätzlich wurden physiologische und cortico-limbische Veränderungen 
identifiziert, die den Fokus für die Ätio-Pathophysiologie und für mögliche Behandlungsmethoden auf 
eine Funktionsstörung im Immun-Entzündung-Dopamin(DA)-System richten. 
Die Krankheitsursache von Depression beinhaltet eine wichtige genetische Komponente: 
Polymorphismen, die in der Anwesenheit von Umweltbelastungen eine Veranlagung zu Depression 
begünstigen. Eine viel zitierte Gen-Umwelt-Interaktion basiert auf einer genotyp-abghängigen, 
reduzierten Serotonin(5-HT)-Transporter(5-HTT)-Funktion. Individuen eines solchen Genotyps weisen 
eine erhöhte Prävalenz von Depression auf, falls sie psychosozialem Stress während ihrer 
Entwicklung, nicht aber im Erwachsensein ausgesetzt waren. Eine reduzierte 5-HTT Funktion ist im 
Erwachsenenalter mit einer erhöhten Immun-Resilienz assoziert. Basierend auf diesen Befunden 
wurde mit Hilfe einer 5-HTT-Knockout-Mauslinie die Interaktion zwischen dem 5-HTT-Genotyp und 
CSD im Erwachsenenalter auf Furchtverhalten, peripherer Immunantwort und zentraler 5-HT- und DA-
Aktivität geprüft. Im Verhältnis zum Wildtyp haben die 5-HTT heterozygoten Mäuse eine erhöhte 
Aktivität von 5-HT und DA im Nucleus Accumbens. Des Weiteren zeigen die Heterozygoten nach der 
CSD Manipulation eine höhere Belastbarkeit in Form von abgeschwächter Furcht- und 
Immunentzündungsreaktion. Die erhöhte Immunresilienz, die mit reduzierter 5-HTT-Funktion assoziert 
ist, könnte zu einer Depressionsresilienz führen. 
Neueste Studien haben gezeigt, dass eine akute, niedrig dosierte Infusion von racemischem 
(RS-) Ketamin zu einem schnellen, anhaltenden antidepressiven Effekt in der Behandlung von 
resistenten, depressiven Patienten führen kann. Inspieriet durch diese Befunde haben verschiedene 
Forschungsgruppen berichtet, dass akute, niedrig dosierte RS-Ketamin-Administrationen einen 
antidepressiven Effekt in Screeningmassnahmen wie dem „Forced Swim Test“ (FST) in der Maus 
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aufzeigen. Die Untersuchungen in dieser Dissertation konzentrieren sich auf den Vergleich der 
Auswirkungen auf das Verhalten im FST und auf die Abgabe von Glutamat im präfrontalen Cortex 
(PFC) bei akuter, niedrig und hoch dosierten RS- und S-Ketamin-Administrationen. Nur die niedrig 
dosierte RS-Ketamin-Dosis zeigte einen Effekt im FST, dies war jedoch unabhängig von Glutamat, da 
dessen Konzentration im PFC nur durch die beiden Hochdosierungen anstiegen. Diese Ergebnisse 
bringen wichtige Aspekte für die Entwicklung von neuen Antidepressiva mit ähnlichem Ketamin-
Wirkungspotential zu Tage. 
Diese Dissertation bringt mit Hilfe von umweltbedingten, genetischen und pharmakologischen 
Ansätzen zwei bedeutende Fortschritte für die translationale Forschung in der Psychopatholgie, Ätio-
Pathopyhsiolgie und Psychopharmakologie von Depression: zum einen bewirkt sie ein besseres 
Verständnis für die Ätio-Pathophysiologie von Depression und zum anderen hilft sie bei der Ermittlung 
von Wirkungsmechanismen für neue Antidepressiva. 
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General introduction 
1. DEPRESSION 
1.1 Prevalence, symptoms and burden 
Major depressive disorder (hereafter referred to as depression) is one of the most prevalent mental 
diseases, and is associated with disability, comorbidity to several other diseases, and mortality 
(Wittchen et al., 2011). It is a high risk factor for suicide and is a major reason of death worldwide 
(Holma et al., 2010). With its high lifetime prevalence (8 – 15 %), co-morbidity, treatment resistance 
and relapse, depression burdens the health care, mortality and workplace costs of Europe and the 
United States immensely (Richards, 2011). Depression is a heterogeneous psychiatric disorder with a 
broad range of symptoms which are described in two international medical classification systems: The 
Diagnostic and Statistical Manual of Mental Disorders, 5
th
 Edition (DSM-5, 2013) and The International 
Classification for Diseases and Related Disorders, 10
th
 Edition (ICD-10, 1994). In ICD-10, the 
symptoms are classified into core symptoms of depressed mood, loss of interest and fatigue, and 
common symptoms of disturbed sleep, poor concentration, low self-confidence, altered appetite, 
slowing of movements, self-blame and thoughts of suicide. To diagnose depression, at least two core 
and three common symptoms have to persist for at least two weeks. 
To understand the psychopathology of depression, the symptoms such as depressed mood, 
loss of interest and fatigue must be first well defined and understood. Relevant here is the concept of 
emotion, describing the psychological states that arise in response to neutral, aversive or pleasant 
environmental stimuli, and are mediated by the punishment and reward systems of the brain. By 
determining the punishment and reward systems as the bases of mood, depressed mood can be seen 
as hyper-sensitivity of the punishment system, and loss of interest, and to some extent fatigue, as 
hypo-sensitivity of the reward system (Pryce and Seifritz, 2011). Clinical studies have shown that 
depressive patients exhibit increased emotional reactivity to aversive stimuli (Disner et al., 2011), 
reduced reactivity to pleasant stimuli (Russo and Nestler, 2013), and reduced pleasure after physical 
activity (Craig et al., 2006). 
1.2 Neuropathology 
Using in vivo brain imaging procedures including magnetic resonance imaging (MRI) and positron 
emission tomography (PET) to compare depressed patients with matched healthy controls, specific 
regions of the central nervous system (CNS) have been identified to exhibit altered functional and 
resting-state activity, altered volume and modified resting-state connectivity between regions (Price 
and Drevets, 2010). These studies indicate an increased processing of negative stimuli and a 
decreased processing of positive stimuli in depressive patients compared to healthy controls (Disner et 
al., 2011). For example, the functional activity of the rostral anterior cingulate cortex (ACC), a brain 
region central to attention, and of the amygdala (AMYG), a brain region central to emotional process, 
are relatively elevated in individuals with depression when aversive stimuli are presented (Drevets, 
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2001; Elliott et al., 2002; Mitterschiffthaler et al., 2008). Both results show that depressive patients are 
more likely to attend to and process aversive stimuli leading to a stronger experience of the negative 
event (Disner et al., 2011). This hypothesis is also supported by the fact that decreased reactivity to 
negative stimuli and decreased resting-state activity have been observed in the left dorsolateral 
prefrontal cortex (PFC) of depressive patients, a region associated with cognitive control and with 
modulation of the emotional processing in the AMYG (Disner et al., 2011; Gotlib and Joormann, 2010; 
Siegle et al., 2002). Furthermore, reduced functional connectivity between the thalamus and the dorsal 
ACC was associated with depression, which indicates a reduced inhibitory modulation of the limbic 
system processing negatively valenced stimuli (Anand et al., 2005). In the case where 
rewards/positive stimuli are presented, depressive patients show a decreased activation in the nucleus 
accumbens (NAcc) and PFC (Pizzagalli et al., 2009). The reduced response of the NAcc is associated 
with decrease positive-valence labeling by the reward circuitry, and that of the PFC with decreased 
reward sensitivity (Disner et al., 2011).  
1.3 Aetiology: genetic and environmental factors 
Depression is likely due to genetic (G) and environmental (E) factors (Sullivan et al., 2000). A major 
aspect of the environmental factors that increase the risk of depression is psychosocial stress as 
associated with adverse life events, including loss of a social partner, chronic stress due to work and 
financial problems, and interpersonal conflict (Kendler et al., 2003). Early life stress such as child 
abuse or neglect, also induces a number of physiological and anatomical abnormalities associated 
with depression (Heim et al., 2010). Whether or not individuals that experienced psychosocial stress 
(adverse life events in early life or adulthood) develop depression could be attributed to interaction of 
the environment with genetically-determined traits (Caspi and Moffitt, 2006). Studies examining the 
genetic factors of depression have identified only a small number of genes (Pryce and Klaus, 2013). In 
a meta-analysis of genome-wide association studies, no single locus was found to be associated with 
depression (Sullivan and Consortium, 2013). Due to the very small contribution of polymorphisms in 
single genes to depression risk and also to the heterogeneity of the disease, the likelihood of 
identifying risk genes by genome-wide association study is extremely low even with large sample 
sizes. (Pryce and Klaus, 2013). A meta-analysis that included case-control studies for candidate 
genes identified six genes  in which a polymorphism is associated with depression risk: dopamine 
(DA) active transporter (DAT), DA receptor D4 (D4), methylenetetrahydrofolate reductase (MTHFR), 
guanine nucleotide binding protein beta polypeptide 3 (GNB3), apolipoprotein (APOE) and serotonin 
(5-HT) transporter (5-HTT) (Lopez-Leon et al., 2008) (for more information on 5-HTT see section 3.2). 
There is increasing evidence that the interaction between genes and environment (GxE), including 
resultant epigenetic modifications, plays an important role in the aetio-pathophysiology of depression 
(Caspi and Moffitt, 2006). To-date, the most studied GxE interaction involves a polymorphism also 
identified in the case-control studies mentioned above; namely the 5-HTT polymorphism and its 
interaction with aversive life events (see section 3.2). Other studies have demonstrated association 
with depression risk of early aversive life events in interaction with single-nucleotide polymorphisms in 
genes modulating the hypothalamic-pituitary-adrenal axis, such as corticotropin-releasing hormone  
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(CRH) receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5) (Bradley et al., 2008; Zimmermann 
et al., 2011). 
1.4 Pathophysiology  
The monoamine hypothesis 
The monoamine hypothesis of depression, including the indoleamine 5-HT and the catecholamines 
norepinephrine (NE) and DA, states that depression is associated with a reduced availability of either 
one specific or a combination from the three monoamines (Richelson, 1996). Monoamines have a 
particular role in modulating depression-relevant forebrain regions with afferent input from the midbrain 
and brainstem: 5-HT from the dorsal raphe nucleus (DRN), NE from the locus coeruleus (LC) and DA 
from the ventral tegmental area (VTA). Their networks regulate negative- and positive-valence 
emotionality, awareness and executive function (Krishnan and Nestler, 2008). Since the serendipitous 
discovery of different antidepressants that act by increasing the availability of monoamines, in 
particular the selective 5-HT reuptake inhibitors (SSRIs) in the mid-1980s, 5-HT and its metabolic and 
signalling pathways have been in the focus of depression research (Mulinari, 2012). In addition to anti-
depressant effects of SSRIs, further clinical evidence in support of the 5-HT hypothesis has been 
reported. Thus, post mortem studies in depressive patients identified decreased 5-HT metabolites in 
cerebrospinal fluid (CSF) and increased 5-HT2 receptor levels in blood cells. In in vivo studies, 
depression was associated with (a) decreased physiological blood levels of 5-HTT and the 5-HT 
precursor L-tryptophan; (b) a polymorphism of the 5-HTT gene; and (c) decreased brain-imaging 
activity of 5-HTT in mesolimbic regions (Saveanu and Nemeroff, 2012). In genetic mouse models in 
which receptors, transporters or enzymes belonging to the 5-HT pathway were deleted, depressive-
like or depression-resilient behaviours have been demonstrated depending on the gene (Dominguez-
Lopez et al., 2012). The action of SSRIs is to increase 5-HT transmission immediately, by inhibiting its 
degradation or reuptake; therefore, it is not understood why the treatment requires weeks for the 
improvement of mood (Szanto et al., 2003). Similar findings were also observed for the NE-ergic 
system; NE reuptake inhibitors increase NE availability and show anti-depressant effects (Saveanu 
and Nemeroff, 2012). Additionally, decreased levels of NE metabolites in CSF and increased density 
of β-adrenergic receptors in post-mortem brain tissue were found in depressed patients, suggesting a 
receptor up-regulation due to lower ligand concentration (Saveanu and Nemeroff, 2012). Due to the 
low remission rates of the NE and 5-HT reuptake inhibitors (NSRIs), a class of antidepressant acting 
on both monoamines, the third monoamine, DA, was also proposed to be important in the 
pathophysiology of depression. Reward anticipation and sensitivity are reduced in depression, and the 
mesolimbic DA-ergic pathway is a major neurotransmitter system in the reward circuit (Salamone and 
Correa, 2012). In animal studies, depletion, pharmacological modulation and electrical and 
optogenetic stimulation of the VTA impact on the responsiveness to reward stimuli (Russo and 
Nestler, 2013). In depressive patients, decreased CSF concentration of DA metabolites has been 
reported, as have reduced DA transporter binding sites and increased density of the D2/D3 receptors. 
Drugs increasing the availability of DA have also been identified to induce anti-depressant effects 
(Saveanu and Nemeroff, 2012). 
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The glutamate hypothesis 
Glutamate is the major excitatory neurotransmitter of the brain. It has been associated with depression 
since the discovery of the antidepressant class of N-methyl-D-aspartate (NMDA) receptor antagonists 
in the early 1990’s (Trullas and Skolnick, 1990). Elevated glutamate levels in blood, CSF and brain 
tissue of frontal cortex were found in depressive patients (Sanacora et al., 2008) and antidepressants 
such as fluoxetine and s-citalopram have been demonstrated to reduce the glutamate level in plasma 
of depressive patients (Kucukibrahimoglu et al., 2009). Brain imaging findings diverge depending on 
the brain region. Decreased glutamate binding was observed in ACC, whereas glutamate binding was 
increased in occipital and parietal cortices of depressive patients. These abnormal glutamate levels 
have been related to changes in glial cell function (Sanacora et al., 2008; Walter et al., 2009). In ACC, 
and also AMYG and hippocampus (HIPP), there is immunohistochemical evidence for reduced glial 
cell counts and density, and reduced glia-to-neuron ratios (Harrison, 2002). Glial cells are responsible 
for glutamate reuptake and conversion to glutamine that is transported back to the neuron and 
reconverted to either glutamate or GABA (Rajkowska and Miguel-Hidalgo, 2007). Expression of the 
glial glutamate transporter and the glutamate degradation enzyme glutamine synthetase is reduced in 
depression (Choudary et al., 2005). Supporting this hypothesis, animal studies have shown that early 
life stress or chronic adult life stress induce a reduction in astrocyte density in prefrontal cortex (PFC), 
HIPP and AMYG and a decrease in escape behaviour of controllable aversive stimuli and in reward 
sensitivity, whereas the glutamate-modulating drug riluzole reversed theses effects (Banasr and 
Duman, 2008; Leventopoulos et al., 2007). Acute and chronic stress also increased the extracellular 
glutamate level and reduced glia mediated glutamate cycling in limbic and cortical areas (Sanacora et 
al., 2008). Recent pharmacological findings in human studies support the glutamate hypothesis of 
depression: ketamine, an NMDA glutamate receptor antagonist exhibits rapid and prolonged 
therapeutic efficacy in treatment-resistant depressed patients (see section 4.3 to 4.6). 
The HPA axis hypothesis 
For many decades, the hypothalamic-pituitary-adrenal (HPA) axis was regarded as the physiological 
signaling pathway responsible for bodily responses to environmental stress. Stress perceived and 
processed by the brain induces an increase in intermediary neuropeptides (CRH, arginine vasopressin 
(AVP)) and hormones (adrenocorticotropic hormone (ACTH)) of the HPA axis resulting in high levels 
of cortisol in blood plasma (corticosterone in rodents). Together with findings in clinical studies, 
including that a majority of depressive patients exhibit higher levels of basal cortisol than those of 
healthy probands, and that Cushing’s syndrome patients (a disease induced by prolonged exposure to 
hypercortisoleamia) exhibit high co-morbidity with depression, the hyperactivity of the HPA axis was 
hypothesized to induce and maintain depression (Saveanu and Nemeroff, 2012). The first intermediate 
neuropeptide, CRH is secreted by the hypothalamus into the hypothalamo-hypophyseal portal system, 
and is also a neurotransmitter. Levels of CRH are increased in the CSF and in cerebrocortical areas of 
depressive patients (Merali et al., 2004). The observed decreased density and decreased mRNA 
expression of the CRHR in the frontal cortex of depressive patients suggest down-regulation due to 
hyper-secretion of CRH in depression (Merali et al., 2004). In animal studies, administration of CRH 
directly into the brain induces depressive-like behaviors (Heinrichs et al., 1995). Two neuroendocrine 
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challenge tests of the reactivity of the HPA axis for clinical and animal research purposes have been 
developed: (a) The dexamethasone (DEX) suppression test (DST), in which DEX administration 
inhibits the secretion of the second mediating hormone ACTH, thereby suppressing the release of 
cortisol or corticosterone. (b) The CRH test in which administration of synthetic CRH increases levels 
of ACTH and cortisol/corticosterone. In the majority of depressive patients, both reactions have been 
shown to be disrupted: DEX suppression of cortisol is reduced, as is synthetic CRH stimulation of 
ACTH. Reduced DEX suppression is consistent with an impaired corticosteroid receptor negative 
feedback which is also consistent with the increased levels of basal cortisol in some depressive 
patients (Saveanu and Nemeroff, 2012). The challenge test considered to be the most effective as a 
biomarker of depression is the combined DEX/CRH test (Ising et al., 2005). Drugs blocking receptors 
of the HPA axis such as the CRHR1 and glucocorticoid receptor have been tested (see section 4.2). 
The cytokine hypothesis 
Recently, evidence has been obtained that associates depression with activation of the immune 
system (Dantzer et al., 2011; Maes et al., 2009; Miller et al., 2009). These data include various clinical 
studies demonstrating: (a) the increase of pro-inflammatory cytokines e.g. tumor necrosis factor (TNF) 
and interleukin(IL-)6 in blood plasma of depressed patients (Dowlati et al., 2010), (b) the association of 
the severity of depressive symptoms with the increased level of cytokines (Raison et al., 2010), (c) the 
anti-inflammatory effect of antidepressants (De Berardis et al., 2010), (d) the reduction of depressive 
symptoms by the TNF antagonist etanercept (Tyring et al., 2006), (e) the induction of depression-
relevant psychological states by immune-stimulation with endotoxin, typhoid vaccine or interferon 
alpha (INF-α (Capuron and Miller, 2004; Eisenberger et al., 2009; Harrison et al., 2009), (f) the co-
morbidity of depression with autoimmune diseases such as multiple sclerosis and diabetes mellitus 
(Dalton and Heinrichs, 2005; Nouwen et al., 2010), and (g) the association of polymorphism in the 
TNF gene with depression (Bosker et al., 2011). Stress such as early life stress or chronic aversive life 
events lead to chronic activation of the immune system. Diverse pro-inflammatory cytokines, e.g. IL-6 
or C-reactive protein (CRP), have been reported to be increased in couples after divorce and in adults 
after childhood maltreatment (Saveanu and Nemeroff, 2012).  
In mice, repeated social stress leads to increased cytokines level in blood (Savignac et al., 
2011) and administration of pro-inflammatory cytokines (e.g. IL-1β and TNF) induces depressive-
relevant behaviors such as social avoidance and decreased motor activity (Dantzer, 2001). Peripheral 
cytokines have been demonstrated to enter the CNS via transporters in the blood brain barrier, and to 
act peripherally on cytokine-producing monocytes which themselves traverse the brain parenchyma 
(Banks, 2006; D'Mello et al., 2009). Pro-inflammatory cytokines modulate other neuronal functions 
implicated in the pathophysiology of depression (see sections above): (a) activation of 5-HTT leading 
to decreased synaptic availability of 5-HT (Zhu et al., 2006), (b) increased expression of DA 
transporter and decreased production of DA leading to decreased synaptic availability of DA, (c) 
activation of glutamatergic signaling, (d) increase in CRH production leading to a hyperactivity of the 
HPA axis, and (e) reduction of hippocampal neurogenesis (Felger and Miller, 2012; Saveanu and 
Nemeroff, 2012). 
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Current and promising aspects of research in depression link the aetiological aspect of 
cytokine hypothesis with pathophysiological states of depression, such as the 5-HT and DA deficiency 
(Felger and Miller, 2012; Maes, 1995). The essential amino acid tryptophan is the precursor of 5-HT 
and it determines the rate of biosynthesis of 5-HT. Tryptophan is either processed to 5-
hydroxytryptophan which is then converted to 5-HT, or to kynurenine (KYN) which is then metabolized 
to kynurenic acid (KA) or quinolinic acid (QA). For the metabolism of KYN two enzymes have been 
identified, tryptophan-2,3-dioxygenase (TDO) and indoleamine-2,3-dioxygenase (IDO). IDO is 
activated by cytokines such as TNF and INF-α (Dantzer, 2009). This activation may be responsible for 
a cytokine-induced reduction of 5-HT production, shifting the tryptophan metabolism to KYN and then 
KA and QA. This hypothesis is supported by many studies: IDO is present in macrophages and 
dendritic cells of the brain, and activity of IDO is increased during acute and chronic immune system 
activation (Wirleitner et al., 2003). In mice, systemic administration of the immune system-stimulating 
lipopolysaccharide (LPS) increases the level of IFNɣ in the periphery and activates IDO in the 
periphery and in brain (Lestage et al., 2002). However, there is no consistent evidence for a change in 
5-HT turnover by IDO. There are several reported effects of this kynurenine pathway:(a) the 
antagonistic or agonistic effects on the NMDA receptor of KA and QA, respectively, altering glutamate 
homeostasis and (b) the neurotoxic effect of QA activating nitric oxide agents (Felger and Miller, 
2012). The latter induces oxidative stress in neurons, reducing the activity of tetrahydrobiopterin 
(BH4), an essential co-factor for tyrosine hydroxylase, the rate-limiting enzyme for the conversion of 
tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) which, in a further enzymatic step, is metabolized 
to DA. Two other pathways in which cytokines reduce the DA availability in synaptic clefts are: (a) 
reduction of the expression of vesicular monoamine transporter 2 (VMAT2) which is responsible for 
the cytosolic package of DA in vesicles ready for release, and (b) increase in the expression of DAT 
(Felger and Miller, 2012). The strength of the cytokine hypothesis is its interface capacity between 
various pathophysiological states of depression. 
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2. ANIMAL MODELS 
2.1 Importance of animal models 
A major reason that depression research has, in the last decades, failed to provide evidence for novel 
pathophysiological mechanisms and antidepressant targets is the lack of valid animal models for 
depression. Animal models  with aetiological, face and construct validity would allow for translational 
research in the form of bi-directional transfer of clinical aetio-pathophysiological knowledge of 
depression to animal models and the transfer of structural, neurochemical, molecular and 
neuropharmacological information in animal models back to depressed patients (Pryce and Seifritz, 
2011). Animal studies are essential to test cause-effect hypotheses for the aetio-pathophysiology of 
stress-related depression and for identification of molecular targets for development of novel effective 
treatments. Establishing such an animal model requires three basic components: (1) genetic and/or 
environmental manipulation(s) of aetiological relevance to depression, (2) behavioural assays of 
relevance to depression neuropsychopathology, and (3) physiological effects analogous to those in 
depression. If well-validated, animal models, especially rodent models, can be widely used to question 
the neurobiological and genetic basis of depression. 
2.2 Validity of animal models 
To define the quality of an animal model in neuropsychiatric disorders, four validity criteria have been 
identified: aetiological, face, construct and predictive validities. Aetiological validity refers to the 
manipulation of the animal, that is, the factors that predispose to and trigger the disease-relevant 
changes. The aetiological process of the disease in human should be mimicked as accurately as 
possible in the animal. Chronic psychosocial stress is a major aetiological factor for depression 
(Kendler et al., 1999) and therefore chronic social defeat (CSD), the mouse model for depression 
presented in section 2.3 and in Project A and B, has potential for high aetiological validity. Face and 
construct validities refer to the similarities of the manipulation-induced changes to the human 
symptoms and pathophysiological states, respectively. Anatomical, biochemical and behavioural 
features in the animal must coincide with the impairment of neuropsychiatric patients. The last 
validation type, predictive or pharmacological validity, demands that the face- and construct-valid 
effects observed in the model are reduced by treatments specific to the disorder i.e. antidepressants in 
the case of depression. For example, one of the few current rodent models with aetiological-face-
predictive validity is the chronic mild stress (CMS) procedure (Willner, 2005). It comprises prolonged 
exposure to various physical and social stressors (aetiological validity). These factors induce a 
gustatory anhedonia (face validity) which can be reversed by imipramine (predictive validity) (Monleon 
et al., 1995). Recently, it has been demonstrated that CMS mice exhibit reduced bursting activity of 
DA neurons and that optogenetic stimulation of firing by DA neurons in the VTA reverses CMS-
induced gustatory anhedonia (Tye et al., 2013). These last results imply also a high construct validity 
of this model. 
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2.3 Social stress as a manipulation with aetiological validity in animal 
depression models 
Social stressors are aetiological factors in human depression (Kendler et al., 1999). In animal 
research, social stress has been used as a manipulation in depression models in various forms. These 
include social isolation (Bartolomucci et al., 2003), exposure to ex-resident odours (Rodgers and Cole, 
1993) and experiencing repeated disruption of social networks (Schmidt et al., 2010). In the last 15 
years, CSD, consisting of a direct attack session between a dominant and a submissive mouse, has 
gained interest as a manipulation with aetiologcal validity for a depression model. Koolhaas and 
colleagues demonstrated in mice that social defeat induces higher stress responses in terms of 
increased corticosterone level in plasma relative to other stressors including foot shock or forced swim 
sessions (Koolhaas et al., 1997). Even a single defeat was enough to sensitize the mouse to have a 
higher response to subsequent minor stressors. The first CSD procedure used BL/6 mice as 
aggressors and subjects (Kudryavtseva et al., 1991). Subsequent modifications were conducted to 
use ex-breeder CD-1 strain mice as aggressors (Golden et al., 2011). The readout effects were 
increased motor retardation measures such as decreased activity in an open field test and in a forced 
swim test (FST) (Kudryavtseva et al., 1991), decreased reward sensitivity in the sucrose preference 
test (Yu et al., 2011) and increased anxiety in the elevated plus maze test (Avgustinovich et al., 2005; 
Krishnan et al., 2007). A major focus of behavioural effects of CSD is the induced social avoidance. It 
is measured using the social approach-avoidance test, consisting of two sessions in an arena 
containing a small wire-mesh cage: in the first session, the subject mouse explores the arena with the 
cage empty and in the second session with the cage containing a novel CD-1 mouse; relative to 
controls, CSD mice exhibit decreased time in proximity of the cage in the second session, i.e. high 
social avoidance. It is noteworthy that such social avoidance tests use the same category of aversive 
stimulus as for CSD; accordingly, a stimulus-specific effect of CSD is being demonstrated and high 
avoidance of this specific stimulus can even be considered as adaptive behaviour. 
2.4 Behavioral readouts with face validity in depression animal models 
Each of the three tests described below provides an example of measuring objective, face-valid animal 
behavior with respect to symptoms of depression. 
Fear conditioned freezing 
Fear conditioning involves the organism acquiring an emotional response to a neutral stimulus (light, 
tone and context) that predicts an innate aversive stimulus (e.g. painful electroshocks). In rodents fear 
can be measured as freezing behaviour to inescapable aversion. This form of fear conditioning and 
responding is mediated primarily by the basolateral and central nuclei of the AMYG (LeDoux, 2000). 
Human studies of emotional reactivity are typically not based on the same behaviour such as freezing 
in the classical conditioning, rather psychopathological scales are used and functional MRI to measure 
regions-specific reactivity to images of happy, neutral or sad faces (Blanchard et al., 2001).  
Learned helplessness 
The concept of learned helplessness (LH) is a major theory for both onset and maintenance of 
depression (Abramson et al., 1978; Pryce et al., 2011). LH comprises the experiencing of an 
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uncontrollable stressor with emotional valence leading to a generalized perception of aversive events 
as uncontrollable, even if they are not (Pryce et al., 2011). In animal studies, the two-way shuttle arena 
is used for measuring the deficit in avoid or escape behaviour. Some of the first LH experiments were 
performed in rats: subjects received either uncontrollable or controllable tail electroshocks which could 
be terminated by turning a wheel and were tested with controllable, escapable foot electroshocks by 
another operant behaviour in another context on the following day (Weiss and et al., 1981). In mice, 
the pre-exposure day and the test have been performed in the same context and demanding the same 
operant behaviour to control the foot electroshock ((Anisman and Merali, 2001; Pryce et al., 2012) see 
Appendix). In both rodent tests, animals that have experienced uncontrollable electroshocks, 
compared to those that experienced controllable electroshocks, exhibit a deficit in escapes in the test 
phase. Pharmacological studies have demonstrated that by inactivating the PFC, rats that experienced 
controllable electroshocks exhibit a deficit in escape, and by activating the PFC, rats that experienced 
uncontrollable electroshocks exhibit normal escape behaviour (Amat et al., 2005). These results 
indicate an important role of the PFC in mediating controllability and helplessness. In human, the tests 
were adapted from the animal paradigms and typically also use inescapable versus escapable 
electroshocks. 
Fatigue during an effortful physical task 
Despite being a core symptom of depression, fatigue is poorly understood and has not been studied in 
animal models of depression. In psychopathological scales and tasks, human fatigue is commensurate 
with decreased motivation and perceived ability to maintain a level of physical or mental effort 
(Hossain et al., 2003; Keller et al., 2007; Weinstein et al., 2010). Self-reported fatigue is associated 
with increased glucose metabolic activity in NAcc and putamen (Capuron et al., 2007). 
1 - General Introduction 
17 
 
3. GENE- ENVIRONMENT INTERACTION 
3.1 Genes 
The example of 5-HTT polymorphisms in human 
Within the promoter sequence of the 5-HTT gene, the 5-HTT gene-linked polymorphic region (5-
HTTLPR), either a short (s) or a long (l) nucleotide sequence is present. The s-allele is associated with 
lower transcriptional efficacy leading to decreased 5-HTT expression and decreased 5-HT reuptake in 
the synaptic cleft and, paradoxically given that 5-HT reuptake constitutes current first-line 
antidepressant therapy, increased risk of depression (Murphy and Lesch, 2008). PET imaging studies 
using radiolabelled RTI-55, a DA- and 5-HT transporter ligand, demonstrate a functional correlate of 
the three genotypes: s/s and s/l individuals exhibit a decrease in 5-HTT binding sites compared to l/l 
individuals (Murphy and Lesch, 2008). MRI studies in healthy controls have shown that s-carriers 
exhibit increased activity in AMYG in response to fearful faces compared to l-carriers (Canli et al., 
2006; Hariri et al., 2002). These findings are not in concordance with the 5-HT deficiency hypothesis of 
depression nor with the SSRI mechanism of action. 
3.2 Environment 
Early Life Trauma 
Childhood maltreatment consisting of emotional and physical neglect or physical and sexual abuse are 
common in our society. Three million cases of child maltreatment are reported annually, and a 
considerable number of abuse and neglect cases are not registered (Saveanu and Nemeroff, 2012). 
Many studies have shown a marked association between aversive life events in children and the onset 
of depression in adulthood. For example, women that experienced sexual abuse as a child compared 
to women with no abuse have a four-fold increased risk of developing depression (Mullen et al., 1996). 
Early life stress also changes the course of depression: it reduces age at first episode onset, prolongs 
episodes, and decreases the rates of remission and recovery (Saveanu and Nemeroff, 2012). 
However, not all maltreated individuals develop depression, and three possible explanations for such 
resiliency are (a) perceived positive parental care and the quality of relationship to peer/partner i.e. 
social support, (b) timing of the aversive events, and (c) genetic predisposition. 
Adulthood aversive life events 
Stressful situations during adulthood i.e. aversive life events are associated with depression and are 
usually categorized as social loss (e.g. death of a loved one, separation from social partner), personal 
insecurity (e.g. personal failure, interpersonal conflicts and insecurity over future), chronic stress (e.g. 
work, financial or legal problems) and health problems (Keller et al., 2007). The different groups 
correlate differently with specific depressive symptoms. The social loss component is most associated 
with a high level of sadness, appetite loss and anhedonia, and the chronic stress component with 
fatigue and hypersomnia (Keller et al., 2007). As mentioned for early life stress, aversive life events 
PhD theisis of Damiano Azzinnari 
18 
 
are also not sufficient to induce depression in all individuals and not all depressive patients show a 
history of aversive life events. Similar explanations may play a role as described above. 
3.3 Gene x Environment interaction 
The first (and most robustly demonstrated) GxE interaction was described by Caspi and collegues 
(Caspi et al., 2003). In this study an association between the s-allele of the 5-HTTLPR of the 5-HTT 
gene and stressful life events in childhood or young adulthood was demonstrated. The effects of adult 
stressful life events between the ages of 21 and 26 on depressive symptoms were significantly higher 
among s-allele than homozygous l-allele carriers. Aversive life events experienced in the same time 
period also increased depressive symptoms and predicted a diagnosis of depression in s-allele 
individuals compared to l/l-allele carriers (Caspi et al., 2003). Another study demonstrated that s/s 
individuals compared to l-allele carriers were more vulnerable to develop depression after aversive life 
events (Kendler et al., 2005). Taken together, these data suggest that the 5-HTT gene modulates the 
relationship between stressful events and depression aetio-pathophysiology. 
3.4 Animal studies of GxE interaction 
The example of 5-HTT KO mice 
A genetic mouse model was created mimicking the effect of the 5-HTTLPR polymorphism in human: 
the 5-HTT partial knockout (5-HTT HET) mouse. By homologous recombination, a segment of the 5-
HTT gene that contains the start codon and a sequence responsible for cellular transport was replaced 
causing an inactivation of gene transcription (Bengel et al., 1998). Compared to wild type (WT), HET 
mice show low 5-HTT levels and increased 5-HT levels in different brain regions (Bengel et al., 1998; 
Mathews et al., 2004). Behaviorally, a small number of studies have shown that HET compared to WT 
mice exhibit anxiogenic behaviors (in the dark-light box emergence test but not in the elevated plus 
maze, (Jansen et al., 2010), intermediate aggressive behavior (Holmes et al., 2003), increased 
acquisition of learned helplessness (Pryce et al., 2012), reduced sensitivity to non-reward in operant 
conditioning (Ineichen et al.,2012), and no altered response in fear conditioning acquisition and 
expression (Narayanan et al., 2011). 
Stress model in mice 
A number of stress mouse models have been developed for examining the effects of early and adult 
life stress (see section 2.3). The most common stress manipulation for early life events in rodents is 
maternal separation (Pryce and Feldon, 2003). In rats, the absence of warmth and food during 
maternal separation leads to behavioural and endocrine phenotypes in adulthood. For example, 
separating pups for 3 hours per day during the first two weeks after birth led to increased emotional 
behaviours and increased physiological response to stress in adulthood (Carlyle et al., 2012). For 
modeling adult life stress in mice, one of the most common procedures is the CSD paradigm (see 
section 2.3).  
GxE interaction in mice 
In a recent GxE interaction study, repeated stress exposure during adolescence (post-natal day 28-47) 
led to increased anxiety and decreased activity in WT and HET mice (Spinelli et al., 2013). In the 
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probabilistic reversal learning task, a test measuring feedback sensitivity, stressed HET relative to 
non-stressed HET and WT mice exhibited poorer performance. In depressed patients and adolescents 
homozygous for the s-allele and exposed to childhood adversities, poorer performance has been 
reported in a human version of this task (Murphy et al., 2003; Owens et al., 2012). When adult stress 
was applied using CSD, 5-HTT HET mice exhibited mildly increased freezing behavior during 
expression of conditioned fear and considerably impaired extinction of learned fear (Narayanan et al., 
2011). Increased sensitivity to CSD in HET mice in terms of increased social avoidance has also been 
reported (Bartolomucci et al., 2010): in this model the same aversive stimulus is used for the 
manipulation and the readout test, the CD-1 mouse, thus the increased avoidance exhibited by HET 
can be considered as adaptive rather than depression-relevant. In terms of physiology, mouse studies 
of 5-HTT gene x CSD interaction effects have reported a stress-induced increase of corticosterone in 
plasma and corticosterone metabolites in faeces but no interaction with genotype (Bartolomucci et al., 
2010; Jansen et al., 2010). 
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4. ANTIDEPRESSANTS 
4.1 Different types of depression treatment 
The efficacy of the current antidepressant drugs, mainly targeting the monoamine systems, is 50- 70% 
in terms of two drug trials of different mechanism-of-action and based on a chronic treatment regimen 
(Fava and Davidson, 1996; Little, 2009). Relapse and remission occur frequently. Patients resistant to 
pharmacotherapy are treated with psychotherapy and, if no improvement occurs, electroconvulsive 
therapy or deep brain electro-stimulation in the dysfunctional limbic-cortical circuit are options for such 
cases of treatment resistance. Different types of psychotherapy exist (e.g. cognitive behavioural 
therapy, interpersonal therapy, psychodynamic psychotherapy or supportive psychotherapy), but 
robust studies on their efficacy relative to placebo and differential efficacy are lacking (Saveanu and 
Nemeroff, 2012). . For deep brain stimulation, still in its infancy as a depression treatment, electrodes 
are placed surgically in the brain and provide electric impulses in depression-relevant brain areas. 
Stimulation of the NAcc has led to sustained remission of depressive symptoms (Schlaepfer et al., 
2008). Because of the unknown action of deep brain stimulation and electroconvulsive therapy and 
their invasive methodology it is important to improve psychopharmacology and psychotherapy. 
4.2 History of antidepressants and novel targets 
In the 1950’s, the serendipitous discovery of two classes of anti-depressant, monoamine oxidase 
(MAO) inhibitors and tricyclic antidepressants (TCA), both elevating the levels of monoamines in the 
brain, started the psychopharmacological era in psychiatry. In the 1940’s, anti-histamines were studied 
and due to some anti-depressant side effects the first TCA, imipramine, was discovered. Similar 
findings were observed with the MAO inhibitors developed against tuberculosis. Iproniazid was 
approved in 1958, but was withdrawn due to its hepatotoxic effects. Since then, more specific MAO 
inhibitors have been developed. In the meantime, clinical studies assessed the importance of 
decreased 5-HT in depression and drugs designed to increase the 5-HT level were developed. In the 
1970’s, the first SSRI, fluoxetine (Prozac), was approved. More recently, drugs acting on NE and 5-HT 
transporters (e.g. SNRI) have been used to treat depression. The increasing use of buproprion, a NE 
and DA reuptake inhibitor, has turned the focus to the DA hypothesis. 
 At the beginning of the new millennium, the CRHR1 antagonist R121919 showed promising 
results but failed due to liver toxicity (Zobel et al., 2000). Due to the HPA hypothesis and supported by 
the high expression of the glucocorticoid and mineralocorticoid receptors (GR and MR) in depression-
relevant brain regions such as AMYG and HIPP (Kennedy and Rizvi, 2009), modulators of these 
receptors have been developed and assessed for anti-depressant efficacy (Ising and Holsboer, 2007). 
Although phase 1 tests of the GR antagonist mifepristone yielded positive results (Kling et al., 2009), it 
failed in advanced phases. 
 There is a need for novel antidepressants with mechanisms-of-action based on goal-directed 
research. Based on evidence from different genetic, brain-imaging and neurochemical studies, 
antidepressants must be developed to act on the specific neural circuitry that is altered in depression, 
not disrupting healthy systems. The present therapeutic drugs in development can be broadly 
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categorized into five groups: (a) multiple monoamine agents such as triple reuptake inhibitors or 
melatonergic receptor agonists (e.g. agomelatine), (b) glutamate signalling modulators such as NMDA 
receptor antagonists (e.g. ketamine) and modulators of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and metabotropic glutamate receptors, (c) agents acting on 
neurotrophic factors such as brain derived neurotrophic factor (BDNF), (d) modulators of the immune 
system such as antagonists of pro-inflammatory cytokines pathways, and (e) agents acting on 
neuropeptides such as neurokinin (Kennedy and Rizvi, 2009). The clinical evidence for the most novel 
drugs is described in section 1.4. 
4.3 Pharmacology of ketamine 
The most common purpose of ketamine concerns its anaesthetic effect. Ketamine acts as a non-
competitive antagonist on the ionotropic glutamate Ca
2+
-channel of the NMDA receptor. It inhibits the 
receptor via the phencyclidine binding site (Hirota and Lambert, 1996). Ketamine modulates also other 
receptors such as opioid, muscarinic and adrenergic receptors (Quibell et al., 2011). The molecule 
possesses a chiral centre leading to the R- and S-enantiomers. However, the equal racemic (RS-) 
mixture of both enantiomers is the most used for clinical studies. S-ketamine has a five-fold higher 
affinity for the NMDA receptor, and it has twice the analgesic potency (Quibell et al., 2011). The liver 
metabolizes both chiral molecules rapidly (half life time of 3 hours, (Katalinic et al., 2013)). 
4.4 Ketamine in humans 
One of the most encouraging rapid antidepressant effects has been provided by ketamine in 
treatment-resistant patients. Since the first study in 2000 demonstrating the antidepressant effect 
(Berman et al., 2000), there have been many confirmatory studies. Intravenous subanaesthetic 
infusion of 0.5 mg/kg ketamine over 40 minutes in depressive patients led to significantly reduced 
scores on the Hamilton Depression Rating Scale (HDRS) within a few hours; this effect persisted up to 
day 3 (Berman et al., 2000) and day 7 (Zarate et al., 2006). A higher ketamine dose of 1.0 mg/kg was 
administered during anaesthesia in depressive patients undergoing surgery. Similar effects could be 
observed with the HDRS at 1 day post-surgery; the effects were no longer significant after 3 days 
(Kudoh et al., 2002). Ketamine also induces side effects, including positive, negative and dissociative 
symptoms of schizophrenia, and manic symptoms (Katalinic et al., 2013). There are few studies of the 
different effects of the two enantiomers. S-ketamine causes less psychotomimetic effects (Paul et al., 
2009). Given the few studies to date, it is still unknown how application, dosage and the different 
enantiomers act on the brain and on depression. However, the results provide evidence that 
dysfunctional glutamate signalling and metabolism are important to the pathophysiology of depression.  
4.5 Ketamine in mice 
To understand the mechanism-of-action of ketamine in human, rodent studies provide translational 
support. High-dose administration of ketamine was related to increased glutamate release in medial 
PFC of rats (Moghaddam et al., 1997). No such study of neurotransmitter effects by low-dose 
ketamine has been reported so far. Studies analysing the quantification of cellular-pathway proteins 
indicate that ketamine effects may have a complex inverted U-shape dose-response relationship 
(Autry et al., 2011; Li et al., 2010). Several mouse studies report effects of acute low-dose RS-
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ketamine (2.5-5.0 mg/kg ip) on behaviour in antidepressant screening tests e.g. the FST (Autry et al., 
2011). 
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5. AIMS OF THE PHD THESIS 
5.1 Aim of Project A (Chapter 2) 
With respect to the aetiology of depression, the Project A of this PhD thesis examines the impact of 
stressful socio-environmental factors on physiology, behaviour and ex vivo brain transcriptome 
expression. The aim was to adapt the CSD procedure so that the physical wounding that occurs in the 
existing protocol was avoided, therefore: (1) the incisors of CD-1 mice were trimmed on a regular 
basis and (2) attack duration was timed to stop the session if the attacks exceeded the certain total 
time of attack. Under these refined conditions, CSD effects on physiological inflammatory markers 
were investigated. With respect to the psychopathology of depression, novel and face-valid 
behavioural readouts were developed and applied. These comprised measures of motoric, emotional, 
motivational and cognitive reactivity to uncontrollable or controllable aversive stimuli. Both short- and 
long-term effects of CSD were measured in these behavioural tests. Given that the innate aversive 
stimulus in each of these tests was painful electroshock, the extent to which experiencing chronic 
psychosocial stress led to generalized hyper-reactivity, including impaired control, to other stress 
stimuli was under study. Having confirmed that the psychosocial stressor of refined CSD induces 
depressant-relevant behavioural changes and induced depression-relevant peripheral inflammation, a 
hypothesis-free analysis of CSD-induced differential gene expression in cortico-limbic brain regions 
was conducted using next generation sequencing and identified de-regulation of immune-inflammation 
and DA genes.  
5.2 Aim of Project B (Chapter 3) 
In Project B, the mouse model validated in Project A was used to investigate the interaction of the 
same environmental stressor on a depressant-relevant genetic mutation. Based on the human 
evidences for the S allele of the 5-HTT promoter region possibly conferring adult stress resilience, the 
corresponding 5-HTT KO mouse line was under investigation. The aim was to find out whether and via 
which mechanisms 5-HTT genotype modulates the impact of adult stress on depression-relevant 
behaviour, immune function and DA-ergic signalling. The CSD x 5-HTT interaction effects on reactivity 
to aversive events were studied in terms of fear-induced freezing in a context conditioning test. That is, 
mouse model evidence was sought in support of both the 5-HT and cytokine hypotheses of 
depression based on their integrative regulation of brain and behaviour. 
5.3 Aim of Project C (Chapter 4) 
In this part of the PhD thesis, important issues raised by the translational evidence of acute low-dose 
ketamine as an antidepressant treatment were addressed. In non-manipulated mice, the following 
effects were investigated: (1) RS- or S-ketamine at equivalent low (3, 1.5 mg/kg) or high (50, 25 
mg/kg) dose in the FST. (2) RS- or S-ketamine at equivalent low dose in the LH paradigm. (3) RS- or 
S-ketamine at equivalent low or high dose on glutamate release in mPFC. (4) RS- or S-ketamine at 
equivalent low or high dose on BDNF in HIPP. (5) RS- or S-ketamine at equivalent low or high dose on 
mTOR in HIPP and mPFC. Of particular interest was whether a low-dose of high-affinity S-ketamine 
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exerted the most robust effect in antidepressant screening tests and, if so, whether this was 
associated with increased mPFC glutamate release, increased BDNF levels and increased mTOR 
phosphorylation as recently hypothesized with the low-dose RS-ketamine administration. 
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Chapter 2 
Mouse model for psychosocial stress-induced depressed mood and fatigue highlights 
inflammation-dopamine aetio-pathophysiology 
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1. SUMMARY 
Animal models of depression invariably lack adequate aetiological and face validity, and therefore 
relevance to much-needed identification of aetio-pathophysiological processes and molecular targets 
for novel antidepressant treatment. Overcoming these short comings requires environmental 
manipulations that confer chronic uncontrollable psychosocial stress without confounding physical 
injury, and objective behavioural readouts under emotional challenge focusing on core 
psychopathology domains such as generalised loss of control (helplessness) and fatigue. C57BL/6 
mice were exposed to 15-day chronic social defeat with novel refinements that circumvented physical 
wounding. Effects were investigated in terms of: passive and active behavioural responses to 
controllable and uncontrollable electroshock; peripheral biomarkers of immuno-inflammatory and 
stress-hormone status; transcriptome-level gene expression status in hippocampus, amygdala and 
prefrontal cortex using next generation sequencing-canonical pathway analysis. Chronic psychosocial 
stress increased: fear of an uncontrollable negative event, as acquisition of freezing in the context of 
electroshocks; helplessness towards a controllable negative event, as reduced avoiding-escaping of 
electroshocks in 2-way active avoidance; psychomotor fatigue in the face of a controllable negative 
event, as reduced running on a moving treadmill to avoid-escape electroshock. Peripheral pro-
inflammation was demonstrated by increased blood levels of tumor necrosis factor and interleukin-6, 
and splenomegaly. In a separate cohort, chronic psychosocial stress induced gene de-regulation in 
canonical pathways of immuno-inflammation and G-protein coupled receptors. In amygdala, gene de-
regulation was consistent with compromised dopamine receptor 2 signalling. This novel mouse 
depression model with unusually high aetiological-face validity places the focus on stress-immuno-
inflammation-dopamine dysfunction as a major depression aetio-pathophysiology and treatment 
target. 
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2. INTRODUCTION 
Depression is a prevalent neuropsychiatric disorder with core symptoms of low mood, anhedonia and 
fatigue (DSM-5, 2013; ICD-10, 1994). It is generally accepted that the majority of current animal 
models for mental disorders, and certainly those for depression, are deficient in aetiological validity 
(manipulations that mimic human genetic and/or environmental depression risk factors and their 
interaction) and face validity (objective behavioural readouts of relevance to psychopathologies) 
(Hyman, 2012; Insel and Sahakian, 2012). Non-valid models and screening tests will not contribute to 
the much needed increased understanding of depression aetio-pathophysiology and identification of 
molecular targets for development of novel antidepressant treatments (Pryce and Seifritz, 2011). This 
paucity of valid models is particularly costly given the high resolution of the technologies available to 
study brain circuitry and cellular-molecular function (Hyman, 2012). For example, one of the few 
current rodent models with aetiological-face validity is gustatory anhedonia induced by chronic mild 
stress (CMS) comprising prolonged exposure to various physical and social stressors (Willner, 1997). 
Recently, it has been demonstrated that CMS mice exhibit reduced bursting activity of dopamine 
neurons and, using optogenetic and viral vector technologies, that optogenetic stimulation of firing by 
dopamine neurons in the ventral tegmental area reverses CMS-induced gustatory anhedonia (Tye et 
al., 2013). The important next step in such a model would be to identify the underlying aetio-
pathophysiology and druggable molecular targets; precisely because of the aetiological-face validity 
there is a high probability that these would be clinically relevant.  
Alongside the need for aetiological-face validity, when designing animal models of depression 
it is also essential to consider, a priori, hypotheses of depression aetio-pathophysiology. One 
hypothesis is that of immuno-inflammation, which proposes that psychosocial stress activates the 
inflammatory response pathway in the periphery, which in turn stimulates inflammation-related 
processes in the brain that substantially inhibit dopamine, serotonin and glutamate signalling (Haroon 
et al., 2012; Miller et al., 2009). Psychosocial stress is proposed as the major aetiological factor in the 
mouse environmental manipulation of chronic social defeat (CSD), which involves subject mice 
experiencing daily social subordinacy to aggressive dominant mice (Kudryavtseva et al., 1991). 
However, bite wounds are a common occurrence in the standard CSD protocol (Golden et al., 2011), 
and this of course confounds its aetiological validity as a mouse model for the psychosocial stress - 
immuno-inflammation hypothesis of depression. Therefore, in the present study, simple but effective 
refinements (also in the context of animal welfare 3Rs) of the CSD protocol were introduced such that 
psychosocial emotional stress was experienced in the absence of physical wounding. 
With respect to behavioural readouts, like chronic mild stress, CSD has also been 
demonstrated to induce gustatory anhedonia (Krishnan et al., 2007). Another major focus has been 
that CSD mice exhibit passive avoidance of mice from the aggressor strain that induces defeat; whilst 
indicative of increased social fear, this is actually an adaptive fear to a specific punishing stimulus, 
rather than a pathological response (Krishnan et al., 2007). A major theory in depression aetiology and 
psychopathology is generalised helplessness: it proposes that a specific uncontrollable stressor of 
high aversive emotional valence (life event) is experienced (Kendler et al., 1999) and that this leads - 
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via neuropathological processes proposed to include deficient prefrontal cortical activity (Amat et al., 
2005) - to a psychopathology of generalised environmental uncontrollability. Behaviourally, 
generalised helplessness is expressed as altered emotionality (aversive hyper-reactivity), motivation 
(deficient effort) and cognition (deficient action-goal expectancy) (Maier and Seligman, 1976; Pryce et 
al., 2011). We have recently established a face-valid paradigm of specific helplessness in which mice 
exposed to controllable electroshocks continue to escape, whereas mice exposed to the same 
electroshocks (duration, intensity) but now uncontrollable, develop deficient motivation to escape 
(Pryce et al., 2011). One major aim of the present study was to investigate whether CSD mice also 
develop an escape deficit to electroshock, which would constitute a novel mouse model of generalised 
uncontrollability/helplessness. Another major aim was to investigate the effect of CSD on psychomotor 
fatigue: although fatigue is a core symptom of depression (Demyttenaere et al., 2005), and although 
effortful-running fatigue has been studied in mice in the context of exercise physiology (Carmichael et 
al., 2006), to our knowledge this is the first study of an animal model of psychosocial stress-induced 
fatigue. 
This novel mouse model -  aetiologically and face valid for depression - was here applied to 
the study of aetio-pathophysiological processes: Firstly, translational physiological markers of immuno-
inflammation (Dowlati et al., 2010; Maes, 2011) and glucocorticoid function (Rhen and Cidlowski, 
2005) were obtained. Second, hypothesis-free transcriptome-level next generation sequencing and 
canonical pathway analysis were applied to investigate CSD de-regulation of gene expression in 
specific brain regions – namely, hippocampus, prefrontal cortex and amygdala – known to regulate the 
behavioural processes studied in the model (Amat et al., 2005; Maren et al., 2013) and to be 
functionally associated with depression psychopathology (Capuron et al., 2007; Price and Drevets, 
2010; Strigo et al., 2008). 
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3. EXPERIMENTAL PROCEDURES 
3.1 Experimental design 
Three separate, inter-related experiments were conducted in C57BL/6 adult male mice to investigate 
the effects of chronic emotional psychosocial stress on behavioural reactivity to a different aversive 
stimulus, namely electroshock, presented in a comprehensive battery that allowed for the study of 
psychomotor activity, contextual fear conditioning, helplessness, pain sensitivity and fatigue. 
Physiological effects of CSD in these same mice were studied in terms of plasma tumor necrosis 
factor (TNF) and interleukin-6 (IL-6) levels and spleen and adrenal gland mass. In a separate cohort of 
CSD and control (CON) mice, transcriptome-level effects on gene expression in hippocampus (HIPP), 
prefrontal cortex (PFC) and amygdala (AMYG) were studied. Experimental designs are presented in 
Figure 1. 
 Experiment A (CON = 13, CSD = 14) investigated the short-term (days 15 to 17) effects of 
CSD on contextual fear conditioning, two-way active escape-avoidance and hot-plate pain sensitivity. 
At day 18, mice were killed and blood/tissues collected for study of effects of CSD on spleen and 
adrenal gland weight, plasma concentrations of pro-inflammatory cytokines and CORT. 
 Experiment B (CON = 10, CSD = 13) investigated the development (day -1 to 16) of effects of 
CSD on basal concentrations of faecal CORT metabolites, motor activity, water consumption and 
saccharin preference, the short- and long-term (days 17-18 and 29, respectively) effects of CSD on 
fatigue, and the long-term (days 30-32) effects of CSD on contextual fear conditioning and two-way 
active escape-avoidance. 
 Experiment C (CON = 12, CSD = 12) investigated the short-term (day 17) effects of CSD on 
region-specific transcriptome expression in fresh-fixed brain. 
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Figure 1: Experimental designs and aims of the three experiments. Experiment A investigated short-
term effects of CSD (i.e. effects in the days immediately post-CSD) in the motor activity (MA) test, 
contextual fear conditioning (FC) test, two-way active escape-avoidance (E-A) test, and hot plate (HP) 
test. Experiment B investigated effects of CSD during the 15-day CSD in the water consumption (WC) 
test, the MA test and the saccharin preference (SP) test, the short-term effects of CSD in the SP test 
and the treadmill (TM) test, and the long-term effects of CSD (i.e. 2 weeks post final CSD day) in the 
TM, MA, FC and E-A tests. Experiment C investigated the short-term effects of CSD in otherwise non-
manipulated mice on genome-wide gene expression in ventral hippocampus, amygdala, and medial 
prefrontal cortex. Euthanasia time point is indicated by E. 
3.2 Animals and maintenance 
Breeding of C57BL/6 mice was conducted in-house. Male offspring were weaned at age 3 weeks and 
caged in groups of 2-3 littermates. The study was conducted with a total of 76 mice born to 26 
breeding pairs. Mice were aged 10-13 weeks and weighed 22.0-30.0 g at study onset. Male CD-1 
mice (Janvier, France, www.janvier-europe.com) were aged 8 months, ex-breeders, and caged singly 
at study onset. Mice were maintained on a reversed 12:12 h light-dark cycle (lights off 07:00-19:00 h) 
in an individually-ventilated caging system (IVC) at 20-22 °C and 50-60% humidity. Cages were type 
2L and contained woodchips, a sleep igloo and tissue bedding. Complete-pellet diet (Provimi, Kliba 
Ltd, Kaiseraugst, Switzerland) and water were available continuously and ad libitum. In the week prior 
to CSD, all C57BL/6 mice were handled and weighed on five days; body weights were used to assign 
mice to CSD and control (CON) groups such that mean weight per group was counter-balanced. 
The study was conducted under a permit (110/2009) for animal experimentation issued by the 
Veterinary Office, Zurich, Switzerland. All efforts were made to minimize the number of mice used and 
any unnecessary stress to those mice that were used, including refinement of the published protocol 
for CSD (Golden et al., 2011). 
3.3 Chronic social defeat 
Social defeat sessions were conducted under dim lighting on 15 consecutive days (versus 10 days in 
the standard protocol). On the day prior to day 1 of CSD, a CD-1 mouse demonstrated to be 
aggressive (Golden et al., 2011) was placed in one compartment of a cage (Indulab, Gams, 
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Switzerland, www.indulab.ch) containing a longitudinal divider made from transparent Plexiglas and 
perforated with multiple holes ( = 10 mm) for sensory interactions. To prevent bite wounds, a major 
concern in the standard protocol (Golden et al., 2011), the lower incisors of these CD-1 mice were 
trimmed using rodent tooth-cutting forceps (Precision Surgical International, USA, www.psint.net) 
under brief isoflurane anasethesia; this was repeated at 3-day intervals across CSD. Daily CSD was 
conducted between 14:00-17:00 h. On day 1, each CSD C57BL/6 mouse was removed from its home 
cage, weighed and placed in the compartment of a CD-1 mouse. Behaviour was observed and the 
duration of each physical attack was timed; mice remained together until either a cumulative total of 
60-sec physical attack had occurred or 10 min had elapsed. The CSD mouse was controlled for the 
absence of wounding; skin abrasions did occur rarely but skin penetration never occurred. The CD-1 
mouse was removed and weighed. The CSD mouse remained in the compartment in which it had 
been attacked and the CD-1 mouse was placed in the opposite compartment, allowing continuous 
olfactory, visual and auditory contact during the following 24 h. Because of the need for careful 
behavioural observation and timing of attacks, CSD was conducted with only two cages at a time, in 
contrast to 10 cages at a time in the standard protocol (Golden et al., 2011). On day 2, the CSD - CD-
1 mice pairings were rotated so that each CSD mouse was confronted with a novel CD-1 mouse and 
vice versa. The procedure was continued until day 15. Thereafter, CSD mice remained caged next to 
the same CD-1 mice and there were no further attack sessions or rotations. Control (CON) mice 
remained in littermate pairs, the standard caging condition in our laboratory, and were handled and 
weighed daily. In the standard protocol, pairs of CON mice are caged singly separated by dividers 
(Golden et al., 2011). Comparison of CON mice pairs maintained together or separated with a divider 
demonstrated no significant effect on behaviour in contextual fear conditioning or two-way active 
escape-avoidance (unpublished data). 
3.4 Motor activity, contextual fear conditioning and aversive stimulus control 
Behavioural tests were conducted under dim lighting in a room adjacent to the mouse holding room, 
between 08:30-12:00 h. Motor activity, contextual fear conditioning and two-way active escape-
avoidance tests were all conducted using a single multi-purpose system co-developed with the 
manufacturer (Multi Conditioning System, TSE Systems GmbH, Bad-Homburg, Germany), details of 
which are given in Pryce et al. (2012). 
Motor activity 
The mouse was placed on the grid floor in the empty arena for 15 min without presentation of any 
further stimuli. Distance moved (arbitrary units/min, a.u./min) and % time spent freezing in the 
horizontal and vertical planes were recorded continuously. When the mouse did not make any 
movement for a period of at least 2 sec this was recorded by the system as freezing. Mean distance 
moved/min and % time spent freezing were calculated. This test was conducted in Experiment (Expt) 
A at CSD day 14 and in Expt B at days -1, 7, 13 and 30. In Expt B, faecal boli were collected from the 
waste tray after each test for measurement of basal concentrations of the major faecal corticosterone 
(CORT) metabolite (see Corticosterone measurement). 
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Contextual fear conditioning 
The mouse was placed on the grid floor in the empty arena and challenged with 15 inescapable 
electroshocks each of 0.15 mA x 3 sec and delivered at inter-electroshock intervals (ITI) of 50 sec. 
Mean distance moved during the electroshocks and mean % time spent freezing during ITIs were 
calculated. This test was conducted in Expt A at day 15 and in Expt B at day 31. 
Two-way active escape-avoidance test/Aversive stimulus control 
The mouse was placed on the grid floor in the arena which contained a central divider with an opening 
(“gate”) through which it could transfer from one side of the arena to the other. A first stage consisted 
of 10 trials in which a 12-sec tone (5 kHz, 85 dB, conditioned stimulus, CS) preceded an inescapable 
electroshock (0.15 mA x 3 sec) with inter-stimulus intervals (ITI) of 50 sec. Immediately thereafter, 
mice were challenged with 30 trials in which the 10-sec CS now preceded an escapable electroshock 
(0.15 mA x 5 sec maximum) with ITI of 50 sec. If the mouse did not transfer from one side of the arena 
to the other during the CS+electroshock, this was scored as an escape failure; if the mouse 
transferred during the electroshock this was scored as an escape response; if the mouse transferred 
during the CS this was scored as an avoid response. The CS-inescapable electroshock stage was 
used to establish the CS as an aversive stimulus and to ensure that all mice were exposed to it equally 
prior to the onset of testing of active escape-avoidance. The following measures were calculated for 
two-way active escape-avoidance: mean motor activity during electroshock, mean % time freezing 
during ITI and CS, total escape failures, total escapes, total avoids, and escape-avoid latency. This 
test was conducted in Expt A at day 16 and in Expt B at day 32. 
3.5 Treadmill fatigue test/one-way active escape-avoidance 
To assess fatigue, mice were tested on a mouse single lane treadmill (Panlab/Harvard Apparatus, 
Cornellà, Spain) inclined at 30° and with an electroshock grid at its lower end. By running up-hill, mice 
could avoid the electroshock grid or, if they had failed to run and travelled back onto the grid, escape 
from it. A pilot experiment in non-manipulated mice demonstrated that a treadmill speed of 20 cm/sec 
was a moderate-running speed, and that 25 cm/sec was a fast-running speed that mice could maintain 
for at least 20 min. The habituation-day session consisted of 2 min at 0 cm/sec, 5 min at 15-20 cm/sec 
at 1 min increments, and 5 min at 20 cm/sec. Total number and duration of electroshocks were scored 
automatically. On test days, the schedule consisted of 2 min at 0 cm/sec, 5 min at 20 cm/sec, and 20 
min at 25 cm/sec i.e. test running speed. Measures, scored automatically, were test duration at 25 
cm/sec (maximum 20 min) and total electroshock duration (maximum 10 sec), i.e. the session was 
terminated prior to 20 min if subjects accumulated a total of 10 sec electroshock. This test was 
conducted in Expt B at days 17-18 and 29. 
3.6 Hot plate test 
To assess pain sensitivity, a hot plate test was conducted using a programmable thermoelectric 
heating plate (Teca, Chicago IL, USA) set at 50 °C, with a transparent Plexiglas chamber placed onto 
the plate (Pryce et al., 2012). Hot plate tests were conducted at 16:00-17:00 h. The mouse was 
removed from the home cage and placed inside the chamber. The latency (sec) from the onset of the 
test until the first occurrence of one of the following behaviours was scored: licking a forepaw, licking a 
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hind paw, lifting a hind paw, jumping. The mouse was then immediately removed from the hot plate. 
The maximum test duration was 60 s and 60 s was the latency score given to mice that did not exhibit 
one of the target behaviours. This test was conducted in Expt A at day 17. 
3.7 Water consumption test and saccharin preference test 
For the water consumption test, water was presented in a 15 ml Falcon™ tube (BD, Franklin Lakes, 
USA). The tube tip was cut off and the filled tube was weighed and placed on the cage grid directly 
after CSD or CON-handling (14:00-17:00 h). After 24 h the tubes were re-weighed to give daily water 
consumption (1 g = 1 ml). For CON mice, consumption was divided by 2 to give the average per 
mouse and only one value per CON pair was taken for statistical analysis. This test was conducted 
daily in Expt B at CSD days 1 to 10. 
For the saccharin preference test, the same modified tubes as for the water consumption test 
were used. Depending on test day, the saccharin (saccharin sodium salt hydrate, Sigma-Aldrich, St. 
Louis, USA) concentration used was 0.15 % or 0.5 % in water (w/v). One saccharin and one water 
tube were placed adjacently on the cage grid from 08:00 to 16:00 h (CSD session started at 16:15 h 
on this day). Percent saccharin preference was calculated as (Δ saccharin mass/(Δ saccharin mass + 
Δ water mass)) x 100. The left-right location of the two tubes was counter-balanced within CSD and 
CON groups. This test was conducted in Expt B at CSD days11 and 16. 
3.8 Blood, brain, spleen and adrenal collection 
For blood factor (Expt A) and fresh-fixed brain (Expt C) studies, mice were decapitated and trunk 
blood was collected in EDTA-coated tubes (Microvette 500 K3E, Sarstedt) and placed on ice. The 
brain was removed, rinsed with ice-cold saline, frozen on dry ice and stored at -80° C. Bloods were 
centrifuged at 3000 rpm and 4° C for 10 min, plasma aliquots transferred to cryotubes (Protein LoBind, 
Eppendorf) and stored at -80° C. Adrenal glands and spleen were removed, cleaned of fat and 
connective tissue and weighed. 
3.9 Plasma cytokine measurement 
Plasma titres of the pro-inflammatory cytokines TNF and IL-6 were measured using a multiplexed 
particle-based flow cytometric cytokine assay (Marques-Vidal et al., 2011). Lower limits of detection for 
TNF and IL-6 were 0.5 pg/mL. 
3.10 Corticosterone measurement 
Plasma CORT concentrations were measured using an EIA kit (AssayMax CORT ELISA kit; 
AssayPro, Saint Charles, MO, USA). Plasma was diluted 1:50 in ELISA diluent and heated at 90° C 
for 10 min for transcortin denaturation (Pryce et al., 2001). All further steps were performed according 
to the manufacturer’s protocol. Faecal samples were dried and powdered, 20-50 mg were extracted in 
80% methanol (Palme et al., 2013). After centrifugation supernatants were stored at -20°C and 
transferred to Vienna. Faecal CORT metabolites were measured using an in-house 5-pregnane-
3ß,11ß,21-triol-20-one EIA (Touma et al., 2003), to provide a non-invasive correlate of basal 
concentrations of blood CORT. 
2 - Mouse psychosocial model of depression 
35 
 
3.11 Brain region-specific transcriptome expression 
Frozen brains were sectioned coronally at 1 mm intervals using a stainless-steel brain matrix (model 
MMCS-1, Plastics One) and single-edge blades (model 10-100-063, Apollo Herkenrath, Solingen, 
Germany). Regions of interest (ROIs), namely ventral HIPP (vHIPP), AMYG and medial PFC (mPFC; 
infralimbic cortex + ventral prelimbic cortex) were micro-dissected bilaterally from the corresponding 
sections using a brain punch ( = 1 mm, model 57397, Stoelting Europe) and a mouse brain atlas 
(Franklin and Paxinos, 2008): mPFC (1 biopsy/hemisphere) at Bregma 2.1 to 1.2 ± 0.2 mm; AMYG (1 
biopsy/hemisphere) at Bregma -0.7 to -1.7 ± 0.3 mm; vHIPP (2 biopsies/hemisphere) at Bregma -2.8 
to -3.9 ± 0.3 mm. Tissue mass was 0.6-0.8 mg per biopsy. All microdissection steps were conducted 
at -18 °C. Brain biopsies were stored in 1.5 ml Protein LoBind polypropylene tubes (Eppendorf, model 
0030 108.116) at -80 °C. 
For RNA isolation, samples were homogenized in 400 µl 1%-ß-mercaptoethanol-RLT-buffer, 
and total RNA was isolated from 200 µl homogenate using the RNeasy Micro Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The high quality of the RNA was determined 
using the RNA 6000 Nano kit and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA). 
Preparation of the mRNA sequencing library for each sample was conducted using 200 ng of total 
RNA in the TrueSeq RNA Sample Preparation Kit v2-Set B (RS-122-2002, Illumina Inc, San Diego, 
USA); this yielded fragments of an average size of 275 bp including the adapters with their library-
specific indices supplied by the manufacturer. Concentration of the libraries was normalized and eight 
libraries were multiplexed and clustered on the cBot Instrument (Illumina Inc) using the TruSeq SR 
Cluster Kit v3 - cBot – HS (GD-401-3001, Illumina Inc). Sequencing was performed with single reads 
of 52 bp using the TruSeq SBS Kit HS - v3 (FC-401-3002, Illumina Inc) on an Illumina HiSeq2000 
instrument. Read alignment of the RNA-seq dataset was performed using STAR aligner software 
(Dobin et al., 2013). Gene expression analysis was conducted using Cufflinks software with differential 
expression of genes in CSD versus CON mice identified using the Cuffdiff 2 test (Trapnell et al., 2013). 
Briefly, the Cuffdiff 2 test assesses between-group log-fold change in gene expression against the null 
hypothesis of no change whilst controlling for false discovery rate (FDR) using the Benjamini-
Hochberg correction for multiple-testing. The criteria used to identify CSD-CON differential gene 
expression were reads per kilo base per million (RPKM) > 5, fold change > 1.4, and q < 0.05. Within 
and between the three regions of interest, those genes that met these criteria for significantly 
increased or decreased differential expression in CSD versus CON mice were investigated in terms of 
canonical pathways and upstream regulator networks, using Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems, Redwood City, USA). 
3.12 Statistical analysis 
Statistical analysis of CSD effects on behaviour and physiology was conducted using SPSS (version 
20, SPSS Inc., Chicago IL, USA). In most cases ANOVA was used, with a between-subject factor of 
group (CSD, CON) and, depending on parameter, a within-subject factor of CSD day block (e.g. body 
weight (BW), water consumption). Post hoc testing was conducted using the Bonferroni correction for 
multiple comparisons. In cases where there was a non-normal distribution of data i.e. IL-6 plasma 
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concentrations, the Mann-Whitney U test was used. Statistical significance was set at p < 0.05. Where 
an estimate of variance is given this is the standard deviation (SD). 
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4. RESULTS 
4.1 Repeated measures of physical and behavioural status 
The mean duration of CSD attacks per C57BL/6 mouse was 473, 444 and 465 sec in experiments 
A, B and C, respectively. Body weight (BW) was taken daily: there was no effect of CSD on absolute 
BW (Fig. 2A), whereas day-to-day BW delta (BW) was increased in CSD relative to CON mice (F(1, 
25) = 8.0, p < 0.009): this was the case at CSD days 2-6 and 7-11 (Fig. 2B and Fig. S1A, S1B and 
S1E, S1F). For basal motor activity in a neutral environment, there was a significant group x time-
block interaction (F(2, 42) = 5.8, p < 0.006): post hoc analysis indicated no CSD effect at day -1 and 
significantly decreased motor activity in CSD versus CON mice at days 7 and 13 (Fig. 2D). Water 
consumption measured at days 2-6 and 6-10 was increased in CSD mice (F(1, 16) = 7.5, p < 0.02; 
Fig. 2C). For saccharin preference in a two-bottle test conducted at days 11 and 16, there was no 
CSD effect (p = 0.07): preference score for CSD mice was 95.93.0 % and that of CON mice 97.91.5 
% (Fig. S1C). Basal concentrations of the major faecal CORT metabolite, measured as a non-invasive 
biomarker of plasma CORT levels, did not differ between CSD and CON mice in faecal samples 
collected at days -1, 7 and 13 (p = 0.78, Fig. S1D). 
 
Figure 2: Effects of chronic social defeat on repeated physical and behavioural measures. (A) 
Absolute body weight at 14:00 h (Expt. A, CON = 13 (open circles), CSD = 14 (filled circles)). (B) 
Percent day-to-day body weight delta (Expt. A, abs(BW day n – BW day n-1))/(BW day n-1)*100). (C) 
24-h water consumption (Expt. B, CON = 10, CSD = 13). (D) Motor activity in neutral arena (Expt. B). 
Values are mean +/- SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0005. 
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4.2 Contextual fear conditioning and pain sensitivity 
Short-term effects of CSD (Expt A, Fig. 1) were tested in terms of psychomotor activity at day 14 and 
contextual fear conditioning at day 15. CSD mice exhibited decreased psychomotor activity: CSD 
39611489 a.u./min, CON 60932272 a.u./min (t = 2.905, df = 25, p < 0.008). In the same test, CSD 
and CON mice spent a similar and low % time freezing (p = 0.55, Fig 3A). In the test of contextual fear 
conditioning, CSD mice exhibited an increased % time freezing relative to CON mice (t = -4.914, df = 
25, p < 0.0005, Fig 3A). In the study of long-term effects of CSD (Expt B, Fig. 1), there was no effect of 
CSD on activity in the psychomotor motor activity test at day 30: CSD 33811625 a.u./min, CON 
46821998 a.u./min (p = 0.10). In the same test, CSD and CON mice spent a similar and low % time 
freezing (p = 0.06, Fig. 3B). In the contextual fear conditioning test at day 31, CSD mice exhibited an 
increased % time freezing relative to CON mice (t = -4.022, df = 21, p < 0.001, Fig 3B).  
 In terms of pain sensitivity measures, there was no short-term effect of CSD on motor 
reactivity to the electroshock in the contextual fear conditioning test (p = 0.13, Fig. 3C), and also no 
effect in the hot plate test at day 17 (t = 1.356, df = 25, p = 0.19, Fig. 3D). In the study of long-term 
effects, in addition to the increased contextual freezing at day 31, CSD mice exhibited decreased 
motor reactivity to the electroshock (t = 4.272, df = 21, p < 0.0005, Fig. 3E). 
 
Figure 3: Short- and long-term effects of chronic social defeat on baseline and conditioned freezing. 
(A) Short-term (Expt. A, CON  = 13 (open circles), CSD = 14 (filled circles)) CSD effect on % time 
freezing in the motor activity test (MA, day 14) and during inter-trial intervals (ITIs) in the contextual 
fear conditioning test (FC, day 15). (B) Long-term (Expt. B, CON = 10 (open circles), CSD = 13 (filled 
circles)) CSD effect on % time freezing in MA (day 30) and ITIs of FC (day 31). Short-term CSD 
effects on (C) motor reactivity to electroshock (E-shock) in FC, and (D) pain response latency in the 
hot plate test (day 17). (E) Long-term CSD effect on motor reactivity to E-shock in FC. * p < 0.05, ** p 
< 0.01, *** p < 0.001, **** p < 0.0005. 
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4.3 Two-way active escape-avoidance/Aversive stimulus control 
On the day following contextual fear conditioning, a two-way active avoidance test was conducted. 
The arena was the same as for contextual fear conditioning with the addition of a central divider and 
gate. The electroshock (5 sec) was now escapable by transferring through the gate; it was preceded 
by a tone CS (10 sec), and transferring through the gate during the CS terminated it and resulted in 
avoidance of the electroshock. Measures were % time freezing during ITIs and CSs, avoids i.e. 
compartment transfer during the CS, electroshock escapes, avoid-escape failures, avoid-escape 
latency (maximum 15 sec), and motor reactivity to electroshock. In the study of short-term effects, at 
day 16 CSD mice exhibited increased % time freezing relative to CON mice during ITIs (t = -4.738, df 
= 24, p < 0.0005, Fig. 4A) and during CSs (t = -3.728, df = 24, p < 0.001, Fig 4A). There was no 
significant effect of CSD on avoid-escape failures (p = 0.38, Fig. 4B) or avoids (p = 0.14, Fig. 4C). 
When mice were categorized according to whether they made ≤ 4 or ≥ 5 avoids, a higher proportion of 
CSD than CON mice exhibited ≤ 4 avoids (χ
2 
(1, N=27) = 4.74, p < 0.03, Fig. 4D). CSD and CON mice 
exhibited similar motor reactivity to the electroshock (p = 1.00, Fig. S2A). In the study of long-term 
effects, at day 32 there was no effect of CSD on % time freezing during either ITIs (p = 0.62, Fig 4E) 
or CSs (p = 0.22, Fig 4E). CSD mice exhibited more avoid-escape failures than did CON mice (t = -
3.168, df = 21, p < 0.005, Fig. 4F). There was no significant effect of CSD on avoids (t = 1.393, df = 
21, p < 0.178, Fig. 4G), but CSD mice exhibited less escapes than CON mice (t = 2.999, df = 21, p < 
0.007, Fig. 4H). CSD mice exhibited decreased motor reactivity to the electroshock (t = 3.640, df = 21, 
p < 0.002, Fig. S2B). The avoid-escape latency was significantly greater in CSD than CON mice (t = -
2.661, df = 21, p < 0.015, Fig. S2C). 
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Figure 4 : Short- and long-term effects of chronic social defeat in two-way active escape-avoidance 
test (aversive stimulus control). Short-term (Expt A, CON = 13 (open circles), CSD = 14 (filled circles)): 
(A) Mean per mouse % time freezing during inter-trial intervals (ITI) and conditioned stimulus 
presentations (CS, 10-s tone). (B) Total escape failures. (C) Total avoid responses. (D) Frequency 
distribution of avoid responses using categories of ≤4 or ≥5 avoids. Long-term (Expt B, CON = 10 
(open circles), CSD = 13 (filled circles)): (E) Mean % time freezing during ITI and CS. (F) Total escape 
failures. (G) Total avoid responses. (H) Total escape responses. * p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0005. 
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4.4 Treadmill fatigue 
The short- and long-term effects of CSD on treadmill behaviour were assessed. At treadmill 
habituation on day 17, there was no effect of CSD on total duration of electroshock received (t = -
1.180, df = 19, p = 0.25, Fig. 5A). At treadmill test on day 18, test running time achieved was 
decreased in CSD mice relative to CON mice (t = 4.900, df = 21, p < 0.0005, Fig. 5B) and total 
duration of electroshock received was significantly increased (t = -3.631, df = 21, p < 0.002, Fig. 5C). 
These CSD effects were observed again in the same mice in the treadmill test at day 29: test running 
time achieved was reduced (t = 6.058, df = 21, p < 0.0005, Fig. 5D) and total electroshock duration 
increased (t = -7.420, df = 21, p < 0.0005, Fig. 5E), in CSD relative to CON mice. 
 
Figure 5: Short- and long-term effects of chronic social defeat in treadmill fatigue test (all data from 
Expt. B, CON = 10 (open circles), CSD = 13 (filled circles)). Short-term: (A) Total duration of 
electroshock (E-shock) received during habituation (day 17), (B) Test running time achieved (day 18), 
(C) Total duration of E-shock received at test (day 18). Long-term: (D) Test running time achieved (day 
29), (E) Total duration of E-shock received at test (day 29). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0005. 
4.5 Physiological status  
In the study of short-term effects, mice were euthanized at day 18. CSD led to an increase in plasma 
basal concentrations of TNF (t = -3.099, df = 25, p < 0.005, Fig. 6A) and IL-6 (U = 45.5, N = (13, 14), p 
< 0.03, Fig. 6B). Relative to CON mice, CSD mice exhibited increased spleen weight, both absolute (t 
= -4.26, df = 25, p < 0.0005, Fig S3A) and relative to BW (t = -3.66, df = 25, p < 0.001, Fig. 6C). There 
was no effect of CSD on plasma basal concentration of CORT (p = 0.60, Fig. 6D). Nonetheless, 
relative to CON mice, CSD mice exhibited increased total adrenal gland weight, both absolute (t = -
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2.76, df = 25, p < 0.01, Fig S3B) and relative to BW (t = -2.57, df = 25, p < 0.02, Fig. 6E). In the 
separate cohort of mice euthanized at day 17 for gene expression analysis, CSD induction of 
splenomegaly and adrenomegaly was again observed (Fig. S3C and D). 
 
Figure 6: Short-term effects of chronic social defeat on physiological measures (Expt. A, CON = 13 
(open circles), CSD = 14 (filled circles)). (A) Blood plasma concentration of tumor necrosis factor 
(TNF). (B) Blood plasma concentration of interleukin-6 (IL-6). (C) Spleen weight relative to body 
weight. (D) Blood plasma concentration of corticosterone. (E) Adrenal gland weight relative to body 
weight. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0005. 
4.6 Brain region-specific transcriptome expression status 
Mice were euthanized at day 17 and differential gene expression was investigated in vHIPP, AMYG 
and mPFC using next generation sequencing. In vHIPP, CSD mice exhibited significantly increased 
and decreased expression of 21 and 33 genes, respectively (Fig. 7, Tables S3 and S4). There was no 
canonical pathway that was enriched by more than one of these differentially expressed genes. 
Upstream analysis identified that each of the pro-inflammatory cytokines TNF, IL-6 and IL-3 are 
regulators of the CSD-induced differential gene expression; the specific cytokine-gene relationships 
are given in Table S1. In AMYG, CSD mice exhibited increased and decreased expression of 22 and 
48 genes, respectively (Fig. 7, Tables S3 and S4). In terms of canonical pathways, these genes were 
primarily associated with T cell receptor signalling (4 genes: Cd4 (), Jun (), Ptprc (), Shb ()), G-
protein coupled receptor signalling (5 down-regulated () genes: Drd2, Adora2a, Chrm3, Htr2a, 
Pde10e), and CCR5 signalling in macrophages (3 genes: Cd4 (), Jun (), Gng7 ()). A number of the 
genes exhibiting altered expression are dopamine (DA) binding and involved in either mediating or 
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regulating DA neurotransmission (Table 1). One of the de-regulated DA-binding genes, Slc29a4 (), 
also binds serotonin (5-HT), and the gene for the 5-HT receptor Htr2a was also de-regulated (). 
Furthermore, upstream analysis identified DA (Table 1), as well as cocaine and BDNF, as significant 
regulators of the genes exhibiting CSD-induced differential expression in AMYG. In mPFC, CSD mice 
exhibited increased and decreased expression of 6 and 14 genes, respectively (Fig. 7, Tables S3 and 
S4). As for AMYG, the canonical pathways enriched by these genes had immuno-inflammatory 
function, namely IL-12 signalling and production in macrophages, and production of nitric oxide and 
reactive oxygen species in macrophages (same 3 genes for both pathways: Apod (), Fos (), Prkcd 
()) (Fig. 7). Upstream analysis identified the NMDA receptor complex as the major regulator of the 
genes that exhibited CSD-induced differential expression in mPFC: this receptor is associated with up-
regulation of each of the genes Arc, Fos and Penk, which exhibited increased expression in CSD mice 
(Table S2). Upstream analysis also identified the NMDA antagonist ketamine as a significant up-
regulator of Arc and Fos. 
 Figure 
7: Short-term effects of chronic social defeat on gene expression assessed using next generation 
sequencing (Expt C, CON = 12, CSD = 12). (A) Venn-diagram of down- () and up-regulated () 
genes in ventral hippocampus, amygdala and medial prefrontal cortex, and the corresponding top 
canonical pathways identified using Ingenuity Pathway Analysis. Representative figures (from 
(Franklin and Paxinos, 2008)) depicting the region of analysis for (B) ventral hippocampus, (C) 
amygdala and (D) medial prefrontal cortex. 
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Table 1. Genes exhibiting altered expression in CSD versus control mice in amygdala that regulate and/or are 
regulated by dopamine neurotransmission 
Gene 
 
Up-/down- 
regulation 
Fold  
change
1
 
Regulator 
of DA 
function 
Regulate
d by DA 
function
2
 Reference 
Adora2a Adenosine A2a receptor ↓ 1.9 +     
Darpp-32  
Dopamine and cAMP regulated 
phosphoprotein 32 ↓ 1.7 + + Li et al. (2013) 
Drd2 Dopamine receptor D2 ↓ 1.8 + 
 
Boison et al. (2012) 
Gabrd 
Gamma-aminobutyric acid 
(GABA) A receptor, delta ↓ 1.6 
 
+ 
 
Gng7 
Guanine nucleotide binding 
protein, gamma 7 ↓ 1.4 + 
 
Sasaki et al. (2013) 
Gpr88 G protein-coupled receptor 88 ↓ 1.8 + 
 
Logue et al. (2009) 
Kcnk2 
Potassium channel, subfamily 
K, member 2 ↓ 1.5 
 
+ 
 Pde10a Phosphodiesterase 10A  ↓ 1.5 
 
+ 
 
Rgs9 
Regulator of G-protein signaling 
9 ↓ 2.0 + 
 
Celver et al. ( 2012) 
Tac1 Tachykinin, precursor 1 ↓ 1.9 
 
+ 
 Gpr68 G protein-coupled receptor 68 ↑ 1.4 
 
+ 
 Jun Jun proto-oncogene ↑ 1.4 
 
+ 
 
Slc29a4 
Solute carrier family 29 
(nucleoside transporters), 
member 4 ↑ 1.4 +   Engel et al. ( 2004) 
1
 q-values for fold change = 0.003 in all cases 
2
 upstream analysis conducted using Ingenuity Pathway Analysis 
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5. DISCUSSION 
In C57BL/6 mice, chronic exposure to uncontrollable psychosocial stress, an environmental 
manipulation with aetiological validity for depression, induced robust short- and long-term behavioural 
effects in the form of increased fear reactivity to a context associated with an aversive stimulus, 
decreased operant control of an aversive stimulus, and increased fatigue when required to exert effort 
to avoid an aversive stimulus. These CSD-induced behavioural states have face validity for some of 
the core psychopathologies of depression. In addition, they are relevant to the generalised 
helplessness theory of depression onset and maintenance, given that the experience of social defeat 
was generalised into altered emotional, motivational and cognitive responses to a different category of 
unconditioned aversive event, namely electroshock. Given its aetiological and face validity, it can be 
deduced that this novel depression model will also possess construct validity, i.e. to depression aetio-
pathophysiology. Accordingly, it could well be relevant to depression and to next-generation anti-
depressant neuropsychopharmacology, that CSD, in mice studied 2-3 days after the end of the 
stressor, induced: immuno-inflammation markers in terms of increased blood titres of TNF and IL-6 
and splenomegaly, in line with the hyper-activity of these systems in depression; cortico-limbic de-
regulation of expression levels of genes important in immuno-inflammation pathways; and cortico-
limbic de-regulation of expression levels of genes important in DA, adenosine, 5-HT and glutamate 
neurotransmission. 
The insightful first development of the CSD manipulation used C57BL/6 mice as both 
aggressors and subjects and was carried out for 20 days (Kudryavtseva et al., 1991). The authors 
emphasized the aetiological validity of CSD for depression given that it primarily comprised chronic 
psychosocial emotional stress i.e. the chronic distal sensory stimuli associated with acute physical 
attacks were important rather than the attacks per se (Kudryavtseva et al., 1991). Their detailed 
observations revealed that daily introduction of a novel aggressor added unpredictability, and that the 
repeated displays of submissive behaviour were ineffective in reducing attacks such that defeat was 
experienced repeatedly, i.e. CSD mice experience stressor uncontrollability (Kudryavtseva et al., 
1991; Pryce et al., 2011). Subsequent modifications were to use ex-breeder CD-1 mice as aggressors 
and to reduce the duration from 20 to 10 days (Golden et al., 2011). In the present study, 15-day CSD 
was used in combination with two refinements aimed at preventing bite wounds, namely trimming of 
the incisor teeth of CD-1 mice and timing of attacks to ensure that they had a maximum duration of 60 
sec/day. The absence of physical injury that resulted from these refinements, together with the 
observation that submissive behaviour did not control aggression received, further added to the 
certainty that a psychosocial emotional stressor with aetiological validity had been achieved. 
The original behavioural effects described for CSD were decreased activity in open field and 
forced swim tests, consistent with psychomotor retardation (Avgustinovich et al., 2005; Haque et al., 
2012). Reward sensitivity, as measured using the sucrose consumption or preference tests, was 
decreased in CSD mice (Haque et al., 2012; Venzala et al., 2013). In the elevated plus maze, an 
approach-avoidance conflict anxiety test, CSD has an anxiogenic effect (Avgustinovich et al., 2005; 
Haque et al., 2012; Krishnan et al., 2007; Venzala et al., 2013). In fear conditioned freezing, CSD 
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induced increased expression of fear to context and CS (Yu et al., 2011). The same study reported 
that CSD impaired spatial working memory in a T-maze test. A major focus for the study of 
behavioural effects of CSD has been social avoidance, measured using the partition test and the 
social approach-avoidance test. In the former, relative to CON mice, CSD mice spend less time near 
the partition that separates them from a novel mouse of the same strain (Avgustinovich et al., 2005). 
The latter test consists of two sessions in an arena containing a small wire-mesh cage: in the first 
session, the subject mouse explores the arena with empty cage and in the second session with the 
cage containing a novel CD-1 mouse; CSD mice exhibit decreased time in proximity of the cage in the 
second session i.e. high social avoidance. Some studies report that CSD leads to a consistent 
increase in social avoidance relative to CON mice (Berton et al., 2006; Haque et al., 2012); other 
studies report that approximately half of the CSD mice exhibit high social avoidance (“susceptible”) 
whereas the other half resemble CON mice (“unsusceptible”/”resilient”) (Krishnan et al., 2007). It is 
noteworthy that such social avoidance tests use the same aversive stimulus for both CSD and readout 
test; that is, a stimulus-specific CSD effect is being demonstrated, and high avoidance of the stimulus 
experienced as aversive and uncontrollable can even be considered as adaptive behaviour. 
In the present study, CSD led to reduced activity in a neutral environment i.e. psychomotor 
retardation, a common symptom in depression (DSM-5, 2013; ICD-10, 1994). As indicated by the hot 
plate test, CSD did not change sensitivity to nociceptive pain. When exposed to brief, mild 
electroshocks in this environment, CSD led to potentiation of contextual fear conditioning, as indicated 
by increased freezing behaviour, in both the short- and long-term experiments. Potentiated fear 
conditioning, i.e. increased attribution of emotional valence to stimuli associated with an aversive US, 
is increased in depression (Nissen et al., 2010). This novel finding that CSD potentiates the acquisition 
of fear conditioning adds to a previous report that it also increases expression of conditioned fear (Yu 
et al., 2011). In rat, chronic mild stress led to increased acquisition and expression of contextual fear 
conditioning (Sandi et al., 2001), and we have also observed that CSD leads to increased acquisition 
and expression of freezing in CS fear conditioning (unpublished data). Both HIPP and AMYG, and 
their interaction, are essential to contextual fear conditioning (Maren et al., 2013), suggesting that CSD 
leads to potentiated aversive stimulus processing in one or both of these regions. Prior to assessing 
CSD effects on two-way active escape-avoidance, mice underwent CS-inescapable electroshock 
conditioning to ensure that they all acquired CS aversion prior to the onset of two-way active escape-
avoidance testing. In the short-term experiment, relative to CON, CSD led to no effect on escape 
failure, increased freezing during ITI and CS, and decreased avoidance; in the long-term experiment, 
CSD led to increased escape failure, decreased electroshock reactivity and no effect on avoidance or 
freezing. Decreased avoidance and increased escape failure are both indices of decreased control in 
an aversive environment, so-called helplessness. Using the same apparatus as that used here, 
repeated exposure of otherwise non-manipulated mice to inescapable electroshocks leads to a 
subsequent increase in escape failure (associated with decreased electroshock reactivity and no 
change in freezing) relative to mice that experienced the same electroshocks as escapable, i.e. 
demonstration of specific learned uncontrollability/helplessness  (Pryce et al., 2012). Triangulating the 
current findings with the evidence that mice are sensitive to (un)controllability leads to the conclusion 
that, in mice, emotional psychosocial stress induces a state of generalised 
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uncontrollability/helplessness relative to aversive events. Potential explanations of the findings that the 
expressions of generalised helplessness differed in the short-term (decreased avoids, increased 
freezing) and long-term (increased escape failures, decreased electroshock reactivity) include 
increased accumulation of the neurobiological changes induced by CSD in the long-term experiment, 
and the methodological difference that treadmill tests preceded the two-way active escape-avoidance 
test in the long-term experiment. As noted above, generalised learned helplessness (LH) is a major 
theory for both onset and maintenance of depression (Abramson et al., 1978; Pryce et al., 2011). The 
proposed mediating processes are increased emotionality (cf. increased freezing in CSD mice), 
decreased motivation (cf. decreased electroshock reactivity in CSD mice and specific-LH mice (Pryce 
et al., 2012)), and decreased cognitive expectancy of operant control (cf. decreased avoids or escapes 
in CSD mice and specific-LH mice). There are rodent and human evidences that (un)controllability, 
involving integration of emotional and cognitive information, is processed by the prefrontal cortex, 
specifically prelimbic and infralimbic cortices in rodent and anterior cingulate cortex in human 
(reviewed in Pryce et al., 2011). Learned helplessness has been associated with increased activity in 
mPFC inhibitory GABA interneurons, modulated by increased signalling in the 5-HT-protein kinase C 
(PKC) pathway (Amat et al., 2005). In the specific LH paradigm (Pryce et al., 2012), DA depletion in 
nucleus accumbens increases specific LH whereas amphetamine reverses it, with both effects 
mediated primarily via the motivational psychomotor reactivity to electroshock (unpublished data). 
  Fatigue is a core symptom of depression (DSM-5, 2013; ICD-10, 1994). It is a multi-faceted 
pathology with components including psychomotor retardation, physical tiredness and mental fatigue 
(Demyttenaere et al., 2005), and is also likely to contribute to the deficient effortful goal-directed 
behaviour that is important in depression. Whilst fatigue is a core symptom of depression and although 
effortful-running fatigue has been studied in mice in the context of exercise physiology, to our 
knowledge this is the first report of an animal model of psychosocial stress-induced fatigue. The deficit 
that CSD induced in mouse running to avoid or escape electroshock was specific to the relatively fast 
treadmill speed, that is, to effortful conditions. Nucleus accumbens DA depletion induces a similar 
deficit to that of CSD (unpublished data). Whereas the focus of this study was the effects of CSD on 
processing of aversive events, one test of reward processing was also studied, namely the two-bottle 
saccharin preference test, and there was no effect of CSD. This is in contrast to previous studies that 
report decreased sweet-reward preference in CSD mice (see above). One potential explanation for the 
absence of effect on saccharin preference is that CSD induced polydypsia and the increase in overall 
fluid intake might have masked any moderate effects on reward sensitivity. Future studies will use 
operant tests to investigate CSD effects on reward-directed behaviour under effortful conditions e.g. 
using a progressive ratio schedule of reinforcement (Pryce et al., 2004). 
In terms of physiology, CSD did not impact on absolute BW but led to increased day-to-day 
change in BW. Previous studies report that CSD increases (Bartolomucci et al., 2009), decreases 
(Kudryavtseva et al., 1991) or has no effect on (Savignac et al., 2011) absolute BW. Both decreased 
and increased absolute BW are diagnostic symptoms of depression (DSM-5, 2013; ICD-10, 1994); 
increased BW variability has been associated with high negative affect and low self-esteem (Foreyt et 
al., 1995; Serdar et al., 2011). Mice that experienced CSD exhibited increased plasma levels of the 
pro-inflammatory cytokines TNF and IL-6 and splenomegaly, indicating chronic activation of the 
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peripheral immuno-inflammatory system. Given that the CSD protocol was refined to prevent physical 
injury, this activation of immuno-inflammatory status can be attributed unequivocally to psychosocial 
emotional stress. In humans, psychosocial stress causes increased blood levels of pro-inflammatory 
cytokines and transcription factors (Bierhaus et al., 2003; Kiecolt-Glaser et al., 2005; McDade et al., 
2006), and meta-analysis has identified that blood levels of TNF and IL-6 are increased in depression 
(Dowlati et al., 2010). A previous study in CSD mice also reports that it induces splenomegaly 
(Bartolomucci et al., 2004). In the present study CSD also led to adrenomegaly, in the absence of 
changes in basal CORT levels as assessed by plasma total CORT and faecal CORT metabolites. 
Previous studies of CSD effects on basal plasma CORT report either an increase (Perez-Tejada et al., 
2013) or no change (Krishnan et al., 2007); both studies report an increased CORT stress response in 
CSD mice. In depression, 40-60% of patients exhibit increased basal cortisol levels relative to healthy 
probands (Parker et al., 2003). The absence of increased basal CORT in the present study indicates 
that pro-inflammatory activation was not counteracted by increased anti-inflammatory CORT activity in 
CSD mice (Rhen and Cidlowski, 2005). 
Short-term effects of CSD on region of interest gene expression were measured using next-
generation sequencing technology in mice that were naïve to behavioural testing, thereby allowing for 
the study of CSD-induced gene de-regulation per se. As described above, the ROIs, namely vHIPP, 
AMYG and mPFC, are integral to the circuitry underlying the depression-relevant behavioural 
processes studied here. In vHIPP, CSD led to de-regulation of 54 genes (33  and 21 ); using 
Ingenuity Pathway Analysis (IPA) upstream analysis, 11 of these genes were identified as having one 
or more of the pro-inflammatory cytokines TNF, IL-6 and IL-3 among their major regulators; the former 
two were increased in plasma of a different cohort of CSD mice. The up-regulated genes included the 
TNF-receptor superfamily gene Tnfrsf25, which stimulates NF- and cell apoptosis. In AMYG, CSD 
led to de-regulation of 70 genes (48  and 22 ). Two of the three top canonical pathways enriched by 
these genes, as identified by IPA, were T cell receptor signalling and CCR5 signalling in 
macrophages, again indicating that CSD triggered changes in immuno-inflammation transcription 
processes in limbic regions of the mouse CNS. In the former pathway, Ptprc, an essential regulator of 
cytokine signalling, was up-regulated in CSD mice; in the latter pathway, shb, an inhibitory regulator of 
T cell receptor, was down-regulated in CSD mice, consistent with disinhibition of T cell signalling 
(Gustafsson et al., 2011). Another CSD-AMYG down-regulated gene in the CCR5 pathway was Gng7: 
Gng7 is coupled to DA 1 receptor and mice deficient in Gng7 exhibit down-regulation of DA 2 receptor 
(D2R) (Sasaki et al., 2013). In mPFC, CSD led to de-regulation of 20 genes (14  and 6 ). Again, the 
top canonical pathways enriched by these genes were immuno-inflammation pathways: IL-12 
signalling and production of macrophages, and production of nitric oxide and reactive oxygen species 
in macrophages. One of the up-regulated genes in mPFC of CSD mice was Prkcd: Prkcd has been 
identified as a major mediator of TNF-induced degeneration of DA neurons (Gordon et al., 2012). 
Several recent human studies have reported increased expression of immuno-inflammation genes in 
depressed relative to healthy-control probands. These include a genome-wide expression study of 
peripheral blood mononuclear cells that identified increased TNF expression in depressed patients, 
who also displayed relatively high hemodynamic responses to sad versus happy faces in HIPP, 
AMYG, and mPFC (Savitz et al., 2013). A post mortem brain tissue microarray study reported 
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increased expression of genes belonging to pro-inflammatory and anti-inflammatory cytokine 
pathways in mPFC of depressed relative to healthy-control subjects (Shelton et al., 2011). Therefore, 
both peripheral biomarkers and central gene expression indicate that the refined CSD impacted on 
immuno-inflammation processes. As noted above, psychosocial stress is a potent activator of 
peripheral inflammation (Bierhaus et al., 2003; Pace et al., 2006) and several mechanisms have been 
either demonstrated or proposed to account for peripheral-to-central activation of immuno-
inflammation in glial cells leading to altered neuronal functioning, including: cytokine passage and 
active transport through the blood-brain barrier, activation of endothelial cells and macrophages lining 
the cerebral vasculature, and passage of tryptophan catabolites to the brain (Dantzer et al., 2008; 
Miller et al., 2009). Furthermore, the impact of immuno-inflammation on monoamine 
neurotransmission – both DA and 5-HT - has been proposed as a major aetio-pathophysiological 
pathway for depression (Felger and Miller, 2012; Haroon et al., 2012). 
With respect to genes that were de-regulated by CSD and are candidates for direct causal 
involvement in the depression-relevant behavioural states identified in CSD mice, it is important that 
for AMYG a number of these genes express proteins that are either mediators or regulators of DA 
function; specifically, Drd2, Adora2a, Gpr88, Darpp-32, Rgs9, Slc29a4 and, as discussed above, Gng7 
(as well as Prkcd in mPFC). Dopamine is released into the basolateral (BLA) and central (CeA) AMYG 
in the presence of emotional stimuli, and both regions express non-overlapping populations of D1 and 
D2 receptors, primarily on glutamate projection neurons in BLA and GABA neurons in CeA (Perez de 
la Mora et al., 2012). D2 receptor expression is high in CeA, as it is in the inter-connected structures of 
the bed nucleus of the stria terminalis and nucleus accumbens (central extended AMYG) and the 
dorsal striatum-external pallidum (Alheid and Heimer, 1988). Systemic injection of a D2R antagonist 
decreased two-way active avoidance in rat (Reis et al., 2004) and injection into CeA increased fear in 
rat (de la Mora et al., 2010); these findings provide supportive evidence that decreased Drd2 
contributed to the increased freezing and decreased active avoidance observed in CSD mice. D2R 
interacts antagonistically with the adenosine receptor A2AR by forming heteromers (Boison et al., 
2012). Given that both Drd2 and Adora2a expression was decreased in CSD mice it is difficult to 
predict the functional consequences. Nonetheless, it is noteworthy that striatum-specific A2AR 
knockout mice exhibited hypo-activity and deficient two-way active avoidance (Singer et al., 2013), as 
observed here in CSD mice. Adora2a and Gpr88 both exhibit enriched expression in the central 
extended AMYG and dorsal striatum (Becker et al., 2008); accordingly, the decreased expression 
observed in CSD relative to CON mice might well have occurred primarily in the CeA, indicating that 
future studies should extend analysis of CSD effects on gene expression to these striatal regions. In 
striatum, GPR88 is expressed on GABA medium spiny neurons also expressing D2R or D1R; Gpr88 
knockout mice exhibited impaired active avoidance (Quintana et al., 2012), as observed here in CSD 
mice. Darpp-32 encodes a signalling phosphoprotein that is expressed in D2R and D1R neurons and 
is a major integrator of signals from neurotransmitters and neuromodulators targeting these neurons; 
again, it has been mainly studied in striatum but decreased expression here and, as observed in CSD 
mice, AMYG, would be expected to have important consequences for DA neuron function and 
behaviour (Bateup et al., 2010). Rgs9 encodes a protein, Rgs9-2, that modulates D2R function: Rgs9 
knockout mice exhibited increased locomotor activation in response to amphetamine, indicating that 
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Rgs9-2 normally reduces D2R signalling (Rahman et al., 2003); however, in such mice there was no 
change in D2R levels, whereas in CSD mice the decrease in Rgs9 might constitute a response to 
decreased D2R levels. Slc29a4 encodes a protein that is expressed presynaptically by monoamine 
neurons and catalyses monoamine reuptake, and is moderately expressed in AMYG of mouse (Dahlin 
et al., 2007). Slc29a4 was up-regulated in the AMYG of CSD mice such that they would be expected 
to exhibit reduced DA and 5-HT levels in the synaptic cleft relative to CON mice. Combining the 
current transcriptional evidence for decreased AMYG D2R function in CSD mice with the growing 
evidence that striatal D2R enhances motivation (Trifilieff et al., 2013), then this valid CSD model can 
be utilized to increase understanding of D2R-motivation mechanisms, in terms of the motivation to 
both exhibit behaviour that leads to relief from punishment and that leads to wanting and liking reward. 
Also with regards to the increased fatigue demonstrated in CSD mice, theory and evidence supports 
de-regulated DA-striatal functioning as a major underlying neuropathology (Capuron et al., 2007; 
Demyttenaere et al., 2005). The relevance of this model is further indicated by the human evidence 
that a polymorphism in D2R associated with reduced D2R density, particularly in dorsal striatum, 
increased risk of depression (Zou et al., 2012). 
 In summary, this mouse model for psychosocial stress induced hyper-reactivity to aversive 
events exhibits levels of both aetiological and face validity that are unusually high, and accordingly it 
constitutes a major step forward in the research field of animal models of depression. The subsequent 
identification of physiological and cortico-limbic transcriptome-expression characteristics of the model 
has put focus on stress-immuno-inflammation-dopamine dysfunction as an aetio-pathophysiological 
pathway and as a target for novel mechanisms of anti-depressant action. 
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7. SUPPLEMENTAL DATA OF CHAPTER 2 
 
Figure S1: Effects of chronic social defeat on repeated physical measures. Expt. B (CON = 10 (open 
circles), CSD = 13 (filled circles)): (A) Absolute body weight. (B) Percent day-to-day body weight delta 
(abs(BW day n – BW day n-1))/(BW day n-1)*100. (C) Percent saccharin preference at 0.15 % (day 
11) and 0.5 % (day 16). (D) Faecal corticosterone metabolite concentrations. Expt. C (CON = 12, 
CSD = 12): (E) Absolute body weight. (F) Percent day-to-day body weight delta. Values are means +/- 
SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0005. 
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Figure S2: Short- and long-term effects of chronic social defeat in two-way active escape-avoidance 
test. Short-term (Expt A, CON = 13 (open circles), CSD = 14 (filled circles)): (A) Mean motor reactivity 
to escapable electroshock. Long-term (Expt B, CON = 10 (open circles), CSD = 13 (filled circles)): (B) 
Mean motor reactivity to escapable electroshock. (C) Mean latency to exhibit an avoid-escape 
response. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0005. 
 
Figure S3: Short-term effects of chronic social defeat on physiological measures. Expt. A (CON = 13 
(open circles), CSD = 14 (filled circles)): (A) Absolute spleen weight. (B) Absolute weight of adrenal 
glands. Expt. C (CON = 12 (open circles), CSD = 12 (filled circles)): (C) Spleen weight relative to body 
weight. (D) Adrenal gland weight relative to body weight. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0005. 
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Table S1. Cytokine-regulated genes exhibiting altered expression in CSD versus control mice in 
ventral hippocampus 
Gene 
 
Up-/down- 
regulation 
Fold  
change
1
 
Upstream 
cytokine
2
 
Ace Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 ↑ 1.6 TNF 
Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 ↑ 1.9 IL6, TNF 
Igf2 Insulin-like growth factor 2 (somatomedin A) ↑ 1.6 IL6, TNF 
Kl Klotho ↑ 1.7 TNF 
Prox1 Prospero homeobox 1 ↑ 1.4 IL3 
Tnfrsf25 Tumor necrosis factor receptor superfamily, member 25 ↑ 1.7 IL6 
Ar Androgen receptor ↓ 1.4 TNF 
Dcn Decorin ↓ 1.7 IL6 
Egr1 Early growth response 1 ↓ 1.6 IL6, TNF, IL3 
Nov Nephroblastoma overexpressed ↓ 1.7 TNF, IL3 
1
 q-values for fold change = 0.005 in all cases 
2
 upstream analysis conducted using Ingenuity Pathway Analysis 
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Table S2. NMDA receptor-regulated genes exhibiting altered expression in CSD versus control mice 
in medial prefrontal cortex 
Gene 
 
Up-/down- 
regulation 
Fold  
change q-value Reference
1
 
Arc 
Activity-regulated cytoskeleton-associated 
protein ↑ 1.5 0.0126 Link et al. (1995) 
Fos 
FBJ murine osteosarcoma viral oncogene 
homolog ↑ 1.4 0.0469 Leveque et al. (2000) 
Penk Proenkephalin ↑ 1.7 0.0126 Leveque et al. (2000) 
1
 upstream analysis conducted using Ingenuity Pathway Analysis 
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Table S3. Genes exhibiting up-regulated expression in CSD versus control mice in ventral 
hippocampus (vHIPP), amygdala (AMYG) and medial prefrontal cortex (mPFC) 
Brain region Gene ID Gene 
RPKM 
control 
RPKM 
CSD 
Fold  
change q-value 
AMYG/mPFC 
mPFC ENSMUSG00000022602 Arc 14.961 22.587 1.5 0.0126 
AMY ENSMUSG00000022602 Arc 17.472 24.853 1.4 0.0030 
AMYG/vHIPP 
AMY ENSMUSG00000050822 Slc29a4 4.429 6.282 1.4 0.0030 
vHIPP ENSMUSG00000050822 Slc29a4 9.567 14.122 1.5 0.0053 
AMYG AMYG ENSMUSG00000048218 Amigo2 4.099 7.621 1.9 0.0030 
AMYG AMYG ENSMUSG00000025128 Bhlhe22 18.400 28.965 1.6 0.0030 
AMYG AMYG ENSMUSG00000067578 Cbln4 6.494 9.973 1.5 0.0030 
AMYG AMYG ENSMUSG00000019929 Dcn 3.786 8.339 2.2 0.0030 
AMYG AMYG ENSMUSG00000047415 Gpr68 5.057 7.206 1.4 0.0155 
AMYG AMYG ENSMUSG00000052684 Jun 25.926 36.914 1.4 0.0030 
AMYG AMYG ENSMUSG00000046523 Kctd4 18.093 28.197 1.6 0.0030 
AMYG AMYG ENSMUSG00000026344 Lypd1 257.074 375.206 1.5 0.0120 
AMYG AMYG ENSMUSG00000067786 Nnat 254.146 364.756 1.4 0.0030 
AMYG AMYG ENSMUSG00000030551 Nr2f2 32.036 45.592 1.4 0.0030 
AMYG AMYG ENSMUSG00000050505 Pcdh20 8.131 11.709 1.4 0.0030 
AMYG AMYG ENSMUSG00000092035 Peg10 15.679 21.241 1.5 0.0030 
AMYG AMYG ENSMUSG00000068744 Psrc1 6.309 9.971 1.6 0.0030 
AMYG AMYG ENSMUSG00000026395 Ptprc 4.378 6.616 1.5 0.0030 
AMYG AMYG ENSMUSG00000029641 Rasl11a 5.674 8.425 1.5 0.0030 
AMYG AMYG ENSMUSG00000030259 Rassf8 5.431 8.282 1.5 0.0030 
AMYG AMYG ENSMUSG00000039087 Rreb1 7.629 11.544 1.5 0.0030 
AMYG AMYG ENSMUSG00000028360 Slc44a5 4.950 7.657 1.5 0.0030 
AMYG AMYG ENSMUSG00000050074 Spink8 10.131 16.526 1.6 0.0030 
AMYG AMYG ENSMUSG00000039239 Tgfb2 5.700 8.521 1.5 0.0030 
vHIPP vHIPP ENSMUSG00000026051 1500015O10Rik 3.353 8.080 2.4 0.0053 
vHIPP vHIPP ENSMUSG00000020681 Ace 4.309 6.845 1.6 0.0053 
vHIPP vHIPP ENSMUSG00000036907 C1ql2 29.315 43.955 1.5 0.0053 
vHIPP vHIPP ENSMUSG00000003657 Calb2 31.411 46.448 1.5 0.0053 
vHIPP vHIPP ENSMUSG00000025370 Cdh9 9.296 14.726 1.6 0.0053 
vHIPP vHIPP ENSMUSG00000030270 Cpne9 3.053 5.402 1.8 0.0183 
vHIPP vHIPP ENSMUSG00000022425 Enpp2 64.721 125.099 1.9 0.0053 
vHIPP vHIPP ENSMUSG00000069919 Hba-a1 6.688 9.821 1.5 0.0213 
vHIPP vHIPP ENSMUSG00000069917 Hba-a2 4.284 6.935 1.6 0.0147 
vHIPP vHIPP ENSMUSG00000052305 Hbb-b1 19.204 28.382 1.5 0.0053 
vHIPP vHIPP ENSMUSG00000048583 Igf2 18.528 30.015 1.6 0.0053 
vHIPP vHIPP ENSMUSG00000058488 Kl 5.237 8.974 1.7 0.0053 
vHIPP vHIPP ENSMUSG00000090291 Lrrc10b 18.318 25.828 1.4 0.0053 
vHIPP vHIPP ENSMUSG00000040998 Npnt 5.872 8.757 1.5 0.0053 
vHIPP vHIPP ENSMUSG00000031557 Plekha2 5.311 8.125 1.5 0.0053 
vHIPP vHIPP ENSMUSG00000035486 Plk5 5.401 8.560 1.6 0.0053 
vHIPP vHIPP ENSMUSG00000010175 Prox1 12.357 17.445 1.4 0.0053 
vHIPP vHIPP ENSMUSG00000040929 Rfx3 11.507 16.908 1.5 0.0053 
vHIPP vHIPP ENSMUSG00000023886 Smoc2 11.647 16.504 1.4 0.0053 
vHIPP vHIPP ENSMUSG00000024793 Tnfrsf25 4.713 8.042 1.7 0.0053 
mPFC mPFC ENSMUSG00000021250 Fos 4.570 6.409 1.4 0.0469 
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mPFC mPFC ENSMUSG00000059991 Nptx2 12.092 19.531 1.6 0.0126 
mPFC mPFC ENSMUSG00000045573 Penk 21.351 36.508 1.7 0.0126 
mPFC mPFC ENSMUSG00000021948 Prkcd 3.521 5.862 1.7 0.0126 
mPFC mPFC ENSMUSG00000046480 Scn4b 4.453 6.706 1.5 0.0126 
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Table S4. Genes exhibiting down-regulated expression in CSD versus control mice in ventral 
hippocampus (vHIPP), amygdala (AMYG) and medial prefrontal cortex (mPFC) 
Brain region Gene ID Gene 
RPKM 
control 
RPKM 
CSD 
Fold  
change q-value 
AMYG 
mPFC 
vHIPP 
mPFC ENSMUSG00000088595 5_8S_rRNA 10.753 1.972 5.45 0.0126 
AMYG ENSMUSG00000088595 5_8S_rRNA 14.137 1.664 8.50 0.0030 
vHIPP ENSMUSG00000088595 5_8S_rRNA 10.558 1.668 6.33 0.0053 
AMYG 
mPFC 
vHIPP 
mPFC ENSMUSG00000065037 7SK 7.024 2.823 2.49 0.0126 
AMYG ENSMUSG00000065037 7SK 7.155 2.801 2.55 0.0030 
vHIPP ENSMUSG00000065037 7SK 6.474 2.745 2.36 0.0053 
AMYG 
mPFC 
vHIPP 
mPFC ENSMUSG00000045999 AY036118 260.950 87.270 2.99 0.0126 
AMYG ENSMUSG00000045999 AY036118 274.707 97.491 2.82 0.0030 
vHIPP ENSMUSG00000045999 AY036118 262.753 79.583 3.30 0.0053 
AMYG 
mPFC 
vHIPP 
mPFC ENSMUSG00000035202 Lars2 71.419 38.563 1.85 0.0126 
AMYG ENSMUSG00000035202 Lars2 75.903 45.526 1.67 0.0030 
vHIPP ENSMUSG00000035202 Lars2 78.720 47.142 1.67 0.0053 
AMYG 
mPFC 
vHIPP 
mPFC ENSMUSG00000092984 Mir5115 88.290 43.319 2.04 0.0126 
AMYG ENSMUSG00000092984 Mir5115 103.499 56.274 1.84 0.0030 
vHIPP ENSMUSG00000092984 Mir5115 107.950 52.222 2.07 0.0053 
AMYG 
mPFC 
mPFC ENSMUSG00000022548 Apod 83.409 56.379 1.48 0.0126 
AMYG ENSMUSG00000022548 Apod 60.026 42.585 1.41 0.0030 
AMYG 
mPFC 
mPFC ENSMUSG00000020774 Aspa 9.687 6.722 1.44 0.0225 
AMYG ENSMUSG00000020774 Aspa 7.626 5.421 1.41 0.0079 
AMYG 
mPFC 
mPFC ENSMUSG00000027375 Mal 90.783 60.801 1.49 0.0126 
AMYG ENSMUSG00000027375 Mal 65.611 45.313 1.45 0.0030 
AMYG 
mPFC 
mPFC ENSMUSG00000032517 Mobp 254.176 171.536 1.48 0.0309 
AMYG ENSMUSG00000032517 Mobp 182.943 127.100 1.44 0.0030 
AMYG 
mPFC 
mPFC ENSMUSG00000050121 Opalin 8.313 5.399 1.54 0.0126 
AMYG ENSMUSG00000050121 Opalin 5.836 3.631 1.61 0.0030 
AMYG 
mPFC 
mPFC ENSMUSG00000015090 Ptgds 159.973 113.552 1.41 0.0126 
AMYG ENSMUSG00000015090 Ptgds 95.532 62.656 1.52 0.0030 
AMYG 
vHIPP 
AMYG ENSMUSG00000065922 n-R5-8s1 5.936 1.380 4.30 0.0030 
vHIPP ENSMUSG00000065922 n-R5-8s1 5.167 0.905 5.71 0.0053 
AMYG AMYG ENSMUSG00000084890 A830036E02Rik 12.318 8.695 1.42 0.0030 
AMYG AMYG ENSMUSG00000020178 Adora2a 39.322 21.111 1.86 0.0030 
AMYG AMYG ENSMUSG00000078958 Atp6ap1l 5.336 2.657 2.01 0.0030 
AMYG AMYG ENSMUSG00000000861 Bcl11a 19.171 13.491 1.42 0.0030 
AMYG AMYG ENSMUSG00000023274 Cd4 5.102 2.418 2.11 0.0030 
AMYG AMYG ENSMUSG00000046159 Chrm3 8.038 5.405 1.49 0.0030 
AMYG AMYG ENSMUSG00000019997 Ctgf 25.467 16.188 1.57 0.0030 
AMYG AMYG ENSMUSG00000061718 Darpp-32 237.205 141.374 1.68 0.0030 
AMYG AMYG ENSMUSG00000032259 Drd2 18.902 10.534 1.79 0.0030 
AMYG AMYG ENSMUSG00000009216 Fam163b 36.595 24.422 1.50 0.0030 
AMYG AMYG ENSMUSG00000029054 Gabrd 18.366 11.142 1.65 0.0030 
AMYG AMYG ENSMUSG00000048240 Gng7 91.722 63.788 1.44 0.0030 
AMYG AMYG ENSMUSG00000046922 Gpr6 8.224 4.088 2.01 0.0030 
AMYG AMYG ENSMUSG00000068696 Gpr88 71.788 39.949 1.80 0.0030 
AMYG AMYG ENSMUSG00000046182 Gsg1l 17.654 10.260 1.72 0.0030 
AMYG AMYG ENSMUSG00000051022 Hs3st1 9.216 6.360 1.45 0.0030 
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AMYG AMYG ENSMUSG00000034997 Htr2a 5.699 3.939 1.45 0.0030 
AMYG AMYG ENSMUSG00000037679 Inf2 32.367 21.208 1.53 0.0030 
AMYG AMYG ENSMUSG00000037624 Kcnk2 13.496 9.097 1.48 0.0030 
AMYG AMYG ENSMUSG00000090291 Lrrc10b 19.161 11.162 1.72 0.0030 
AMYG AMYG ENSMUSG00000026765 Lypd6b 7.754 4.989 1.55 0.0030 
AMYG AMYG ENSMUSG00000040258 Nxph4 5.197 3.059 1.70 0.0030 
AMYG AMYG ENSMUSG00000090223 Pcp4 325.298 217.974 1.49 0.0030 
AMYG AMYG ENSMUSG00000038370 Pcp4l1 54.503 34.383 1.59 0.0030 
AMYG AMYG ENSMUSG00000023868 Pde10a 38.252 26.137 1.54 0.0030 
AMYG AMYG ENSMUSG00000017491 Rarb 7.408 5.193 1.43 0.0030 
AMYG AMYG ENSMUSG00000032946 Rasgrp2 34.295 20.586 1.67 0.0030 
AMYG AMYG ENSMUSG00000042453 Reln 14.411 10.147 1.42 0.0138 
AMYG AMYG ENSMUSG00000020599 Rgs9 28.862 14.761 1.96 0.0030 
AMYG AMYG ENSMUSG00000046480 Scn4b 37.309 15.126 2.47 0.0030 
AMYG AMYG ENSMUSG00000052133 Sema5b 9.332 6.288 1.48 0.0030 
AMYG AMYG ENSMUSG00000044813 Shb 5.152 3.649 1.41 0.0220 
AMYG AMYG ENSMUSG00000030688 Stard10 38.296 26.358 1.45 0.0030 
AMYG AMYG ENSMUSG00000061762 Tac1 43.398 22.810 1.90 0.0030 
AMYG AMYG ENSMUSG00000071234 Tmem90a/SYNDIG1L 16.047 8.463 1.90 0.0030 
AMYG AMYG ENSMUSG00000062151 Unc13c 9.057 5.481 1.65 0.0030 
vHIPP vHIPP ENSMUSG00000097789 AC129605.1/Gm2115 28.558 19.843 1.44 0.0053 
vHIPP vHIPP ENSMUSG00000078137 Ankrd63 7.013 3.596 1.95 0.0053 
vHIPP vHIPP ENSMUSG00000046532 Ar 5.550 3.899 1.42 0.0053 
vHIPP vHIPP ENSMUSG00000017978 Cadps2 39.851 28.209 1.41 0.0053 
vHIPP vHIPP ENSMUSG00000060402 Chst8 11.340 7.636 1.49 0.0053 
vHIPP vHIPP ENSMUSG00000052560 Cpne8 9.797 6.252 1.57 0.0053 
vHIPP vHIPP ENSMUSG00000019929 Dcn 44.317 26.463 1.67 0.0053 
vHIPP vHIPP ENSMUSG00000075707 Dio3 5.241 3.039 1.72 0.0053 
vHIPP vHIPP ENSMUSG00000040856 Dlk1 5.549 3.210 1.73 0.0053 
vHIPP vHIPP ENSMUSG00000038418 Egr1 21.222 13.301 1.60 0.0053 
vHIPP vHIPP ENSMUSG00000004151 Etv1 16.751 11.922 1.41 0.0053 
vHIPP vHIPP ENSMUSG00000026841 Fibcd1 57.023 30.129 1.89 0.0053 
vHIPP vHIPP ENSMUSG00000033316 Galnt9 54.938 39.213 1.40 0.0053 
vHIPP vHIPP ENSMUSG00000040836 Gpr161 15.670 10.917 1.44 0.0053 
vHIPP vHIPP ENSMUSG00000039706 Ldb2 21.073 14.055 1.50 0.0053 
vHIPP vHIPP ENSMUSG00000038793 Lefty1 5.169 2.846 1.82 0.0053 
vHIPP vHIPP ENSMUSG00000028184 Lphn2 10.808 7.164 1.51 0.0053 
vHIPP vHIPP ENSMUSG00000003746 Man1a 17.329 12.061 1.44 0.0053 
vHIPP vHIPP ENSMUSG00000041708 Mpped1 103.821 72.814 1.43 0.0053 
vHIPP vHIPP ENSMUSG00000005125 Ndrg1 48.680 33.154 1.47 0.0053 
vHIPP vHIPP ENSMUSG00000027977 Ndst3 7.412 5.106 1.45 0.0053 
vHIPP vHIPP ENSMUSG00000037362 Nov 85.742 49.584 1.73 0.0053 
vHIPP vHIPP ENSMUSG00000075270 Pde11a 9.312 6.490 1.43 0.0053 
vHIPP vHIPP ENSMUSG00000027674 Pex5l 90.665 64.210 1.41 0.0053 
vHIPP vHIPP ENSMUSG00000090125 Pou3f1 18.616 11.094 1.68 0.0053 
vHIPP vHIPP ENSMUSG00000028909 Ptpru 25.736 15.855 1.62 0.0053 
vHIPP vHIPP ENSMUSG00000050074 Spink8 34.428 22.560 1.53 0.0053 
mPFC mPFC ENSMUSG00000013523 Bcas1 49.974 35.271 1.42 0.0126 
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mPFC mPFC ENSMUSG00000043448 Gjc2 6.617 4.660 1.42 0.0126 
mPFC mPFC ENSMUSG00000093077 Mir5105 917.167 612.185 1.50 0.0126 
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1. SUMMARY 
Interaction between the serotonin (5-HT) transporter (5-HTT) genotype and life stress events provides 
the most robust evidence to-date for gene-environment (G-E) interaction in the aetiology of 
depression. Nonetheless the evidence is controversial and the understanding of underlying 
mechanisms is scant, such that valid animal models are essential. Adult male wildtype (WT) and 
heterozygous (HET) littermates of a 5-HTT knockout (KO) mouse strain were each assigned to either 
psychosocial emotional stress as chronic social defeat (CSD) or control handling (CON), and studied 
in terms of monoamine neurochemistry, immuno-inflammation, endocrinology, and emotional 
behaviour. 5-HTT HET KO mice exhibited endophenotypes (HET-CON vs. WT-CON) of increased 
tissue levels of 5-HT and dopamine (DA) and their respective metabolites in nucleus accumbens, and 
increased basal plasma corticosterone. 5-HTT HET KO mice exhibited increased resilience to CSD: In 
WT mice, CSD induced increased basal plasma TNF levels and splenomegaly, and increased the 
acquisition of fear conditioned freezing to a discrete tone predicting electroshock. In contrast, none of 
these depression-relevant state markers were exhibited by HET-CSD relative to HET-CON mice. That 
endophenotypes of increased central 5-HT and DA activity are associated with absence of stress-
induced emotional hyper-reactivity is consistent with the monoamine hypothesis of depression. That 
increased basal corticosterone and absence of stress-induced immuno-inflammation are associated 
with absence of emotional hyper-reactivity is consistent with the inflammation hypothesis of 
depression. Furthermore, these different HET-dependent pathways could be inter-dependent. The 
present G-E mouse model provides both translational support for the growing human evidence that 
decreased 5-HTT function increases stress resilience in adulthood, and a system with which to identify 
the responsible mechanisms and therefore targets for novel anti-depressant treatments. 
3 – Psychosocial stress on a genetic mouse model 
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2. INTRODUCTION 
Two major hypotheses of depression aetio-pathophysiology are the serotonin (5-HT) deficiency 
hypothesis (Ruhe et al., 2007; Sharp and Cowen, 2011) and the pro-inflammatory cytokine hypothesis 
(Dantzer et al., 2008; Maes et al., 2009; Miller et al., 2009). The 5-HT deficiency hypothesis is based 
largely on the serendipitous discovery of antidepressant drugs that act on 5-HT neurotransmission, 
including current-generation selective 5-HT reuptake inhibitors (SSRIs), as well as physiological 
biomarkers including low blood levels of the 5-HT precursor tryptophan and low cerebrospinal fluid 
levels of 5-HT metabolites (Saveanu and Nemeroff, 2012; Sharp and Cowen, 2011). The cytokine 
hypothesis is based on association of depression with increased plasma levels of pro-inflammatory 
cytokines including tumor necrosis factor (TNF) and interleukin-6 (IL-6), high co-morbidity with 
autoimmune disorders, depression remission when autoimmune patients and depressed patients are 
treated with anti-inflammatory medication, high depression risk in patients of disorders requiring 
cytokine treatment, cytokine-gene polymorphisms as risk factors for depression, and up-regulation of 
cytokine genes in the brain in depression (Dantzer et al., 2008; Dantzer et al., 2011; Maes et al., 2009; 
Miller et al., 2009; Raison et al., 2013). Further to these two hypotheses of depression aetio-
pathophysiology, there are several important lines of evidence inter-linking them, including increased 
pro-inflammatory cytokine levels leading to reduced 5-HT synthesis (Dantzer, 2009; Maes et al., 
2011), and 5-HT suppression of pro-inflammatory cytokines and 5-HT stimulation of splenic T cell 
proliferation and anti-inflammatory cytokine synthesis (Kubera et al., 2000; Kubera et al., 2005). 
Intriguingly, it has also recently been proposed that increased cytokine release is essential to SSRI 
mechanism of action/efficacy, in direct contradiction to the cytokine hypothesis (Hernandez et al., 
2013; Warner-Schmidt et al., 2011). 
 There exists a major paradox in the link between 5-HT and depression: whereas blocking the 
5-HT transporter (5-HTT) is the basis of SSRI antidepressant action (Cowen, 2008), a 5-HTT gene 
polymorphism – namely the “short” (S) deletion versus “long” (L) insertion at the 5-HTT-linked 
polymorphic region (5-HTTLPR) - that, similar to SSRIs, reduces 5-HT reuptake (Murphy and Lesch, 
2008), is currently the best-described genetic risk factor for depression (Lesch and Mossner, 1998). 
The S allele of the 5-HTT gene is associated with personality endophenotypes including anxiety and 
neuroticism (Lesch et al., 1996). Furthermore, it is a risk factor in interaction with environmental stress 
(GxE) (Caspi et al., 2010; Caspi et al., 2003). Meta-analysis yields strong statistical support for 
association between S x early-life stress (ELS) and depression, suggesting a neurodevelopmental 
process. However, there is marginal support for association between S x adult stress (AS) and 
depression (Karg et al., 2011). Given the high likelihood that the populations included in the studies of 
AS association with depression would also have experienced a representative level of ELS, the dual 
findings of S x ELS high association and S x AS low association is actually consistent with net S x AS 
negative association. That is, the S allele and a phenotype of low 5-HT reuptake are protective against 
AS leading to depression. This integrated interpretation of the two meta-analysis findings and the 
resultant hypothesis has, to our knowledge, not been proposed previously but is certainly worthy of 
investigation. This is not least because an S x AS interaction associated with resilience to depression 
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would resolve the paradox of low 5-HTT function = depression risk factor versus SSRI = mechanism of 
antidepressant action. Indeed, there already exists some supportive evidence, including: (1) The 
increase in new onset of depression following stress in teenager years tends to be greater in LL than 
SS carriers, and this despite the increase in chronic depression following early-life stress being greater 
in SS than LL carriers (Brown et al., 2013). (2) Individuals, including those exposed to pro-
inflammatory cytokine medication, who have high 5-HT activity exhibit lower pro-inflammatory 
interleukin-6 levels and lower depression scores (Raison et al., 2009). (3) Globally, in geographical 
regions with a relatively high historical prevalence of pathogens the frequency of the S allele in the 
current population is also relatively high and the prevalence of depression is relatively low, suggesting 
that high 5-HT activity is protective against infection and depression (Chiao and Blizinsky, 2010). 
To provide a genetic mouse model of some relevance to the human S 5-HTTLPR 
polymorphism, a 5-HTT null mutant mouse strain on a C57BL/6J background was generated (Bengel 
et al., 1998). Compared to wildtype (WT) mice, heterozygous 5-HTT mutant (HET) mice have 
decreased 5-HTT expression and increased 5-HT levels in various brain regions (Bengel et al., 1998; 
Mathews et al., 2004). A number of behavioural endophenotypes of relevance to depression risk and 
resilience have been reported for HET relative to WT mice, including: increased anxiety in approach-
avoidance conflict tests (Jansen et al., 2010)and increased acquisition of learned helplessness in a 
two-way escape test (Pryce et al., 2012); but reduced sensitivity to omission of reward in an operant 
probabilistic reversal learning test (Ineichen et al., 2012). There was no evidence for a genotype effect 
on either acquisition or expression of fear conditioned freezing (Narayanan et al., 2011). 
Psychosocial stressors are aetiological factors in human depression (Kendler et al., 1999), 
and animal models of depression that incorporate psychosocial emotional stress are likely to possess 
relatively high aetiological validity ((Krishnan and Nestler, 2008) Chapter 2). Mouse chronic social 
defeat (CSD) consists of exposure of adult C57BL/6 mice to daily brief physical attacks by different 
aggressive and dominant CD-1 mice and continuous sensory exposure to these aversive conspecifics. 
Depression-relevant behavioural effects of this psychosocial emotional stress include motor 
retardation in an open field test and a forced swim test (Kudryavtseva et al., 1991), increased anxiety 
in an elevated plus maze test (Avgustinovich et al., 2005; Krishnan et al., 2007), decreased reward 
sensitivity in a sucrose preference test (Yu et al., 2011), increased social avoidance (Krishnan et al., 
2007), increased fear conditioned freezing to context, generalised helplessness, and increased fatigue 
(Chapter 2). At the physiological level, CSD induces immuno-inflammation in terms of increased 
plasma levels of pro-inflammatory cytokines and splenomegaly (Chapter 2). Centrally, CSD induces 
de-regulation of expression of genes in inflammatory pathways in the medial prefrontal cortex and 
amygdala, and in the latter it induces gene re-regulation consistent with compromised dopamine 
receptor 2 signalling (Chapter 2). 
Based on the above evidence, the aim of the present study was to utilise a 5-HTT knockout 
mouse strain to investigate the effects of a genotype of reduced 5-HTT expression on 
trait/endophenotype status and on sensitivity/resilience to CSD in terms of the following measures: 
aversive emotional processing using classical fear conditioning; stress and anti-inflammatory 
endocrinology using plasma corticosterone; immuno-inflammation using plasma pro-inflammatory 
cytokines and spleen size; and tonic levels and turnover of serotonin and dopamine in the nucleus 
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accumbens. It was hypothesized that heterozygous knockout of 5-HTT would lead to increased 
resilience of adult mice to CSD-induced activation of immune-inflammation and, related to this, 
increased resilience to CSD-induced increased classical conditioning to an aversive stimulus. 
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3. EXPERIMENTAL PROCEDURES 
3.1 Animals and maintenance 
Breeding pairs of wildtype (WT) dams and heterozygous (HET) sires yielded WT and HET offspring. 
Male offspring were weaned at age 3 weeks and caged with littermates. At age 4 weeks an ear punch 
was taken, mice were genotyped (Bengel et al., 1998) and littermates of the same genotype were 
maintained together in groups of 2-3. The study was conducted with a total of 50 mice born to 12 
breeding pairs. Mice were aged 9-12 weeks at study onset and weighed 23-30 g. The male CD-1 mice 
(Janvier, France, www.janvier-labs.com) used as aggressors in chronic social defeat (CSD) were aged 
8 months, ex-breeders, and caged singly at study onset. Mice were maintained on a reversed 12:12 h 
light-dark cycle (lights off 07:00-19:00 h) in an individually-ventilated caging system (IVC) at 20-22 °C 
and 50-60% humidity. Cages were type 2L and contained woodchips, a sleep igloo and tissue 
bedding. Complete-pellet diet (Provimi, Kliba Ltd, Kaiseraugst, Switzerland) and water were available 
continuously and ad libitum. The study was conducted under a permit (110/2009) for animal 
experimentation issued by the Veterinary Office, Zurich, Switzerland, in accordance with the Animal 
Protection Act (1978) Switzerland. All efforts were made to minimize the number of mice used and any 
suffering of those mice that were used, including refinement of the published protocol for the stressor, 
CSD (Golden et al., 2011). 
3.2 Chronic social defeat 
Chronic social defeat comprised a CSD mouse being placed in the cage of an aggressive CD-1 mouse 
on CSD day 1 so that bouts of attack occurred. The mice remained together for a maximum of 60 sec 
of attack or for a maximum of 10 min. Thereafter the mice were separated by a central Plexiglas 
divider that was transparent and perforated to allow sensory communication but prevent physical 
attacks. After 24 h, the CSD mice were rotated between CD-1 mice cages and therefore confronted 
each day with a novel CD-1 aggressor. This procedure was repeated across 15 consecutive days 
between 14:00-17:00 h. Bite wounds were prevented by trimming the incisor teeth of the CD-1 mice 
every third day using rodent tooth-cutting forceps. The detailed CSD protocol is given in Chapter 2. 
Control mice remained in same-genotype littermate pairs, and were handled daily.  
3.3 Experimental design 
Wildtype and HET mice were each allocated at random to either the Control (CON; WT-CON N = 13, 
HET-CON N = 13) or the CSD condition (WT-CSD N = 14, HET-CSD N = 10). As schematised in 
Figure 1, CSD and CON-handling were conducted on days 1-15. At days 14, 15 and 17, respectively, 
mice were tested in terms of motor activity, discrete stimulus fear conditioning and hot plate pain 
sensitivity. Body weights (BW) were recorded daily. At day 18, mice were killed and trunk blood was 
collected for determination of plasma concentrations of pro-inflammatory cytokines and corticosterone, 
and spleen and adrenal glands were collected for weighing. Brains were fresh-frozen for region-
specific determination of monoamine concentrations.  
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Figure 1. Experimental design. The effects of chronic social defeat (CSD) in wildtype and 
heterozygous mice of a serotonin transporter knockout strain were investigated in tests of motor 
activity (MA), discrete stimulus fear conditioning (FC) and hot plate (HP) pain sensitivity, followed by 
euthanasia (E) and ex vivo analyses.  
3.4 Motor activity and CS fear conditioning 
Behavioural testing was conducted under dim lighting in a room adjacent to the mouse holding room, 
between 08:30-12:00 h. Motor activity and discrete stimulus fear conditioning were conducted using a 
single multi-purpose system co-developed with the manufacturer (Multi Conditioning System, TSE 
Systems GmbH, Bad-Homburg, Germany) (details of which are given in (Pryce et al., 2012)). 
Motor activity.  
On day 14, the mouse was placed on the grid floor in the empty arena for 15 min without presentation 
of any further stimuli. Distance moved in the horizontal and vertical planes was recorded continuously. 
When the mouse did not make any movement for a period of at least 2 sec then this was recorded 
automatically as freezing. Distance moved/min (arbitrary units/min) and % time spent freezing were 
calculated. 
CS fear conditioning 
On day 15, the mouse was placed in the same arena and challenged with 10 trials of 12-sec tone (5 
kHz, 85 dB, conditioned stimulus, CS) followed by 3 sec x 0.15 mA inescapable electroshock delivered 
at a constant inter-trial interval (ITI) of 50 sec. Distance moved during electroshock and % time spent 
freezing during CS were calculated. 
3.5 Hot plate test 
To assess pain sensitivity, the hot plate test was conducted using a programmable thermoelectric 
heating plate (Teca, Chicago IL, USA) set at 50 °C, with a transparent Plexiglas chamber placed onto 
the plate (Pryce et al., 2012). . On day 17, at 16:00-17:00 h, the mouse was placed inside the 
chamber and the latency (in sec) from the onset of the test until the first occurrence of one of the 
following behaviours was scored: licking a forepaw or hind paw, lifting a hind paw, jumping. The 
maximum test duration was 60 sec. 
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3.6 Blood, brain, spleen and adrenal gland collection 
At day 18, for blood factor and fresh-fixed brain studies, mice were decapitated and trunk blood was 
collected in EDTA-coated tubes (Microvette 500 K3E, Sarstedt, Germany) and placed on ice. The 
brain was removed, snap-frozen on dry ice and stored at -80° C. Bloods were centrifuged at 3000 rpm 
and 4° C for 10 min, plasma aliquots transferred to cryotubes (Protein LoBind, Eppendorf, Germany) 
and stored at -80° C. Adrenal glands and spleen were removed, cleaned of fat and connective tissue 
and weighed. 
3.7 Plasma cytokine measurement 
Plasma titres of the pro-inflammatory cytokines IL-6 and TNF were measured using a multiplexed 
particle-based flow cytometric cytokine assay (described in (Marques-Vidal et al., 2011; Vignali, 
2000)). Lower limits of detection for IL-6 and TNF were 0.5 pg/ml. 
3.8 Corticosterone measurement 
Plasma corticosterone titres were measured using an EIA kit (AssayMax Corticosterone ELISA kit; 
AssayPro, Saint Charles MO, USA). Plasma was diluted 1:50 in ELISA diluent and heated at 90° C for 
10 min for transcortin denaturation. All further steps were performed according to the manufacturer’s 
protocol. 
3.9 Brain tissue monoamine determination 
Frozen brains were sectioned coronally at 1.0 mm intervals using a stainless-steel brain matrix 
(Plastics One, model MMCS-1, Roanoke VA, USA) and single-edge blades (Apollo Herkenrath, model 
10-100-063, Solingen, Germany). The nucleus accumbens (NAcc) was micro-dissected bilaterally 
from the corresponding section using a brain punch ( = 1.00 mm, Stoelting Europe, model 57397, 
Dublin, Ireland) and a mouse brain atlas (Franklin and Paxinos, 2008): 1 biopsy/hemisphere at bregma 
1.5 to 0.5 ± 0.2 mm. Tissue mass was 1.5 ± 0.5 mg per sample. All micro-dissection steps were 
conducted at -18.0 °C. Brain biopsies were stored in 1.5 ml cryotubes (Protein LoBind) at -80.0 °C 
until tissue processing. 
For tissue homogenization, ice-cooled perchloric acid (0.4 M, 350 µl) was added to each 
sample and ultrasonication was conducted for 10 sec (VibraCell, VCX130PB, Sonics and Materials, 
Inc., Newtown CT, USA) followed by centrifugation at 20,000×g for 10 min at 4°C (refrigerated 
microcentrifuge, CT15RE, VWR/Hitamachi, Lutterworth, UK). The supernatant was passed through a 
0.22 µm filter (Minisart RC4, Sartorius AG, Göttingen, Germany) and kept on ice until analysis. 
High performamce liquid chromatography (HPLC) and electrochemical detection (ED) were 
conducted for monoamine determination in brain tissue homogenates according to a published 
protocol (Oeckl and Ferger, 2012). Samples were analysed for serotonin (5-HT) and its metabolites 5-
hydroxyindoleacetic acid (5-HIAA) and 3-methoxytyramine (3-MT), and dopamine (DA) and its 
metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Isocratic separation of 
5-HT and DA was carried out with a reversed-phase C18 column (YMC-Pack ODS-AQ, 100×2.1 mm, 
S-3 μm, YMC Europe GmbH, Dinslaken, Germany). An electrochemical cell with a glassy carbon 
electrode and an ISAAC Ag/AgCl reference electrode (VT-03, Antec, Zoeterwoude, Netherlands) was 
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used for ED. The mobile phase consisted of 1.7 mM 1-octanesulfonic acid sodium salt, 1.0 mM 
Na2EDTA×2 H2O, 8.0 mM NaCl, 100 mM NaH2PO4×2 H2O (pH 3.80), mixed with 9.3% acetonitrile, 
and was delivered at a flow rate of 0.4 ml/min. Aliquots (20 µl) were injected onto the HPLC system by 
an autosampler with a cooling module set at 4°C; the loading order of samples was counterbalanced 
between groups. Concentrations of each monoamine/metabolite were calculated using an external 
standard calibration and expressed as ng/mg brain tissue. Monoamine turnover was calculated as: 5-
HT = ([5-HIAA]+[3-MT])/[5-HT], DA = ([DOPAC]+[HVA])/[DA]. 
3.10 Statistical analysis 
Statistical analysis was conducted using SPSS (version 20, SPSS Inc., Chicago IL, USA). Firstly, one 
way ANOVA with a between-subject factor of group (WT-CSD, WT-CON, HET-CSD, HET-CON) was 
conducted, and a priori pair-wise comparisons of interest were WT-CON vs HET-CON, WT-CSD vs 
WT-CON and HET-CSD vs HET-CON. In the case of a significant effect of group attributable to at 
least one of these pair-wise comparisons, a 2 x 2 factorial ANOVA with between-subject factors of 5-
HTT genotype (WT, HET) x environment (CSD, CON) (GxE) was conducted. For body weight (BW) 
and % day-to-day BW delta (BW), ANOVA was conducted with the between-subject factor of group 
and a within-subject factor of CSD day block (CSD day -3 to 1, 2 to 6, 7 to 11). Post hoc testing was 
conducted using the least significance difference (LSD) correction for multiple comparisons. Statistical 
significance was set at p < 0.05. Where an estimate of variance is given this is standard deviation 
(SD). 
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4. RESULTS 
4.1 Repeated measures of physical status 
The mean duration of attacks per CSD mouse was 47.0  2.8 sec. The development of CSD effects 
was monitored across 5-day blocks of CSD day -3 to 1, 2 to 6 and 7 to 11. For absolute BW, there was 
a main effect of group (F(3, 58) = 4.14, p < 0.01; Fig. 2A). Post hoc analysis indicated that HET-CON 
mice were heavier than WT-CON mice (p < 0.001), and that this was the case for each time block (p < 
0.02–0.04). For BW, there was a main effect of group (F(3, 59) = 3.67, p < 0.02; Fig. 2B). Post hoc 
analysis indicated that BW was increased by CSD in WT mice (p < 0.005); block-specific analysis 
indicated that BW was greater in WT-CSD than WT-CON mice at days 2 to 6 (p < 0.03) and 7 to 11 
(p < 0.03). There was no effect of CSD on BW in HET mice (p = 0.13), and this also applied to each 
specific block (p ≥ 0.07).  
Figure 2. Effects of genotype and chronic social defeat on body weight measures. (A) Absolute body 
weight, (B) Percent day-to-day body weight delta (abs(BW day n – BW day n-1))/(BW day n-1)*100). 
Body weights were measured at 14:00 h each day and mean per mouse way calculated per time 
block. Values are mean +/- SD. * p < 0.05 for WT-CSD vs. WT-CON specifically. 
4.2 Motor activity, CS fear conditioning and pain sensitivity 
The effects of CSD were tested in terms of motor activity at day 14, CS fear conditioning and reactivity 
to electroshock at day 15, and pain sensitivity in the hot plate test at day 17. In the motor activity test, 
there was a main effect of group on distance moved/min (F(3, 46) = 5.95, p < 0.002): post hoc analysis 
indicated that WT-CON mice (60932272 arbitrary units (a.u.)/min) exhibited increased distance 
moved relative to HET-CON mice (46291050 a.u./min, p < 0.02) and WT-CSD mice (39611489 
a.u./min, p < 0.001). In the GxE ANOVA there was no interaction effect (p = 0.18). In the same motor 
activity test, all groups spent a similar and low % time freezing (p = 0.48; Fig 3A). In the test of CS fear 
conditioning, there was a main effect of group on average % time freezing (F(3, 44) = 6.92, p < 0.001; 
Fig 3A). Post hoc analysis indicated that freezing was increased by CSD in WT mice (p < 0.0005) and 
not in HET mice (p = 0.07). In the GxE ANOVA there was not a significant interaction effect (p = 0.17). 
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In terms of motor reactivity to electroshock, there was no main effect of group (p = 0.15; Fig. 3B). In 
the hot plate test there was a main effect of group (F(3, 41) = 2.86, p < 0.05; Fig 3C): post hoc 
analysis indicated that HET-CSD mice exhibited decreased response latency relative to HET-CON 
mice (p < 0.04). There was no significant interaction effect in the GxE ANOVA (p = 0.47). 
Figure 3. Effects of chronic social defeat on baseline and conditioned freezing. (A) Average per cent 
time freezing in the motor activity test (MA, day 14) and during the tone conditioned stimulus (CS) in 
the fear conditioning test (FC, day 15). (B) Average motor reactivity to electroshock in FC. (C) Pain 
response latency in the hot plate test (day 17). * p < 0.05, **** p < 0.0005. 
4.3 Physiological status  
Mice were decapitated at day 18 and trunk blood and tissues were collected. For spleen weight 
relative to BW there was a main effect of group (F(3, 46) = 3.44, p < 0.02; Fig. 4A): in WT mice 
specifically, CSD induced an increase in relative spleen weight (p < 0.004). There was a borderline 
non-significant interaction effect in the GxE ANOVA (p = 0.08). For basal plasma concentrations of 
TNF, there was a main effect of group (F(3, 45) = 8.21, p < 0.0005; Fig 4B): in WT mice specifically, 
CSD induced an increase in plasma TNF levels (p < 0.0005). There was a borderline non-significant 
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interaction effect in the GxE ANOVA (p = 0.09). For basal plasma concentrations of IL-6, there was no 
main effect of group (p = 0.37; Fig 4C). For adrenal gland weight relative to BW there was a main 
effect of group (F(3, 46) = 5.69, p < 0.002; Fig 4D): CSD induced adrenomegaly in both WT mice (p < 
0.006) and HET mice (p < 0.005). There was no interaction effect in the GxE ANOVA (p = 0.79). For 
basal plasma concentrations of corticosterone, there was a main effect of group (F(3, 45) = 8.08, p < 
0.0005; Fig 4E): basal plasma corticosterone was increased in HET-CON relative to WT-CON mice (p 
< 0.0005); CSD induced a decrease in plasma corticosterone in HET mice specifically (p < 0.03). 
There was no GxE interaction effect (p = 0.18). 
Figure 4. Effects of chronic social defeat on physiological measures. (A) Spleen weight relative to body 
weight. (B) Basal plasma concentration of tumor necrosis factor (TNF). (C) Basal plasma 
concentration of interleukin-6 (IL-6). (D) Total adrenal gland weight relative to body weight. (E) Basal 
plasma concentration of corticosterone. * p < 0.05, ** p < 0.01, **** p < 0.0005. LD, limit of detection of 
immunoassay. 
4.4  Monoamine levels in nucleus accumbens 
From brains collected at day 18, the NAcc was dissected out and analysed in terms of its content of 5-
HT, DA and their respective metabolites. For 5-HT (F(3, 37) = 5.79, p < 0.002) as well as 5-HIAA F(3, 
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37) = 3.84, p < 0.02) and 3-MT (F(3, 37) = 4.76, p < 0.007), there was a main effect of group (Fig 5A-
B). Post hoc analysis indicated in the case of each parameter that HET-CON mice exhibited increased 
concentrations relative to WT-CON mice (p < 0.05). There was no effect of CSD in either WT or HET 
mice; as would be predicted therefore, levels of 5-HT and its metabolites were also increased in HET-
CSD relative to WT-CSD mice: 5-HT (p < 0.001), 5-HIAA (p < 0.02), 3-MT (p < 0.004). There was no 
main effect of group on 5-HT turnover (p = 0.50; Fig. 5C). For DA (F(3, 37) = 3.89, p < 0.02), DOPAC 
(F(3, 36) = 7.88, p < 0.0005) and HVA (F(3, 36) = 5.28, p < 0.004), there was a main effect of group 
(Fig 5D-E). Post hoc analysis indicated in the case of each parameter that HET-CON mice exhibited 
increased concentrations relative to WT-CON mice (p < 0.004-0.03). There was no effect of CSD in 
either WT or HET mice; as would be predicted therefore, levels of DA and its metabolites were also 
increased in HET-CSD relative to WT-CSD mice: DA (p < 0.03), 5-DOPCA (p < 0.001), HVA (p < 
0.005). There was no main effect of group on DA turnover (p = 0.45; Fig 5F). 
Figure 5. Effects of chronic social defeat on tissue concentrations of 5-HT and DA and respective 
metabolites in nucleus accumbens. (A) Serotonin, (B) Metabolites 5-hydroxyindoleacetic acid (5-HIAA) 
and 3-methoxytyramine (3-MT), (C) 5-HT turnover = ([5-HIAA] + [3-MT])/[5-HT]. (D) Dopamine, (E) 
Metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanilic acid (HVA), (F) DA turnover = 
([DOPAC] + [HVA])/[DA]. * p < 0.05. 
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5. DISCUSSION 
In humans, polymorphism in the 5-HTT gene leading to decreased 5-HTT expression and function is 
associated with endophenotypes of increased anxiety and neuroticism in adulthood and an increased 
long-term risk that early-life stress will lead to depression. However, the net GxE evidence is also 
consistent with decreased 5-HTT expression actually increasing resilience to adulthood stress. 
Furthermore there is anthropological evidence that decreased 5-HTT expression is protective against 
infection and depression, and immunological evidence that high 5-HT levels protect against pro-
inflammatory responses and depression. To our knowledge this is the first animal-model study of 
these complex Gendophenotype and GxEstate marker inter-relationships. Evidence is presented 
that, relative to WT littermates, adult 5-HTT KO HET mice exhibit endophenotypes of increased basal 
5-HT and DA and respective major metabolites in nucleus accumbens and increased basal plasma 
corticosterone. Furthermore, adult 5-HTT KO HET mice exposed to psychosocial stress exhibit, 
relative to WT littermates, resilience markers in the form of an absence of increased plasma TNF, 
absence of spleonomegaly, decreased basal plasma corticosterone, and an absence of increased fear 
conditioning. As such, the current findings provide important new insights into how reduced 5-HTT 
expression can increase stress resilience, with high 5-HT levels acting to reduce the pro-inflammatory 
response to stress appearing to be a major factor in this complex network. 
Endophenotypes of 5-HTT genotype 
Adult male control mice that were heterozygous knockout for the 5-HTT gene demonstrated increased 
tissue levels of 5-HT and its major metabolites 5-HIAA and 3-MT in the NAcc, relative to WT. This 
finding is consistent with increases in each of tonic 5-HT release, reuptake and metabolism at 5-HT 
terminals in the NAcc of HET mice. The lack of genotype effect on 5-HT turnover suggests that there 
would not be a major effect on 5-HT synaptic levels. These findings are clearly not explicable in terms 
of a simple reduction in 5-HTT reuptake of 5-HT and suggest that the effects of reduced 5-HTT on 5-
HT neurochemistry are complex. In a microdialysis study, HET mice had increased basal 5-HT release 
in both regions studied, namely dorsal striatum and frontal cortex, relative to WT (Mathews et al., 
2004). In an ex vivo study of tissue levels in frontal cortex, there was no genotype effect on absolute 5-
HT levels or turnover (Bartolomucci et al., 2010). In the present study, HET mice also demonstrated 
increased NAcc tissue levels of DA and its major metabolites DOPAC and HVA relative to WT. This 
further indicates the complex effects of 5-HTT genotype-phenotype on monoamine neurochemistry. As 
for 5-HT, the DA findings are consistent with increases in tonic DA release, reuptake and metabolism, 
and the turnover values suggest that DA synaptic levels are increased in HET relative to WT mice. 
Clearly it will be important to measure effects of 5-HTT genotype on monoamine levels in other brain 
regions and in blood. 
 Control-HET mice exhibited a further endophenotype in the form of increased basal plasma 
corticosterone relative to WT. A previous study reports no HET versus WT difference for this 
parameter (Bartolomucci et al., 2010). In healthy humans, 5-HTTLPR S-allele carriers exhibited 
increased salivary waking cortisol levels relative to L-allele carriers (O'Hara and Hallmayer, 2007), 
indicating an interesting similarity to the current data. One of the major functions of glucocorticoids is 
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their antagonism of pro-inflammatory processes (Rhen and Cidlowski, 2005). Whilst this anti-
inflammatory effect has been most studied in terms of pathogen-induced inflammation, it has also 
been put forward in the context of psychosocial stress-induced inflammation (Miller et al., 2009). 
Therefore, the endophenotype of increased blood levels of corticosterone might contribute to the 
absence of immuno-inflammatory responses to CSD that was observed in HET mice (see below).  
 In terms of behavioural measures, there was no evidence for 5-HTT-related endophenotypes. 
To our knowledge there is no previous study of acquisition of CS fear conditioning in HET versus WT 
5-HTT KO mice. A study of expression and extinction of tone CS-conditioned fear reports an absence 
of genotype effects on both expression and extinction (Narayanan et al., 2011). In other behavioural 
tests or paradigms of emotionality, there was no HET-WT difference in an elevated plus maze test of 
anxiety and an anxiogenic endopheotype of HET mice in terms of increased latency to enter and 
decreased time spent in the light compartment in a dark-light box test (Jansen et al., 2010). In human, 
the S allele of the 5-HTTLPR polymorphism is associated with increased neuroticism and anxiety in 
healthy probands (Lesch 1996). Furthermore, it is associated with increased fMRI activation of 
amygdala and hippocampus in response to emotionally negative facial expressions, e.g. fear (Canli et 
al., 2006; Hariri et al., 2002). 
5-HTT-genotype modulation of the effects of chronic social defeat 
In the wildtype mice, the effects of psychosocial emotional stress induced by CSD were robust and 
directly in line with those obtained previously (see Chapter 2). Therefore, CSD led to increased day-to-
day body weight variation, elevated plasma TNF level and splenomegaly, and increased emotional 
reactivity to an aversive stimulus in the form of increased fear conditioned freezing. In a previous study 
of the effects of CSD in WT mice of a 5-HTT KO strain, CSD led to increased absolute body weight 
and increased plasma basal corticosterone relative to WT-CON mice (Bartolomucci et al., 2010); both 
of these effects are in contrast to the present findings. At the behavioural level, CSD led to increased 
social avoidance in WT mice, suggesting increased expression of fear to the social stimuli associated 
with the unconditioned stimulus of social aggression/defeat. 
 Each of the stress state markers demonstrated by WT-CSD mice is relevant to state markers 
of depression. Therefore, loss or gain of body weight are depression symptoms (DSM-5, 2013; ICD-
10, 1994) and low self-esteem and negative affect are associated with increased body weight variation 
(Foreyt et al., 1995; Serdar et al., 2011). Psychosocial stress increases blood levels of pro-
inflammatory cytokines (Kiecolt-Glaser et al., 2005; McDade et al., 2006) and a meta-analysis found 
that TNF is increased in depressive patients (Dowlati et al., 2010). In depression there is increased 
aversive fear conditioning (Nissen et al., 2010). The lack of effect of CSD on basal plasma 
corticosterone in WT mice is somewhat inconsistent with human depression, in which 40-60% of 
patients exhibit increased basal cortisol levels relative to healthy probands (Parker et al., 2003). With 
respect to aetio-pathophysiology, the inflammation hypothesis of depression proposes that 
psychosocial stress-induced immune-inflammation in the periphery activates central inflammatory 
processes (Miller et al., 2009). Furthermore, the negative impact of immuno-inflammation on 
monoamine neurotransmission – both 5-HT and DA – has been proposed as a major aetio-
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pathophysiological pathway for depression (Felger and Miller, 2012; Haroon et al., 2012). The current 
findings, and in particular a companion study (Chapter 2), provide strong support for this hypothesis. 
 Interestingly, in comparison with WT, the effects of CSD were attenuated in their 5-HTT KO 
HET littermates. Therefore, there was no consistent effect of CSD on day-to-day body weight 
variation, plasma TNF level, spleen weight, and fear conditioned freezing. This relative resilience to 
CSD in HET mice cannot be attributed to basal HET-WT differences because HET mice did not exhibit 
an endophenotype on any of these parameters. The parameters on which HET-CON mice did exhibit 
an endophenotype relative to WT-CON were basal NAcc 5-HT and DA and their metabolites, which 
were increased in HET-CON (and HET-CSD), and basal plasma corticosterone, which was also 
increased in HET-CON. Given the evidence that 5-HT exerts important inhibitory effects on pro-
inflammatory cytokines (Kubera et al., 2005), then the increase in 5-HT activity could be protective in 
HET mice against stress-induced inflammation. Given the evidence that corticosterone exerts 
important antagonistic effects on pro-inflammatory processes (Rhen and Cidlowski, 2005), then the 
high basal level could be protective in HET mice against stress-induced inflammation. Also, with 
respect to the hypothesis that immuno-inflammation reduces 5-HT and DA neurotransmission, then 
the high tissue levels of these monoamines in NAcc (and possibly other regions) exhibited by HET 
mice could be protective. Indeed, in the companion CSD study, CSD induced de-regulation in 
expression of genes involved in DA signalling in AMYG in C57BL/6 mice (Chapter 2). It has been 
reported that, relative to WT-CSD mice, HET-CSD mice exhibit increased avoidance of CD-1 mice 
indicating, as noted above, increased reactivity to a specific aversive stimulus. Similarly, we have 
demonstrated that HET mice are more sensitive than WT mice to specific learned helplessness, using 
electroshock during both pre-exposure and test (Pryce et al., 2012). This increased reactivity to 
specific social or physical stimuli experienced as aversive is adaptive, suggesting that reduced 5-HTT 
function both increases adaptive aversive learning and decreases generalisation across stimuli which 
is indeed maladaptive (Chapter 2). 
 As noted in the Introduction of this Chapter, there is meta-analytical evidence that reduced 5-
HTT expression/function increases resilience to life stress events in adulthood, as measured in terms 
of depression prevalence (Karg et al., 2011). The current mouse-model study provides evidence for a 
protective effect of reduced 5-HTT in terms of preventing the increase in emotional reactivity to 
aversive physical stimuli induced by chronic psychosocial stress in adulthood. Furthermore, it provides 
novel evidence that increased central 5-HT and DA basal activity, increased plasma corticosterone 
and, possibly related to these endopheotypes, absence of stress-induced immuno-inflammation, 
underlie the increased emotional resilience. 
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1. SUMMARY 
Ketamine is of marked interest in psychiatry in various contexts, most recently as a low-dose, acute 
experimental therapy for treatment-resistant depression. The latter has stimulated rodent studies of 
low-dose ketamine aimed at elucidating antidepressant mechanism-of-action. Fundamental issues 
require clarification. Enantiomer: nearly all human and rodent studies have used the less-specific and -
potent RS-ketamine and not S-ketamine. Glutamate release: only medium-high dose RS-ketamine has 
been studied. Signalling pathway: studies of putative major proteins including brain-derived 
neurotrophic factor (BDNF) and mammalian target of rapamycin (mTOR) have used RS-ketamine 
specifically. In the present mouse experiments the effects of acute RS- and S-ketamine at equivalent 
low (3.0, 1.5 mg/kg) and high (50, 25 mg/kg) doses were compared in terms of effects on: floating in a 
desipramine-validated forced swim test (FST), escape in an imipramine-validated learned 
helplessness (LH) paradigm, glutamate release in medial prefrontal cortex (mPFC), BDNF levels in 
hippocampus (HIPP), and mTOR levels in HIPP and mPFC. Floating in FST was decreased by RS-
ketamine at 3.0 mg/kg specifically; escapes in the LH paradigm were unaffected by all ketamine 
treatments; mPFC glutamate release was increased by RS- at 50 mg/kg and S-ketamine at 25 mg/kg, 
specifically; HIPP BDNF was increased by 1.5 mg/kg S-ketamine specifically; HIPP and mPFC mTOR 
were unaffected by all ketamine treatments. This study presents novel and important evidence that the 
acute ketamine effect in the FST antidepressant screening test is low-dose RS-ketamine-specific, and 
that it occurs independently of increased mPFC glutamate release, increased HIPP BDNF and 
increased HIPP and mPFC mTOR. 
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2. INTRODUCTION 
Depression is a prevalent neuropsychiatric disorder and has one of the highest overall burdens across 
all disease classes (Wittchen et al., 2011). Treatment resistance and relapse are common (Little, 
2009) and novel efficacious treatments are needed. Several small clinical studies report rapid-onset 
antidepressant efficacy of ketamine in treatment-resistant depression (Berman et al., 2000; Zarate et 
al., 2006). Ketamine is an antagonist at the NMDA glutamate receptor by blocking the phencyclidine 
binding site (Mion and Villevieille, 2013; Vollenweider et al., 1997). Ketamine is used as an 
anaesthetic despite psychotomimetic side-effects. The psychotomimetic effects are of interest to 
psychiatry as a means of increasing psychotherapy responsiveness (Vollenweider and Kometer, 
2010); they also account for ketamine being a drug of abuse (De Luca et al., 2012). Medium-high 
(sub-anaesthetic) doses of ketamine have been applied in rodents to induce neurobehavioural states 
relevant to positive, cognitive and negative schizophrenia symptoms (Brody et al., 2003; Neill et al., 
2010; Ong et al., 2005). To-date, most translational psychiatry research has used RS-ketamine. This 
is despite S-ketamine having a 4- and 2-fold higher affinity for the NMDA phencyclidine binding site 
relative to R- and RS-ketamine, respectively (Mion and Villevieille, 2013; Vollenweider et al., 1997). 
RS-Ketamine also acts at sigma and opioid receptors (Hustveit et al., 1995; Narita et al., 2001; 
Robson et al., 2012); the relative affinities of the ketamine enantiomers for these additional binding 
sites are currently unknown. 
 Ketamine studies in treatment-resistant depression have almost exclusively used a single low-
dose infusion of RS-ketamine, e.g. 0.5 mg/kg during 40 min (Zarate et al., 2006). Rodent studies of 
ketamine induction of schizophrenia-relevant behavioural states use medium-high dose RS-ketamine 
(rat: 10-30 mg/kg, mouse: 100 mg/kg) (Brody et al., 2003; Neill et al., 2010; Ong et al., 2005). In rat, 
this regimen stimulates glutamate release in the medial prefrontal cortex (mPFC) (Lorrain et al., 2003; 
Moghaddam et al., 1997). The recent reports of ketamine therapy for treatment-resistant depression 
have stimulated rodent studies of ketamine effects in antidepressant screening tests (e.g. forced swim 
test (FST)) and models of depression (e.g. chronic unpredictable mild stress-induced loss of sucrose 
preference). These studies have also used RS-ketamine and primarily at low-medium doses, 
consistent with the low antidepressant dose in human studies and the importance of distinguishing 
from the schizophrenia animal models. Findings are heterogeneous: For example, in the FST in 
mouse and rat there are reports of a lack of effect of acute RS-ketamine at low doses, with effects only 
emerging at medium-high doses (Cruz et al., 2009; Reus et al., 2011). However, there are prominent 
reports that acute low-dose RS-ketamine (2.5-5.0 mg/kg) induces increased activity (decreased 
floating) in the FST in mice (e.g. (Autry et al., 2011)), analogous to the effects of selective monoamine 
reuptake inhibitor antidepressants (Cryan et al., 2002), and increased escape responses in a mouse 
learned helplessness (LH) paradigm (Maeng et al., 2008). In rat, acute medium-dose (10 mg/kg) RS-
ketamine induced increased activity in the FST (Li et al., 2010), an effect analogous to that of 
antidepressants (Porsolt et al., 1977), and 10 mg/kg RS-ketamine reversed the loss of sucrose 
preference induced by chronic unpredictable mild stress in rats (Li et al., 2011).  
4 - Ketamine enantiomers and anti-depressant effects 
81 
 
 Regarding an antidepressant mechanism-of-action of low-dose ketamine, the triggering effects 
of NMDA-receptor blocking are considered to be two-fold: (1) Increases in binding of glutamate and 
signaling by AMPA receptors (AMPA-R) on post-synaptic pyramidal neurons in the PFC. (2) Inhibition 
of GABA interneurons acting at glutamate projection neurons, resulting in disinhibition of and 
increased glutamate release by the latter into synapses with PFC pyramidal neurons (Autry et al., 
2011; Duman et al., 2012; Vollenweider and Kometer, 2010). Regarding point (2), it is important that 
the evidence for increased PFC glutamate release was obtained in rat using RS-ketamine at medium-
high doses (10-30 mg/kg: (Lorrain et al., 2003; Moghaddam et al., 1997)) and therefore mainly 
exceeding those used to demonstrate low-dose RS-ketamine effects in rodent screening tests (e.g. 
(Autry et al., 2011)) and depression models (e.g. (Li et al., 2011)). Increased AMPA-R signaling has 
been proposed to activate the pathway leading to increased translation of brain-derived neurotrophic 
factor (BDNF), occurring in hippocampus (HIPP) within 30 minutes of low-dose RS-ketamine (Autry et 
al., 2011). BDNF release leads to local activation of TrkB receptors and the pathway leading to 
phosphorylation of mammalian target of rapamycin (mTOR). Phosphorylated mTOR is a major and 
rapid regulator of synaptic protein synthesis and its level in mPFC increases within 30 minutes of low-
medium-dose RS-ketamine (Li et al., 2010). Increased BDNF release and mTOR phosphorylation has 
been proposed as the proximate mechanism underlying low-dose ketamine antidepressant action 
(Duman et al., 2012). 
 In the present study, important issues raised by this translational evidence for acute low-dose 
ketamine as an antidepressant treatment were addressed. In C57BL/6 mice, the following effects were 
investigated: (1) RS- or S-ketamine at equivalent low (3, 1.5 mg/kg) or high (50, 25 mg/kg) dose in the 
FST. (2) RS- or S-ketamine at equivalent low dose in a LH paradigm. (3) RS- or S-ketamine at 
equivalent low or high dose on glutamate release in mPFC. (4) RS- or S-ketamine at equivalent low or 
high dose on BDNF in HIPP. (5) RS- or S-ketamine at equivalent low or high dose on mTOR in HIPP 
and mPFC. Of particular interest was whether a low-dose of high-affinity S-ketamine exerted the most 
robust effect in antidepressant screening tests and, if so, whether this was associated with increased 
mPFC glutamate release, increased BDNF levels and increased mTOR phosphorylation. 
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3. EXPERIMENTAL PROCEDURES 
3.1 Animals and maintenance 
Male C57BL/6J mice were obtained from Janvier (Le Genest Saint Isle, France). At study onset mice 
weighed 22.0-30.0 g. They were maintained on a reversed 12:12 h light-dark cycle (lights off 07:00-
19:00 h) in an individually-ventilated caging system (IVC) at 20-22 °C and 50-60% humidity. Cages 
were type 2L and contained woodchips, a sleep igloo and tissue bedding. Complete-pellet diet 
(Provimi, Kliba Ltd, Kaiseraugst, Switzerland) and water were available continuously and ad libitum. 
The study was conducted under a permit (110/2009) for animal experimentation issued by the 
Veterinary Office of Zurich, Switzerland. All efforts were made to minimize the number of mice used 
and any unnecessary stress. 
3.2 Drugs and administration 
RS-ketamine (Ketasol-100, Graeub, Bern, Switzerland) and S-ketamine (Keta-S, Graeub) were used; 
with respect to relative NMDA-Phencyclidine affinities a ratio of 1:2 was assumed (Mion and 
Villevieille, 2013; Vollenweider et al., 1997). In each experiment the following treatments were 
included: 0.9% saline (SAL), RS-ketamine at 3 and 50 mg/kg (except LH paradigm, 3 mg/kg only), S-
ketamine at 1.5 or 25 mg/kg (except LH paradigm, 1.5 mg/kg only), and in some experiments S-
ketamine also at 7.5 mg/kg. In the FST, desipramine (DES, desipramine hydrochloride, Sigma-Aldrich, 
St. Louis (MO), USA) at 10 mg/kg was used as a positive control. In the LH paradigm, imipramine (IMI, 
imipramine hydrochloride, Sigma-Aldrich) at 20 mg/kg was used as a positive control. All drugs were 
administered in a volume of 5 ml/kg and concentrations refer to the base. 
3.3 Effects of ketamine on behaviour in FST and LH paradigm 
Forced swim test 
Mice aged 9-12 weeks were singly caged, and maintained in the experimental room and handled on 
the 3 days prior to the experiment. The FST was conducted using a 5 L Plexiglas cylinder ( = 18 cm, 
height = 25 cm) filled with 4 L clean water at 23-24°C. The sample size was 8-12 mice per drug group. 
Mice were injected acutely i.p. with ketamine, SAL or DES. Two separate experiments were conducted 
at 10:00-13:00 h, one investigating acute drug effects at 30 min and the other at 180 min. The mouse 
was placed gently in the water and behaviour was scored by two independent observers who were 
blind to drug group. The instantaneous sampling method of behavioural scoring was used with an 
interval of 10 sec, such that at every 10
th
 second the on-going behaviour from the following mutually-
exclusive list was given a score of 1: climbing: scratching on the cylinder with both of the forelimbs; 
swimming: cycling movement of the entire hind limbs; paddling: one or both hind paws is/are extended 
and flexed; floating: either no movement of hind limb(s) or maximally one hind limb slowly extended 
and flexed for balancing. The duration of the test was 6 min per mouse. The mouse was then 
removed, dried and warmed under a heating lamp and returned to its home cage. The test measure 
was the total score for floating during min 3-6 inclusive (maximum score = 4 x 6 = 24). Inter-observer 
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reliability, expressed as the Pearson correlation for observers’ floating scores for 20 tests selected at 
random, was r = +0.98. 
Learned helplessness 
Mice aged 10-14 weeks were housed in littermate pairs and handled on the 3 days prior to the 
experiment. The LH paradigm was conducted using a multi-purpose aversive conditioning apparatus 
(Multi Conditioning System, TSE Systems GmbH, Bad Homburg Germany (Pryce et al., 2012)). 
Briefly, a quadratic arena (30 x 30 x 24 (H) cm) was placed on an electrified grid floor and was divided 
into equal left and right compartments by a central divider raised off the floor so that the mouse could 
transfer between compartments by passing underneath it. All procedures were conducted at 13:00-
16.00 h. The sample size was 4-9 mice per group. The protocol was as follows: Day 1, arena 
habituation: 15 min session without electroshocks. Day 2, pre-exposure to escapable electroshocks 
(ES): 30 x 0.2 mA x 5 sec ES at 50 sec intervals. Days 3-4, pre-exposure to inescapable 
electroshocks (IS): 24 x 0.15 mA x 1-5 sec IS at 50 sec intervals. Day 5, screening escape test: 24 x 
0.15 mA x 5 sec ES at 50 sec intervals. Mice were allocated to drug groups by counter-balancing 
according to number of escape responses at day 5. Day 6, escape test: Mice were injected acutely i.p. 
with ketamine or SAL at 180 min pre-test, and test conditions were 30 x 0.15 mA x 5 sec ES at 50 sec 
intervals. For the positive control experiment, IMI or SAL were injected acutely i.p. at 30 min pre-test. 
The test measure was frequency of escape failure in each of three 10-trial blocks. 
3.4 Effects of ketamine on mPFC glutamate release 
Mice were 11–16 weeks at study onset. For brain cannulation, mice were anaesthetized (i.p cocktail: 
fentanyl 0.04 mg/ kg, midazolam 4 mg/kg, medetomidin 0.4 mg/kg). The head of the mouse was fixed 
in a stereotaxic frame and an intracerebral guide cannula (MAB 4.6. IC, Microbiotech, Stockholm, 
Sweden) was placed above the mPFC of the right hemisphere using the following coordinates relative 
to bregma: AP: +1.7 mm, ML: +0.2 mm (Franklin and Paxinos, 2008) with modification based on pilot 
study for the mouse strain used). The cannula was fixed onto the skull with dental cement (Paladur, 
Heraeus, Hanau, Germany) using two stainless steel screws for additional fixation. Post-surgery, mice 
were singly caged for a 6-13 day recovery period. 
 The evening before microdialysate collection, mice were anaesthetised briefly using 
sevoflurane and a microdialysis probe with a membrane of 1 mm length and a shaft length set so that 
the membrane tip extended DV -3.0 mm (from skull) (MAB 4.6.1. Cuprophane, Microbiotech) was 
inserted into the guide cannula. The mouse was placed into a 20 L Plexiglas cylinder containing food 
and water. The cannula inlet/outlet were connected via fine tubing to the pump and dual-channel 
swivel. Artificial cerebrospinal fluid (aCSF, M: KCl 2.7, NaCl 147.0, CaCl2 1.2, MgCl2 0.85, NaH2PO4 
1.0, pH 7.4) was pumped at 1 µl/min for overnight equilibration. Beginning at 08:00 h, four baseline 
samples were collected at 20 min (20 µl) intervals. The mouse was held, injected s.c. and returned to 
the microdialysis cylinder. Sampling at 20 min intervals was conducted for 120 min. Samples were 
frozen on dry ice and stored at -80 °C. The mouse was then deeply anaesthetized and aCSF was 
replaced with 1% methylene blue-H2O for 10 min infusion to facilitate determination of probe location. 
The brain was fixed, then frozen and cut at 100 µm on a microtome for localization of the methylene 
blue spot. The total sample was 9-15 mice per drug group and following exclusion due to either 
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missing dialysate samples or probe mis-location, the final sample size was 6-11 complete sample sets 
per drug group. For mice accepted into the data set the average location of the probe was AP +1.62 
mm (range 1.34-1.94 mm, Fig. 3D). As a positive control for glutamate release, in several mice, after 
completion of drug-sample collection, the aCSF was replaced with potassium-enriched aCSF (mM: 
NaCl 99.7, KCl 50.0, CaCl2 1.2, MgCl2 0.85 and Na2HPO4 1.0, pH 7.0–7.4) for 20 min and 
microdialysates were collected at 20-min intervals for a further 120 min (see (Buck et al., 2009)). 
 Glutamate concentration in microdialysates was measured using high performance liquid 
chromatography (HPLC) coupled with fluorescence detection (HPLC–FD), using a method based on 
that described for glycine (Voehringer et al., 2013). Glutamate standards were prepared using L-
glutamic acid (G1251, Sigma-Aldrich) in Millipore H2O (1-10000 nM). Microdialysate (5 µl) was diluted 
with 20 µl Millipore H2O, and 15 µl were combined with 3 µl OPA-reagent (0.5% 2-mercaptoethanol 
(4227.3, Carl Roth, Karlsruhe, Germany) in phthaldialdehyte reagent (P7914, Sigma-Aldrich) and 
injected onto the HPLC-FD column. Mobile phase A consisted of 4625 ml 0.1 M sodium acetate, 250 
ml methanol and 125 ml tetrahydrofuran, and mobile phase B of 97.5 % methanol and 2.5 %  
tetrahydrofuran. The gradient elution profile was as follows at a constant flow rate of 1.2 ml/min: 0.0 
min 100 % A → 3.0 min 100 % A → 4.0 min 100 % B → 6.0 min 100 % B → 7.0 min 100 % A → 8.5 
min 100 % A. For each mouse, post-drug microdialysate glutamate concentrations were expressed as 
a percentage of its mean baseline concentration. Reported values are non-corrected for in vitro 
estimated recovery (15 %). 
3.5 Effects of ketamine on region-specific BDNF and mTOR 
Brain tissue preparation 
Mice were aged 10 weeks and singly caged. They were injected i.p. at 07:00-08:00 h, returned to the 
home cage and decapitated after 30 min. Brains were removed and fresh fixed on dry ice. Frozen 
brains were sectioned coronally at 1.0 mm intervals using a stainless steel brain matrix (model MMCS-
1, Plastics One, Roanoke VA, USA) and single-edge blades (model 10-100-063, Apollo Herkenrath, 
Solingen, Germany). Regions of interest, namely dorsal (d) HIPP and mPFC (infralimbic cortex + 
prelimbic cortex) were microdissected bilaterally from the corresponding sections using a brain punch 
( = 1.00 mm, model 57397, Stoelting Europe, Dublin, Ireland) and a mouse brain atlas (Franklin & 
Paxinos, 2008): dHIPP (2 biopsies/hemisphere) at bregma -1.5 to -2.4 ± 0.2 mm and mPFC (1 
biopsy/hemisphere) at bregma 2.2 to 1.3 ± 0.2 mm. Tissue mass was 0.6-1.0 mg per biopsy. All 
microdissection steps were conducted at -18 °C. Brain biopsies were stored in 1.5 ml Protein LoBind 
tubes (Eppendorf, Hamburg, Germany) at -80 °C. Samples were sonicated (VibraCell, VCX130PB, 
Sonics and Materials, Newtown CT, USA) in 100 µl lysis buffer: 100 mM NaCl, 1 mM EGTA, 20 mM 
Tris (pH 7.5), 1 mM EDTA, 1% Triton-X-100, 1% Protease inhibitor solution (Thermo Fisher Scientific, 
Waltham MA, USA), 1% Phophatase inhibitor I (Sigma-Aldrich), 1% Phosphatase inhibitor II (Sigma-
Aldrich). After centrifugation at 20,000-g for 10 min at 4°C the supernatant was pipetted into a LoBind 
tube and stored on ice. Total protein concentration was quantified using the Coomassie Plus Bradford 
assay kit (Thermo Fisher Scientific) according to manufacturer’s instructions with minor modifications. 
The assay was run in a 96-well microtitre plate (Nunc, Roskilde, Denmark) and the albumin standard 
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(25-750 µg protein/ml) was run in triplicate using 10 µl standard and 2 µl lysis buffer per well. Lysates 
were measured in duplicate using 2 µl and 10 µl H2O per well. Coomassie Plus protein assay reagent 
was added at 250 µl per well and optical density was measured at 650 nm (SpectraMax M2, Molecular 
Devices, Sunnyvale CA, USA). 
BDNF immunoassay 
Brain-derived neurotrophic factor was measured in dHIPP lysates using an enzyme-immunoassay kit 
(BDNF Emax ImmunoAssay system, Promega, Madison, USA). The assay was conducted according 
to the manufacturer’s instructions, with lysates (100 µl/sample) prepared without acid-treatment and 
diluted 1:10 in block and sample buffer, and measured in duplicate within a single microtitre plate. 
BDNF concentrations were normalized to protein concentrations (pg BDNF/mg protein). For mPFC, 
BDNF levels were below the limit of detection (3 pg/ml). 
Phosphophorylated and total mTOR immunoassay 
Phosphorylated and total mammalian target of rapamycin were measured in mPFC and dHIPP lysates 
using a 2-spot electrochemiluminescence immunoassay kit (Phospho(Ser2448)/Total mTOR Assay 
Whole Cell Lysate Kit, Meso Scale Discovery, Rockville, USA). The assay was conducted according to 
the manufacturer’s instructions. Per sample, a volume containing 20 µg protein (5-30 µl) was added in 
duplicate to wells of the microtitre plate and the volume adjusted to 30 µl with lysis buffer. The plate 
was read using a SECTOR® Imager 2400 (Meso Scale Discovery). Electrochemiluminescence signals 
for phospho- and total-mTOR for all drug groups were expressed relative to the mean total mTOR 
signal of the SAL group. It is important to note that in the present study and in previous studies from 
other laboratories (e.g. (Bradtmoller et al., 2012)), for all samples, the estimate of phospho-mTOR was 
greater than that of total-mTOR; the kit manufacturer attributes this to the increased affinity for 
phospho-mTOR of the specific phospho-mTOR antibody relative to the total-mTOR antibody as used 
in the kit (MSD, personal communication).  
3.6 Statistical analysis 
Statistical analysis of ketamine effects on antidepressant screening-test behavior, glutamate release 
and region-specific signaling protein concentrations was conducted using SPSS (version 20, SPSS 
Inc., Chicago IL, USA). In most cases ANOVA was used, with a between-subject factor of drug dose 
and, depending on parameter, a within-subject factor (e.g. trial-block in LH paradigm, sampling interval 
in microdialysis experiment). Post hoc testing was conducted using Bonferroni correction for multiple 
comparisons. Statistical significance was set at p < 0.05. Where an estimate of variance is given this is 
the standard deviation (SD). 
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4. RESULTS 
4.1 Forced swim test 
Relative to SAL, DES, a positive control, led to decreased floating at the 30-min (t(18) = 6.20, p < 
0.0005, Fig. 1A) and not at the 180-min test (p = 0.52, Fig. 1B). For RS-ketamine, at 30 min there was 
a borderline non-significant effect of dose on floating (F(2, 24) = 3.2, p < 0.06, Fig. 1C), with 3 mg/kg 
associated with a mean decrease relative to SAL. At 180 min, there was a main effect of dose (F(2, 
25) = 6.76, p < 0.005, Fig. 1D): 3 mg/kg RS-ketamine decreased floating relative to SAL (p < 0.003) 
and 50 mg/kg was without effect. For S-ketamine, at 30 min there was a borderline non-significant 
effect of dose (F(2, 25) = 3.3, p < 0.06, Fig. 1E), with 1.5 mg/kg associated with a mean decrease 
relative to SAL. At 180 min, there was no effect of S-ketamine at 1.5, 7.5 or 25 mg/kg relative to SAL 
(p = 0.80, Fig. 1F). 
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Figure 1. Scatter plots depicting effects of acute i.p. treatment with desipramine (DES), RS- or S-
ketamine (-ket) on mouse floating behavior in the forced swim test (FST). (A-B). DES (10 mg/kg) 
positive control versus saline (SAL) at (A) 30-min test or (B) 180-min test. Sample size was 8-12 mice 
per dose/experiment. (C-D). RS-Ket (3, 50 mg/kg) at (C) 30-min test or (D) 180-min test. Sample size 
was 8-12 mice per dose/experiment. (E-F) S-Ket (1.5, 7.5, 25 mg/kg) at (E) 30-min test or (F) 180.min 
test. Sample size was 8-12 mice per dose/experiment. Black bar denotes the mean. 
4.2 Learned helplessness paradigm 
With IMI, used as a positive control, there was a significant dose x trial-block interaction in the escape 
test (F(2, 22) = 7.5, p < 0.003, Fig. 2A): post hoc analysis indicated decreased escape failure by IMI 
mice relative to SAL mice in trials 11-20 (p < 0.05) and 21-30 (p < 0.02). For low-dose RS- and S-
ketamine there was no effect on escape failure in the escape test (p = 0.77, Fig. 2B). 
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Figure 2. Effects of acute i.p. treatment with imipramine (IMI), RS- or S-ketamine (-ket) on escape 
behavior in the two-way escape test. Mice were pre-exposed to inescapable electroshock on two days 
and were allocated to dose groups by counter-balancing according to escape failures in a screening 
escape test on the previous day. The escape test consisted of 30 trials of escapable electroshocks 
(maximum 5 sec) that were analysed as three 10-trial blocks. (A) IMI (20 mg/kg, N=4) positive control 
versus saline (SAL, N=9) at 30 min before the escape test. (B) RS-ket (3 mg/kg, 3 RS-ket, N=8) and 
S-ket (1.5 mg/kg, 1.5 S-ket, N=6) versus SAL (N=8) at 180 min before the escape test. Values are 
mean +/- standard deviation. * p < 0.05 in trials 11-20 and 21-30. 
4.3 mPFC glutamate release 
For RS-ketamine, mean absolute basal glutamate concentrations were similar across drug groups: 
SAL 401176 (nM), 3 mg/kg 511154, 50 mg/kg 538143 (p = 0.30). There was a main effect of dose 
on mPFC glutamate concentrations relative to baseline (F(2, 20) = 3.4, p < 0.05) and no effect of 
sampling interval (p = 0.87) (Fig. 3A): post hoc analysis indicated that 50 mg/kg increased glutamate 
release relative to SAL (p < 0.05) whereas 3 mg/kg was without effect (p = 0.92). The maximum 
increase in glutamate release induced by 50 mg/kg was observed at min 100 post-injection (Fig. 3A). 
 For S-ketamine, mean absolute basal glutamate concentrations were similar across drug 
groups: SAL 401176 (nM), 1.5 mg/kg 364128, 7.5 mg/kg 534390, 25 mg/kg 329156 (p = 0.41). 
There was a main effect of dose on mPFC glutamate concentrations relative to baseline (F(3, 32) = 
6.8, p < 0.001) and a main effect of sampling interval (F(6, 187) = 2.4, p < 0.03) (Fig. 3B). Regarding 
dose, post hoc analysis indicated that 25 mg/kg increased glutamate release relative to SAL (p < 
0.001), 1.5 mg/kg (p < 0.05) and 7.5 mg/kg (p < 0.003). The maximum increase in glutamate release 
induced by 25 mg/kg was observed at min 20 post-injection (Fig. 3B). Regarding time, post hoc 
analysis indicated that no two sampling intervals differed significantly in terms of overall mean 
glutamate release.  
 Potassium-enriched aCSF provided a positive control, as indicated by the main effect of 
sampling interval (F(8, 32) = 5.9, p < 0.0005, Fig 3C): post hoc analysis indicated increased glutamate 
release relative to baseline at min 40 post-injection (p < 0.003). 
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Figure 3. Effects of acute s.c. RS- or S-ketamine (-ket) on glutamate release (concentration as % of 
mean baseline concentration) in the mouse medial prefrontal cortex. (A) Time course for RS-ket at 3 
mg/kg (N=8) or 50 mg/kg (N=6) versus saline (SAL, N=9). * p < 0.05 for 50 mg/kg RS-ket versus SAL 
for 100-120 min sample. Inset: Mean (+ SD) glutamate release (% baseline) indicating the significant 
main effect of 50 mg/kg RS-ket versus SAL; * p < 0.05. (B) Time course for S-ket at 1.5 mg/kg (N=9), 
7.5 mg/kg (N=11) or 25 mg/kg (N=7) versus SAL (N=9), * p < 0.05 for 25 mg/kg RS-ket versus SAL for 
0-20 min sample; **** p < 0.0005 for 25 mg/kg RS-ket versus SAL for 20-40 min sample. Inset: Mean 
(+ SD) glutamate release (% baseline) indicating the significant main effect of 25 mg/kg S-ket versus 
SAL and lower S-ket doses; * p < 0.05, ** p < 0.003, *** p < 0.001. (C) Positive control using K+-
enriched artificial cerebrospinal fluid (aCSF) in a random sample of mice after completion of 2-hour 
microdialysate sampling for the main experiment (N = 5, mean + SD). Glutamate concentration was 
expressed as percent glutamate relative to the mean of the four samples collected before the K+-
enriched aCSF.. ** p < 0.003 for glutamate release in the 40-60 min sample relative to baseline. (D) 
Drawings  of coronal sections from the mouse brain atlas (Franklin and Paxinos, 2008) with filled 
circles depicting the locations of the microdialysis probes accepted as viable, as estimated by infusing 
methylene blue and brain sectioning. 
4.4 Signalling proteins  
For BDNF concentrations in dHIPP at 30 min post-ketamine, there was no effect of RS-ketamine (p = 
0.50, Fig. 4A). In contrast, there was an effect of S-ketamine (F(2, 12) = 4.90, p < 0.03, Fig. 4B): post 
hoc analysis indicated that 1.5 mg/kg induced an increase in dHIPP BDNF concentration relative to 
SAL (p < 0.03). 
 In all cases, the concentration-signal for phosphorylated mTOR was greater than for total 
mTOR (see Materials and Methods for explanation). Regarding RS-ketamine, for total mTOR 
concentration in dHIPP and mPFC at 30 min post-ketamine, there was no effectf: dHIPP p = 0.30 (Fig. 
5A) and mPFC p = 0.94 (Fig. 5B), and this was also the case for phosphorylated mTOR specifically: 
dHIPP p = 0.64 (Fig. 5A) and mPFC p = 0.64 (Fig. 5B). Regarding S-ketamine, for total mTOR 
concentration in dHIPP and mPFC at 30 min post-ketamine, there was no effect: dHIPP p = 0.51 (Fig. 
5C) and mPFC p = 0.67 (Fig. 5D), and no effect on phosphorylated mTOR: dHIPP p = 0.39 (Fig. 5C) 
and mPFC p = 0.57 (Fig. 5D). 
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Figure 4. Scatter plots depicting effects of acute i.p. RS- or S-ketamine (-ket) on BDNF concentrations 
in the mouse dorsal hippocampus at 30 min post-injection. (A) RS-ket (3, 50 mg/kg) and (B) S-ket (1.5, 
25 mg/kg) versus saline (SAL). Sample size was 4-6 per dose, with two 1.5 S-ket and one 25 S-ket 
samples nullified during sample processing. 
 
Figure 5. Effects of acute i.p. RS- or S-ketamine (-ket) on total- and phosphorylated-mTOR 
concentrations in the mouse brain at 30 min post-injection. (A-B) RS-ket in (A) dorsal hippocampus 
(dHIPP) and (B) medial prefrontal cortex (mPFC). (C-D) S-ket in (C) dHIPP and (D) mPFC. Sample 
size was 6 mice per dose, values are mean + SD. 
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5. DISCUSSION 
This integrative study presents novel and important evidence that in otherwise non-manipulated 
C57BL/6 mice, the positive effect of acute ketamine in the mouse FST antidepressant screening test 
was specific to RS-ketamine and at a low-dose, and that this regimen was without effect on mPFC 
glutamate release or HIPP BDNF level - both of which were increased by other specific ketamine 
regimens - or on HIPP or mPFC mTOR phosphorylated or total level. This dissociation of behavioural, 
neurochemical and signalling protein effects challenges current hypotheses of ketamine mechanism-
of-action as a pharmacotherapy for treatment-resistant depression. 
 With respect to the behavioural findings, the evidence that increased mobility (decreased 
floating) in the FST at 3 h post-treatment was specific to low-dose (3 mg/kg i.p.) RS-ketamine both 
confirms and expands on previous findings. For example, low-dose RS-ketamine increased mobility in 
the FST after intervals of 30 min, 3 h, 24 h and 1 week (Autry et al., 2011). The validity of the present 
FST as an antidepressant screening test was demonstrated with the tricyclic desipramine at 30-min 
post-treatment, as described previously (e.g. (Lucki et al., 2001)). For RS-ketamine the effect was 
borderline at 30 min and robust at 3 h. The equivalent low dose of the more potent S-enantiomer (1.5 
mg/kg i.p.) had no effect on immobility at 3 h, as was the case with 7.5 mg/kg. These findings are 
consistent with the RS-ketamine effect not being mediated by NMDA-R antagonism and with off-target 
effects of the racemate, or R-ketamine specifically, being responsible. In a recent study, neonatal mice 
were exposed to the glucocorticoid receptor agonist dexamethasone, which increases FST immobility 
in juveniles, and the efficacies of R- or S-ketamine in reversing this effect were investigated. At 24 h 
post-injection with either enantiomer at 10 mg/kg i.p., both enantiomers decreased FST immobility to a 
similar extent; lower doses and shorter treatment-test intervals were not studied (Zhang et al., 2014). 
In the LH paradigm, low-dose RS-ketamine was without effect on 2-way escape behaviour at 3 h post-
treatment, as were all other ketamine regimens investigated. The validity of this LH paradigm for 
antidepressant screening was demonstrated using the tricyclic imipramine at 30-min post-treatment. In 
the LH paradigm, repeated pre-exposure to inescapable electroshock leads to a gradual reduction in 
escape reactivity (motivational effort) across days; as such, the neurobiology underlying the escape 
deficit in the LH paradigm is unlikely to be equivalent to that underlying rapid-onset floating in the FST 
(Pryce et al., 2012). It has been previously reported that RS-ketamine at 2.5 mg/kg decreased escape 
failure (reversed LH) in a mouse LH paradigm, with ketamine administered immediately after the 
single inescapable electroshock session and 24-h prior to the escape test ((Maeng et al., 2008); 
personal communication). However, in light of the present findings, the possibility that ketamine 
inhibited the consolidation of LH rather than inducing its reversal,, should be investigated.  
 To our knowledge this is the first study of effects of low-dose ketamine on mPFC glutamate 
release in rodents. Both low-dose RS- and S-ketamine were without effect, whereas high-dose RS-
ketamine increased mPFC glutamate release, as reported previously for rat (Lorrain et al., 2003; 
Moghaddam et al., 1997), and this was also the case for an equivalent high-dose of S-ketamine. The 
glutamate increase was more rapid and acute for S- than RS-ketamine, perhaps reflecting different 
pharmacokinetics in terms of transport to the brain. Therefore, the effect of RS-ketamine in the FST at 
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3 h post-treatment was not dependent on a detectable increase in extracellular glutamate release in 
mPFC during hours 1-2 post-treatment. This negative evidence for low-dose RS-ketamine is important 
given that hypotheses to-date on the mechanism-of-action of low-dose ketamine have had to 
extrapolate from findings obtained with medium-high ketamine doses. For example, increased mPFC 
glutamate release has been inferred to underlie the molecular and cellular actions of low-dose 
ketamine as an antidepressant, including increased glutamate-AMPA receptor activation, followed by 
increased BDNF release and mTOR signalling ((Duman and Li, 2012; Duman et al., 2012); see 
below). The present findings contradict this hypothesis, although despite the absence of increased 
extracellular glutamate it is still possible that there is a net increase in glutamate-AMPA activation 
relative to glutamate-NMDA activation, due to low-dose ketamine blocking of the latter glutamate 
receptor-type specifically.  
 It has been proposed that major down-stream effects of ketamine-induced increased 
glutamate-AMPA activation include increased expression and release of BDNF in the mPFC (e.g. 
(Duman and Li, 2012; Duman et al., 2012)). The intra-cellular BDNF level is viewed as a marker for 
general activity in signalling pathways promoting synaptic protein synthesis and synaptogenesis 
(Duman et al., 2012; Thoenen, 1995). Increased BDNF expression has been proposed as a relevant 
neurobiological effect of various antidepressants, including ketamine, and in this context the 
hippocampus has been a region of interest (Castren and Rantamaki, 2010). For technical reasons it 
was not possible to measure mPFC BDNF levels in the present study, but HIPP BDNF was measured. 
Low-dose RS-ketamine was without effect on the HIPP BDNF level at 30 min post-treatment, whereas 
low-dose S-ketamine increased it; high-dose RS- and S-ketamine were both without effect. This 
negative finding for low-dose RS-ketamine is in contrast to the HIPP BDNF increase in mice described 
by Autry et al. using the same dose and interval as those used here (Autry et al., 2011). In rat, HIPP 
BDNF was not increased by RS-ketamine at 5 mg/kg (low-dose) after 30 or 60 min and was increased 
by 10 mg/kg (medium-dose) (Garcia et al., 2008; Yang et al., 2013). Integrating the current and 
existing evidence, one interpretation is that, depending on other factors, central BDNF levels can be 
increased by ketamine and that S- is more potent than RS-ketamine in this respect. An additional 
major function assigned to BDNF, and in particular to its release, is activation of the BNDF-TrkB-
Akt/ERK-mTOR pathway, leading to increased neuroplasticity (Duman et al., 2012; Li et al., 2010). 
mTOR is activated via phosphorylation, and in rat, RS-ketamine at 10 mg/kg increased the level of 
phosphorylated mTOR after 30 min in mPFC and HIPP (Li et al., 2010; Yang et al., 2013). In the 
present study there was no effect of any ketamine regimen on phosphorylated or total mTOR in mPFC 
or HIPP, including the 1.5 mg/kg S-ketamine dose that increased HIPP BDNF. It is important to note 
that there are technical differences between the present study and those that describe ketamine-
induced mTOR phosphorylation which could contribute to study differences: these include 
homogenates (current study) versus synaptosomes (e.g. (Li et al., 2010)) and immunoassay (current 
study) versus western blot (e.g. (Autry et al., 2011)).  
 In summary, the present mouse study provides the first evidence that a low dose of acute RS-
ketamine that functions as “antidepressant” in the FST screening test does so in the absence of 
increased mPFC glutamate release, increased HIPP BDNF or increased HIPP or mPFC phospho- or 
total-mTOR. The low dose of acute S-ketamine was without a behavioural or mPFC glutamate effect 
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despite increasing HIPP BDNF. The high doses of acute RS- and S-ketamine increased mPFC 
glutamate release, as predicted, but were without effect on behaviour, HIPP BDNF or HIPP and mPFC 
phospho- or total-mTOR. The current findings indicate that RS-ketamine affinity to receptors other 
than NMDA-R, which includes the μ-opiate, sigma and monoaminergic receptors (Kapur and Seeman, 
2001; Robson et al., 2012; Wong et al., 1996), should be taken into account when interpreting its 
behavioural effects in the FST. Furthermore, these findings demonstrate the importance of studying 
enantiomer-specific effects of ketamine, both in animal models of depression and in human clinical 
studies, to elucidate the mechanism-of-action mediating between low-dose acute ketamine 
administration and remission from treatment-resistant depression. 
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General discussion 
1. INTEGRATION OF DIFFERENT NEURO-
TRANSMITTER PATHWAYS UNDERLYING 
DEPRESSION 
1.1 CYTOKINES 
Among other factors such as obesity, early life stress, leaky gut and T cell dysfunction, psychosocial 
stress is likely to be the major source for an increased chronic inflammatory response (Haroon et al., 
2012). The main focus has been centred on the sympathetic nervous system, which is activated during 
psychosocial stress and hypothesized to lead to an increase in peripheral inflammation. In humans, 
the pharmacological blockade of this system prevents the increased levels of cytokines in the blood 
(Mazzeo et al., 2001). The increased concentration of cytokines has been associated with depression 
in several studies (Dowlati et al., 2010) leading to the recent cytokine hypothesis of depression. In the 
present field of depression research, there is increasing evidence to support the hypothesis that the 
increased inflammatory activity is indeed an aetiological factor in depression, resulting in induction of 
various pathophysiological pathways that have been demonstrated to be associated with the disease.  
Project A (see Chapter 2) has demonstrated that chronic social defeat (CSD) induced a 
peripheral stimulation of the pro-inflammatory response and a central cortico-limbic de-regulation in 
expression of genes involved in inflammatory and DA-ergic pathways; the latter specifically in the 
amygdala (see below section Cytokines and dopamine). These molecular changes are likely to be 
important contributors to the psychopathology-relevant behaviours exhibited by the stressed mice. In 
human it has been demonstrated that chronic psychosocial stress activates the peripheral immune 
system (Saveanu and Nemeroff, 2012), and in animals that it increases peripheral and central 
inflammatory responses (Kubera et al., 2011). There is human evidence that the peripheral activated 
inflammatory system leads to an increased inflammatory response in the brain; for example, peripheral 
administration of cytokine interferon-alpha (IFN-) increases interleukin 6 (IL-6) and monocyte 
chemoattractant protein-1 in the cerebrospinal fluid (Raison et al., 2009). A main on-going scientific 
discussion concerns the mechanism(s) underlying cytokine crossing of the blood-brain barrier. Several 
routes have been either demonstrated or proposed, including cytokines: (a) passing directly through 
leaks in the blood-brain barrier, (b) being actively transported by carrier proteins across the barrier, (c) 
activating perivascular macrophages and endothelial cells to release cytokines in the brain 
parenchyma, (d) recruiting immune cells which themselves cross the barrier, (e) stimulating nerve 
afferents in the periphery which stimulate inflammatory responses in specific brain regions (review by 
(Felger and Miller, 2012)) (Fig. 1, black frames). Further detailed studies will be required to establish 
which of these pathways is relevant in the case of mouse CSD. 
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In CSD mice, a specific number of de-regulated genes were found to be involved in 
inflammatory regulation processes. In the ventral hippocampus (vHIPP), 11 of the de-regulated genes 
were identified as having one or more of the pro-inflammatory cytokines TNF, IL-6 and IL-3 among 
their major regulators. In the amygdala (AMYG) and the medial prefrontal cortex (mPFC), two of the 
three top canonical pathways enriched by the de-regulated genes belonged to immuno-inflammation 
signalling processes. In depression, post mortem brain tissues show increased expression of genes 
belonging to pro-inflammatory and anti-inflammatory cytokine pathways in mPFC (Shelton et al., 
2011). Additionally, a polymorphism in the TNF gene has also been correlated with depression 
(Bosker et al., 2011). 
Further evidence that peripheral activation of cytokines leads to modifications in the brain is 
provided by human and animal studies demonstrating cytokine-induced psychopathology. For 
example, in cancer and hepatitis C patients treated with IFN-, symptoms of depression such as 
fatigue, cognitive impairment and psychomotor slowing are observed (Capuron and Miller, 2011). In 
primates and rodents, peripheral pro-inflammatory cytokine administration (e.g. IL-1β, TNF and INF-) 
induces depression-relevant behaviors such as social avoidance, decreased psychomotor activity and 
sleep alterations (Dantzer, 2001; Felger et al., 2007). In Project A, the CSD manipulation which led to 
increased blood levels of TNF and IL-6 also led to changes in behaviour, namely increased 
psychomotor fatigue, decreased psychomotor activity, increased fear of uncontrollable electroshock 
and increased helplessness to controllable electroshock. These are all depression-relevant 
behaviours, since fatigue and psychomotor retardation are classified as symptoms of depression 
(DSM-5, 2013; ICD-10, 1994), fear conditioning is potentiated in depressive patients (Nissen 2010), 
and generalised learned helplessness is a major theory for both onset and maintenance of depression 
(Abramson et al., 1978; Pryce et al., 2011). 
 The impact of immune-inflammation on monoamine neurotransmission, both on dopamine 
(DA) and serotonin (5-HT), has been discussed and demonstrated (Felger and Miller, 2012), and is 
supported by some of the major findings of this PhD thesis (see below sections Cytokines and 
dopamine, Cytokines and serotonin). Another central effect of pro-inflammatory processes, namely 
disruption of glutamate signalling via the NMDA receptor, will also be discussed (see section 
Cytokines and ketamine). 
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Figure 1: Putative mechanisms via which cytokine-triggered inflammatory processes act on 
dopamine, serotonin and glutamate pathways 
Peripheral and central immune systems act through different routes on brain signalling pathways. 
Dopamine signalling (red frames): Central cytokines act on the expression of vesicular monoamines 
transporter 2 (VMAT2) and dopamine transporter (DAT). Serotonin signalling (blue frames): Peripheral 
cytokines shift tryptophan metabolism away from serotonin towards kynurenine (kynurenine pathway) 
and central cytokines interfere with the expression of the serotonin transporter (5-HTT). Glutamate 
signalling (green frames): The end products of the kynurenine pathways, kynurenic acid and quinolinic 
acid, modulate the NMDA receptor which results in modification of glutamatergic signalling. 
5-HTT: serotonin transporter, AMPAR: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor, D1/D2: dopamine receptor D1/D2, DAT: dopamine transporter, Glu: glutamate, IDO: 
indoleamine-pyrrole 2,3-dioxygenase, NMDAR: N-methyl-D-aspartate receptor, ROS: reactive oxygen 
species, VMAT2: vesicular monoamines transporter 2. 
Figure adapted from (Felger and Miller, 2012). 
  
5 – General Discussion 
99 
 
1.2 CYTOKINES AND DOPAMINE 
Concerning the hypothesis of DA deficiency in depression, there is growing evidence that 
psychosocial stress increases or decreases its availability depending on the type of stress (acute or 
chronic) and on the brain region (mPFC or nucleus accumbens (NAcc)). In rodents, single social 
defeat increased the DA turnover in the mPFC and to a larger extent than in the NAcc (Tanaka et al., 
2012). This effect was attenuated in the mPFC by chronic exposure to the social stressor for 10 days. 
Chronic stress appears to reduce mesocortical DA activity, but to increase it in the mesoaccumbal 
pathway. Chronic social stress has been reported to either increase (Krishnan et al., 2007) or 
decrease (Tye et al., 2013) firing activity of DA neurons in the VTA, In the case where DA-ergic neuron 
activity was increased by CSD, elevated BDNF levels in the NAcc were also observed and were 
hypothesized to be responsible for the depression-relevant behaviours in these CSD mice (Krishnan et 
al., 2007). The NAcc receives a major input of BDNF from the VTA, and pharmacological blockade of 
BDNF in the NAcc prevents the CSD-induced behavioural effects (Krishnan et al., 2007). Additionally, 
BDNF administration into the NAcc increases depression-like behaviour after chronic social stress. A 
study of antidepressants in rat provides evidence in support of the mPFC and NAcc exhibiting 
opposite DA neuropharmacology: fluoxetine, imipramine and desipramine increase the extracellular 
DA concentration in the mPFC, but not in the NAcc (Tanda et al., 1994). In the study where chronic 
social stress decreased firing by VTA DA-ergic neurons, optogenetic activation of these neurons in 
chronically stressed mice reversed their depression-like behavioural phenotype, whereas optogenetic 
inhibition of these neurons induced such a phenotype in non-stressed mice. Furthermore, it was 
demonstrated that the DA-ergic neurons in the NAcc are essential for this regulation (Tye et al., 2013). 
In vivo data for DA levels are rare in depressive patients. However, in healthy humans, a positron 
emission tomography (PET) imaging study has shown increased DA release during stressful situations 
in the NAcc of young adult probands who reported having received relatively low levels of parental 
care during their childhood (Pruessner et al., 2004). 
As discussed above, cytokines could be important mediators of the effects of stress on 
neurobiological changes and psychopathologies. Some rodent studies report altered concentration of 
DA after administration of IFN-α, with increases in cortical and hypothalamic regions (Kumai et al., 
2000) and decreases in the AMYG (Kitagami et al., 2003). There are two major hypotheses of how 
cytokines can influence gene expression of DA-ergic signalling proteins, with both pertaining to 
reduced availability of DA: (a) reduction of the expression of vesicular monoamine transporter 2 
(VAMT2) which packages DA in vesicles ready for release, and (b) increase in the expression of DA 
transporter (DAT, (Felger and Miller, 2012), see Fig. 1, red frames, Nr. 1 and 2). Another putative 
action of the inflammatory system is mediated by action on intracellular proteins such as through the 
oxidative reduction of the enzyme co-factor tetrahydrobiopterin (BH4), which is essential for DA 
synthesis. Activated microglia produce nitric oxide and quinolinic acid (QA, see section Cytokines and 
serotonin) which induce reactive oxygen species reducing the availability of BH4 and therefore also 
DA synthesis (Felger and Miller, 2012). In the AMGY of the CSD mice, a large number the de-
regulated genes, specifically Drd2, Adora2a, Gpr88, Darpp-32, Rgs9, Slc29a4 Gng7, regulate or are 
regulated by DA. Interestingly, DA receptor D2 (DRD2) has been demonstrated to interact with 
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proteins encoded by a high proportion of the other genes de-regulated by CSD. Thus, it forms 
antagonistic dimers with adenosine A2 receptor (A2AR, (Boison et al., 2012)) and it is modulated by 
regulator of G Protein-9-2 (Rgs9-2) (Rahman et al., 2003). Dopamine- and cyclic AMP-regulated 
phosphoprotein-32 (Darpp-32) is a signalling phosphoprotein that is expressed mainly in DRD1 and 
DRD2 neurons (Bateup et al., 2010), and solute carrier family 29, member 4 (Slc29a4) encodes a 
protein that is expressed presynaptically and catalyses the uptake of DA and other monoamines 
(Dahlin et al., 2007). The expression of Drd2 is high in central AMYG, as it is in the dorsal and ventral 
striata (Alheid and Heimer, 1988). In a post mortem study of depressed patients, altered density of 
DA-ergic receptors was also observed suggesting a dysfunction in the DA-ergic system; increased 
binding capacity of DRD2 and DRD3 and reduced DAT density were found in the AMYG (Klimek et al., 
2002). Further evidence that dysfunction of DA plays an important role in depression is demonstrated 
by polymorphisms in DA-ergic genes that are associated with the disease (Antypa et al., 2013; Feng et 
al., 2010; Liou et al., 2009; Zou et al., 2012) or with specific symptoms such as fatigue (Lim et al., 
2012; Malyuchenko et al., 2010). These include catechol-o-methyl transferase (Comt), Dat1, Drd2, 
GABA receptor subunit delta (Gabrd), potassium channel, subfamily K, member 2 (Kcnk2) and 5-HT 
receptor 2a (Htr2a). Together with the findings in the CSD mice, there is growing evidence that 
proteins contributing to DA-ergic signalling, especially DRD2, contribute to the aetio-pathophysiology 
of depression, and constitute antidepressant targets with novel mechanism-of-action, (see Fig. 2, red 
frames, Nr. 1). 
The AMYG is important in the formation and expression of the emotional responses acquired 
during fear conditioning, which were increased in the CSD mice. In rats, emotional stimuli release DA 
into the basolateral and central AMYG (Perez de la Mora et al., 2012), with the AMYG being 
innervated by DA-ergic terminals from both the VTA and substantia nigra (Fuxe et al., 2003). The 
NAcc and AMYG are central to the reward system and regulate motivational processes and the ability 
to experience pleasure (Dunlop and Nemeroff, 2007; Salamone and Correa, 2012). D-amphetamine, 
which increases DA synaptic release, raises the experience of reward to a greater extent in severely 
depressed patients relative to control subjects (Tremblay et al., 2002; Tremblay et al., 2005). In mice, 
increasing the DRD2 in the NAcc via viral vector techniques is sufficient to elevate motivation in 
several behavioural tests (Trifilieff et al., 2013). The CSD mice expressing less Drd2 in the AMYG also 
show an increased fatigue indicating a motivational deficit. These results are in line with de-regulated 
DA-striatal functioning constituting a major underlying neuropathology (Capuron et al., 2007; 
Demyttenaere et al., 2005). 
The CSD model provides evidence that psychosocial stress leads to an elevation of peripheral 
pro-inflammatory activity and to de-regulation of expression of immune-inflammation and DA-ergic 
genes in cortico-limbic brain regions that are important in the circuitry of depression-relevant 
behavioural states such as increased fear, helplessness and fatigue. Similar inflammatory response, 
molecular dysfunction and behavioural alteration can be observed in depressive patients, thereby 
providing evidence that the physiological states identified in the CSD model have high aetio-
pathophysiological relevance for human depression. 
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Figure 2: Possible mechanisms-of-action for antidepressants acting on cytokine-triggered 
inflammatory processes 
Dopamine signalling (red frame): Elevated levels of cytokines that are induced via psychosocial stress 
modulate the expression of genes expressed specifically in dopaminergic neurons. Compounds 
activating or inhibiting the action of their corresponding proteins could be efficacious in treating 
depression. Serotonin signalling (blue pathways): Heterozygous serotonin transporter (5-HTT) 
knockout mice showed depression-relevant resilience after psychosocial stress. Increased serotonin in 
the blood could inhibit cytokine stimulation and action. Additionally, the action of cytokines on the 5-
HTT protein in the brain is reduced due to the genotype which could mediate the anti-depressant 
effect. Glutamate signalling (green frames): The proposed anti-depressant effect of ketamine could be 
due to an inhibition of cytokine stimulation in the periphery or through the action on AMPA or non-
NMDA receptors. 
5-HTT: serotonin transporter, AMPAR: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor, D1/D2: dopamine receptor D1/D2, DAT: dopamine transporter, Glu: glutamate, IDO: 
indoleamine-pyrrole 2,3-dioxygenase, NMDAR: N-methyl-D-aspartate receptor, ROS: reactive oxygen 
species, VMAT2: vesicular monoamines transporter 2. 
Figure adapted from (Felger and Miller, 2012). 
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1.3 CYTOKINES AND SEROTONIN 
There are several important lines of evidence that link the 5-HT deficiency and the pro-inflammatory 
cytokine hypotheses. It has been demonstrated that, in the periphery, increased pro-inflammatory 
cytokine levels lead to reduced 5-HT synthesis via the kynurenine pathway. The enzyme indoleamine-
2,3-dioxygenase (IDO) is activated by cytokines such as TNF and INF-α (Dantzer, 2009) and is 
responsible (rate-limiting) for shifting tryptophan metabolism away from 5-HT towards kynurenine 
(KYN) and finally, to either kynurenic acid (KA) or QA (see Fig 1, blue frame, Nr. 1). Project B 
demonstrated suppression of CSD-induced TNF production in 5-HT transporter (5-HTT) heterozygous 
knockout (HET) mice. This suggests an association between the genotype and the peripheral 
inflammation response. Assuming that reduced 5-HTT leads to an overall increase in 5-HT, including 
in the periphery, the elevated 5-HT level could be responsible for a suppression of inflammatory 
response. This effect has been demonstrated in vitro: 5-HT decreased the levels of TNF and IL-6 in a 
human whole blood study (Kubera et al., 2005) (see Fig 2, blue arrow, Nr. 1). This suppressive effect 
could lead to the observed stress-resilience of HET mice of the 5-HTT KO strain relative to wildtype.  
Cytokines and catabolites of the kynurenine pathway have effects on the 5-HT-ergic pathway 
in the brain. For example, IDO is present in macrophages and dendritic cells of the brain and its 
activity is increased during immune system activation (Wirleitner et al., 2003) e.g. lipopolysaccharide 
(LPS) activates IDO in the periphery and in the brain (Lestage et al., 2002). Furthermore, the 
metabolic end products KA and QA have opposing effects on the NMDA receptor (see section 
Cytokines and ketamine). 
Interestingly, a direct effect of cytokines on the 5-HTT protein has been demonstrated in vitro 
and in vivo (Zhu et al., 2006; Zhu et al., 2010). IL-1 and TNF enhance 5-HTT activity i.e. 5-HT uptake 
in serotonergic cell lines. Mice deficient of 5-HTT or IL-1 receptor provide evidence that cytokines 
require 5-HTT expression to induce psychopathological behaviours (see Fig 1, blue frame, Nr. 2). 
According to these findings, humans, including those exposed to pro-inflammatory cytokine 
medication, who have high 5-HT activity exhibit lower pro-inflammatory IL-6 levels and lower 
depression scores (Raison 2009). Together with the absence of cytokine activation, the reduced 
expression of 5-HTT could play an important role in the reduced fear conditioning response observed 
in the 5-HTT HET relative to WT mice in Project B (see Fig 2, blue lines, Nr. 2).  
There is a paradox in psychiatry between 5-HT and depression: on the one hand blocking 5-
HTT is the basis of selective 5-HT reuptake inhibitor (SSRI) antidepressant, whilst on the other hand a 
5-HTT gene polymorphism – namely the “short” (S) deletion insertion - that, similarly to SSRIs, 
reduces 5-HT reuptake, is currently the best-described genetic risk factor for environmental stress-
induced depression. Meta-analysis yields strong statistical support for association between the S-allele 
x early-life stress and depression, suggesting a neurodevelopmental process. However, there is only 
marginal support for association between S x adult stress and depression, suggesting a net protective 
effect of the S allele against adult stress. Confounding results have been shown also with the 5-HTT 
KO mouse line. The majority of studies report an anxiolytic phenotype of 5-HTT HET and homozygous 
KO mice, but investigating gene x environmental (GxE) interactions various outcomes have been 
reported. Interestingly, stress during adolescence in 5-HTT HET mice has been reported to induce 
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anxious behaviour and depression-like responses in the probabilistic reversal learning task (Spinelli et 
al., 2013). Taken together, human and mice studies support the hypothesis that the S allele or partial 
deficiency of the 5-HTT possibly confer with adult stress resilience. 
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1.4 CYTOKINES AND KETAMINE 
Recent studies in treatment-resistant depression patients have demonstrated that ketamine, a NMDA 
receptor antagonist, improves the symptoms (Berman et al., 2000; Zarate et al., 2006). The 
mechanism of anti-depressant action of ketamine is under investigation. Ketamine has been shown to 
be anti-inflammatory (Zunszain et al., 2013). In humans, ketamine administration inhibits the post-
operative IL-6 inflammatory response (Dale et al., 2012) and suppresses experimentally induced TNF 
and IL-6 activation in the blood (Kawasaki 1999). In animals and in vitro studies, co-administration of 
ketamine with LPS suppresses TNF production (Lankveld et al., 2005; Taniguchi et al., 2003) (see Fig 
2, green frame, Nr. 1). Ketamine could directly inhibit the expression of nuclear factor-kappa B which 
induces inflammation (Welters et al., 2010). However, as shown in rats, the doses of ketamine that 
were shown to suppress the cytokine levels are in the medium to high range (Taniguchi et al., 2003). 
Another potential anti-inflammatory mechanism-of-action of ketamine involves the kynurenine 
pathway. As described above (see General introduction and section Cytokines and dopamine), 
cytokines induce a shift away from end product 5-HT towards QA and KA (see Fig 1, green frame, Nr. 
1). These tryptophan-pathway catabolites act with opposing effects on the NMDA receptor: QA is an 
NMDA receptor agonist, whilst KA is an antagonist. QA also induces intracellular oxidative stress via 
activation of nitric oxide. In depressive patients, QA-KA disequilibrium is observed. The increase in QA 
and reduction in KA suggest a larger neurotoxic versus a lower neuroprotective effect of the 
kynurenine pathway during depression (Myint et al., 2007; Steiner et al., 2011). 
Given that the CSD manipulation of Project A led to depression-relevant behaviours, this 
model could be applied to investigate ketamine. Specific doses (low, medium or high) could reverse 
the stress-induced peripheral cytokine response and reverse the psychopathological behaviours 
demonstrating its anti-depressant effect. Interestingly, the upstream analysis of the genes that were 
de-regulated in the mPFC of the CSD mice identified that both the NMDA receptor and ketamine are 
significant regulators. The ketamine-influenced genes, namely Arc, Fos and Penk, were all up-
regulated in the CSD mice. Inhibition of the NMDA receptor leads to decreases in Arc mRNA (Link et 
al., 1995), and activation to increases of Fos mRNA (Herdegen and Leah, 1998). The findings suggest 
that ketamine could normalize the expression of these genes by balancing deregulation in the 
glutamate signalling of the mPFC which is responsible for some depression-relevant behaviours (see 
Fig 2, green frame, Nr. 2). 
Project C demonstrated that a low-dose of either racemic (RS-) or S-ketamine did not change 
extracellular glutamate release in the mPFC. These results suggest that: (1) low-dose ketamine, even 
if it influences cortical NMDA:AMPA receptor signalling, does not do so by increasing the extracellular 
glutamate level; (2) the behavioural effects of low-dose RS-ketamine reported in this and in previous 
studies are independent of increased cortical glutamate release (Autry et al., 2011). Low-dose RS-
ketamine did not modify the depression-relevant behaviour of learned helplessness (LH) in non-
manipulated mice. However, it was positive in the antidepressant screening test of reduced immobility 
in the forced swim test (FST, for differences between FST and LH see the section Limitations of the 
thesis). The latter effect was not mimicked by the low-dose S-ketamine indicating a divergent effect 
from the RS-racemate suggesting the action on different receptors by the two enantiomers. This 
5 – General Discussion 
105 
 
divergence was additionally confirmed by an increase in hippocampal BDNF level induced only by low-
dose S-ketamine. 
Taken together, if ketamine has an anti-depressant effect this could be regulated via (a) non-
NMDA receptors, (b) altered intracellular signalling, or (c) suppression of peripheral inflammatory 
response. Furthermore, these findings demonstrate the importance of studying enantiomer-specific 
effects of ketamine, both in animal models of depression and in human clinical studies, to elucidate the 
mechanism-of-action mediating between low-dose acute ketamine administration and remission from 
treatment-resistant depression. 
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2. LIMITATIONS OF THE THESIS 
It is often discussed that psychosocial stress induced by CSD in mice is different and more severe 
than the psychosocial stress seen in humans (Nestler and Hyman, 2010) and additionally, that the 
ruminative aspects of aversive events in human are impossible to model in rodents. However, 
modifying the CSD protocol as done in Projects A and B removed all physical injuries and therefore 
reduced the severity of the psychosocial stress. This made the stress purely emotional and more 
aetiologically valid for translational research. 
An anhedonic effect was not induced by CSD although several studies report this effect 
(Haque et al., 2012; Venzala et al., 2013). First, saccharin was used in the present study and not the 
normally used sucrose. This was done to avoid any nutritional effect that sucrose may have and to 
reduce the effect to a purely gustatory one. Second, the results show a high, almost 100% preference 
of the saccharin solution in all mice before the stress. It is not to exclude that by reducing the 
preference to around 80% with a different saccharin dose before the CSD session, as described in the 
literature with sucrose solution (Yu et al., 2011), an anhedonic effect in CSD mice could be observed. 
Third, since the CSD mice show an increased fatigue that suggests compromised effortful motivation, 
a test based on effort-dependent reward motivation would be expected to show differences between 
the groups. This would increase the construct validity of the model, since drugs acting on the DA-ergic 
system have been demonstrated to modify effortful choices in human (Wardle et al., 2011). 
For the ketamine study in Project C, it has to be emphasized that the action of the NMDA 
receptor antagonist was tested in non-manipulated mice. In human studies, its anti-depressant effect 
was demonstrated in depressive patients. With respect to translational research, ketamine would need 
to be tested in terms of reversal of a prior-induced depression-relevant behaviour (see Outlook). 
However, the major aim of Project C was to address a number of open issues pertaining to the study 
of ketamine in non-manipulated mice. 
The forced swim test is a widely-used screening test for antidepressants, but has marginal 
validity as a model for depression (Cryan and Mombereau, 2004). In the ketamine study, this test was 
used to replicate the results found in previous studies (e.g. (Autry et al., 2011)), and not for validating 
ketamine as an antidepressant. To provide more information about the effects of ketamine on the 
psychopathology of depression, the learned helplessness test was used.  
Concerning neuroanatomy, the punching procedure of the regions of interest provided only a 
small amount of tissue; especially for the medial prefrontal cortex where only one biopsy per 
hemisphere was taken. For the analysis of both proteins (BDNF and mTOR), the lysed homogenate 
had to be split for the two kits which resulted in a loss of detectability of BDNF in this region.  
Another general problem with the punching is the low spatial resolution. It is not possible to be 
more specific than in the range of 100ths of a millimetre. For example in the Next Generation 
Sequencing measurement in Project A, hierarchical clustering analysis demonstrated a region-specific 
sampling of biopsy (data not shown). But within the region, it would be impossible to separate different 
nuclei e.g. the central from the basolateral AMYG. 
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3. OUTLOOK 
With respect to the long-term behavioural effects caused by CSD, it would be interesting to analyse 
the gene expression at the same time point, i.e. two weeks after the last CSD session. One would 
expect to have larger effects of gene expression alterations in the mPFC - the region that regulates the 
controllability which is compromised the most in the learned helplessness test at exactly this time 
point. In the AMYG, the de-regulation of the DA-ergic genes should persist and/or increase indicated 
by the sustained fatigue in the treadmill test. The results of the DA-ergic genes turned the focus on the 
reward system and on its centres such as dorsal and ventral striatum and ventral tegmental area. In 
future, further gene expression studies of CSD vs CON mice in these regions should be performed. 
Among others, the concentration of the neurotransmitters DA and 5-HT and their metabolites should 
be analysed in brain homogenates. Concerning the results of the reduced Drd2 gene expression in the 
AMYG and the evidence that central and basolateral AMYG express non-overlapping populations of 
D1 and D2 receptor neurons (Perez de la Mora et al., 2012) it would be important to examine the 
structural changes of D1- and D2-expressing neurons in the AMYG with the help of 
immunohistochemichal techniques. Another possibility is that other regions with similar DA receptor 
distribution, such as the medium spiny neurons of the dorsal and ventral striatum, are also affected by 
CSD. A mouse magnetic resonance imaging and spectroscopy study should be performed. This would 
allow for the in vivo study of (1) the resting-state connectivity between cortical (mPFC), limbic regions 
(AMYG) and basal ganglia (dorsal and ventral striatum) and (2) depression-relevant neurotransmitters 
and their metabolites (e.g. GABA, glutamate). Further readout experiments could be conducted 
relating to specific symptoms of depression, including CSD effects on reward motivation measured 
with effort-dependent reward seeking and on architecture and homeostatic regulation of sleep. To 
provide more evidence on the immune-inflammatory state of CSD mice, activation of innate immune 
cells in the spleen and of microglia in specific brain regions should be measured using various 
approaches including fluorescent flow cytometry and immunohistochemistry. Additionally, the effects 
of specific cytokine administration (e.g. TNF) in the periphery or of viral over-expression in specific 
brain regions should be tested in terms of neurobiological and behavioural effects. Concerning the 5-
HTT HET mice that underwent CSD, further brain regions (mPFC, AMYG and vHIPP) should be 
analysed for DA and 5-HT levels and turnover. This will allow for assessment of the extent of the 
effects of heterozygous knockout of the 5-HTT gene on DA and 5-HT. From the gene expression data 
in Project A, it is important to investigate whether the DA level of the CSD WT mice is altered relative 
to CON WT in the AMYG and, if so, whether this effect is modulated by knockout of one 5-HTT gene 
copy. Finally, the CSD model should be utilised to investigate the antidepressant effects and 
mechanism-of-action of different ketamine enantiomers, as well as other drug classes including anti-
inflammatory low molecular weight compounds and biologics. 
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Helplessness is a major concept in depression and a major theme in preclinical and clinical depression
research. For example, in rodents and humans, the learned helplessness (LH) effect describes a speciﬁc deﬁcit
in behaviour to control aversive stimuli that is induced by prior exposure to uncontrollable aversive stimuli.
The LHeffect is objective andvalid in that the cause of the behavioural deﬁcit, namely uncontrollability, is clear;
furthermore, the deﬁcit induced is underlain by emotional, motivational and cognitive processes that are
relevant to depression psychopathology. As a further example, helplessness, hopelessness, external locus of
control and causal attribution are inter-related and major themes in psychological theories (primarily
cognitive theories) of depression. Despite this broad interest in helplessness, it can be argued that its potential
usefulness as a scientiﬁc and clinical concept has so far not been investigated optimally, including with respect
to its application in research aimed at development of improved anti-depressant pharmacotherapy. The ﬁrst
aim of this review was to describe and integrate the psychological evidence and the neurobiological evidence
for the LH effect in rodents and healthy humans and for helplessness in depressed patients. The second aimwas
to conduct three systematic reviews, namely of rodent studies of the LH effect, rodent studies of effects of
psychopharmacological agents on the LH effect, and human studies of efﬁcacy of pharmacotherapeutic and
psychotherapeutic treatment on helplessness in depressed patients. With respect to the ﬁrst aim, the major
ﬁndings are: the speciﬁcity of the LH effect in otherwise non-manipulated rodents and healthy humans has
been under-estimated, and the LH effect is a speciﬁc learned aversive uncontrollability (LAU) effect. There is
theoretical and empirical support for a model in which a speciﬁc LAU effect induced by a life event of major
emotional signiﬁcance can function as an aetiological factor for generalised helplessness which can in turn
function as an aetiological andmaintenance factor for depression. However, to date such models have focused
on cognitive mediating processes whereas it is emotional–motivational–cognitive processes (as proposed for
the LAU effect) that need to be invoked and understood. The evidence is for analogous neural processes
underlying the LAU effect in rodents and healthy humans and helplessness in depression, with the ventro-
medial prefrontal cortex exhibiting aversive uncontrollability-dependent activity. With respect to the second
aim, the major ﬁndings are: the LAU effect is demonstrated quite consistently using a number of different
paradigms in rat but is poorly studied inmouse. The rat LAU effect can be reversed by chronic administration of
monoamine reuptake inhibitors. The effects of antidepressants on human helplessness have been scarcely
studied to-date. The major conclusion is that the LAU effect and generalised helplessness constitute major
neuropsychological concepts of high value to future translational research aimed at increased understanding of
depression and development of novel, improved antidepressant treatments.
© 2011 Elsevier Inc. All rights reserved.
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1. Introduction
1.1. Background
Mood disorders, especially unipolar depressive disorders, such as
major depressive disorder (MDD) and dysthymia, are among themost
prevalent mental disorders (Kessler, Berglund, et al., 2005; Kessler,
Chiu, et al., 2005; Kessler, Demler, et al., 2005). They place substantial
burden on individuals with these disorders and on society (Lopez
et al., 2006), and their prevalence is still increasing (Mathers & Loncar,
2006). Moreover, whilst mental disorders are strongly associated
with suicidal behaviour worldwide, mood disorders are the strongest
predictor of suicide ideation and attempts in developed countries and
suicide is among the leading causes of death (Fawcett et al., 1990;
Nock et al., 2008; Nock et al., 2009). MDD is more common in women
than in men, although the gender difference is decreasing as gender
roles becomemore equable in society (Seedat et al., 2009). Depressive
disorders affect individuals across all age groups, including children
(Merikangas et al., 2010) and the aged (Byers et al., 2010; Kessler,
Birnbaum, et al., 2010).
In the majority of cases, depression shows a high rate of recur-
rence and substantial chronicity, indicating that the disorder is
frequently not treated adequately (Gonzalez et al., 2010). Even in a
primary care setting, only about one-quarter of identiﬁed patients
with MDD achieved and maintained full remission for 18 months,
whilst another quarter failed to remit at all. The remaining patients
suffered either from residual symptoms or recurrences during follow-
up (Vuorilehto et al., 2009). Randomised clinical trials show some
efﬁcacy of several types of interventions, including cognitive beha-
vioural therapy or selective serotonin reuptake inhibitors (Gelenberg
et al., 2010). However, given the substantial percentage of subjects
who do not respond to treatment or who relapse after treatment dis-
continuation (Gelenberg et al., 2010), a better understanding of the
psychopathology and pathophysiology, and their bi-directional inter-
action, of depressive disorders is essential. In turn, this should facilitate
new and more efﬁcacious preventative and therapeutic treatments
(Belmaker & Agam, 2008).
Major depressive disorder presents as a disorder of feelings,
thoughts and somatic functions that debilitate daily functioning and,
as stated above, can be life threatening. The symptoms are heteroge-
neous and include emotional, cognitive and somatic dysfunctions that
are used tomake a nosological diagnosis. As for other mental disorders,
twonosological classiﬁcation systemsexist for depression, and these are
the Diagnostic and Statistical Manual of Mental Disorders (DSM), 4th
edition, text revision (DSM-IV, 1994) and the International Classiﬁca-
tion of Diseases (ICD), 10th edition, chapter V: Classiﬁcation of Mental
and Behavioural Disorders (ICD-10, 1994). Both DSM and ICD recognise
several forms of depressive disorder and grades of severity within these
forms. According to DSM,MDD is themost common formof depression,
and an approximate equivalent of MDD in ICD is (recurrent) depressive
episode. According to DSM,MDDwill be diagnosed if the clinical course
is one or more major depressive episodes, with each such episode
characterised by ﬁve (or more) symptoms during a minimum 2-week
period, where at least one of the symptoms is either depressed mood
(sadness, emptiness) or anhedonia (loss of interest or pleasure in
(almost) all activities). According to ICD-10, (recurrent) depressive
episodewill be diagnosed if the clinical course is one (ormore) episodes
during a minimum 2-week period of at least two of three typical/core
symptoms i.e. depressedmood, loss of interest and enjoyment, reduced
energy leading to increased fatigability and diminished activity, and at
least three (preferably four) common symptoms.
Based on describable and observable symptoms, the DSM and ICD
nosologies allow for relatively clear diagnosis of and communication
about MDD. However, the clinical entity MDD is not based on its
neuropsychopathology, i.e. the changes in psychological processes,
brain circuitry, and inter-cellular and intra-cellular brain functions,
which causally underlie the symptoms of MDD. As such, there is
incompatibility between the current diagnostic system and psycho-
logical and neurobiological research that would aim to increase
understanding of MDD neuropsychopathology and, based on this,
could lead to development of novel, improved treatments. Commen-
surate with this problem, some integration of the focus on speciﬁc
symptoms and their underlying pathology— a dimensional diagnostic
approach — is under consideration for the upcoming revision of the
DSM (Hyman, 2007). Clearly, integration and translation across a
number of disciplines in the clinical, social and biological sciences is
needed to achieve the goal of a neuropsychopathology-based system
of diagnosis and treatment in psychiatry.
The core/typical symptoms of depression can be viewed as
disrupted emotional–motivational–cognitive states. Emotions e.g.
sadness, helplessness, grief, relief, pleasure, are distinct psychological
states that vary in intensity and that arise in response to environmental
stimuli or events that are either aversive or rewarding, as processed by
the brain's punishment system and reward system (Rolls, 2000). The
punishment system and reward system are the bases of emotions, and
emotions are the bases of mood; therefore, the punishment and
reward systems are also the bases ofmood. Cognitive processes enable
the individual in her/his emotional categorisation of environmental
stimuli/events, and also allow an environmental event to be re-
experienced, or ruminated on, in the absence of its physical presence.
The MDD core symptom of depressed mood therefore constitutes
dysfunction(s) in the brain's punishment system, that manifests as
chronic hyper-sensitivity to aversive events and is associated with
symptoms/states such as sadness, pessimism, helplessness (Elliott et al.,
2002). The MDD core symptom of reduced interest and pleasure
constitutes dysfunction(s) in the brain's reward system that manifests
as chronic hypo-sensitivity to rewarding events (Haber & Knutson,
2010). In this sense, MDD shifts from an absolute, abnormal emotional–
cognitive nosological entity, to several emotional–cognitive states that
are each at the extreme end of their continuous distribution (Hyman,
2007).
Emotional–cognitive assessment of environmental stimuli/events is
not absolute, neither within individuals across time nor between
individuals. For each individual, the emotional response to a stimulus/
event is determined by: his/her alleles for genes that regulate emotional
responsiveness (Pezawas et al., 2005); the expression levels of these
alleles and their products in the speciﬁc brain regions that contribute to
emotional–cognitive circuits (Choudary et al., 2005); and his/her life
history with respect to prior emotional experiences (Caspi & Mofﬁtt,
2006; Jacobs et al., 2006). Thus, the extent towhich an aversive stimulus
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activates the punishment system and elicits an emotion such as sadness
or helplessness, or the extent to which a rewarding stimulus activates
the reward system and elicits an emotion such as pleasure, will depend
on current and prior experience as determined by genetic and
environmental factors (Berridge & Robinson, 2003; Cools et al., 2007).
Given that these same genetic and environmental factors determine
personality, then personality is logically also a major predictor of
emotional reactivity. Mood or mood state refers to the general
emotional experiences, and therefore disposition, of an individual at a
typical time point within a certain time period e.g. day, week, month.
The viewpoint has been presented above that MDD constitutes
a psychopathology of chronically altered emotional–motivational–
cognitive processing of aversive and/or rewarding environmental
events, and that genetic and environmental factors are aetiological
in the neuropsychopathology of MDD. It is of course striking that one
or more environmental events can impact mental functioning to the
extent that a healthy individual subsequently develops symptoms
of emotional–cognitive disorder. Coming now to themajor focus of this
review, it is essential to ask:What are the environmental events that are
most salient to MDD aetiology and neuropsychopathology, and why? It
is of course a substantial challenge to study life events that occur in the
contexts of e.g. employment, ﬁnance, housing, health, social relation-
ships, with the aims of identifying which of these events are relevant to
MDD and, if relevant, what their salient features are (Agid et al., 2000;
Monroe&Reid, 2008).There is strongevidence that aversive/adverse life
events occurring during development (e.g. childhood abuse, neglect)
(Green et al., 2010; Kessler, McLaughlin, et al., 2010) and/or adulthood
(Brown et al., 1995; Kendler et al., 2002; Monroe & Reid, 2008; Kendler
& Gardner, 2010) are associated with increased vulnerability to MDD
and that aversive/adverse environmental events proximate to the onset
of MDD can trigger the disorder. The adverse life event categories
identiﬁed in one major MDD study (Keller et al., 2007) were: death
of a loved one, ending of a romantic relationship, personal failure or
abandoned goal, chronic stress (due to work, ﬁnances, legal problems,
etc.), own health problems, interpersonal conﬂict between self and
other, and distress over future events. In this study, the different adverse
life events predicted different MDD symptoms: for example, death of
loved ones and romantic breakups were marked by high levels of
sadness, anhedonia andappetite loss; chronic stress andpersonal failure
were associated with fatigue and hypersomnia. It has been proposed
that themostMDD-relevant aversive/adverse life events involve threat,
loss or humiliation; are very threatening or unpleasant; are experienced
by the person directly; and are of a distinct onset i.e. acute (Brown et al.,
1995; Monroe & Reid, 2008). If such events are associated with
MDD, then they have typically occurred within 3–6 months prior to
MDD onset. With regard to childhood adversities, the strongest
associationswith (onset and persistence of) a broad spectrumofmental
disorders, including mood disorders, are found with: maladaptive
family functioning such as parental mental illness, substance abuse
disorder, and criminality; family violence; physical abuse; sexual abuse;
and neglect (Green et al., 2010; McLaughlin et al., 2010). Therefore,
it might well be that the current mood of an individual can be linked
to one or more identiﬁable major emotional events in the past, and
that this is dominating emotional processing in the present.
A further characteristic of aversive/adverse environmental events
that has been proposed to be central to MDD aetiology and
psychopathology is the uncontrollability of the event. Thus, with
respect to aetiology, if an environmental event is aversive and
uncontrollable, it will perhaps be more likely to contribute to the
aetiology of MDD than an event that is equally aversive in every other
respect but, indeed, controllable. For example, in one major study
(Kendler et al., 2003) life events that involved major loss, humiliation
or entrapment predicted MDD. Whilst it is not possible to isolate
and independently study the contribution of the uncontrollability of
these life-event dimensions, uncontrollability is certainly a major
characteristic of each of them. In the laboratory, it is possible to
manipulate the (un)controllability of an aversive event, and studies
doing so have demonstrated that uncontrollability per se is a major
determinant of behaviour, leading to the theory of the learned
helplessness effect (Seligman et al., 1971), the central theme of
this review. If an individual is exposed to a real uncontrollable
aversive life event of major emotional signiﬁcance and consequently
develops a generalised emotional–cognitive state of perceiving their
environment as uncontrollable, then this state would appear to be
central to the onset andmaintenance of MDD. Indeed, this would be the
emotional–cognitive state of (feelings of) helplessness and hopeless-
ness, as frequently reported by MDD patients (Beck & Steer, 1988). In
clinical psychology and psychiatry, the concepts of helplessness and
hopelessness have been prominent in theories of depression and its
treatment, as exempliﬁed by the various psychometric instruments
that have been developed to assess them.
In summary, the study of discrete emotional–cognitive states in
MDD can provide essential data and insights with respect to the
aetiology, pathophysiology and neuropsychopathology of the disorder
and, therefore, to its treatment. Whilst helplessness is not a symptom
according to current nosological classiﬁcation, the learned helplessness
effect is a neuropsychological process potentially of high importance
to MDD aetiology, and helplessness is an emotional–cognitive state
potentially of high importance to MDD neuropsychopathology.
1.2. Rationale for this review
The learned helplessness effect/helplessness constitutes the most
prominent example of where an emotional–cognitive psychological
concept has been proposed to be relevant to understanding and
treating MDD. Learned helplessness (LH) has been proposed to be a
major aetiological process in vulnerability to and onset of MDD
(Seligman, 1972), and helplessness has been proposed as a major
psychopathological mechanism in maintenance of MDD (Abramson
et al., 1978). Originally, the LH effect was used as an explanatory
variable for animal behaviour in the laboratory, and was subsequently
translated to human behaviour, both in healthy circumstances and
in MDD (Seligman, 1972). We are not aware of any systematic review
that aimed to integrate LH/helplessness with concepts that are central
to current psychiatry, including adverse life event aetiology, state
markers and dimensional diagnosis. Given that a major advantage of
the dimensional approach is that it is commensuratewith translational
(inter-species) research, and given that LH is a proven translational
concept, then it would appear to be logical, important and timely
to provide such a review. It should be comprehensive, considering
LH with respect to animal psychology and neurobiology; animal
modelling relevant to MDD; human neuropsychology; and MDD
and emotional–cognitive state markers of MDD. Such a review should
facilitate assessment of the utility of LH/helplessness with respect
to increasing understanding of MDD aetiology, pathophysiology,
neuropsychopathology and treatment response. Given the conceptual
and translational importance of LH/helplessness in the study of MDD,
then LH/helplessness should also be a focus of translational research
aimed at discovery, validation and development of novel therapies
for MDD. To the best of our knowledge, there has been no systematic
review of either the evidence for the effects of antidepressants and
other pharmacological classes on LH in animals, or for the effects of
antidepressants and psychotherapy on helplessness in MDD patients.
Such a comparative systematic review would provide insights into
the potential utility of helplessness as a dependent variable in anti-
depressant discovery and development.
1.3. Objectives of this review
The ﬁrst major objective of this article is to present an integrative
overviewof the theory and evidence for the psychology andneurobiology
of LH/helplessness in laboratory rodents (rats,mice), healthy humans and
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humans with depression. The second major objective is to present the
ﬁndingsof systematic reviewsofpublicationson the following themes: LH
in rats and mice in terms of the laboratory paradigms used and whether
LH was demonstrated; effects of pharmacological interventions on LH in
laboratory rodents; randomised control trials into effects of pharma-
cotherapeutic interventions, psychotherapeutic interventions, or com-
bined pharmaco-/psycho-therapeutic interventions, on helplessness in
MDD patients. Based on the ﬁndings of the ﬁrst two objectives, the third
objective is to clarify the current status of LH/helplessness as a
translational research concept in MDD, and to make recommendations
for future research strategyviawhich the studyofhelplessness canmakea
signiﬁcant contribution to MDD research and to discovery and develop-
ment of improved antidepressant therapies.
2. Integrative overview of the learned
helplessness effect, helplessness and depression
2.1. Protocols, theory and evidence
for the learned helplessness effect and helplessness
2.1.1. Rodents
2.1.1.1. The learned helplessness effect paradigm. Solomon, Seligman,
Overmier and Maier were studying animal operant learning, and the
development of theories which could account for how animals learn
associations between their behaviour and the occurrence of rewarding
or aversive events (e.g. the two-process theory of avoidance learning,
Rescorla & Solomon, 1967). Iconoclastically, they focused on the
contingencywhere the probability that an aversive eventwill terminate
following any behaviour is exactly equal to theprobability that the same
event will terminate in the absence of any behaviour. This, as Seligman
and colleagues emphasised, is the response-aversive event contingency
of uncontrollability (or the zero-operant contingency) (Fig. 1A) (e.g.
Overmeier & Seligman, 1967; Maier & Seligman, 1976). For example: if
the aversive event is an electro-shock (e-shock) administered to a rat in
a 2-way shuttle box and the rat can always terminate the e-shock (i.e.
escape) by moving from the side of the box it is occupying to the
opposite side, then the rat will learn this contingency and exhibit such
shuttling (escape) behaviour in response to e-shock. Now, if the
contingency is that the termination of the e-shock is externally
controlled, there will be no predictable relationship between any
behaviour in the rat's repertoire (e.g. shuttle, jump, turn) and the
termination of the e-shock. That is, the rat experiences uncontrollability
of an aversive environmental event. Seligman and colleagues observed
that experiencing uncontrollability of aversive events at one point in
time and in one situation leads to animal subjects behaving in the same
or a new situation as if there was still no response-aversive event
contingency. The important difference was, though, that in this second
experimental phase there was indeed a contingency i.e. escape
responses were now possible but were not exhibited (Fig. 1A).
Furthermore, even if escape responses were exhibited they did not
lead to the learning of consistent escape responding. This observation
was described as the learned helplessness effect.
The term LH effect is anthropocentric as applied to animal
behaviour: helplessness is an emotional feeling that can be ascribed
and quantiﬁed in humans on the basis of their verbal or written
responses to questions. It cannot be ascribed on the basis of
behavioural observation in humans and this is also true for animals,
of course. Indeed, the term interference effect (e.g. Anisman & Merali,
2001) ismore objective. Nonetheless, one of themajor strengths of the
LH effect was — and compared to many paradigms used currently,
most certainly still is — the robust, unambiguous and objective
manipulation used to induce it. Animal subjects are assigned at
random to the treatment groups. The durations of the aversive stimuli
experienced by the “no aversive control (NAC) group” are determined
by and equal to the latencies tomake escape responses to these stimuli
exhibited by the “aversive control (AC) group”. Using this so-called
yoked design, the number, intensity and duration of the aversive
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(B) Learned helplessness effect: Psychological causality
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Fig. 1. Schematic presentation of the learned helplessness effect proposed by Seligman and colleagues, in terms of (A) experimental procedure and (B) causality at the psychological
level. (A) The LH effect is demonstrated using a two-phase experimental design. The pre-exposure phase involves dividing subjects at random into three groups, aversive control
(AC, referred to in the case of e-shock studies as escapable e-shock, ES), no aversive control (NAC, inescapable e-shock, IS) and Naive to aversive stimuli (Naïve, no e-shock, NS). The
AC and NAC groups are exposed to a series of aversive events/stimuli, typically electro-shock, each of which has a maximum duration e.g. 5 s or 30 s. The AC subjects are able to
terminate each aversive event via a speciﬁc operant behaviour, typically an active motor response. The AC subjects acquire the appropriate response via reinforcement, learning the
contingency between behaviour and e-shock termination, with the relief of the latter the presumed major emotional response and major incentive-motivational factor. The latency
to perform AC to each e-shock determines the duration of the e-shock presented to the paired (yoked) NAC subject. NAC subjects cannot terminate the e-shock; no speciﬁc response
is reinforced any more (or any less) than any other response. On the day following the (last) pre-exposure session the test phase is conducted: all subjects are exposed to aversive
events/stimuli, typically e-shocks, and are able to terminate each aversive event via a speciﬁc operant behaviour, typically an active motor response. Subjects in the AC and Naive
groups exhibit active motor responses and acquire and exhibit the operant response that terminates (controls) aversive events. Subjects in the NAC group exhibit reduced active
motor responses and do not acquire and exhibit the operant response that terminates (controls) aversive events. (B) The psychological causality of the LH effect is proposed to
comprise three components, emotional, motivational and cognitive. AC subjects acquire the control response via reinforcement, with the relief of e-shock termination the presumed
major emotional response and the major incentive-motivational factor. NAC subjects learn the absence of both contingency between responding and e-shock termination and of
reinforcement. Any relief of e-shock termination is independent of behaviour. This could increase the aversive valence of the e-shock and the emotional response to it and to the
environment in which it occurs. This could lead to reduced incentive-motivation to engage in behaviour that might terminate e-shock. The deﬁcit in control responses is expressed
during the test phase, suggesting that these cognitive, emotional and motivational effects pertain beyond the situation that induced them. Nonetheless, they could have speciﬁcity
with respect to the circumstances inwhich they are exhibited and to longevity. Therefore, learned aversive uncontrollability (LAU)might be amore parsimonious descriptor than LH,
with a chronic LAU being a necessary pre-requisite of generalised LH.
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stimuli experienced are identical in the two groups. Accordingly, the
reduced number and/or the increased latency of escape responses
exhibited by the NAC group in the test phase of the experiment can
be attributed to the prior experience of uncontrollable aversion
speciﬁcally (Fig. 1A). That is, the LH effect is a model for the study
of the effects of uncontrollability of aversive events on subsequent
behaviour with respect to events that are controllable but are not
perceived as such.
A further important characteristic of the animal experiments used
by Seligman and colleagues to demonstrate the LH effect was the
triadic design. That is, in addition to the AC and NAC groups there is
a third group, the “naive to aversive stimuli (Naive) group”, which is
pre-exposed to the context without the explicit aversive stimuli
(Fig. 1A). The Naive group is essential in order to control for the
possibility that animals in the AC group are acquiring a speciﬁc form of
escape behaviour in the context of the ﬁrst (pre-exposure) phase and
then using this to perform escapes in the second (test) phase. If this
were the case, then the Naive group would behave similarly to the
NAC group. As demonstrated by Seligman and colleagues, and
subsequently by other groups, this is not the case and the Naive
group exhibits a high level of escape behaviour comparable to the AC
group, with the NAC group exhibiting a deﬁcit relative to both of these
groups. That is, the subjects in the AC group exhibit natural escape
responding during the ﬁrst and second phases of the LH protocol and
the NAC group cannot do so during the ﬁrst phase and consequently
does not do so during the second phase. The triadic design is essential
where the LH effect is induced in one situation (e.g. wheel turning is
the operant that terminates/fails to terminate tail e-shock) and tested
in a different situation (e.g. two-way shuttling is the operant that
terminates paw e-shock). If the same situation (e.g. two-way
shuttling) is used for both phases then the LH effect cannot be
attributed to speciﬁc learning during the ﬁrst phase and the Naive
group becomes redundant (in effect the Naive group would be a
second AC group). It is justiﬁable, therefore, to study the LH effect
without the Naive group under these conditions. However, it is not
possible to study the LH effect without the AC group, i.e. by
comparison of an NAC group with a Naive group. As expected, such
a comparison does yield an escape deﬁcit in the NAC group: this
deﬁcit is described as the US pre-exposure effect (Randich & LoLordo,
1979) and is fundamentally different to the LH effect because it is not
measuring the effect of aversive uncontrollability, the central tenet of
the LH concept. As illustrated by the two systematic reviews of animal
studies reported on in this paper, the US pre-exposure design has
been used inmany studies and is often inaccurately reported as the LH
design (see Appendix A Fig. A1).
2.1.1.2. Psychological causality of the learned helplessness effect. As an
explanation for the LH effect at the psychological level, Seligman and
colleagues proposed that three intervening processes underlie the
development of the deﬁcit in the control response as exhibited by the
NAC group; namely, emotional, motivational, and cognitive (Fig. 1B)
(Maier & Seligman, 1976). The emotional process in the LH effect is
an increase in negative emotion, inferred from observations that
NAC rats exhibit altered behavioural repertoires and physical status
during the test phase and in the home cage. These include increased
stereotypy, decreased appetitive discrimination, altered feeding
behaviour, and increased ulceration and heart rate. The motivational
process is a reduced motivation to escape, inferred from observations
in the test phase that NAC rats exhibit a reduced physical response
to the aversive stimulus (e-shock) relative to the AC and Naive
rats. That is, it is not the case that NAC rats are exhibiting the same
level of physical activity during e-shock as are AC rats but that this is
non-directional and therefore does not result in escape. Rather, the
motor response is reduced, and could indicate a deﬁcit in incentive-
motivation to escape. The cognitive LH process is reduced ability
to detect an association between an adaptive behavioural response
and the consequences of that response. This was inferred from the
ﬁndings that NAC rats do exhibit some escape responses, even at the
beginning of the test phase, but do not exhibit a learning curve, i.e.
escape responses do not become more frequent as a consequence of
escape responding as the escape test progresses. Given that rodents
exhibit goal-directed behaviour (Toates, 1986; Balleine & Dickinson,
1998), then it might be that this deﬁcit is due to development of
reduced expectancy that behavioural responding will exert predict-
able, reinforcing effects on the environment (Fig. 1B).
Alternative explanations have been proposed for the LH effect that
would, if supported by the evidence, certainly question the relevance
of the LH effect to the translational study of the inter-relationships
between uncontrollability, helplessness and MDD. For example, it has
been proposed that the deﬁcit in the control response exhibited by
the NAC group reﬂects a psychomotor deﬁcit i.e. escape responding in
the test phase requires a vigorous motor response of which NAC
subjects are not physically capable. Evidence purported to support
this interpretation of the LH effect includes the demonstration that
NAC mice exhibit reduced locomotion in an open ﬁeld test as well as
a two-way escape deﬁcit in the LH test phase (e.g. (Anisman et al.,
1978a)). Of course, even if the deﬁcit in the control phase is due to a
motor deﬁcit, this still begs the question of why this is speciﬁc to the
NAC group, given that the amount of aversive stimulus pre-exposure
received is equal to that received by the AC group. It is also important
to note that psychological and psychomotor explanations are not
mutually exclusive, particularly given that psychomotor retardation
is a common symptom of MDD (DSM-IV, 1994).
Altered nociception dependent on the controllability of painful stimuli
applied in the pre-exposure phase has also been proposed as an
explanatory variable: uncontrollable e-shocks have been proposed to
lead to an analgesic effect relative to identical e-shocks that
are controllable (Whitehouse et al., 1985). Such an effect would be
problematic given that the control response deﬁcit in NAC subjectswould
then be due to reduced sensitivity to the aversive stimulus during the test
phase relative to AC counterparts. Using independent measures of pain
sensitivity, e.g. thehot plate test, to study effects of e-shock onnociception
has not yielded evidence that mice exposed to e-shocks exhibit reduced
nociception (Chourbaji et al., 2005). If pain sensitivity is reduced by
uncontrollable painful stimuli, then hyper-activity in the endogenous
opiate system would be a candidate mediating mechanism. As reviewed
below (Section 3.3.3), pharmacological studies do not provide strong
support for this interpretation,with sub-chronicmorphine administration
actually increasing escape behaviour in the NAC group.
2.1.1.3. From learned helplessness effect to generalised helplessness?.
Therefore, the robust and observable LH effect in rodents might be
mediated by a complex constellation of psychological processes: When
an aversive event occurs it causes a heightened state of negative
emotionality. The subject is motivated to terminate this aversive state
and any behaviour that does sowill result in relief and be reinforced and
therefore repeated, based on the expectation that the aversive event
can be controlled (Maier & Seligman, 1976). If the subject learns that its
behaviour cannot control the aversive event then the negative
emotionality will persist, the expectation that the aversive event
can be controlled will decrease, and the motivation to control it will
decrease, as will the abilities to learn that the contingency has changed
and to acquire the expectation that the aversive event can be controlled.
Accepting the evidence for the LH effect, and the explanation that it
has emotional, motivational and cognitive components, it is essential
to consider the inter-relationships between the LH effect in rodents and
(i) a state of helplessness in rodents, and (ii) the LH effect, helplessness
andMDD, in humans.We discuss inter-relationship i here and the inter-
relationships ii in the next section.
The classical design of LH experiments in rats involves exposing
subjects to aversive stimuli in one environment and testing for aversive-
stimulus escape behaviour in a different environment (see section
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3.2.2.1). Typically, the formof the aversive stimuluswill be similar inboth
phases/environments, e.g. painful e-shock, but the nature of the stimulus
delivering the aversive stimulationwill be different, e.g. metal rod on tail
at pre-exposure phase versus grid ﬂoor at test phase. Maier andWatkins
(2005) refer to this set-up and the demonstration of the LH effect with it,
as trans-situationality. Indeed, they propose that such trans-situation-
ality provides evidence that the LH effect is generalised. Furthermore,
they argue that the processesmediating trans-situational LH andwithin-
situational LH could well be different (Maier & Watkins, 2005). For
example, fear conditioning to context couldbemore important inwithin-
situational LH.Whilst thedemonstrationof the trans-situational LHeffect
certainly provides evidence for a psychological state that is generalised,
this state is also temporary, with a duration of several days maximum
(Maier & Watkins, 2005).
A further issue of generalisation is whether the LH effect persists
when the form or intensity of the stimulus used in the test phase is
altered. For example, e-shock amplitude could be greater at test than
at pre-exposure. This example has been investigated, with the ﬁnding
being that NAC rats exhibit similar levels of escape behaviour to AC
rats i.e. no LH effect (Jackson et al., 1978). This indicates that the
LH effect can be speciﬁc rather than generalised. Another approach
has been to compare operant behaviour for reward in NAC versus
AC subjects and this has provided evidence for a generalised deﬁcit:
The paradigm used was signalled-punishment suppression of
operant behaviour for reward, in which a tone CS signalled periods
when subjects would be punished for operant responding. The NAC
rats exhibited reduced CS-suppression of responding, suggesting a
cognitive deﬁcit in learning a contingency between their behaviour
and aversive outcomes. One caveat with respect to interpreting this
ﬁnding as evidence for generalised helplessness is that the aversive
stimulus in both the LH effect and the signalled punishment
experiments was the same i.e. e-shock (Jackson et al., 1978; Pryce &
Seifritz, 2011). It will be important to test additional forms of aversive
stimuli in LH subjects to try and increase the robustness of an
interpretation of generalised helplessness.
The extent to which an LH effect extends to a generalised
helplessness effect is very likely to depend on the severity of the
aversive stimulation during the pre-exposure phase. As can be seen
from the studies listed in Tables 2 and 3 (Section 3.1), there is marked
variation in the duration and intensity of aversive pre-exposure
deployed across studies: e.g. the wheel-turn tail e-shock paradigm
uses 30-s maximum duration and two-way paw e-shock often uses 5-s
maximum duration. There could well be a positive association between
severity of aversive stimulation and extent of generalised helplessness
developed. However it also needs to be emphasised that the more
severe the aversive stimulus is for theNACgroup then themore severe it
is for the AC group also. A severe aversive stimulation, e.g. long latency
until escape possible in the AC group, during the pre-exposure phase
might lead to a statistical LH effect but a generalised helplessness
effect might then pertain in both the NAC and AC groups, such that
the aversive stimulation per se and not its controllability would be
responsible, thereby rendering the study irrelevant to the relationship
between uncontrollability, helplessness and depression.
Finally, it is important to note that, in addition to the LH effect,
NAC animals could exhibit additional states of translational relevance to
depression symptoms, such as weight loss, sleep disturbance, anhedo-
nia. If this is the case, then it could well constitute strong supportive
evidence for a generaliseddepression-relevant state that includes, and is
also causally attributable to, the LH effect (see Discussion).
2.1.1.4. Translational validity of the learned helplessness effect.
The validity of the LH effect in rodents as a translational model of
relevance to MDD is, of course, dependent on the relevance of human
LH and helplessness to MDD, and these issues are discussed next.
According to the validity criteria proposed for animal models of
human mental disorders (Willner, 1984; Markou et al., 2009), the
rodent LH effect has high validity as a model for a human LH effect:
There is aetiological validity with respect to aversive uncontrollability
being the unambiguous causal factor in both rodents and humans.
There is construct validity with respect to changes in emotion,
motivation and cognition due to experiencing uncontrollable aversive
event(s) appearing to underlie, at the psychological level, the
perception of future events as uncontrollable, in both rodents and
humans. There is face validity with respect to a deﬁcit in goal-directed
operant responding to controllable aversive events being the major
dependent variable in both rodents and humans.
As noted above, the extent of the translational validity of the LH
effect in rodents to the study of human MDD depends not only on the
robustness of the LH effect, and of its generalisation to a helplessness
state, but also on the relevance of a human LH effect and human
helplessness to MDD risk, onset and maintenance. Consideration
of these inter-relationships in humans needs to be carried out in a
step-wise manner, by providing evidence relevant to the following
questions: Can the LH effect be demonstrated in healthy humans
using laboratory paradigms? Is the experience of uncontrollable
aversive events a major aetiological factor in MDD onset? Do MDD
patients exhibit increased helplessness relative to healthy control
probands in laboratory LH paradigms? Is assessment of the general
controllability of events reduced in MDD and, if yes, does this
contribute to the maintenance of MDD? Is there evidence that the
emotional, motivational and cognitive mediating processes proposed
for the animal LH effect also pertain in humans and particularly so in
MDD patients? Is reduction of helplessness therapeutic in MDD?
We now proceed to a concise review of the evidence pertinent to
the above questions on human LH effect–helplessness–MDD.
2.1.2. Humans
2.1.2.1. Laboratory learned helplessness paradigms. The two-phase
(aversive pre-exposure, aversive test)×three group (AC, NAC, Naive)
paradigm designed to investigate the LH effect in animals has been
translated directly into laboratory paradigms for the study of the
LH effect in healthy humans. These studies have been reviewed
elsewhere (e.g. Hiroto, 1974; Abramson et al., 1978; Miller & Norman,
1979) and will be summarised here, in terms of design, ﬁndings and
interpretation. As in animal LH effect paradigms, either the same or a
different aversive stimulus has been used in the pre-exposure phase
and the test phase, in human LH effect studies (Fig. 1A). Aversive
stimuli used have been either a painful noxious stimulus such as an
e-shock to the ﬁnger or heat shock to the wrist, a noxious loud noise,
or a non-noxious high-demand cognitive task. Each of these stimulus
types has beenused at the pre-exposure phase and/or the test phase, in
various combinations. At the pre-exposure phase, the AC group is
given either a noxious escapable stimulus, e.g. press a button to
terminate an e-shock, or a solvable cognitive task. The NAC group is
given, respectively, either a noxious inescapable stimulus, the duration
of which is yoked to the escape latency of the AC group, or an
unsolvable cognitive task, and theNaive group is not given any stimuli.
At the test phase, all groups are given either a noxious escapable
stimulus or a solvable cognitive problem and the level of their control
responding ismeasured. Typically, both the inability to escape noxious
stimulation or to solve cognitive problems in the NAC group, induces
deﬁcits in the test phase, on either escaping escapable noxious stimuli
or solving solvable cognitive tasks, relative to the other two groups.
With regards to the psychological process(es) mediating the LH effect,
Seligman and colleagues have, as in animals, proposed that induction
of a cognitive state of non-contingency between (own) behaviour and
environmental events is a major mediating factor (Abramson et al.,
1978). Other authors (e.g. Buchwald et al., 1978) have proposed that it
is not necessary to infer non-contingency as a mediating mechanism;
rather, uncontrollability at the pre-exposure phase is proposed to be
responsible for failure at the test phase. However these authors have
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not provided an alternative explanation in terms of what process
mediates the observed effects of uncontrollability.
In addition to the 2 phase×3 group design that is essential to study
the LH effect, cross-over designs have also been used in humans to
study the effects of aversive stimulus (un)controllability on task
performance and on self-reports of feelings of control and helpless-
ness. Such designs might require fewer subjects, and have typically
been the designs of choice in studies that have compared effects
of uncontrollability in MDD patients versus healthy probands. All
subjects are studied across either two or three consecutive phases, i.e.
either an initial NAC phase is followed by an AC phase (e.g. Bolz &
Giedke, 1981), or an initial AC phase is followed by an NAC phase (i.e.
withdrawal of control), which in turn is followed by a second AC
phase (i.e. reinstatement of control e.g. Diener et al., 2009). The major
outcomemeasures are: does the NAC phase result in a deﬁcit in the AC
phase; do subjects report reduced feelings of control during NAC;
do subjects report increased feelings of helplessness during NAC.
Studies using cross-over designs have typically not demonstrated
a deﬁcit in the control response (e.g. latency to button press to
terminate e-shock) following reinstatement of AC but do nonetheless
induce states of reduced controllability and increased helplessness
as based on self-report (e.g. Diener et al., 2009). Furthermore, cross-
over designs have demonstrated phase-speciﬁc differences in con-
trollability and helplessness state betweenMDD and healthy subjects,
as reported below (section 2.2.2).
2.1.2.2. Helplessness as a consequence of uncontrollable life events. In the
laboratory, exposure to (un)controllable aversive events will typically
lead to the LH effect in animals and humans (Maier & Seligman, 1976;
Abramson et al., 1978). However, in animals and humans, generalised
helplessness is certainly not a necessary consequence of uncontrollable
real-life events. It has been proposed that uncontrollable outcomes will
only be sufﬁcient to induce generalised helplessness if the estimated
probability of the occurrence of a highly aversive outcome is high or of
the occurrence of a highly desired outcome is low (Abramson et al.,
1978). As noted above (Section 1.1), life events that involve severe
forms of loss, humiliation or entrapment that are beyond the
individual's control do indeed predict MDD (e.g. Kendler et al., 2003).
2.1.2.3. Learned helplessness theory of depression: original. The LH effect
was put forward as an aetiological explanation for animal behaviour
and then human behaviour in a set of speciﬁc test conditions, and
emotional, motivational and cognitive processes were invoked. The
extent to which the LH effect should, if at all, be extrapolated to a
learned helplessness theory of depression has been a matter of debate,
even among the original proponents of the LH effect. Abramson,
Seligman, and Teasdale (Abramson et al., 1978) argued that “the
learned helplessness hypothesis claims that depressed affect is a
consequence of learning that outcomes are uncontrollable” (p. 50).
However,Maier andWatkins stress that the learnedhelplessness theory
was not developed in order to provide an animal model of depression
or of any other clinical condition: “Indeed, the word ‘depression’ did
not appear in any of the original papers concerning this phenomenon,
and did not do so for at least 7 years. The term behavioural depression
was not used to describe stressor controllability phenomena till some
15 years later (…).” (p. 830) (Maier & Watkins, 2005). Furthermore,
they argue that consequences of exposure to uncontrollable stressors
are equally similar to symptoms of depression and symptoms of
extreme anxiety, and sensitive to both antidepressants and anxiolytics
(Maier & Watkins, 2005).
Nonetheless, during the past four decades, the LH effect has
been extrapolated to a model of depression and to the LH theory
of depression. In referring to the LH effect, Seligman observes: “Such
uncontrollable events can signiﬁcantly debilitate organisms: they
produce passivity in the face of trauma, inability to learn that
responding is effective, and emotional stress in animals, and possibly
depression in man.” (p. 407) (Seligman, 1972). Seligman stresses the
multiple parallels between animal behaviour in the LH paradigm and
features of depression in humans. Both animals in the LH paradigm and
humans suffering from depression show “reduced response initiation as
well as a ‘negative cognitive set’ — difﬁculty in believing or learning that
one's own responses will succeed even when they do” (p. 411). He also
alluded to neurobiological parallels between the two conditions (Selig-
man, 1972). Furthermore, already in the late 1960s, studies showed that
through behavioural interventions it was possible to reverse or prevent
learned helplessness in animals (Seligman &Maier, 1967; Seligman et al.,
1968), and Seligman interpreted these ﬁndings as an analogue to
prevention and intervention in humans (Seligman, 1972).
In sum, the LH effect as described in animals and humans was by
some, and soon after its initial description, reformulated as a theory to
account for the psychopathology of depression.
2.1.2.4. Learned helplessness theory of depression: reﬁned. Approximately
10 years after its original formulation, the LH theory of depression
underwent a major revision to embrace a more differentiated picture
of cognitive processes related to helplessness in humans. This revision
followed the general acceptance of cognitive processes as being of
scientiﬁc interest in (clinical) psychology (often referred to as the
‘cognitive turn’) and drew on previous concepts, such as attribution
theory (Heider, 1958; Rotter, 1966; Abramson et al., 1978). Some authors
have stated that from the very beginning, the LH concept included a
“cognitive” component, in that it postulated that mere exposure to
uncontrollability is not sufﬁcient to induce helplessness; rather the
organism must come to expect that outcomes are uncontrollable
(Abramson et al., 1978). Nonetheless, until the late 1970s, a differentiated
picture of cognitive processes related to LH theory was lacking.
According to Seligman and colleagues, the need for the revision was
basedon threemajorproblemswhenapplying a LH theory tohumans and
depression: i) the theory did not distinguish between cases in which
outcomes are uncontrollable for all people and cases in which outcomes
are uncontrollable only for some people (universal versus. personal
helplessness); ii) the theory did not explain when helplessness is speciﬁc
and when it is general; and iii) the theory did not explain when
helplessness is acute and when it is chronic (Abramson et al., 1978).
According to the revised helplessness theory, it is not necessarily
low control over the environment itself, but rather how an individual
subjectively perceives his control over a situation. How subjects
attribute their current loss of control is argued to be the central
process (Abramson et al., 1978). Once an individual perceives non-
contingency, he/she attributes it to a cause. This cause can be stable or
unstable, global or speciﬁc, and internal or external. Moreover, the
individual will perceive helplessness as personal (the person expects
the outcome is contingent on a response in the repertoire of a relevant
other) or universal (the person expects the outcome is not contingent
on a response in the repertoire of any relevant other). The attributions
will inﬂuence whether expectation of future helplessness will be
chronic or acute, broad or narrow, and whether helplessness will
lower self-esteem or not (Abramson et al., 1978).
The LH theory of depression has since undergone several smaller
speciﬁcations and reﬁnements. Ten years after the Abramson–Selig-
man–Teasdale reformulation, another major extension of the LH
theory of depression, the ‘hopelessness theory of depression’, was put
forward (Abramson et al., 1989). This introduced hopelessness
depression as a subtype of depression, stating that hopelessness is a
sufﬁcient cause of depression, deemphasising the relevance of causal
attributions and instead emphasising inferred negative characteristics
about the self (Abramson et al., 1989). Most empirical data have been
supportive of such a hopelessness depression subtype (Spangler et al.,
1993; Joiner et al., 2001).
Therefore, the LH effect provides an aetiological explanation for
how experience of uncontrollable aversive stimuli leads to a deﬁcit in
control and invokes emotional, motivational and cognitive processes,
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in animals and humans. The original LH theory of depression proposes
that human depression is a cognitive deﬁcit in perceiving an association
between own behaviour and environmental events; it is not a theory of
depression aetiology and does not invoke emotional or motivational
processes. The reﬁned LH theory of depression is a reﬁnement of the
description of the cognitive deﬁcit, and is also not a theory of depression
aetiology and continues to de-emphasise the relevance of emotional and
motivational processes. Perhaps for theﬁrst time, therefore, Fig. 2presents
a hypothetical model that extends the LH effect to a learned helplessness
hypothesis of depression aetiology, onset and maintenance, invoking
emotional, motivational and cognitive processes.
2.1.2.5. Helplessness rating scales and their relationship tomajor depressive
disorder. Numerous psychometric instruments have been developed to
capture concepts that fall in the broad ﬁeld of helplessness, such as
causal attribution, locus of control or perception of control (Lefcourt,
1991). The BeckHopelessness Scale (BHS) (Beck & Steer, 1988) is one of
the most commonly used of these instruments worldwide. Using the
BHS it has been shown that subjects diagnosed with depression show
higher rates of hopelessness than unaffected individuals (Beck & Steer,
1988). Hopelessness is also related more generally to current state
of health, perceived health, disability, and some socio-demographic
variables (Hamzaoglu et al., 2010). Since the development of the
revised LH theory of depression, numerous studies have conﬁrmed the
association between helplessness, attributional style and depressive
disorders (Nolen-Hoeksema et al., 1992). Appropriately, the extent
of causality in the association of helplessness attribution/feeling
of hopelessness with depression has been a matter of debate. As an
important indication that cognitions related to helplessness (assessed
with an attributional style questionnaire) are at least markers of
depression, Seligman and colleagues (Seligman et al., 1988) showed
that in patients with unipolar depression treated with cognitive
therapy, both explanatory style and depressive symptoms improved
by the end of therapy; moreover, changes in explanatory style were
correlated with change in depressive symptoms. However, as this
study did not include a randomised intervention (experimental
manipulation) component, conclusions about the causality between
helplessness related cognitions and depression are not possible.
Taking the explanation proposed for the LH effect, that it is the
product of emotional, motivational and cognitive effects of exposure
to uncontrollable aversive stimuli, then helplessness should probably
also be studied as a composite of these three processes, and not as
a speciﬁcally cognitive domain. This might then lead to increased
understanding of the role of helplessness in the aetiology of MDD and
as a state marker of MDD (Pryce & Seifritz, 2011).
2.1.2.6. Comparison of major depressive disorder patients and controls
on laboratory LH paradigms. As emphasised above, care needs to be
taken whenever bringing together discussion of the LH effect with
discussion of MDD, its aetiology, onset and maintenance. The cross-
species demonstrations of the LH effect do not by anymeans constitute
evidence that LH is involved in the aetiology, onset or maintenance of
MDD, or that the psychological processes that underlie LH are also
causally involved in MDD. At the same time it is pertinent to discuss
experimental designs that would further understanding of the inter-
relationships between the LH effect, helplessness and MDD. In this
respect the obvious experiment is to apply the 2 phase×3 pre-
exposure group design to MDD versus healthy control subjects, with
subjects allocated at random to their respective pre-exposure groups.
This design and the outcome predictions are presented in Fig. 3. There
are actually very few studies to-date that have used this design. Those
that have were carried out primarily by Seligman and colleagues
(e.g. Abramson et al., 1978). They provide supportive evidence
for the outcomes depicted in Fig. 3. Namely, that healthy subjects
pre-exposed to NAC exhibit, relative to healthy subjects pre-exposed
to AC, a similar deﬁcit in control response at test phase to depressed
subjects pre-exposed to AC, whereas depressed subjects pre-exposed
to NAC exhibit a marked deﬁcit in control responding. However, in
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Fig. 2. Extension of the LH effect to an LH hypothesis of depression aetiology, onset and maintenance. The pre-exposure phase of the LH effect paradigm is replaced by an aetiological
phase, where an uncontrollable aversive life event occurs and the individual experiences the uncontrollability as an absence of reinforcement in the form of failing to ﬁnd a response
that brings relief from the aversive event. A speciﬁc LH effect ensues. If sufﬁciently severe and chronic, the LH effect will induce pathophysiological processes that underlie onset of
generalised helplessness. The generalised helplessness will include increased emotional reactivity to aversive but every-day stimuli, reduced motivation to engage these aversive
every-day stimuli, and reduced cognitive expectancy that these aversive every-day stimuli are controllable. The generalised helplessness state will induce additional
pathophysiological processes that induce (additional) symptoms of depression.
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Fig. 3. Experimental design and predictions of outcome for comparison of depressed versus healthy proband performance in the LH paradigm. Healthy probands and depressed
probands are both allocated at random to AC or NAC groups for the pre-exposure phase. In the test phase, all probands are exposed to an AC test, and the control response is
measured. It is hypothesised that the amount of the control response will differ between the groups as follows: Healthy×ControllableNHealthy×Uncontrollable=
MDD×ControllableNMDD×Uncontrollable. In addition to measuring the control response, it is also possible to assess subjects on a helplessness scale or a controllability scale at
each stage of the paradigm. It is also possible to utilise the paradigm in an fMRI context.
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these studies, the validity of the diagnostic status of the depressed
subjects (typically, undiagnosed students who scored high on the
Beck depression scale) and therefore the validity of the ﬁndings, have
rightly been questioned (e.g. Buchwald et al., 1978).
There would appear to be a need for further such studies, therefore.
Furthermore, test phase responses should be integrated with psycho-
metric scores for controllability and helplessness, and the behavioural
and psychometric measures should be intergrated with neurobiological
studies, using functional imaging techniques.
2.2. Neurobiological regulation and correlates
of the learned helplessness effect and helplessness
2.2.1. Rodents
Given that the LH effect is likely mediated by emotional,
motivational and cognitive processes and their complex interaction,
the neurobiology of LH is also complex. Several substantive reviews of
speciﬁc, major aspects of the neurobiology of the LH effect in rodents
exist (Anisman et al., 1979; Weiss & Simson, 1986; Maier & Watkins,
2005). The current evidence for the brain regions, neurocircuits,
neurotransmitters, neuropeptides and receptors involved is reviewed
here brieﬂy (and in Fig. 4A), but sufﬁciently to allow comparison with
the human evidence derived from imaging studies, as reviewed below.
The neurobiology of acute responding to aversive stimuli and the
evidence for chronic effects of aversive stimuli on neurobiology, per
se, i.e. regardless of whether or not the stimuli are controllable, are
obviously relevant to the neurobiology of the LH effect. With respect
to brain regions involved in processing aversive stimuli, there is
evidence, obtained primarily with the rat, for important involvement
of: speciﬁc brain-stem nuclei including the dorsal raphé nucleus
(DRN) and locus coeruleus (LC); the amygdala, periaqueductal grey
(PAG), habenula, hippocampus and hypothalamus; and the prefrontal
cortex (PFC), including the prelimbic (PL) region, infralimbic (IL) region
and anterior cingulate cortex (ACC) (Millan, 2003). With respect to
neurotransmitters, serotonin (5-HT) (Maier & Watkins, 2005; Ansorge
et al., 2007), noradrenaline (NE) (Arnsten, 2009) and dopamine (DA)
(Moghaddam, 2002) have important neuromodulatory effects on
acute responding to aversive stimuli, and these monoamines and their
receptors can be modiﬁed by chronic exposure to aversive stimuli
(Duman et al., 1997). The major excitatory neurotransmitter glutamate
and the major inhibitory neurotransmitter gamma-aminobutyric
acid (GABA) mediate acute responses to aversive stimuli within and
between regions (Moghaddam, 2002; Hashimoto, 2009), and their
signalling functions are modiﬁed by chronic exposure to aversive
stimuli, including via modiﬁed neuron-glia interactions (Sanacora et al.,
2008). A number of neuropeptides and hormones, including cortico-
trophin releasing factor (symbol approved by the Human Genome
Organisation Gene Nomenclature Committee is CRH) and corticoste-
rone, are acutely and chronically increased by aversive environmental
exposure (Koob, 1999; Maier & Watkins, 2005).
With respect to the neurobiology of stimulus (un)controllability,
evidence has been obtained using various methods, including
immediate–early gene (e.g. Fos) expression, lesioning, and pharma-
cological infusion. In mouse, Fos expression was compared in e-shock
AC, NAC and Naive subjects, in amygdala, hypothalamus, LC and DRN.
In each of these regions, Fos protein was increased in the NAC mice
relative to the other two groups which were similar to each other,
thereby indicating acute signalling of aversive uncontrollability per se
(Liu, Tang & Sanford, 2009). Using lesioning, it has been demonstrated
in rat that an intact DRN, during both pre-exposure and test phases, is
necessary for NAC to lead to deﬁcits in the control response (Maier
et al., 1993). Processing of the (un)controllability of an aversive
stimulus requires integration of somatosensory input indicating
aversive stimulation onset/offset with somatomotor feedback indi-
cating when a motor response has been made. The cortex is the
primary region of such sensory–motor integration. The ventro-medial
PFC (vmPFC) of the rodent brain is the analogue of the ACC of the
human brain (Ongur & Price, 2000; Brown & Bowman, 2002). The two
major regions of the rodent vmPFC are the PL and IL cortices, and, in
rat at least, these two regions account for nearly all of the cortical
input to the DRN (Gabbott et al., 2005). This input takes the form of
long-range glutamatergic projections, which synapse on GABAergic
interneurons in the DRN that project to 5-HT synthesising neurons
of the ascending 5-HT system (Jankowski & Sesack, 2004). Under
conditions of vmPFC activation, therefore, this circuitry exerts an
inhibitory effect on 5-HT release from the DRN (Celada et al., 2001),
that would perhaps counter-act the direct excitatory inputs to the
DRN from regions such as the amygdala via, for example, synaptic
CRH release (Mo et al., 2008; Magalhaes et al., 2010).
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Fig. 4. Schematic representations of current evidence for (A) regulation of the learned
helplessness effect in rat and (B) correlates of helplessness in human depression. (A) In
rat there is evidence that the controllability of aversive stimuli is processed by and
controls output from the ventro-medial prefrontal cortex (PFC). This PFC output is in
the form of glutamate projections to GABA (G) interneurons in the dorsal raphé nucleus
(DRN), and inhibits prolonged serotonin (5-HT) output. In the absence of inhibition
of prolonged ascending serotonergic output to corticolimbic circuitry i.e. during periods
of uncontrollable aversive stimulation, changes in this corticolimbic circuitry mediate
the LH effect. Such changes presumably involve PFC assessment of controllable stimuli
as uncontrollable. (B) In human there is evidence in healthy subjects that perceived
state of uncontrollability is positively associated with activity in the anterior cingulate
cortex (ACC: supragenual ACC, Cg24a, b; subgenual cingulate, Cg25), and in MDD
patients that perceived state of helplessness is positively associated with ACC/PFC
activity, and dysfunctional attitude is associated with 5-HT receptor changes in
terminal regions, particularly in the PFC. Additional abbreviations: LC, locus coeruleus;
PAG, periaqueductal gray; AMYG, amygdala; HIPP, hippocampus; nACC, nucleus
accumbens. Copyright belongs to Sarah Steinbacher, SIVIC Scientiﬁc Visualisation and
Visual Communication, University of Zurich, Zurich, Switzerland.
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Using pharmacological infusion, it has been demonstrated in rat
that vmPFC inhibition using the GABAA receptor agonist muscimol,
followed by exposure to controllable aversive stimuli (AC group)
leads to a subsequent test-phase deﬁcit in the control response, i.e. as
if these rats were in the NAC group. Furthermore, such rats exhibit a
marked acute 5-HT response to the AC pre-exposure, again of a
magnitude that would be typical of NAC pre-exposure (Amat et al.,
2005). Conversely, excitation of the vmPFC via infusion of the GABAA
receptor antagonist picrotoxin in rats then pre-exposed to NAC leads
to control responding typical of AC pre-exposure (Amat et al., 2008).
These rat ﬁndings suggest that the (un)controllability of an aversive
stimulus is detected in/relayed to the vmPFC, and that controllability
is positively associated with excitatory output from long-range
glutamatergic projection neurons in the vmPFC to the DRN.
Uncontrollability results in inhibition of vmPFC output and therefore
a marked, acute 5-HT response and synaptic release in the ascending
mesocorticolimbic pathway, including at the amygdala, hippocampus
and PFC. How this acute response could lead to a chronic effect in
terms of a deﬁcit in the test-phase control response, also requires
explanation of course. One possibility would be that high excitatory
5-HT input to the vmPFC, in synergy with other neuromodulators e.g.
CRH, leads to a chronic increase in activity in GABAergic interneurons
in the vmPFC (Tan et al., 2004) and thereby to a chronic “under-
estimation” of the controllability of aversive stimuli i.e. the LH effect.
2.2.2. Humans
2.2.2.1. Studies of neural correlates of aversive stimulus (un)controllability
in healthy subjects. A small number of studies have investigated neural
activity in association with manipulations of the controllability of
aversive stimuli in healthy subjects speciﬁcally. These studies provide
insights into neural circuitry relevant to the LH effect. It is important to
note that all of these studies used a cross-over design with aversive
stimuli and that the sequence of (un)controllability used was the same
for all subjects, thereby precluding the possibility to study the LH effect.
One of these studies reports on the neural correlates of controlla-
bility in terms of the post-imperative negative variation (PINV) of
the electroencephalogram (EEG) (Diener et al., 2010). The paradigm
comprised a warning tone (S1) that preceded a tone CS (S2) that
was followed by a 1 ms e-shock to the index ﬁnger. Subjects were
instructed to press a button as fast as possible when S2 was presented
to avoid the aversive stimulus. There were three consecutive phases:
control, loss of control and restitution of control. During the control
and restitution of control phases, the aversive stimulus could be
avoided and during the loss of control phase the aversive stimulus
was uncontrollable in 50% of trials. Helplessness and controllability
were measured on self-report scales of 0 to 100. The PINV was
increased during the loss of control phase, when subjects reported
feelings of low controllability and high helplessness. Using electro-
magnetic tomography, the source of the PINV increase during loss of
control was localised to the anterior cingulate cortex (ACC).
Another study focused on neural responses to heat stimuli to the
forearm, measured using functional magnetic resonance imaging
(fMRI). Subjects were misleadingly informed that on some trials,
indicated by a discriminatory visual stimulus, they could control the
duration of the heat stimulus and that on other trials they could
not. The impact of perceived uncontrollable pain on responding
to controllable pain, i.e. the LH effect, was not investigated. When
pain was perceived as uncontrollable, subjects exhibited increased
activation in areas consistently linked with pain processing, namely
secondary somatosensory cortex, ACC and insula (Salomons et al.,
2004). In a follow-up correlational study (Salomons et al., 2007),
neural activity was studied in relation to inter-individual differences
in the impact of perceived controllability of the duration of the heat
stimulus on self-reported pain perception. Some subjects reported
higher levels of pain during perceived NAC versus perceived AC; these
subjects exhibited greater activation in the pregenual ACC (pACC).
Some subjects reported lower levels of pain during perceived NAC
versus perceived AC; these subjects exhibited greater activation in the
ventrolateral PFC (VLPFC) in the anticipatory period. These data
indicate that the (perceived) controllability of pain stimuli impact on
PFC activity, with uncontrollable pain associated with higher activity
in the ACC (and insula) than controllable pain. During pain
anticipation, uncontrollability is associated with relatively high
activity in the VLPFC, and it has been proposed that high activity in
VLPFC represents an attempt to regulate the emotional response to
uncontrollable pain (Salomons et al., 2007).
Association between aversive stimulus controllability and frontal
activity is also reported by Fretska et al. (1999). In the opposite order
to that used to investigate the LH effect, subjects were ﬁrst presented
with solvable (induction of control) arithmetic tasks and then to
unsolvable (withdrawal of control) such tasks. Using EEG to measure
event-related slow cortical potential (SCP), when the tasks became
unsolvable there was a positive neocortical potential shift (indicative
of cortical activity reduction) for all neural regions except for fronto-
polar regions. The latter exhibited negative potential changewhen the
tasks became unsolvable; this is considered indicative of neuronal
excitation and it was concluded that fronto-polar regions were
engaged in the processing of uncontrollability. In a follow-up study
using the same paradigm, Bauer et al. (2003) measured SCP in women
and identiﬁed an activity decline localised in the ACC during
the unsolvable condition. The decline was speciﬁc to a subgroup of
female subjects who exhibited high de-motivation scores during the
unsolvable task condition.
Each of the above studies identiﬁed the ACC as a region that is
differentially activated depending on the perceived (un)controlla-
bility of an aversive stimulus (Fig. 4B). With various methods, the
ACC exhibited increased activity during NAC, thereby implicating
the ACC as an important candidate region in the mediation of the
LH effect. However, discrepant results also need to be mentioned
here. Using solvable and unsolvable anagrams and measuring
regional cerebral blood ﬂow (rCBF) changes using positron
emission tomography (PET), rCBF was increased relative to baseline
during unsolvable tasks in mamillary bodies and amygdala and
decreased in hippocampus; during solvable tasks, rCBF was reduced
in mammillary bodies and increased in hippocampus. Both
conditions increased rCBF in frontal and temporal regions. The
authors suggested that uncontrollability predominantly affected
limbic areas relative to frontal or temporal regions (Schneider et al.,
1996).
2.2.2.2. Studies of neural correlates of aversive stimulus uncontrollability
and helplessness in MDD and healthy subjects. A systematic review
was conducted of human studies that have compared depressive
patients and controls, applying any form of neural activity, and
either assessing helplessness and/or controllability and related
variation of brain activity, or experimentally modifying controlla-
bility of a situation and investigating associated variation of neural
activity. Out of 143 human studies identiﬁed by literature search and
assessed for eligibility, nine studies fulﬁlled the inclusion criteria
and were included in quantitative analysis. Characteristics of the
studies included are depicted in Table 1. It is important to note that
in all of the below studies that used a cross-over design with
aversive stimuli, the sequence of (un)controllability used was the
same for all subjects, thereby precluding the possibility to study the
LH effect.
Diener et al. (2009) assessed PINV of the EEG in unmedicated
depressed subjects and controls using the forewarned S1–S2 ﬁnger
e-shock paradigm (described above). Task performance was similar
in MDD and control subjects across the three phases. Controllability
scores were similar between MDD and healthy subjects and were
reduced during the loss of control phase. Helplessness scores were
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higher in the MDD group compared to controls across all phases. In
addition, whilst helplessness increased during loss of control and
returned to control levels during restitution of control in healthy
subjects, MDD subjects reported high helplessness during the loss
of control phase and this persisted into the restitution of control
phase. Depressed subjects showed relatively higher frontal PINV
during the loss of control and restitution of control phases. The
relatively high helplessness scores of MDD subjects, particularly
during the restitution of control phase, indicate a lack of association
between the (speciﬁc) task controllability measure and the (general)
helplessness measure. It is noteworthy that persistence of both
high helplessness and high PINV activity into the restitution of
control phase characterised the MDD group. These results expand
on previous ﬁndings of higher PINV in depressed patients compared
to controls during NAC conditions (Bolz & Giedke, 1981). This study
of Diener et al. also demonstrates that feelings of controllability
over a speciﬁc aversive stimulus task and feelings of helplessness
are not necessarily correlated in MDD (Table 1).
An fMRI study compared MDD and healthy subjects in terms of
neural correlates of exposure to aversive painful stimuli (Strigo et al.,
2008). The aversive stimulus was moderate heat pain to the forearm
and was always uncontrollable (NAC), with a signalled anticipation
phase preceding aversive stimulation. All subjects were unmedicated.
During the anticipation of painful (NAC) stimuli, MDD subjects
showed increased blood oxygen level-dependent (BOLD) activity in
the right anterior insula and dorsal ACC compared to controls.
A follow-up region-of-interest analysis of the amygdala showed
increased right amygdala BOLD activity in MDD subjects compared
to controls. In MDD subjects, right amygdala BOLD signal correlated
positively with perceived helplessness as measured using a pain
catastrophising scale during the anticipation phase. The ﬁndings
suggest that increased helplessness in MDD is associated with
abnormal amygdala activity.
In two other fMRI studies (Grimm, Boesiger, et al., 2009; Grimm,
Ernst, et al., 2009) and one EEG study (Chiu & Deldin, 2007), all of
which used the Beck Hopelessness Scale (BHS), correlations between
hopelessness scores and frontal cortex activity were compared
between MDD and control subjects (Fig. 4B). Again, these studies
did not investigate the LH effect. Grimm, Boesiger, et al. (2009)
investigated subject-group differences in negative BOLD response
(NBR) during an emotional processing task, in which subjects were
shown pictures and were required to judge the picture as negative or
positive. The MDD subjects showed decreased NBR in the pregenual
and supragenual ACC and the ventromedial PFC (VMPFC), compared
to healthy controls. In the MDD group, low NBR was associated with
high feelings of hopelessness. Using the same task, Grimm, Ernst,
et al. (2009) showed that in MDD subjects the dorsomedial PFC
(DMPFC) was activated less than in controls during emotional picture
judgement, and that low DMPFC activation was associated with
high BHS scores and also with scores on the Beck Depression Inventory
(BDI).
Three PET studies describe correlations between 5-HT receptor
availability (deﬁned as binding potential, BP) and hopelessness levels
measured using the Dysfunctional Attitudes Scale (DAS). DAS scores
are considered to indicate negatively biassed views of oneself, the
world, and the future, and DAS scores are correlated highly with BHS
scores in MDD subjects. Two PET studies describe higher 5-HT2A
receptor (5-HT2AR) BP in both MDD and remitted MDD subjects
compared to healthy controls (Meyer et al., 2003; Bhagwager et al.,
2006). DAS scores were positively associated with 5-HT2AR BP in
several cortical regions in unmedicated MDD subjects (Meyer et al.,
2003) and in frontal regions in remitted MDD subjects (Bhagwager
et al., 2006). High 5-HT2AR BP suggests receptor up-regulation in
depression, and particularly so in subjects with high DAS scores, and
might be a consequence of chronically impaired 5-HT release (Meyer
et al., 2003). The third PET study (Meyer et al., 2004) reports an
absence of differences between MDD and control subjects in 5-HT
transporter (SLC6A4; alias 5-HTT) BP. However, within MDD subjects
there were correlations between DAS scores and 5-HTT BP in brain
regions that receive 5-HT projections, including the PFC, ACC,
thalamus, caudate, and putamen. Overall the PET data indicate that
those MDD subjects with more severe dysfunctional attitudes,
suggestive of high hopelessness, show more severe changes in 5-HT
terminal regions, particularly in the PFC (Fig. 4B).
Integrating the current human evidence above, it is noteworthy
that in healthy subjects, perceived state of uncontrollability is
positively associated with ACC activity, and in MDD patients
perceived state of helplessness is positively associated with ACC/PFC
activity. These ﬁndings suggest that the ACC is central to both the LH
effect and the state of helplessness in MDD, and could therefore be
important in mediating any causal relationship between these two
processes (Fig. 2). Furthermore, in the rat, the brain region which is
analogous to the human ACC is central to mediation of the LH effect.
Future translational studies can build on this comparative evidence,
to establish a detailed neuro-psychological understanding of the LH
effect, helplessness and MDD, and their inter-relationships.
Table 1
Overview of studies that assessed correlates of brain function in relation to controllability and helplessness in MDD patients and controls.
Reference Method/Helplessness-related measure Subjects
Bhagwager et al., 2006 PET 7 female/13 male controls
Dysfunctional Attitudes Scale 8 female/12 male remitted MD subjects
Bolz & Giedke, 1981 EEG 10 female/8 male controls
10 female/8 male subjects with MD
Chiu & Deldin, 2007 EEG 17 controls
Beck Hopelessness Scale 18 subjects with MD
Diener et al., 2009 EEG 14 female/12 male controls
Controllability and Helplessness measures 16 female/8 male unmedicated subjects with MD
Grimm, Boesiger, et al., 2009 Functional MRI 21 female/8 male controls
Beck Hopelessness Scale 11 female/8 male subjects with MD
Grimm et al., 2009 Functional MRI 12 female/13 male controls
Beck Hopelessness Scale 9 female/16 male subjects with MD
Meyer et al., 2004 PET 10 female/10 male controls
Dysfunctional Attitudes Scale 11 female/9 male subjects with MD
Meyer et al., 2003 PET 5 female/11 male controls
Dysfunctional Attitudes Scale 5 female/11 male unmedicated subjects with MD
Strigo et al., 2008 Functional MRI 10 female/5 male controls
Controllability measure and Pain 12 female/3 male unmedicated subjects with MD
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3. Systematic reviews of rodent studies of the learned helplessness
effect, rodent studies of drug effects on the learned helplessness
effect, and human studies of therapeutic intervention efﬁcacy on
helplessness in major depressive disorder
3.1. Methods of the rodent and human systematic reviews
3.1.1. Criteria for including studies in the reviews
Three sets of inclusion criteria were applied, one for each of the
rodent reviews (Triadic design, Pharmacology), and one for the
human review (randomised controlled trial (RCT)).
3.1.1.1. Rodent. Triadic design: all randomised studies using a triadic
yoked design comparing the effects of three types of aversive stimulus
pre-exposure on behaviour were considered for inclusion in this
review: controllable (AC; escapable stress, ES), uncontrollable (NAC;
inescapable stress, IS), no pre-exposure (Naïve; no stress, NS).
Pharmacology: all randomised studies using a triadic yoked design
(AC, NAC, Naive) or a dyadic design (NAC, Naive) to investigate the
effect of a pharmacological, vehicle-controlled intervention after the
pre-exposure phase on test phase behaviour were considered for
inclusion in this review.
3.1.1.2. Human. All randomised controlled human studies comparing
measures of helplessness (see below) between subjects with MDD
receiving active treatment and subjects receiving either another active
treatment or a control intervention or no intervention (e.g. wait-list
control group),were considered for inclusion in this review. The exposure
had to consist of any interventionaimedat treatingdepressionor reducing
symptoms of depression (active treatment), which was compared with
either another active treatment, a control intervention (e.g. placebo or
another intervention not including the assumed active component of the
active treatment intervention), or no intervention (e.g. wait-list control
group). Case reports were excluded.
3.1.2. Subjects
3.1.2.1. Rodent. Triadic design and Pharmacology: all studies using post-
pubertal rats (genus: Rattus) or mice (genus:Mus) were included.
3.1.2.2. Human. We included all studies involving adult (≥18 years)
subjects that fulﬁlled the criteria for a diagnosis from the category of
depressive disorders, according to DSM-IV; or depressive episode or
recurrent depressive disorder or dysthymia, according to ICD-10,
regardless of any comorbid mental disorders. The diagnosis had to be
established through adiagnostic interviewor by above cut-off scores in an
established depression scale (e.g. Center for Epidemiological Studies
Depression Scales (CES-D) (Radloff, 1977), Beck Depression Inventory
(Beck et al., 1961), Hamilton Rating Scale for Depression (Hamilton,
1960)), indicating the presence of (mild,moderate, or severe) depression.
3.1.3. Outcome measures
3.1.3.1. Rodent. Triadic design and Pharmacology: outcomes of interest
were animal behaviour assessed by behavioural measures considered
to be indicative of helplessness or deﬁcit in controllability/contin-
gency, analysed as primary or secondary outcome. These included
escape behaviour, lever pressing, freezing, immobility.
3.1.3.2. Human. Outcomes of interest were changes in levels of
helplessness, hopelessness or locus of control, as assessed by a
diagnostic instrument (questionnaire, interview) and analysed as
primary or secondary outcome. Information extracted and reported
comprises: i) changes from pre- to post-treatment in helplessness
measures in the active treatment group(s) and control group(s); ii)
differences in helplessness measures between the active treatment
and comparison group at post-treatment, and; iii) differences
between the active treatment and comparison group regarding
change from pre- to post-treatment in helplessness measures.
3.1.4. Search strategy for identiﬁcation of studies
3.1.4.1. Rodent. Triadic design and Pharmacology: ﬁrst, we searched
Embase andMedline via the web-based advanced search and retrieval
system provided by Embase (http://www.embase.com/search/
advanced), from 1975 (for Embase) or 1966/1950 (for Medline/Old
Medline, respectively) up to July 2010, using theweb-browser Firefox.
We applied the following string that excludes any type of review,
moreover restricting our search to articles on animals and articles
published in English: (((helplessness OR uncontrollab* OR controllab*
OR “escape failure”) AND (rat OR rats OR mouse OR mice)) NOT
[review]/lim NOT [conference review]/lim”). Second, we searched
Psycinfo via the OvidSP search and retrieval system provided by Ovid
Technologies Inc. (http://ovidsp.ovid.com/ovidweb.cgi?T=JS&MODE=
ovid&PAGE=main&NEWS=n&DBC=y&D=psyh) from 1806 up to July
2010, via theweb-browser Firefox, and using theﬁeld-search option.We
restricted our search to articles on animals and articles published in
English, and excluded any type of review. We combined (AND) the
following twostrings (using the calibrations: “KeyConcepts”: id, “Subject
Heading”: sh, “Tile”: ti, “Abstract”: ab, “Heading Word”: hw, “Original
Title”: ot, and “PublicationType”: pt): 1. (helplessness oruncontrollab: or
controllab: or “escape failure”), 2. (rat or rats or mouse or mice).
Combining the search in the different databases and removing
duplicates led to 1314 hits. The articles identiﬁed by this search were
assessed according to the criteria of consideration, and separately for
the Triadic design and Pharmacology reviews. There was no contact
with authors. Furthermore, we hand-searched bibliographies of the
ten most-recent original publications identiﬁed and evaluated them
according to the criteria of consideration for this review outlined
above. The ﬂowcharts of the study inclusion procedure for the
searches Triadic design and Pharmacology are provided in Appendix A
Fig. A1.
3.1.4.2. Human. Information on the use of scales assessing helplessness
or related constructs are usually not primary study outcomes within
RCTs and hence often not reported in the title, abstract or key words.
Therefore, we used Google Scholar in order to be able to perform a
full-text search.We searched Google Scholar on August 7th 2010 from
Switzerland, via the web-based search and retrieval system provided
by Google Inc. (http://scholar.google.com), using the web-browser
Firefox, selecting “Google Scholar in English” and articles (unselecting
the inclusion of patents) with the search term:
(“efﬁcacy scale” OR “helplessness subscale” OR “control scales” OR
“I-E scale”OR “helplessness scale”OR “control scale”OR “hopelessness
scale”) AND (intitle:depressive OR intitle:depression OR intitle:
depressed) AND “randomised controlled”) We restricted our search
to articles providing at least summaries, but did not place any
restriction on the date.
The search revealed166hits. Thepublications identiﬁedby this search
were assessed according to the criteria of consideration for this review
outlined above. There was no contact with authors. The ﬂowchart of the
study inclusion procedure for RCT is provided in Appendix A Fig. A2.
3.1.5. Selection and coding of the data
3.1.5.1. Rodent. Triadic design: One investigator (DA) reviewed all
articles. If there was ambiguity in selection or coding, DA and CRP
discussed this issue and resolved disagreements until they reached
consensus.We identiﬁed 43 published studies from the last 42 years that
met our inclusion criteria (Appendix A Fig. A1). The extracted data
included the species, type of pre-exposure aversive stimulus, apparatus
used to apply the aversive stimulus, type of aversive test stimulus, nature
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of the control response, apparatus used to assess the control response,
indicator/measure of the control response, and main results regarding
behavioural differences in control responding between study groups.
Pharmacology: one investigator (DA) reviewed all articles. If there
was ambiguity in selection or coding, DA and CRP discussed this issue
and resolved disagreements until they reached consensus. We
identiﬁed 15 published studies from the last 33 years that met our
inclusion criteria. The extracted data included the species, type of pre-
exposure aversive stimulus, apparatus used to apply the aversive
stimulus, pharmacological class and drug/compound name, type of
aversive test stimulus, nature of the control response, apparatus used
to assess the control response, indicator/measure of the control
response, and main results regarding: i) differences in control
responding between the pharmacologic and vehicle groups at test
phase, and; ii) differences between the NAC (IS) group and
comparison group(s) with respect to differences in control respond-
ing between the pharmacologic and vehicle groups.
3.1.5.2. Human. Two investigators (MT and GM) reviewed all articles
independently. If there was ambiguity in selection or coding, these
investigators discussed this issue and resolved disagreements until
they reached consensus. We identiﬁed 10 published studies, all from
the last 7 years, that met our inclusion criteria. The extracted data
included patient diagnosis, diagnostic instruments, types of treatment
and control intervention, target construct and applied scale to
measure target construct, number of patients included, and main
results, including: i) changes from pre- to post-treatment in
helplessness measures in the active treatment group; ii) differences
in helplessness measures between the active treatment and compar-
ison group at post-treatment, and; iii) differences between the active
treatment and comparison group regarding change from pre- to post-
treatment in helplessness measures.
3.1.6. Assessment of heterogeneity
3.1.6.1. Rodent. Heterogeneity of studies was assessed with regard to
relevant study characteristics, including rat/mouse strain, type,
intensity and number of aversive stimuli in the pre-exposure stage,
paradigm used to assess the control response, and sample size.
Triadic design: in sum, there was substantial heterogeneity of the
studies in several key aspects (see Sections 3.2.2.1, 3.2.2.2), including
statistical procedures. The mean number of animals was 10 per group
(median: 10, range: 8 to 17).
Pharmacology: in sum, there was substantial heterogeneity of the
studies in several key aspects (see Results section 3.3.3), including
statistical procedures. The mean number of animals was 11 per group
(median: 10, range: 6 to 14).
3.1.6.2. Human. Heterogeneity of studies was assessed with regard to
relevant study characteristics, including diagnosis, intervention, mea-
sure of helplessness, and sample size. In sum, there was substantial
heterogeneity of the studies in several key aspects (see Results
section3.4.3). Themediannumber of subjectswas54 (range: 32 to267).
As previously suggested, in case of substantial heterogeneity
across studies, pooled estimates should not be published (Blettner et
al., 1999). Even though several procedures exist that allow for
quantitative synthesis in spite of heterogeneity, we refrained from
applying them, as in our case their caveats (Ioannidis et al., 2008)
would have outweighed the advantage of producing summary scores
with questionable explanatory power.
3.2. Systematic review of rodent studies of the learned helplessness effect
3.2.1. Study selection
Since the original rat experiments of Seligman and colleagues a
number of studies of the effects of aversive stimuli on subsequent
escape behaviour have been conducted in rats and mice. A systematic
review of these studies was conducted, with randomised studies that
used the triadic yoked design to compare the effects of three types of
aversive stimulus exposure (AC (ES), NAC (IS), Naive (NS)) on
subsequent operant behaviour, being the criteria for inclusion.
Appendix A Fig. A1 presents a ﬂowchart of the literature search. Out
of 1314 studies identiﬁed by literature search and assessed for
eligibility, there were 38 rat publications and six mouse publications
that fulﬁlled the inclusion criteria and were included in quantitative
analysis. The great majority of studies did not use the triadic design
but rather the dyadic design of NAC versus Naive and therefore the LH
effect could not be measured.
3.2.2. Synthesis of results
3.2.2.1. Rat. The rat ﬁndings are presented in Table 2. Firstly, it is
interesting to note the publication year of the 38 relevant publications: 5%
were published in 1960–69, 18% in 1970–79, 34% in 1980–89, 21% in
1990–99, and 21% in 2000–2009. That is, the number of publications has
remained consistent since the initial description of the LH effect. Thirty six
of the studies were conducted with male rats only, one with males and
females, and only one study focused on females. The 38 relevant
publications present a total of 48 experiments. In a minority of
experiments (26%), a tone or light was used as a conditioned stimulus
(CS) to predict the aversive unconditioned stimulus (US), either in the
pre-exposure phase, test phase, or in both phases. These experiments are
discussed separately below. The most commonly used aversive stimulus
during the pre-exposure phase is paw e-shock (58%), the second most
common is tail e-shock (31%), and the remaining experiments (10%) use
water, either immersion under water or forced swimming. Different
forms of apparatus are used to present and control paw e-shocks. The
most common is an operant set-up in which rats in the AC group
terminate e-shocks by pressing a lever (35%) and the second most
common set-up is a 2-way shuttle boxwhere the e-shock can be stopped
by AC rats crossing from one compartment to the other (15%). The next
most common set-up is an operant box using a platform to jumponto or a
pole to climb up, to terminate paw e-shocks, in the AC group (8%). All tail
e-shock experiments are performed in a wheel-turn arena in which the
e-shock can be terminated in the AC group by the rat turning thewheel.
For the test phase in rats, paw e-shocks are the escapable stimulus
in 67% of studies. A number of apparatus types are used to present
these e.g. 44% of all studies use a 2-way shuttle box to present paw e-
shocks, 15% use a lever operant box. Tail e-shock is not used at all as
the aversive stimulus in the test phase. Six experiments use water
paradigms, three involving swimming duration in a forced swim test
(Weiss et al., 1981; Brown et al., 2001; Drugan et al., 2005) and the
other three escape via a ramp (Braud et al., 1969) or via a guillotine
door (both experiments in Altenor et al., 1977). In the remaining
experiments, no aversive US is used, and the test takes the form of
elevated plus maze (Grahn et al., 1995; Korte et al., 1999) or context-
conditioned freezing (e.g. Rosellini et al., 1987; Baratta et al., 2007).
With respect to the combination of pre-exposure and test phases
used, two groups prevail: paw e-shock in lever press operant box
followed by paw e-shock two-way shuttle box is used in 10
experiments (21%), and tail e-shock wheel-turn followed by paw
e-shock two-way shuttle box is used in seven experiments (15%).
The integration of classical conditioning into the experimental
design, as used in ten experiments, involves a tone or a light CS
predicting the aversive US. In those studies deploying such CS-US
conditioning, it is used in the pre-exposure phase only (e.g. Korte et al.,
1999), in the test phase only (e.g. Baratta et al., 2007), or in both phases
(e.g. Bersh et al., 1986). In some cases the CS predicts the escapable US
and in other cases the CS can itself be escaped, therefore allowing US
avoidance (e.g. Korte et al., 1999). Some experiments use different CSs
in the two phases (Cotton et al., 1982; Cotton & Smith, 1990). In some
experiments in which the same CS is used in both phases, the US
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Table 2
Overview of studies that used the IS-ES-NS design to test for the learned helplessness effect in rat.
Reference Pre-exposure phase Test phase
Stressor Apparatus Escape
response
Stressor Apparatus Measure
LH effect demonstrated
Volpicelli, 1983, 1984 Foot electro-shock 2-way shuttle box Locomotor transfer Foot electro-shock Operant arena w/o CS Lever press=shock termination
Leuner, 1994 Aversive CS Eyeblink conditioning chamber CS
(light), US (periorbital shock)
Eyeblink expression to CS
Altenor et al., 1977, Blustein, 1992a;
Hemingway & Reigle, 1987, Wellman,
1998; Whitehouse et al., 1985
Operant arena Lever press Foot electro-shock 2-way shuttle box w/o CS Locomotor transfer=escape
Follick, 1981, Mauk, 1979 Foot electro-shock Operant arena w/o CS Lever press/chain pull=shock
termination
Seligman, 1975b Activity arena with platform Jump onto platform=escape
Rosellini et al., 1987, Warren, 1988 Activity arena with platform Avoid grid ﬂoor
Telner & Singhal, 1981 Activity arena with platform Jump on to platform Foot elector shock 2-way shuttle box w/o CS Locomotor transfer =escape
Hannum, 1976, Seligman, 1975a Foot electro-shock Operant arena w/o CS Lever press/chain pull=shock
termination
Braud et al., 1969 Arena Pole-climbing Water exposure Water tank Swimming to target=escape
Korte et al., 1999 Foot electro-shock with
CS (tone, light)
2-way shuttle box Locomotor transfer
(escape/avoid)
Elevated plus maze Time in open arm
Ilin & Richter-Levin, 2009 Foot electro-shock 2-way shuttle box Freezing expression to context
Ilin & Richter-Levin, 2009 w/o shock, with CS Freezing expression to CS
Locomotor transfer=escape CS
Cotton et al., 1982; Cotton & Smith, 1990 Operant arena Lever press Foot electro-shock 2-way shuttle box with different CS Locomotor transfer=Avoid /escape
Bersh et al., 1986; Bersh et al., 1990 Operant arena Lever press Foot electro-shock 2-way shuttle box w/o CS Locomotor transfer=Avoid /escape
Bersh et al., 1986 Foot electro-shock 2-way shuttle box with CS Locomotor transfer=Avoid /escape
Amat 2001, 2005, Blake-Mortimer,
1998, Hellhammer, 1984, Maier,
1977, 1988
Tail electro-shock Operant arena Wheel turn Foot electro-shock 2-way shuttle box w/o CS Locomotor transfer=Escape
Glazer, 1976 Foot electro-shock Operant arena w/o CS Lever press=shock termination
Glazer, 1976 Foot electro-shock Arena with barrier with CS (tone) Jump barrier=Avoid /escape
Amat et al., 2005, Baratta et al., 2007 Aversive context Operant arena w/o CS Freezing expression to context
Baratta et al., 2007 Aversive CS Operant arena with CS Freezing expression to CS
Rozeske, 2009 Aversive context 2-compartment-box with shock Conditioned place preference
Kelsey, 1977 Tail electro-shock with CS
(Tone, Light)
Operant arena Wheel turn (only escape) Foot electro-shock 2-way shuttle box with different CS Locomotor transfer = Escape
Weiss et al., 1981 Tail electro-shock with
feedback signal
Operant arena Wheel turn Water exposure Forced swim test Immobility
Altenor et al., 1977 Underwater exposure Water tank Door escape Electro foot-shock 2-way shuttle box w/o CS Locomotor transfer=escape
Drugan et al., 2005 Water swim stress Operant water tank Lever press Water exposure Force swim test Immobility
Brown et al., 2001 Electro foot-shock 2-way shuttle box w/o CS Locomotor transfer=escape
LH effect not demonstrated
Shors, 2007b Foot electro-shock 2-way shuttle box Locomotor transfer Electro foot-shock 2-way shuttle box w/o CS Locomotor transfer=escape
Altenor et al., 1977c Operant arena Lever press Water exposure Underwater maze Swimming to target=escape
Ragusa, 1969 Electro foot-shock 1-way runway apparatus Locomotor transfer=escape
Grahn et al., 1995 Tail electro-shock Operant arena Wheel turn Aversive context Elevated plus maze Time in open arm
Altenor et al., 1977c Underwater exposure Water tank Door escape Water exposure Underwater maze Swimming to target=escape
Brown et al., 2001c Water exposure Water tank with lever Lever press Water exposure Forced swim test Immobility
a Study conducted with females
b Study conducted with females and males.
c Same study as above showing LH effect, in which a different experiment did not obtain an LH effect.
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(e-shock) is renounced in the test phase such that CS-motivated
freezing or 2-way avoidance responding is measured under extinction
conditions (Ilin & Richter-Levin, 2009). It is interesting to assess
whether or not inclusion of a CS impacts on the magnitude of the LH
effect. Very few of the studies identiﬁed used a design where analysis
of the CS per se on the LH effect was the aim of the study. In one such
study, rats were pre-exposed to nine daily sessions of paw e-shocks
that were paired on between 50% and 100% of trials with a tone CS.
Only in those rats where the CS-US contingency was 100% and only
when the CSwas also used at the test phase,was the LH effect observed
(Bersh et al., 1986). This and related studies (e.g. Bersh et al., 1990)
provide evidence that CS-US conditioning can be essential to or
increase the LH effect under speciﬁc conditions of AC-NAC pre-
exposure. A gross overviewof the studies cited in Table 2 does not yield
any qualitative evidence that, under the experimental conditions
typically used, an LH effect ismore or less likely to be obtained by using
a CS at pre-exposure and/or test phase; a reliable assessment of
quantitative effects can only be assessed within study.
Of the 48 rat experiments using the triadic design, 42 (88%) report the
LH effect: the NAC (IS) group exhibits a signiﬁcant reduction in
performance of the control response during the test phase relative
to the AC (ES) and Naïve (NS) groups, with the latter two groups
exhibiting similar, high levels of control responses (Table 2). Of
the six experiments that did not demonstrate the LH effect, there
is no consistent characteristic of the paradigm used in either the pre-
exposure phase or the test phase that could provide a methodological
explanation for the lack of effect.
3.2.2.2. Mouse. The mouse ﬁndings are presented in Table 3. Six mice
studies fulﬁl the search criteria for the triadic design. Five of these are
performed in males only and one in males and females (Anisman
et al., 1978b). Only one study has been performed since 2000
(Palermo-Neto et al., 2003). In each of these studies, paw e-shock
is used in the pre-exposure phase: four studies are conducted with a
2-way shuttle box (including one study that also used a CS) and two
studies with a lever operant box. The test phase comprised escapable
paw e-shock in four studies: two in a shuttle box (Anisman et al.,
1978b; Anisman et al., 1980), one in an activity arena with platform
(additional experiment in Anisman et al., 1978b), one in a lever press
operant box (Caspy & Lubow, 1981) and one in a free-choice T-maze
(Anisman et al., 1984). One study uses water in the test phase with
latency to climb onto a ramp to escape being the dependent measure
(Caspy et al., 1979), and one uses the elevated plus-maze and the total
distance moved on it (Palermo-Neto et al., 2003). There is a single
study applying a CS during the pre-exposure phase, during which the
escape group can avoid or escape the CS-paw e-shock pairings
(Palermo-Neto et al., 2003). All six studies demonstrated the LH
effect, with the NAC (IS) group exhibiting a signiﬁcant reduction
in performance of the control response during the test phase relative
to the AC (ES) and Naive (NS) groups, with the latter two groups
exhibiting similar, high levels of control responses (Table 3).
3.3. Effects of pharmacological treatments on the learned helplessness
effect in rodents
3.3.1. Study selection
A systematic review was conducted of all randomised studies that
used a triadic yoked design (AC, NAC, Naive) or a dyadic design (NAC,
Naive) to investigate the effect of a pharmacological, vehicle-
controlled intervention on the relationship between the type of pre-
exposure and behaviour in the test phase. Appendix A Fig. A1 presents
a ﬂowchart of the literature search. With respect to the timing of
the pharmacological manipulation, the aim was to review the studies
where the intervention follows the pre-exposure i.e. therapeutic
design. Such studies can provide insights into the pharmacological
reversal of the LH effect, and therefore have translational predictive
relevance. With respect to the design of the pre-exposure manipu-
lation, the primary interest was to study the effects of pharmacolog-
ical treatments on the LH effect; that is, the effect on the deﬁcit in the
control response exhibited by the NAC group relative to the AC group.
The systematic review identiﬁed two drug studies that used such a
triadic design and the remaining drug studies used the NAC versus
Naive comparison only. The latter design is problematic because it
is unclear whether any control response deﬁcit in the NAC group is
due to prior exposure to aversive stimulation generally or to aversive
uncontrollability speciﬁcally. However, given that the studies were
conducted using pre-exposure+test phase paradigms in which the
LH effect is robust, then the Naive group provides a reasonable
surrogate for the absent AC group. Of major interest was whether the
pharmacological effect on test-phase behaviour was speciﬁc to the
NAC group, i.e. in statistical terms was there a Pre-exposure group x
Drug interaction effect, with the Drug effect speciﬁc to the NAC
group?
Out of 1314 rodent publications identiﬁed by literature search and
assessed for eligibility, 15 fulﬁlled the inclusion criteria.
3.3.2. Study characteristics
The characteristics of these studies are presented in Table 4.
Fourteen of the studies were conducted in rat and one in mouse
(Anisman et al., 1980). As noted above, two of these studies were
based on the triadic design (Whitehouse et al., 1985; Hemingway &
Reigle, 1987) and the remainder on a dyadic design. In the rat, the
most commonly used aversive stimulus during the pre-exposure
phase was paw e-shock (80% of studies), the second most common
was tail e-shock (13%). For the test phase the 2-way shuttle box (69%)
and the operant box with lever press (31%) were the arrangements
used. In the 2-way shuttle box, six of the eight studies used a CS to
predict the paw e-shock in the test phase.
The 15 publications report on a total of 33 experiments (Table 4).
These experiments investigate the effects of several different drug
classes, namely antidepressants, neurotransmitters, catecholamine
receptor agonists or antagonists, endogenous opioid receptor antag-
onist or agonist, a NMDA-receptor antagonist, a benzodiazepine
Table 3
Overview of studies that used the IS-ES-NS design to test for the learned helplessness effect in mouse.
References Pre-exposure phase Test phase
Stressor Apparatus Escape response Stressor Apparatus Measure
Anisman et al., 1978a,
1980*
Foot electro-shock 2-way shuttle box Locomotor transfer Foot electro-shock 2-way shuttle box
w/o CS
Locomotor transfer=escape
Anisman et al., 1978b Foot electro-shock Activity arena with
platform
Jump onto platform=escape
Anisman et al., 1984 Foot electro-shock T-maze with footshock Correct discrimination response
Caspy et al., 1979 Foot electro shock Operant arena Lever press Water exposure Water tank Ramp escape
Caspy & Lubow, 1981 Foot electro-shock Operant box Lever press=escape
Palermo-Neto et al., 2003 Foot Electro-shock
with CS (tone/light)
2-way shuttle box Locomotor transfer
(escape/avoid)
Aversive context Elevated plus maze Open arm entries
a Study conducted with females and males.
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receptor agonist and a nitric oxide synthase inhibitor. The treatment is
acute (0–60 min pre-test phase), sub-chronic (5 days pre-test phase)
or chronic (14 days pre-test phase). The treatment was administered
either systemically (intra-peritoneal, subcutaneous, oral) or infused
into a speciﬁc brain region using stereotactic methods. In ﬁve of the
experiments (e.g. Danchev et al., 1989) the drug was administered to
NAC group only, so it is not possible to determine whether any drug
effect was speciﬁc to the subjects that were exhibiting a deﬁcit in the
control response. That it is possible that drug effects are not group-
speciﬁc is demonstrated by the study of Harrell et al. (1978), in which
it is reported that acute administration of the α1-adrenoceptor
agonist aramine increased the control response in the test phase in
both the NAC and Naive groups (Table 4).
3.3.3. Results of individual studies and synthesis of results
The studies of effects of existing antidepressant drugs are especially
important given that theseprovideevidence on thepredictive validity of
the LH effect as a “model of depression”. Eight experiments were
conducted with antidepressants: six with a tricyclic, namely desipra-
mine (four), imipramine or nortriptyline, and two with the selective
serotonin reuptake inhibitor (SSRI) zimelidine (Table 4). Four of these
experiments report that the deﬁcit in test-phase control responding in
the NAC x vehicle group was reversed by drug, with the drug treatment
being acute nortriptyline (Telner & Singhal, 1981), acute desipramine
infused into the dorsal hippocampus (Joca et al., 2006), acute
desipramine infused into the frontal neocortex (Sherman & Petty,
1980), and acute zimelidine infused into the dorsal hippocampus (Joca
et al., 2006). In the other four antidepressant experiments there is no
evidence for an effect of drug treatment.
Such a (acute) drug effect in the NAC group speciﬁcally, i.e. reversal
of the LH effect, is also reported for several other drugs. With respect to
neurotransmitters, GABA infused into the hippocampus or the lateral
geniculate body reversed theNAC group deﬁcit (but not in several other
regions e.g. frontal cortex, septum, amygdala) (Sherman & Petty, 1980).
Serotonin infused into the frontal neocortex or the septum reversed the
NAC effect (but not in several other regions e.g. hippocampus, lateral
geniculate body, amygdala, nucleus accumbens) (Sherman & Petty,
1980). Interest in exogenous opioid agonists is in part related to the
clinical evidence that they are therapeutic in MDD: the mu-opioid
receptor agonist morphine, after sub-chronic treatment, increased the
control response in NAC rats speciﬁcally (Besson et al., 1996). In the
same study, sub-chronic treatment with the mu-opioid receptor
antagonist naloxone reduced the control response in both groups
(Besson et al., 1996). In contrast to this latter ﬁnding, another study of
naloxone, using an acute treatment at a high dose, reversed the NAC
effect (Hunziker, 1992). Furthermore, in a triadic-design study with
another mu-opioid receptor antagonist, naltrexone, administered
acutely, the LH effect was also reversed (Whitehouse et al., 1985).
Acute naloxone at low doses did not impact on the LH effect
(Hemingway & Reigle, 1987; Hunziker, 1992). The rationale for these
opioid antagonist studies is thehypothesis that painful stimuli such as e-
shocksmight increase analgesiawhen they are uncontrollable, which in
turn leads to the deﬁcit in the control response, andhyper-activity in the
endogenous opiate system mediates this analgesia (Whitehouse et al.,
1985) (See Section 2.1.1.2 for a discussion of this issue).
As reviewed above (Section 2.2.1), exaggerated excitation of 5-HT
neurons in the DRN during NAC pre-exposure has been proposed as
an important mediator of the LH effect in rats. In relation to this
evidence, the nitric oxide synthatase inhibitor Nw-nitro-L-arginine
methyl ester (L-NAME) was microinjected into the DRN, on the basis
that glutamate induced nitric oxide formation within the DRN might
contribute to the LH effect via protracted effects within this nucleus:
indeed, treatmentwith L-NAME did reverse the LH effect (Grahn et al.,
2000). This ﬁnding is difﬁcult to reconcile with the evidence that
disinhibition of vmPFC glutamate signalling prevents the LH effect
(see Section 2.2.1). More consistent with the latter evidence is the
ﬁnding that antagonising DRN NMDA glutamate receptors using the
antagonist 2-amino-5-phosphonovaleric acid (APV) did not reverse
the LH effect ((Grahn et al., 2000); Table 4). As reviewed above
(Section 2.1.1.2), it has been hypothesised that the LH effect can be
accounted for in terms of a motor deﬁcit that is mediated by depletion
of DA and NE speciﬁc to subjects that experienced NAC. In an attempt
to test this hypothesis, in mice, the DA receptor agonist morphine and
the NE receptor agonist clonedine were tested: in support of the
hypothesis, acute treatment with either morphine or clonedine
reversed the LH effect (Anisman et al., 1980).
A number of the other ﬁndings summarised in Table 4 need to be
highlighted. In addition to those anti-depressant experiments that did
not demonstrate a reversal of theNAC effect, therewas also no evidence
for a therapeutic-like effect with several other drug classes. Noradren-
aline infused speciﬁcally into each of the following regions waswithout
effect: frontal neocortex, septum, hippocampus, lateral geniculate body,
entorhinal cortex, posterior neocortex, caudate, nucleus accumbens,
amygdala (Sherman & Petty, 1980). No evidence was obtained for
therapeutic effects of clinical anxiolytics on theNAC effect: thus, neither
sub-chronic treatment with the antihistamine hydroxyzine nor the
benzodiazepine diazepam increased control responding in the NAC
group (Porsolt et al., 1989). A modulatory role for noradrenaline in the
DRN in the mediation of the LH effect has been proposed: however,
infusion into the DRN of the α1-adrenoceptor antagonist benoxathian
prior to the test phase did not affect the NAC effect (Grahn et al., 2002).
There are additional Pre-exposure group x Drug interaction effects but
these are not due to a therapeutic drug effect speciﬁc to the NAC group:
acute treatment with the DA2-R receptor antagonist haloperidol
reduced the control response in the NAC and Naive groups and indeed
more so in the latter (Besson et al., 1998).
3.4. Effects of pharmacological and/or
psychotherapeutic treatment on helplessness in MDD patients
3.4.1. Study selection
A systematic review was conducted of all randomised controlled
human studies comparing measures of helplessness between patients
receiving active treatment and those receiving either another active
treatment or a control intervention or no intervention (e.g. wait-list
control group). Appendix A Fig. A2 presents a ﬂowchart of the literature
search. Out of 166 human studies on the effects of pharmaco- or psycho-
therapeutic treatment on measures of helplessness in MDD patients,
identiﬁed by literature search and assessed for eligibility, 10 studies
fulﬁlled the inclusion criteria andwere included in quantitative analysis.
In eight of these studies psychotherapywas the active intervention and in
two of these studies combined psychotherapy–pharmacotherapy was
the active intervention.
3.4.2. Study characteristics
Characteristics of the studies included are depicted in Table 5. Three
studies focused on MDD (Lynch et al., 2003; Smit et al., 2005; Laidlaw
et al., 2008), one study focused onmajor orminor depressive disorder or
dysthymia (Singh et al., 2005), one study focused on remitted chronic
MDD and dysthymia (Petersen et al., 2010), two studies focused on
depression not further speciﬁed (Tsang et al., 2006; Liu, Chen, et al.,
2009), and three studies focused on co-morbid depressive disorder in
medical patients (Brody et al., 2006; Freedland et al., 2009; Sims et al.,
2009). Four studies included patients identiﬁed with clinical interviews
(Smit et al., 2005; Brody et al., 2006; Laidlaw et al., 2008; Freedland et al.,
2009), three studies included patientswith values above cut-off scores in
established depression scales (Singh et al., 2005; Tsang et al., 2006; Liu,
Chen, et al., 2009), and in three studies diagnosis by clinical interview
plus above cut-off scores in established depression scales were required
for inclusion (Lynch et al., 2003; Sims et al., 2009; Petersen et al., 2010).
Active psychotherapeutic approaches included depression recur-
rence prevention (Smit et al., 2005), self-management (Brody et al.,
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Table 4
Overview of studies that assessed test-phase control behaviour in rodents after pre-exposure to uncontrollable aversive stimulation and pharmacological challenge.
Reference Inescapable
variable
Dependent variable Description of injection Effect
Apparatus Measure Drug Acute/
chronic
Injection time
before test
Concentration Type of
injection
Group Drug Group×drug
Hunziker,
1992
Foot electro
shock
2-way
shuttlebox
Locomotor
transfer: escape
Naloxone (μ-opioid
receptor antagonist)
Acute 1× 10 min 5/10/20 mg/kg ip Yes Yes Esc Lat reduced in IS;
Esc Lat
increased in NS
Telner &
Singhal,
1981
Nortriptyline (tricyclic
antidepressant)
Acute 1× 30 min 2/4/6/12.5 mg/kg ip Yes: Esc
Resp+Esc
Lat
No: Esc Resp+
Esc Lat
Esc Lat and Esc
Resp reduced in IS
Anisman
et al., 1980b
2-way
shuttlebox
with CS
Locomotor
transfer:
avoid/escape
Apomorphine hydrochloride
(dopamine receptor agonist)
Acute 1× 15 min 0.3/1.5/3 mg/kg ip Yes No Esc Lat reduced
in IS
Clonidine (norepinephrine
receptor agonist)
Acute 1× 15 min 0.75/1.5 mg/kg ip Yes No Esc Lat reduced
in IS
Besson et al.,
1998
Haloperidol (D2-dopamine
receptor antagonist)
Rep. acute 3× 15 min
(all 3 times)
37.5/75/150 mg/kg ip Yes Yes Esc Fail increased
in NSN IS
Haloperidol and morphine
(D2-dopamine receptor
antagonist and μ-opioid
receptor agonist)
Hal: as above
Mor: sub
chronic 5×
Hal: as above
Mor: day 1: 2 h
after stress
(dose 1) days 2–5:
bef. test (dose 2)
after test: (dose 3)
Hal: as above; Mor:
dose1: 6 mg/kg dose2:
4 mg/kg dose 3: 2 mg/kg
Hal: ip; Mor: sc Yes No: Morphine alone
No: Morphine+
haloperidol
Yes: Morphine
alone reduced
Esc Fail in IS
no: morphine+
haloperidol
Besson et al.,
1996
Morphine (μ-opioid receptor
agonist)
Sub
chronic 5×
Mor: day 1: 1×
days 2–5: 2×
0.25/0.5/1/2/4/8 mg/kg sc Yes No Esc Fail reduced
in IS
Naloxone (μ-opioid receptor
antagonist)
Rep. acute 3× 10 min 0.25/0.5/1/2 mg/kg ip Yes Yes: Esc Fail increased
in NS and IS
No
Naloxone and morphine
(μ-opioid receptor agonist)
Nal: rep.
acute. 3×
Mor: sub
chronic 5×
As both above Nal: 0.5 mg/kg; Mor:
1/8 mg/kg
Nal: ip Mor: sc No NS Yes: Nal antagonises
Mor effect on Esc
Fail in IS
Porsolt et al.,
1989
Hydroxyzine (antihistamine) Sub. chronic
5×
30 min (all 3 tests) 8/16/32 mg/kg ip Yes No No
Diazepam (GABAa-receptor
agonist)
Sub. chronic
5×
30 min (all 3 tests) 2 mg/kg ip Yes No No
Joca et al.,
2006
Zimelidine (SSRI) Acute 1× After stress 100 nmol/0.5 μl Intracr. Dorsal
hippocampus
Yes No Esc/avoid Lat
reduced in IS
Desipramine (tricyclic
antidepressant)
Acute 1× After stress 3/30 nmol/0.5 μl Intracr. dorsal
hippocampus
Yes No Esc/avoid Lat
reduced in IS
Zimelidine (SSRI) Acute 1× 2 h after stress 100 nmol/0.5 μl Intracr. dorsal
hippocampus
No No No
Desipramine (tricyclic
antidepressant)
Acute 1× 2 h after stress 3/30 nmol/0.5 μl Intracr. dorsal
hippocampus
No No No
Danchev
et al., 1989
Locomotor
transfer: avoid
Salbutamol
(β2-adrenoceptor agonist)
Chronic 14× 24 h (all 3 tests) 1/5 mg/kg Orally No No No drug in NS
Trimethoquinol
(β2-adrenoceptor agonist)
Chronic 14× 24 h (all 3 tests) 1/5 mg/kg Orally No No No drug in NS
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Reference
Inescapable
variable
Dependent variable Description of injection Effect
Apparatus Measure Drug Acute/chronic Injection
time
before test
Concentration Type of
injection
Group Drug Group×drug
Propanol (β2-adrenoceptor
antagonist)
Chronic 14× 24 h (all 3 tests) 1/3 mg/kg Orally Yes Yes No drug in NS
3B (β2-adrenoceptor
antagonist)
Chronic 14× 24 h (all 3 tests) 0.3/1/3 mg/kg Orally Yes Yes No drug in NS
Harrell et al.,
1978
Operant
arena
Lever
press=shock
termination
Aramine
(metaraminol bitartrate)
(α1-adrenoceptor agonist)
Acute 1× 20 min 0.002 mg/kg ?? Yes Yes Esc Lat reduced
in IS and NS
Sherman &
Petty, 1980
Desipramine (tricyclic
antidepressant)
Acute 1× 1 h 1 μg Intracr. FNC Yes No Esc Fail reduced
in IS
Desipramine (tricyclic
antidepressant)
Acute 1× 1 h 1 μg Intracr. HC,
SEPT, LGBc
Yes No No
GABA Acute 1× 1 h 1 μg Intracr. HC,
LGB
Yes No Esc Fail reduced
in IS
GABA Acute 1× 1 h 1 μg Intracr. FNC,
SEPTc
Yes No No
NE Acute 1× 1 h 1 μg Intracr. FNC,
HC, SEPT, LGBc
Yes No No
5-HT Acute 1× 1 h 1 μg Intracr. FNC,
SEPT
Yes No Esc Fail reduced
in IS
5-HT Acute 1× 1 h 1 μg Intracr. HC,
LGBc
Yes No No
Whitehouse
et al., 1985a
Naltrexone opioid
receptor antagonist
Acute 1× 15 min 10 mg/kg ip Yes: IS
versus. ES/
NS
No Yes: Esc Lat
reduced in IS; Esc
Lat increased in
ES/NS
Hemingway
& Reigle,
1987a
Naltrexone (opioid
receptor antagonist)
Acute 1× 10 min 3 mg/kg No data Yes: IS
versus. ES/
NS
No No
Petty 1979 No data Operant
arena
Lever
press=shock
termination
Imipramine (tricyclic
antidepressant)
Sub chronic
5×
1 h 1/2/5/10/20/40 mg/kg ip Yes Yes: high
subchronic dose
No drug in NS
Grahn et al.,
2002
Tail electro
shock
2-way
shuttle
box
Locomotor transfer:
escape
Benoxathian
(α1-adrenoceptor
antagonist)
Acute 1× Bef. test 4 μg/1 μl Intracr. DRN Freez: yes
Esc Lat: yes
Freez: no
Esc Lat: no
Freezing reduced
in IS
Esc Lat: no
Grahn et al.,
2000
APV (2-amino-5-phospho-
novaleric acid)
(NMDA-receptor antagonist)
acute 1x 10 min 5 ng/1 μl Intracr. DRN Freez: yes
Esc Lat: yes
Freez: no
Esc Lat: no
Freezing reduced
in IS
Esc Lat increased
in NS
L-NAME (L-N-nitro-L-
arginine methyl ester)
(Nitric oxide synthase inhibitor)
Acute 1× 10 min 5 μg/1 μl Intracr. DRN Freez: yes
Esc Lat: yes
Freez: no
Esc Lat: no
Freezing reduced
in IS
Esc Lat reduced
in IS
SSRI, selective serotonin reuptake inhibitor; 5-HT, serotonin; GABA, gamma-aminobutyric acid; NE, noradrenaline; Rep. Acute, repeated acute schedule; ip,intra-peritoneal; sc, sub-cutaneous; intracr., intra-cranial;
DRN, dorsal raphé nucleus; FNC, frontal neocortex; HC, hippocampus; LGB, lateral geniculate body; SEPT, septum
ES, escapable stressor; IS, inescapable stressor; NS, no stressor; Esc Fail, escape failure; Esc Lat, escape latency; Freez, Freezing response
a These studies were conducted using a triadic design.
b These studies were conducted in mice.
c Additional injection sites that were studied: entorhinal cortex, posterior neocortex, caudate, n. accumbens and amygdala.
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Table 5
Overview of RCT studies that assessed measures of helplessness in MDD patients before and after treatment.
Reference Subjects Independent variable Dependent variable Sample
size
Major results
Diagnosis of patient Diagnostic instrument of
depression (interview/
questionnaire)
Treatment intervention Control
intervention
Target
construct
Scale Changes from pre-
to post-treatment
Group differences post-
intervention
Delta pre-
post-
differences
between
groups
Smit et
al., 2005
Major depressive disorder
(DSM-IV)
Composite International
Diagnostic Interview
Depression-Recurrence
Prevention (DRP); DRP
+Psychiatrist (DRPp);
DRP+Cognitive
Behaviour Therapy
(DRPcbt)
Care as usual
(CAU)
Perceived self-
efﬁcacy for
managing
depression
Depression Self-
Efﬁcacy Scale
267 DRP: prebpost CAU:
prebpost DRPp:
pre=post DRPcbt:
pre=post
DRP=DRPp=DRPcbt=CAU ns
Brody et
al., 2006
Major or minor
depressive disorder
(DSM-IV) in patients with
age-related macular
degeneration
Structured Clinical Interview
for DSM-IV
12-hour self-
management program
(SM)
12-hour tape-
recorded
health
education;
Wait list
Expectations
for handling
deﬁned
situations
related to
macular
degeneration
Macular
Degeneration
Self-Efﬁcacy
Scale
32 SM: prebpost
Controls: pre=post
SM=controls SMNcontrols
Further results: SM: decrease of depressive symptoms associated
with increase in self-efﬁcacy (not associated in control groups);
coefﬁcient of association signiﬁcantly different between groups
Freedland
et al., 2009
Major or minor
depressive disorder
(DSM-IV) in patients who
had undergone coronary
artery bypass graft
surgery in the past year
Depression Interview and
Structured Hamilton
Cognitive Behaviour
Therapy (CBT); Supportive
Stress Management (SM)
Care as usual
(CAU)
Hopelessness
towards the
future
Beck
Hopelessness
Scale
123 Total group:
prebpost
CBT=SM; CBTNCAU;
SM=CAU
ns
Laidlaw
et al., 2008
Major depressive disorder
(DSM-IV)
Schedule for Affective
Disorders and schizophrenia —
Life time version
Cognitive Behaviour
Therapy (CBT)
Care as usual
(CAU)
Hopelessness
towards the
future
Beck
Hopelessness
Scale
44 CBT: prebpost CAU:
pre=post
CBT=CAU CBTNCAU at
6 months
only
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Reference
Subjects Independent variable Dependent variable Sample size Major results
Diagnosis of
patient
Diagnostic instrument of
depression (interview/
questionnaire)
Treatment intervention Control intervention Target
construct
Scale Changes from pre-
to post-treatment
Group differences post-
intervention
Delta pre-
post-
differences
between
groups
Lynch et
al., 2003
Major depressive disorder
(DSM-IV)
Duke Depression Evaluation
Schedule and (Hamilton Rating
Scale for Depression-17, cut-
off: N=19 or Beck Depression
Inventory, cut-off: N=19)
Dialectical Behaviour
Therapy+Medication
(DBT+MED)
Medication
only (MED)
Hopelessness
towards the
future
Beck
Hopelessness
Scale
34 DBT+MED:
prebpost; MED:
pre=post
DBT+MED=MED ns
Singh et
al., 2005
(Major or minor
depressive disorder or
dysthymia (DSM-IV))
Geriatric Depression Scale, cut-
off: N=14
High intensity
progressive resistance
training (HPRT)
Low intensity
progressive
resistance
training
(LPRT); Care
as usual (CAU)
Health locus of
control (LC);
Self-efﬁcacy
(SE) regarding
behaviour
Self-Efﬁcacy
Scale;
Multidimensional
Health Locus of
Control
60 Total group: LC:
pre=post; SE:
prebpost
LC: not reported; SE:
HPRT=LPRT; SE: HPRTNCAU
LC: ns; SE: ns
Sims et
al., 2009
“Depression” (not further
speciﬁed) in stroke
survivors
Patient Health Questionnaire-
9; Present State Examination,
depression module
Progressive resistance
training (PRT)
Wait list
(WL)
Recovery locus
of control
Recovery Locus
of Control Scale
45 PRT: prebpost; WL:
not reported
Not reported Not reported
Liu, Chen,
et al., 2009
Depression Beck Depression Inventory-II,
cut-off: 10bpatientb47 and
not suicidal ideation
Cognitive Bibliotherapy
(CB)
Wait list
(WL)
Learned
resourcefulness
Self-Control
Schedule
52 CB: prebpost; WL:
pre=post
CBNWL CBNWL
Learned resourcefulness partially mediated the effect of CB on
cognitive-affective symptoms of depression.
Petersen
et al., 2010
Remitted chronic major
depressive disorder (and
dysthymia) (DSM-III-R)
Acute phase: Structured
Clinical Interview for DSM-III-
R; Hamilton Rating Scale for
DepressionN=16; Remission:
Hamilton Rating Scale for
Depressionb=7
Cognitive Behaviour
Therapy+placebo
(CBTp); Fluoxetine
(40 mg) only (F);
Cognitive Behaviour
Therapy+ﬂuoxetine
(40 mg) (CBTf)
Placebo only
(P)
Hopelessness
towards the
future
Beck
Hopelessness
Scale
55 Inference statistics
not reported
Descriptive: CBTp:
prebpost; CBTf:
prebpost; F:
preNpost; P:
preNpost
Not reported ns
Tsang et al.,
2006
Depression (not further
speciﬁed: diagnosis or
obvious features)
Geriatric Depression Scale, cut-
off: total score N8
Qigong (Q) Newspaper
reading
group (N)
Conﬁdence in
ability to deal
with novel or
demanding
situations
The Chinese Self-
Efﬁcacy Scale
82 Q: prebpost; N:
preNpost
QNN QNN
Note: b worse than, N better than, ns not signiﬁcant
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2006), cognitive behaviour therapy (Laidlaw et al., 2008; Freedland et
al., 2009; Petersen et al., 2010), dialectical behaviour therapy (Lynch et
al., 2003), progressive resistance training (Singh et al., 2005; Sims et al.,
2009), cognitive bibliotherapy (Liu, Chen, et al., 2009) and qigong
(Tsang et al., 2006). Active pharmacotherapeutic approaches included
ﬂuoxetine (Petersen et al., 2010) or standard antidepressantmedication
not further speciﬁed (Lynch et al., 2003). One study compared its active
treatment with another active treatment (Tsang et al., 2006), three
studies compared active treatments with care-as-usual (Smit et al.,
2005; Laidlawet al., 2008; Freedland et al., 2009), two studies compared
active treatmentswithwait list (Liu, Chen, et al., 2009; Sims et al., 2009),
two studies compared their active treatments with both another active
treatment and wait list or care as usual (Singh et al., 2005; Brody et al.,
2006), two studies compared active treatments with placebo or
medication (Lynch et al., 2003; Petersen et al., 2010).
Helplessness-related target outcomes of interest included self-efﬁcacy
(Singh et al., 2005; Smit et al., 2005; Brody et al., 2006; Tsang et al., 2006),
hopelessness (Lynch et al., 2003; Laidlaw et al., 2008; Freedland et al.,
2009; Petersen et al., 2010), locus of control (Singh et al., 2005; Sims et al.,
2009), and learned resourcefulness (Liu, Chen, et al., 2009).
3.4.3. Results of individual studies and synthesis of results
Major study ﬁndings are presented in Table 5.
Changes from pre-to post-treatment: in all studies, measures of
helplessness were improved by the active psychosocial treatment,
except for Smit et al. (2005) in which the depression-recurrence
prevention in combination with either psychiatrist-consulting or
cognitive behaviour therapy did not improve self-efﬁcacy. In the
Singh et al. (2005) study, health locus of control did not change from
pre- to post-intervention. Pharmacological treatment alone either
resulted in no change or in deterioration of helplessness measures
(Lynch et al., 2003; Petersen et al., 2010).
Treatment group differences post-treatment: in four studies, patients
in the active treatment group showed less helplessness post-treatment
as compared to the patient control group. The active treatments were
cognitive behaviour therapy, high-intensity progressive resistance
training, cognitive bibliotherapy, or qigong (Singh et al., 2005; Tsang
et al., 2006; Freedland et al., 2009; Liu, Chen, et al., 2009).With regard to
the type of helplessness measure, the reduction was seen for self-
efﬁcacy (Singh et al., 2005; Tsang et al., 2006), hopelessness (Freedland
et al., 2009), and learned resourcefulness (Liu, Chen et al., 2009). No
differences between active treatment and control groups at post-
treatment were seen for: self-efﬁcacy, using the depression-recurrence
prevention programme (Smit et al., 2005), the self-management
programme (Brody et al., 2006), or high-intensity resistance training
(Singh et al., 2005); hopelessness, using one cognitive behaviour
therapy trial (Laidlaw et al., 2008), supportive stress management
(Freedland et al., 2009), or dialectical behavioural therapy plus
medication (Lynch et al., 2003). Two studies, focusing on locus of
control and hopelessness, did not report data regarding post-treatment
group differences (Sims et al., 2009; Petersen et al., 2010).
Delta of the pre-post differences between treatment groups: in four
studies, the active treatment, including self-management, cognitive
behaviour therapy, cognitive bibliotherapy, and qigong, resulted in
greater improvement of self-efﬁcacy, hopelessness or learned re-
sourcefulness, than did the control interventions (Brody et al., 2006;
Tsang et al., 2006; Laidlaw et al., 2008; Liu, Chen, et al., 2009). This was
not seen for: depression-recurrence prevention programme focusing
on self-efﬁcacy (Smit et al., 2005); cognitive behaviour therapy,
supportive stress management, ﬂuoxetine, or dialectical behavioural
therapy plus medication focusing on hopelessness (Lynch et al., 2003;
Freedland et al., 2009; Petersen et al., 2010), or high-intensity
progressive resistance training focusing on self-efﬁcacy and locus of
control (Singh et al., 2005). One study, focusing on locus of control, did
not report data regarding the group differences of changes from pre-
to post-treatment (Sims et al., 2009).
Therefore, focusing on pharmacotherapy and helplessness inMDD,
there is currently no RCT study for depression that has included a
measure of helplessness as target outcome and has demonstrated a
therapeutic effect for an antidepressant drug in terms of an
improvement on the helplessness measure. According to the search,
one RCT study has been conducted with helplessness as a target
outcome and with a pharmacotherapy-only arm. This was a study
with the anti-depressant ﬂuoxetine: scores on the BHSwere increased
after ﬂuoxetine treatment whereas cognitive behaviour therapy
reduced BHS scores in the same study.
4. Discussion
Firstly, a review and integration of the theory and evidence for the
learned helplessness effect in rodents, and that for the learned
helplessness effect, the learned helplessness theory of depression and
helplessness in depression, in humans, are presented. The LH effect is
a relatively speciﬁc psychological state that translates across species.
For rodents, primarily the laboratory rat, there is evidence that
emotional, motivational and cognitive effects of uncontrollable
aversive stimulation mediate the LH effect. In humans, the LH effect
and the LH theory of depression have been largely treated as cognitive
processes. At the neurobiological level, a circuitry model of the LH
effect in the rat proposes that both controllable and uncontrollable
aversive stimuli activate CNS punishment systems, such as seroto-
nergic output from the DRN in response to painful stimuli. The
controllability of the stimulus is proposed to be processed in the
vmPFC, the rat analogue of the human ACC. The presence of control is
relayed out of the vmPFC to regions sensitive to aversive stimulation
per se, to reduce the response of these punishment systems, such that
a state of controllability is maintained/LH effect is prevented. Human
imaging and EEG ﬁndings provide evidence that perceived state of
uncontrollability is associated positively with ACC activity, and in
MDD patients perceived state of helplessness is associated positively
with ACC/PFC activity. Secondly, systematic reviews are presented for
studies of the effects of pharmacological agents on control behaviour
in rodents exposed to uncontrollable aversive stimulation, and of
pharmaco- and/or psycho-therapy in MDD patients on measures and
reports of helplessness and related constructs.
As discussed below, the ﬁndings of these reviews and systematic
reviews allow for clariﬁcation of a number of translational issues and
serve to identify areas for future translational research into the LH
effect and helplessness. It would appear that there is real potential for
translational research into the LH effect and helplessness to yield
important novel insights into the neuropsychopathology of depres-
sion, in terms of aetiology, maintenance and treatment.
4.1. Clariﬁcation of translational issues
4.1.1. Uncontrollability versus helplessness
The use of the term helplessness to describe the robust but relatively
situation-speciﬁc, short-term effect of uncontrollable aversive stimuli on
behaviour that is the LH effect, would appear to have inhibited progress,
within and between animal and human studies, in our understanding of
helplessness and its relevance toMDDaetiology, onset andmaintenance.
Within animal studies, the term LH as applied to the AC-NAC-Naive
model has contributed to the general view that this and other, situation-
speciﬁc short-term manipulations, such as the forced swim test and tail
suspension test, induce helplessness and constitute models of helpless-
ness in depression (Pryce & Seifritz, 2011). Within human studies, the
term LH has also been associated with a too literal extrapolation of the
effects of speciﬁc uncontrollable aversive stimuli on behaviour of healthy
individuals to the psychopathological state of helplessness in depression.
To use a more parsimonious terminology, what the LH effect demon-
strates is learned aversive uncontrollability (LAU). The LAU effect has
been demonstrated in healthy animals and healthy humans. The LAU
262 C.R. Pryce et al. / Pharmacology & Therapeutics 132 (2011) 242–267
effect demonstrates the sensitivity of healthy individuals to the unique
organism–environment situation of uncontrollability.
An intense, chronic LAU effect, elicited by a major aversive
stimulus/life event that is uncontrollable, could well be aetiological
in inducing generalised helplessness, which in turn could be themajor
aetiological and maintenance factor in MDD, and the necessary focus
of its treatment. Re-naming the LH effect as the LAU effect is aimed at
clarifying and not de-valuing the importance of this effect. On the
contrary, by using themore parsimonious descriptor of the LAU effect,
the inter-relationships between the LAU effect and generalised
helplessness and between generalised helplessness and MDD can be
clariﬁed. This clariﬁcation should serve to facilitate research aimed at
furthering understanding of these inter-relationships, within and
between animals and humans.
4.1.2. Cognitive versus emotional–motivational–cognitive causality
The major strength of the LH effect (hereafter referred to as the LAU
effect) is the non-ambiguity of the independent variable, namely
aversive uncontrollability. This clarity results in a marked aetiological
and construct validity of the LAU effect relative to other aversive
stimulation models used in preclinical depression research (Pryce &
Seifritz, 2011). The psychological processes proposed to underlie the
effect, namely a constellation of emotional, motivational and cognitive
processes, and their interactions, would appear to represent a realistic
assessment of the complexity of the LAU effect. Furthermore, studies of
each of these processes and the changes in their state as a consequence
of uncontrollability, is likely to be necessary for a proximate under-
standing of the LAU effect. These same processes and their interactions
are alsomajor candidates as aetiological andmaintenance factors in the
psychopathology of helplessness in MDD. It is unfortunate, therefore,
that the discussion of the relevance of LH to MDD, including the LH
theory of MDD, has focused on cognitive processes, such as contingency
and attribution, to the near exclusion of the role of emotional and
motivational processes. Psychological theories such as incentive-
motivation, which integrate physiological motivation with cognitive
processes such as goal-directed expectancy (e.g. Balleine & Dickinson,
1998), are clearly relevant andneed to be integrated into theoretical and
empirical helplessness research in the future.
4.1.3. Neurobiological translation
Animal and human studies of the neurobiological underpinnings of
the LAU effect and helplessness are still at an early stage but already
some striking parallels have been identiﬁed, primarily in terms of a
central role for analogous PFC regions and an important modulatory
role of 5-HT in these regions. These ﬁndings suggest that the mPFC/
ACC is central to both the LAU effect and the state of helplessness in
MDD, and could therefore be important in mediating any causal
relationship between these two processes.
4.2. Directions for future research
4.2.1. From the learned aversive
uncontrollability effect back to the learned helplessness effect
If it is accepted to be constructive to re-deﬁne the LH effect as the LAU
effect, then this should facilitate the design of rodent models that do
indeed measure an LH effect i.e. that demonstrate a generalised chronic
state of a deﬁcit in respondingwith control or expectancy in contexts and
towards stimuli other than those used to induce this state. In LAUmodels
it is perdeﬁnitionestablished that adeﬁcit in a speciﬁc control response in
theNACgroup is the result of experiencingaversiveuncontrollability. This
deﬁcit can then serve as a comparator, such that should animals exhibit
the same deﬁcit following exposure to other aversive environments, this
deﬁcit can be interpreted as being underlain by the psychological state of
generalised uncontrollability i.e. a true LH effect. Candidate aversive
manipulations are chronic unpredictable stress or chronic social defeat
stress (e.g. Krishnan & Nestler, 2008). Furthermore, in such models the
control deﬁcit used to deﬁne the LH state is likely to co-occur with a
number of other depression-relevant state markers e.g. loss of body
weight and condition, disturbance of circadian activity, reduced wanting
and liking of rewarding stimuli, increased fatigability. These models will
allow for the study of the inter-relationships between LH and other state
markers, including whether treatments that increase control/reduce LH
also lead to reduction of the other markers.
4.2.2. The importance of individual differences
A characteristic of the original LH effect model in rodents and
humans is that subjects are allocated randomly to the study groups i.e.
AC, NAC, Naive. The underlying assumption is that the average
sensitivity to uncontrollability will be equal between the individuals
in the yoked AC and NAC groups. Assessment of the (un)controlla-
bility of an aversive environment is of course individual-speciﬁc and
these individual differences will be extremely important. Depending
on the paradigm, a proportion of individuals allocated to the AC group
would be expected to experience the controllable aversive stimulus/
context as (to some extent) uncontrollable and to develop a LAU state.
Also, a proportion of individuals allocated to the NAC group would be
expected to persist with control attempts and to be resistant to
developing a LAU state. This variation is to be welcomed, given that
LAU effect and LH effect models need to provide insights into the
human inter-individual differences in vulnerability-resilience in
responses to aversive uncontrollability. Animal models of the LAU
effect and generalised LH effect that are designed to allow for the
study of the contribution of (epi-)genetic and development–environ-
mental factors to these effects will be of high validity and importance.
4.2.3. Translational models and studies based
on dynamic psychological–neurobiological processes
According to current LAU effect theory based on the rat data, aversive
stimuli exert acute effects on the brain in terms of stimulating emotional,
motivational and cognitiveprocessing. Anyperceiveduncontrollability of
these aversive stimuli will feed back onto these psychological processes
and therefore onto the neurobiological processes underlying them.
Extrapolating to the human situation, in a situation where a life event of
high emotional signiﬁcance is being proposed to lead to a chronic state of
helplessness because of its uncontrollability, then this situation also
needs to be studied at the reciprocal level of neurobiological processes
controlling psychological responses and psychological state feeding back
onto neurobiological state. To-date, the emphasis has been more on the
acute onset of the LAU effect and less on how this effect can lead to
chronic, bi-directional feedback between psycho(patho)logical and
neuro(patho)logical states.
4.2.4. Valid models and state
markers for drug discovery and development
The primary rationale for improved understanding of the LH effect
and of helplessness as they relate to depression is to facilitate the
accurate assessment of the importance and relevance of helplessness
as a psychopathological target for therapy, and the discovery and
development of effective pharmacological and psychotherapeutic
treatments with which to achieve this. It is hoped that the current
review will make a helpful contribution here, and will stimulate
much-needed advancement in our understanding and treatment of
MDD.
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Appendix A
Fig. A1. Flowchart of the literature search for studies on the learned helplessness effect and on test-phase control behaviour in rodents after pre-exposure to uncontrollable aversive
stimulation and pharmacological challenge.
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Fig. A2. Flowchart of the literature search for randomised control studies on measures of helplessness and controllability in MDD patients and control probands after therapeutic
treatment.
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a b s t r a c t
Uncontrollability of major life events has been proposed to be central to depression onset and mainte-
nance. The learned helplessness (LH) effect describes a deﬁcit in terminating controllable aversive stimuli
in individuals that experienced aversive stimuli as uncontrollable relative to individuals that experienced
the same stimuli as controllable. The LH effect translates across species and therefore can provide an
objective-valid readout in animal models of depression. Paradigms for a robust LH effect are established
and currently applied in rat but there are few reports of prior and current study of the LH effect in mouse.
This includes the C57BL/6 mouse, typically the strain of choice for application of molecular-genetic tools
in pre-clinical depression research. The aims of this study were to develop a robust paradigm for the LH
effect in BL/6 mice, provide evidence for underlying psychological processes, and study the effect of
a depression-relevant genotype on the LH effect. The apparatus used for in/escapable electro-shock
exposure and escape test was a two-way shuttle arena with continuous automated measurement of
locomotion, compartment transfers, e-shock escapes, vertical activity and freezing. Brother-pairs of BL/6
mice were allocated to either escapable e-shocks (ES) or inescapable e-shocks (IS), with escape latencies
of the ES brother used as e-shock durations for the IS brother. The standard two-way shuttle paradigm
was modiﬁed: the central gate was replaced by a raised divider and e-shock escape required transfer to
the distal part of the safe compartment. These reﬁnements yielded reduced superstitious, pre-adaptive e-
shock transfers in IS mice and thereby increased the LH effect. To obtain a robust LH effect in all brother
pairs, pre-screening for minor between-brother ES differences was necessary and did not confound the
LH effect. IS mice developed reduced motor responses to e-shock, consistent with a motivational deﬁcit,
and absence of a learning curve for escapes at escape test, consistent with a cognitive deﬁcit. When
a tone CS was used to predict e-shock, IS mice exhibited increased reactivity to the CS, consistent with
hyper-emotionality. There was no ESeIS difference in pain sensitivity. Mice heterozygous knockout for
the 5-HTT gene exhibited an increased LH effect relative to wildtype mice. This mouse model will allow
for the detailed molecular study of the aetiology, psychology, neurobiology and neuropharmacology of
uncontrollability of aversive stimuli, a potential major aetiological factor and state marker in depression.
This article is part of a Special Issue entitled ‘Anxiety and Depression’.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Helplessness, external locus of control and impaired coping
ability, are inter-related and major concepts in depression, as
predisposing, aetiological and pathological psychological processes
(Abramson et al., 1989; Alloy et al., 1999; Harrow et al., 2009). These
terms describe the individual’s perceived lack of control over
environmental events and, although they are not symptoms
according to current diagnostic criteria, they are important state
markers for therapy, both per se and as a potential route to
ameliorate core and common depression symptoms such as
depressed mood, fatigue, pessimistic views of the future and
recurrent thoughts of suicide (DSM-IV, 1994; ICD-10, 1994).
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Learned helplessness (LH) refers to the process in which the
experiencing of major aversive life events that are uncontrollable
(in terms of their outcome and termination) can lead to the indi-
vidual responding to subsequent events as if they are also uncon-
trollable when in fact they are not (Abramson et al., 1978; Miller
and Norman, 1979). Learned helplessness has been proposed to
comprise the following three dimensions: emotional, in terms of
increased arousal, anxiety and fear relative to stimuli/events;
motivational, in terms of the reduced level of incentive to terminate
the stimulus/event; cognitive, in terms of the reduced expectancy
that the stimulus/event can be terminated by own behaviour
(Maier and Seligman, 1976). In addition to embracing these three
central dimensions of brain-behaviour function, LH is also distin-
guished by being the ﬁrst example of a translational concept in
psychiatric research. Thus, LH was ﬁrst demonstrated in animal
experimental psychology, including in dog and rat studies (Maier
and Seligman, 1976), and the observations and interpretations
made with these species were then applied to human behaviour
and affective disorders thereof (Abramson et al., 1978; Miller and
Norman, 1979; Seligman, 1972). Importantly, the LH effect
demonstrated in animals is a deﬁcit in responding to a speciﬁc
stimulus/event (see below) and not a generalized helplessness,
which is the form of helplessness regarded to be important in
depression psychopathology (Abramson et al., 1978). Nonetheless,
the LH effect model is important in terms of what it could reveal
about the underlying neurobiology of speciﬁc and generalized
helplessness, and therefore depression and its treatment (Amat
et al., 2005; Robbins, 2005).
Most LH experiments have been conducted in the rat. Subjects
are allocated at random either to exposure to controllable (escap-
able) or uncontrollable aversive stimuli and this is followed by
a test in which all subjects are assessed in terms of their behaviour
relative to controllable aversive stimuli. In the exposure phase, the
operant latencies to terminate the escapable stimuli (ES) in the ES
group are used as the durations of the inescapable stimuli (IS) in the
IS group; as a result of this yoking principle the only difference
between ES and IS is the controllability of the aversive stimuli
experienced (Maier and Seligman, 1976). The current most
commonly used rat LH model comprises exposure to tail electro-
shock that can be terminated in the ES group by operant turning
of a wheel, and testing in terms of escaping electro-shock by
operant running in a two-way shuttle box: IS rats exhibit an escape
deﬁcit at test in terms of reduced number of escapes/increased
latency to escape, where the escape response involves crossing
from one side of the shuttle box to the other and back again (Amat
et al., 2005). A distinguishing feature of the LH effect as a model in
pre-clinical depression research is that the process underlying the
behavioural change and being measured is clear: it is the prior
experience of uncontrollability. This is not the case for other
models: for example, the forced swim test is often claimed to
measure “behavioural despair” (e.g., Castagné et al., 2011), “help-
lessness” (e.g. El Yacoubi et al., in press), “passive coping” (e.g. Keck
et al., 2003) or even “active coping” (e.g. Lu et al., 2008) but,
because there is no equivalent of the ES comparison group in the LH
effect paradigm, it is difﬁcult to interpret what underlies the
reduction in swimming exhibited by rats and mice and, therefore,
what the test actually measures.
Despite the high use and potential of mice in pre-clinical
research into affective disorders, and despite the high face and
construct validity of the LH effect paradigm, there have been rela-
tively few published studies of amouse LH effect. A recent literature
search (Embase, Medline and Psycinfo, from 1806 to 2011) of rat
and mouse LH effect studies that used the ESeIS paradigm yielded
38 rat studies and 6 mouse studies (Pryce et al., in press) and the
most recent mouse study was published in 2003 (Palermo-Neto
et al., 2003). There are a large number of mouse publications
which include comparison of an IS groupwith a group that received
no aversive stimuli prior to test, the so-called unconditioned-
stimulus (US) pre-exposure effect paradigm (e.g. Chang et al., 2007;
Maeng et al., 2008). These studies do not allow for assessment of
the effect of aversive uncontrollability per se and thereby lack the
very essence of the LH effect paradigm. One laboratory that has
made a signiﬁcant contribution to establishing and studying the LH
effect in mice is that of Anisman, with the majority of studies
conducted with Swiss-Webster mice and using electro-shocks for
ESeIS pre-exposure and e-shock two-way escape behaviour as
readout (e.g. Anisman et al., 1978, 1979, 1980; Anisman and Merali,
2001). As noted (Anisman and Merali, 2001), one possible reason
for the relative scarcity of mouse LH effect studies is the challenge
of designing an aversive manipulation such that those mice pre-
exposed to the escapable form (ES) continue to exhibit high
levels of escape behaviour up to and including the escape test,
whilst those mice pre-exposed to the inescapable form of the
manipulation (IS) e which is identical in intensity and duration to
ES e develop a robust escape deﬁcit that is expressed during the
escape test.
Given its common application in molecular-genetic models in
pre-clinical depression research, the ﬁrst aim of the current study
was to establish an LH effect paradigm in the C57BL/6 mouse strain.
Both ESeIS pre-exposure and escape test were carried out using
a two-way e-shock escape apparatus that allowed for concurrent
data collection on several relevant behavioural measures. The
apparatus was modiﬁed across experiments to increase the
robustness of the LH effect. The experimental design was based on
brother-pairs, such that each ESeIS dyad was also a brother-pair.
This was commensurate with the yoked design of the ESeIS para-
digm and, given that inter-individual differences are pronounced
even within inbred mouse strains such as C57BL/6 (e.g. Siegmund
et al., 2009), using brother pairs could also reduce existing indi-
vidual (trait) differences between mice allocated to the same ESeIS
dyad and thereby further increase the robustness of the LH effect
obtained. The second aim of the study was to use features and
behavioural measures provided by the apparatus to identify the
extent to which emotional, motivational and cognitive processes
contributed to the LH effect. The third aim was to study the effects
of heterozygote knockout (HET) of the serotonin transporter gene
(Slc6a4, commonly abbreviated to 5-HTT) on the LH effect. Reduced
5-HTT activity in human due to the short variant of the 5-HTT gene-
linked polymorphic region is associated with a relatively high risk
of depression in individuals exposed to several aversive life events
(Caspi et al., 2003; Karg et al., 2011). In mouse, 5-HTT HET mice
exhibit reduced two-way escape responding following IS relative to
wildtype in the US pre-exposure effect paradigm (Muller et al.,
2011). An increased LH effect in 5-HTT HET mice would demon-
strate that this phenotype is due to increased uncontrollability and
demonstrate the translational validity of the mouse LH effect for
neuro-biological and epharmacological study of depression and its
treatment.
2. Materials and methods
2.1. Animals and maintenance
Male C57BL/6J mice (RCC, Füllinsdorf, Basel, Switzerland) were delivered to the
laboratory at age 8 weeks and allowed 2 weeks to adjust to a reversed lightedark
cycle (lights off at 07:00e19:00 h). Male and female 5-HTT knockout mice on
a C57BL/6J background (>20 backcross generations) were transferred from the
University of Würzburg (Bengel et al., 1998) and breeding was established in-house
with wildtype (WT) dams and 5-HTT heterozygote knockout (HET) sires. Study mice
were weaned at 4 weeks and genotyped.
Mice were held in individually-ventilated cages (type 2 long) containing
sawdust, a sleeping house and bedding, with continuous access to food and water.
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Mice were housed as brother-pairs, each pair from a different litter and of the same
genotype in the case of the 5-HTT strain, and were maintained in these pairs for 10
days (C57BL/6J) or 6 weeks (5-HTT). Four days before the onset of the experiments,
mice were singly housed in new cages of the same type and under the same
conditions; they remained singly housed throughout the experiment.
All behavioural testing was conducted in a dimly lit room adjacent to the mouse
holding room. Each separate experiment was conducted with naive mice.
All procedures were conducted under a permit for animal experimentation
issued by the Veterinary Ofﬁce, Zurich, Switzerland, in accordance with the Animal
Protection Act (1978) Switzerland. All efforts were made to minimise the number of
mice used and any suffering of those mice that were used (see also Discussion for
relevance of paradigm developed to the 3R’s).
2.2. Hot plate test
Mice were given two hot plate tests to assess pain sensitivity, one at 3 days prior
to the onset of the LH-effect experiment and one at 1 day after its completion. The
hot plate test was conducted using a programmable thermoelectric heating plate
(Teca, Chicago IL, USA) set at 50 C, with a transparent Plexiglas chamber plus
removable lid ﬁxed onto the plate. All hot plate tests were conducted between
15:00e17:00 h. The mouse was removed from the home cage, weighed, placed
inside the chamber and the lid closed. The latency (seconds) from the onset of the
test until the ﬁrst occurrence of one of the following behaviours was scored: licking
a forepaw, licking a hind paw, lifting a hind paw, jumping. The mouse was then
immediately removed from the hot plate. The maximum test duration was 60 s and
60 s was the latency score given to mice that did not exhibit one of the target
behaviours.
2.3. Learned helplessness effect experiments
Electro-shock (e-shock) stimulation and behavioural assessment were con-
ducted using a fully-automated apparatus, speciﬁc hardware and software features
of which were purpose-built/-written for this study (Multi Conditioning System, TSE
Systems GmbH, Bad-Homburg, Germany) (Fig. 1). An e-shock grid ﬂoor measuring
30 30 cm comprising 29 stainless steel rods (Ø¼ 4mm, inter-rod centre-to-centre
distance¼ 10mm)was ﬁxed in a frame. A quadratic arenamade out of dark Plexiglas
on three sides and transparent Plexiglas at the front, measuring 30 30 24 (H) cm,
was positioned on top of the grid. Running from front to back of the arena and
situated at its midline, was either: (i) a dark Plexiglas wall containing an opening
(“gate”) at its midline with dimensions 3.5 (W) 10.0 (H) cm, allowing themouse to
transfer from one compartment of the arena/grid to the other through the gate; (ii)
a transparent Plexiglas divider: except for two 1.5 cm-wide feet extending down to
just above the grid at both ends, the bottom edge of the divider was 2.5 cm above the
grid, allowing for transfer of the mouse from one side of the arena/grid to the other
across nearly the entire depth of the arena/grid. The frame surrounding the arena/
grid included three infrared light-beam sensor systems with sensors spaced 14 mm
apart. Two of these systems were for movement detection in the XeY horizontal
plane, and allowed measurement of quadrupedal locomotion distance, number of
transfers from one arena side to the other, and number and duration of freezing
episodes, deﬁned as no detection of any movement for a minimum of 2 s. The third
sensor system, placed on top of the Y system, was for movement detection in the Z
vertical plane, and number of rears (XYZ bipedal standing), climbs (XYZ bipedal
leaning and upward movements against an arena surface) and jumps (Z detection
only) were scored with this system. Whilst full jumps could be measured unam-
biguously, some responses scored as rears and climbs were actually low jumps and
therefore a composite score of rears/climbs/jumps was used. A transparent Plexiglas
lid was placed on top of the arena, and a metal waste tray was positioned under-
neath the grid ﬂoor. This apparatus was contained in an attenuating chamber,
equipped with a ventilation fan, house lights (set to provide 8 lux), a loud speaker
emitting low-level white noise, and an observation window. Four such units were
used, interfaced with a dedicated control unit, which in turn was connected to a PC
running control and data collection software. Although all data collection was
automated, all sessions were also observed directly by the experimenters.
Four experiments were conducted. In experiment I (Standard conditions), the
gate was used, transfer through the gate terminated the e-shock immediately, and
mice in brother-pairs (N ¼ 12) were allocated to groups at random, one to the
escapable e-shock (ES) group and one to the inescapable e-shock (IS) group. In
experiment II (Reﬁned conditions, Random allocation), the divider was used,
termination of the e-shockwas not physically or temporally coincident with transfer
under the divider (see below), and mice in brother-pairs (N ¼ 12) were allocated to
the ES and IS groups at random. In experiment III (Reﬁned conditions, Screening
allocation), the divider was used, termination of the e-shock was not phys-
icallyetemporally coincident with transfer under the divider, and mice in brother-
pairs (N ¼ 17) were allocated to the ES and IS groups based on their relative
escape performance during an initial ES session (screening). An additional experi-
ment was conducted to attempt to validate the screening procedure. In experiment
IV (5-HTT HET versus WT, Reﬁned conditions, Screening allocation), the conditions
were the same as in experiment III and mice were in brother-pairs of WTeWT
(N ¼ 8) or HETeHET (N ¼ 8). The speciﬁc protocols for the four experiments are
detailed below. General conditions were: All sessions were conducted between
08:30e12:00 h. After each session on each day, the arenas were removed and wiped
with 70% ethanol. The grids were wiped dry of any urine with dry absorbent paper
and then wiped with 70% ethanol. The waste tray was removed, rinsed with hot
water and wiped dry with absorbent paper. The correct functioning of the grids and
the movement detection systemwas controlled prior to running each group of four
mice.
2.3.1. Experiment I: Standard conditions
Day 1, Habituation: The mouse was removed from its home cage, weighed, and
placed on the grid in the arena. The gate was used as the central divider.
A 15-min session was started during which the mouse could locomote in and
explore the arena. No e-shocks were administered.
Day 2, Paired ESeIS pre-exposure 1: The mouse allocated at random to the ES
group was placed in the arena for 2-min habituation. ES mice were exposed to
30 e-shocks each of 0.15 mA amplitude and 5-s maximum duration on a 50-s
constant inter-trial interval (ITI). The gate was used as the central divider.
Parameters were set so that 100% of the grid-side on which the mouse was
standing emitted e-shock and 100% of the opposite grid-side was “safe for
escape”, such that as soon as the mouse transferred once through the gate the e-
shockwas terminated and the next ITI was initiated. Mice could transfer through
the gate at any time. For each trial, the grid-side on which the mouse was
positioned at the onset of e-shock was the aversive side and the opposite side
the escape side. Therefore, the aversive side and escape side on each trial were
Fig. 1. A schematic of the experimental set-up. Mice were placed on a ﬂoor of electriﬁable stainless steel rods in an arena with three solid walls and a transparent front wall, and
with a central divider running from back to front and raised off the ground. The mouse could pass under the central divider. (A) The sketch depicts an ES mouse in Pre-exposure 1 in
Experiments IIeIV. The mouse is in compartment Left and the e-shock is presented Left and Right. Transfer of the mouse under the central divider and crossing with the head
beyond the ﬁrst 25% of the Right compartment results in termination of the e-shock. (B) The sketch depicts an ES mouse in Pre-exposure 2 or 3 or an ES or IS mouse in Escape test, in
Experiments IIeIV. The mouse is in compartment Right and the e-shock is presented Right and Left. Transfer of the mouse under the central divider and crossing with the head
beyond the ﬁrst 70% of the Left compartment results in termination of the e-shock.
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determined by the mouse. ES mice received 30 escapable e-shocks in total and
the maximum possible e-shock exposure was 150 s. The total duration of the
session was 22 min. The IS session, with the brother of the ES mouse,
commenced after the ES session was completed: the e-shock escape latencies of
the ES brother were used one-to-one as the durations for inescapable e-shock
exposures for the IS brother. That is, the yoked design used traditionally in ESeIS
studies (Maier and Seligman, 1976) was changed to a successive paired design.
ES and IS brothers were run in the same apparatus unit.
Day 3, Paired ESeIS pre-exposure 2: The conditions were the same as for ESeIS
pre-exposure 1.
Day 4, Paired ESeIS pre-exposure 3: The conditions were the same as for ESeIS
pre-exposures 1e2 except the total number of trials was 24, the maximum
duration per shock was 4 s, and the total duration of the session was 18 min.
Day 5: No session
Day 6, Escape test: Following a 48-h period during which ES and IS mice
remained undisturbed in their home cages, themicewere placed in the arena for
a session identical to ES pre-exposure 3, except that the e-shock was now
escapable for ES and IS mice.
2.3.2. Experiment II: Reﬁned conditions, Random allocation
The experimental parameters were the same as for Experiment I, with the
exception of the following changes.
Day 1, Habituation: The divider was used.
Day 2, Paired ESeIS pre-exposure 1: The mouse allocated to the ES group was
placed in the arena for 2-min habituation. The divider was used. ES mice were
exposed to 30 e-shocks each of 0.15 mA amplitude and 5-s maximum duration
on a 50-s constant inter-trial interval (ITI). For each trial, the grid-side onwhich
the mouse was positioned at the onset of e-shock was the aversive side and the
opposite side the escape side. For e-shocks 1e10, 100% of the grid-side on
which the mouse was standing emitted shock and the most distant 75% of the
opposite grid-side was “safe”, such that if the mouse passed under the divider
and entered this 75% safe area the e-shock was terminated and the next ITI
initiated (Fig. 1A). For e-shocks 11e20, 100% of the grid-side on which the
mouse was standing emitted e-shock and the most distant 50% of the opposite
grid-side was “safe” such that if the mouse passed under the divider and
entered this 50% safe area the e-shock was terminated and the next ITI initi-
ated. For e-shocks 21e30, 100% of the grid-side on which the mouse was
standing emitted e-shock and the most distant 30% of the opposite grid-side
was “safe” such that if the mouse passed under the divider and entered this
30% safe area the e-shock was terminated and the next ITI initiated (Fig. 1B).
The IS session, with the brother of the ES mouse, commenced after the ES
session was completed, so that the e-shock escape latencies of the ES brother
were used one-to-one as the durations for inescapable e-shock exposures for
the IS brother.
Day 3, Paired ESeIS pre-exposure 2: The conditions were the same as for ESeIS
pre-exposure 1 except that the safe area of the opposite grid was 50% for
e-shocks 1e10 and 30% for e-shocks 11e30.
Day 4, Paired ESeIS pre-exposure 3: The conditions were the same as for ESeIS
pre-exposure 2 except for the following: the total number of trials was 24, the
maximum duration per e-shock was 4 s, and the safe area of the opposite grid
was 30% for all e-shocks.
Day 5: No session.
Day 6, Escape test: Following a 48-h period during which ES and IS mice
remained undisturbed in their home cages, themicewere placed in the arena for
a session identical to ES pre-exposure 3, except that the e-shock was now
escapable for ES and IS mice.
2.3.3. Experiment III: Reﬁned conditions, Screening allocation
The experimental parameters were the same as for Experiment II, with the
exception of the following changes.
Day 2, ES Screening: Both mice of each brother-pair were given ES pre-exposure
1 as described above for the ES group in Experiment II i.e. there was no IS
condition. The brother with the lower mean escape latency to e-shocks 21e30
(and therefore lower total duration of e-shock exposure on trials 21e30) was
allocated to the ES group and the other brother was allocated to the IS group.
Day 3, Paired ESeIS pre-exposure 1 (not 2, otherwise identical to Day 3 in
Experiment II).
Day 4, Paired ESeIS pre-exposure 2 (not 3, otherwise identical to Day 4 in
Experiment II).
Day 9, CS-uncontrollable e-shock conditioning: Following the LH procedure on
days 1e6, this test was carried out in 11 of the 17 brother-pairs. In addition, 8
mice that had experienced the Habituation session only (i.e. naive to e-shock,
NS) were also tested. Following a 72-h period during which ES, IS and NS mice
remained undisturbed in their home cages, they were placed in the arena and
after 2-min habituation were exposed to pairings of a tone (5 kHz, 85 dB,
emitted from a loudspeaker situated above the centre of the arena) and
unavoidable/inescapable e-shock. Each tone was of 14-s duration and the ﬁnal
4 s were paired with a 0.15 mA  4-s e-shock. Sixty such pairings were given
with a constant ITI of 50 s. The total duration of the session was 65 min. The
e-shock was uncontrollable to ensure that all mice received equal exposure to
CSs, e-shocks, and CS e e-shock pairings. It was hypothesized that if the prior
chronic experience of the (un)controllability of e-shock is of emotional valence
to mice, then neutral stimuli that predict e-shock will, at least initially, elicit
different behavioural responses from ES and IS mice. The NS group was neces-
sary a priori to facilitate interpretation of any ESeIS differences. Locomotor
distance, number of rears/climbs/jumps and time spent freezing, during ITI’s
and CS’s, were of particular interest.
In a validation experiment for the screening procedure, both brothers
(N ¼ 10 pairs) went through ES screening, ES Pre-exposures 1 and 2, and Escape
test i.e. there was no IS group. The aim was to investigate whether the mice
with higher total duration of e-shock exposure on trials 21e30 (i.e. the criterion
for allocation to IS) exhibited reduced escape behaviour at escape test even in
the absence of IS pre-exposure. If this was the case then clearly the LH effect
could not be inferred as a mediating mechanism when the ES Screening method
was used.
2.3.4. Experiment IV: Reﬁned conditions, Screening allocation in 5-HTT knockout
mice
Brother-pairs had the same genotype i.e. WTeWT, HETeHET; using mixed-
genotype brother-pairs would have been problematic if one genotype consistently
exhibited a lower mean escape latency at ES screening, because the distribution of
genotypes across ES and IS would then not have been counter-balanced. The
experimental parameters were the same as for Experiment III on Day 1e6, with the
exception of the following changes.
Day 2, ES Screening: As in Experiment III, both mice of each brother-pair were
given ES pre-exposure and there was no IS condition. Because pilot studies
demonstrated that the 5-HTT ko strain developed more escape failure across
daily sessions of 30 trials of escapable e-shock (ES) in comparison with the
C57BL/6J strain, less trials were used. Thus, mice were exposed to 24 e-shock
trials rather than 30. For e-shocks 1e8,100% of the grid-side onwhich themouse
was standing emitted shock and the most distant 75% of the opposite grid-side
was “safe”; for e-shocks 9e16, 100% of the grid-side on which the mouse was
standing emitted e-shock and themost distant 50% of the opposite grid-sidewas
“safe”; for e-shocks 17e24, 100% of the grid-side on which the mouse was
standing emitted e-shock and themost distant 30% of the opposite grid-sidewas
“safe” (Fig. 1B).
Day 3, Paired ESeIS pre-exposure 1: Again 24 rather than 30 e-shock trials were
used. The safe area of the opposite grid was 50% for e-shocks 1e8 and 30% for
e-shocks 9e24.
2.4. Statistical analysis
All statistical analyses were conducted using SPSS (version 17, SPSS Inc., Chi-
cago IL, USA). For body weight and hot plate test, conducted both pre- and post-e-
shock, Group (ES, IS) and Time (pre-, post-) were included in ANOVA as between-
and within-subject factors, respectively. For LH effect experiments IeIII, data for
each behavioural measure per session were analysed for ESeIS brother-pairs using
the paired t-test. In Experiment III, validation statistics were conducted to inves-
tigate whether there were behavioural differences between ES and IS mice at ES
Screening on Day 2 that predicted escape responses at Escape test on Day 6. The
most relevant ES Screening measures were the total duration of e-shock exposure
(directly proportional to mean escape latency) on trials 21e30 i.e. the measure
used to allocate each brother per pair to ES or IS, and total duration of e-shock
exposure on trials 1e30. Any predictive associations would confound the inter-
pretation that differences in ES and IS mice at Escape test were attributable
primarily to their differential treatment at Pre-exposures 2 and 3. Firstly, regression
analysis was conducted to investigate whether, within either the ES or IS group,
inter-individual differences in Escape-test escape responses correlated signiﬁcantly
with either of the ES-Screening measures. Second, each of the ES Screening
measures was included as the covariate in ANCOVA with the between-subject
factor of Group (ES, IS) and the dependent variable of Escape test escape
responses. To ensure that these validation statistics were sufﬁciently powered,
a relatively large sample size of 17 brother-pairs was included in Experiment III.
The signiﬁcance of the regression was based on the F-distribution and correlations
were calculated using Pearson’s r. To analyse the effect of Group (ES, IS and NS) on
behavioural scores in the CS-uncontrollable e-shock test, analysis of variance
(ANOVA) was conducted. To analyse the effect of Genotype (WT, HET) and Group
(ES, IS) on behavioural scores per session in Experiment IV, factorial ANOVAs were
conducted. All post hoc testing was conducted using the Bonferroni correction for
multiple comparisons. Signiﬁcance was set at p < 0.05. All data are presented as
mean  standard deviation (SD).
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3. Results
3.1. Experiment I: Standard conditions
In brother pairs allocated randomly to the groups ES and IS,
there were no behavioural differences during Habituation or Pre-
exposure 1. During Pre-exposures 2 and 3, there were consistent
ESeIS differences in e-shock escapes/transfers: at Pre-exposure 2,
ES mice exhibited more escapes than IS mice exhibited e-shock
transfers (t ¼ 3.09, df ¼ 11, p < 0.02). This effect was increased at
Pre-exposure 3 (t ¼ 3.46, df ¼ 11, p < 0.006; Fig. 2A). During the
Escape test, there was a borderline non-signiﬁcant difference in
the number of escape responses of ES and IS mice (t ¼ 2.18,
p < 0.06; Fig. 2B) and no signiﬁcant difference in the mean escape
latency (ES: 2.5  0.9 s, IS: 3.2  0.8 s; t ¼ 1.58, p < 0.11; Fig. 2B).
ES mice made a similar number of escape responses in Pre-
exposure 3 and Escape test (t ¼ 0.22, p < 0.81) and within ES
mice number of escape responses at Pre-exposure 3 predicted
number of escape responses at Escape test (r ¼ 0.98, N ¼ 12,
p < 0.0005). IS mice made signiﬁcantly more escape responses at
Escape test than transfers at Pre-exposure 3 (t ¼ 3.25,
p < 0.009), and within IS mice number of transfers at Pre-
exposure 3 predicted number of escape responses at test
(r ¼ 0.97, N ¼ 12, p < 0.0005). As evident in Fig. 2, there was
marked intra-group variability in both ES and IS mice during both
Pre-exposure 3 and Escape test: in the two ES mice that made the
fewest escape responses, their IS brothers made more transfers/
escape responses, and despite long inescapable e-shock pre-
exposures.
Data for pain response latency in the hot plate test and body
weight are given in Table 1. Therewas no effect of Group or Time on
pain response latency or body weight.
Given that (i) the LH effect observed was borderline and, in IS
mice, (ii) there were more e-shock escapes at test than e-shock
transfers at Pre-exposure 3 and (iii) transfers at Pre-exposure 3
predicted e-stimulus escapes at Escape test, the apparatus was
modiﬁed in an attempt to reduce e-shock transfers by IS mice
during pre-exposure sessions. It was hypothesized that replace-
ment of the gate with a divider would reduce the number of
e-stimulus transfers and therefore subsequent escapes in the IS
condition whilst not affecting escapes in the ES group. This
hypothesis was tested in Experiment II.
3.2. Experiment II: Reﬁned conditions, Random allocation
In brother pairs allocated randomly to the groups ES and IS,
there were no ESeIS behavioural differences during Habituation.
During e-shock pre-exposure sessions, escapes/transfers was the
single parameter that exhibited consistent ESeIS group differences.
Thus, at Pre-exposure 1, ES mice exhibited more escapes than IS
mice exhibited e-shock transfers (t ¼ 6.76, df ¼ 11, p < 0.0005;
Fig. 3A), and this effect persisted during Pre-exposure 2 (t ¼ 4.05,
p < 0.003) and Pre-exposure 3 (t ¼ 2.55, p < 0.04; Fig. 3B). During
the Escape test, IS mice exhibited signiﬁcantly fewer escapes than
did ES mice (t ¼ 2.83, p < 0.03; Fig. 3C), and had a signiﬁcantly
longer mean escape latency (ES: 2.6  0.8 s, IS: 3.6  0.4 s; t ¼ 2.69,
p < 0.03). The ES mice made a similar number of escape responses
in Pre-exposure 3 and Escape test (t ¼ 1.97, p < 0.09) and within
ES mice number of escape responses at Pre-exposure 3 predicted
number of escape responses at Escape test (r ¼ 0.96, N ¼ 12,
p < 0.0005; Fig. 3D). IS mice made a similar number of escape
responses at Escape test to transfers at Pre-exposure 3 (t ¼ 0.42,
p¼ 0.68), and within IS mice number of transfers at Pre-exposure 3
predicted number of escape responses at test (r ¼ 0.84, N ¼ 12,
p < 0.0005; Fig. 3E). As evident in Fig. 3, there was marked intra-
group variability in escape responding in both ES and IS. Further-
more, in the three brother-pairs where the ES mouse exhibited few
escapes, the IS brother (i) exhibited more escapes, despite long
inescapable e-shock pre-exposures, and (ii) exhibited the highest
numbers of escape responses within the IS group.
Data for pain response latencies in the hot plate test and body
weight are given in Table 1. There was a signiﬁcant main effect of
Time on pain response latency (F(1, 22) ¼ 5.32, p < 0.04), with
latencies being greater at Post-Escape test. A posteriori analysis of
ES-Pre, ES-Post, IS-Pre and IS-Post did not yield a signiﬁcant effect
(F(1, 22) ¼ 2.89, p < 0.09). For body weight, there was a borderline
non-signiﬁcant interaction effect of Group  Time (F(1, 22) ¼ 4.49,
A B
Fig. 2. E-shock escape and transfer data (individual values for 12 brother-pairs and
group means) for Experiment I, Standard conditions. (A) Pre-exposure session 3:
number of escapes by ES mice and transfers by IS mice in response to 24  4-s
maximum  0.15 mA e-shocks. (B) Escape test: number of escapes by ES mice and
IS mice in response to 24  4-s maximum  0.15 mA e-shocks. P values are for paired t-
tests.
Table 1
Data summary for body weight and hot plate behaviour pre- and post-LH effect
testing in Experiments IeIV.
Parameter ES IS
Pre-Test Post-Test Pre-Test Post-Test
Experiment I, N ¼ 12 pairs
Body weight (g) X 24.7 25.3 25.3 24.8
SD 1.4 1.0 0.7 1.2
Pain response latency (sec) X 32.1 26.2 25.8 33.4
SD 15.0 14.8 11.4 8.7
Experiment II, N ¼ 12 pairs
Body weight (g) X 26.6 27.1 26.9 26.9
SD 2.1 1.8 1.3 1.5
Group  Time p < 0.06
Pain response latency (sec) X 30.3 39.7 31.8 36.9
SD 10.3 10.3 6.7 17.7
Time p < 0.04
Experiment III, N ¼ 17 pairs
Body weight (g) X 26.8 26.7 27.2 27.4
SD 1.9 1.8 2.5 2.1
Pain response latency (sec) X 37.4 30.5 33.0 35.6
SD 11.8 11.1 11.6 10.0
Group  Time p < 0.04
Experiment IV, N ¼ 8, 8 pairs
Body weight (g)
WT X 27.2 25.6 26.0 26.2
SD 3.7 1.2 1.5 1.3
HET X 25.3 25.6 23.7 23.1
SD 2.8 2.4 6.6 8.5
Pain response latency (sec)
WT X 32.4 30.6 35.0 25.8
SD 13.1 12.2 6.3 9.8
HET X 29.3 30.0 25.2 27.4
SD 9.0 6.8 15.6 16.4
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p < 0.06). A posteriori analysis also yielded a signiﬁcant effect
(F(2, 22)¼ 4.98, p< 0.03), which was due to increased body weight
in ES mice at Post- versus Pre-Escape test (p < 0.04).
In contrast to the gate, using the divider there was no increase in
escapes at Escape test relative to transfers at Pre-exposure 3 in the
IS group. In both Experiments I and II there was a minority of
brother-pairs in which the mouse allocated at random to ES made
few escapes relative to other ES mice and its IS brother, and the
latter made a high number of escapes relative to other IS mice and
its ES brother. This led to high intra-group variability in both ES and
IS groups. It was hypothesized that exposing both brothers to
a screening session in which they both received ES and then allo-
cating the brother with the shorter mean escape latency (lower
total e-shock exposure) in the ﬁnal third of the screening session to
the ES group, would reduce intra-group variability. This hypothesis
was tested and the method validated in Experiment III.
3.3. Experiment III: Reﬁned conditions, ES Screening allocation
Retrospective analysis demonstrated that there were no
“ES”e“IS” behavioural differences during Habituation, including ITI
distance moved (Table 2). At ES Screening, both brothers per pair
were exposed to escapable e-shocks and the brother that exhibited
the lower mean escape latency (and therefore lower total e-shock
exposure) at trials 21e30 was allocated to the ES group and vice
versa. Across trials 1e30, “ES” mice made signiﬁcantly more
e-stimulus escapes than “IS” mice (t ¼ 2.83, df ¼ 16, p < 0.03;
Fig. 4A, Table 2) and mean escape latency was signiﬁcantly shorter
in “ES” mice than in “IS” mice (t ¼ 2.80, p ¼ 0.02; Table 2). Across
trials 1e20, e-stimulus escapes were not signiﬁcantly different in
“ES” and “IS” mice (“ES” 17  3, “IS” 16  3, p < 0.80) and nor were
mean escape latencies (“ES” 1.9  0.7, “IS” 2.3  0.8 s, p < 0.12).
Across trials 21e30, “ES” mice made 9  1 escape responses with
a mean escape latency of 2.0  0.8 s and “IS” mice made 7  2
escape responses with a mean escape latency of 2.9  0.8 s.
At Pre-exposure 2, ES mice exhibited signiﬁcantly more e-shock
escapes than IS mice exhibited e-shock transfers (t ¼ 11.25,
p < 0.0005; Fig. 4B). The IS mice exhibited signiﬁcantly shorter
e-shock distance moved (t ¼ 3.64, p < 0.003), and signiﬁcantly
greater ITI distance moved (t ¼ 3.10, p < 0.008) (Table 2). At Pre-
exposure 3, ES mice exhibited signiﬁcantly more e-shock escapes
than IS mice exhibited e-shock transfers (t ¼ 11.82, p < 0.0005;
Fig. 4C). The ISmice exhibited signiﬁcantly shorter e-shock distance
moved (t ¼ 3.68, p < 0.003), signiﬁcantly greater ITI distance
moved (t ¼ 4.62, p < 0.0005), signiﬁcantly more ITI transfers
(t ¼ 4.91, p < 0.0005), signiﬁcantly more ITI rears/climbs/jumps
(t ¼ 3.16, p < 0.007) and signiﬁcantly less ITI % time freezing
(t ¼ 3.10, p < 0.008) (Table 2). At Escape test, IS mice exhibited
signiﬁcantly fewer e-shock escapes than ES mice (t ¼ 11.86,
p< 0.0005; Fig. 4D) and a signiﬁcantly longer mean e-shock escape
latency (t ¼ 8.29, p < 0.0005; Fig. 4D). The IS mice also exhibited
a signiﬁcantly shorter e-shock distance moved (t ¼ 4.73,
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Fig. 3. E-shock escape and transfer data (individual values for 12 brother-pairs and group means) for Experiment II, Reﬁned conditions, Random allocation. (A) Pre-exposure session
1: number of escapes by ES mice and transfers by IS mice in response to 30  5-s maximum  0.15 mA e-shocks, with 10 trials each at 75%, 50% 30% safe area in the escape
compartment. (B) Pre-exposure session 3: number of escapes by ES mice and transfers by IS mice in response to 24  4-s maximum  0.15 mA e-shocks, with 30% safe area in the
escape compartment. (C) Escape test: number of escapes by ES mice and IS mice in response to 24  4-s maximum  0.15 mA e-shocks. AeC: p values are for paired t-tests. (D)
Scattergram, regression line and associated probability, and Pearson’s r for Pre-exposure 3 escapes versus Test escape responses in ES mice. (E) Scattergram, regression line and
associated probability, and Pearson’s r for Pre-exposure 3 escapes versus Test escape responses in IS mice.
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p < 0.0005) (Table 2). Fig. 4E presents the e-shock escapes for ES
and IS mice as 4 blocks of 6 trials each: both groups maintained
a consistent frequency of escape responses across the session
(Block main effect: F < 1, p < 0.67). The ES mice made a similar
number of escape responses at Escape test and Pre-exposure 3
(t ¼ 1.33, p < 0.22) and number of escape responses at Pre-
exposure 3 predicted number of escape responses at Escape test
(r ¼ 0.67, N ¼ 17, p < 0.004; Fig. 4F). IS mice made a similar number
Table 2
Summary table for experiment III, in which brother-pairs were allocated to ES and IS treatment groups following screening.
Parameter Habituation
(150)
Pre-exposure 1
(22.50 , 30 trials)
Pre-exposure 2
(22.50 , 30 trials)
Pre-exposure 3
(180 , 24 trials)
Escape test
(180 , 24 trials)
ES IS ES IS ES IS ES IS ES IS
E-shock, ES Escapes/IS Transfers (Total) X 26 23* 24 10**** 20 4**** 18 5****
SD 3 4 3 4 5 4 4 4
E-shock Escape Latency (Mean, sec) X 1.9 2.5* 2.0 2.0 2.1 3.6****
SD 0.5 0.7 0.6 0.9 0.7 0.4
E-shock exposure (Total duration, sec) X 57 75* 61 61 47 47 51 77****
SD 16 21 16 16 20 20 18 17
E-shock Distance/sec (X, Y, Z) (Mean) X 341 315 308 256** 317 236** 282 179****
SD 49 57 66 54 79 86 69 66
ITI Distance/min (X, Y, Z) (Mean) X 8263 8828 3996 4953 4122 5004** 3978 5151**** 4376 4961
SD 1695 1258 1079 1298 985 966 1050 908 1018 907
ITI Transfers (Total) X 56 58 20 30 27 26 20 30**** 20 25
SD 11 13 13 13 11 7 9 7 6 8
ITI Rears/Climbs/Jumps (Total) X 50 50 18 21 24 27 13 25** 17 23
SD 10 12 9 7 8 8 8 14 9 10
ITI Freezing/% Time X 3 2 18 14 22 16 25 15** 20 14
SD 2 1 10 7 12 6 10 8 9 7
N ¼ 17, 17 brother pairs; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005.
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Fig. 4. Number of e-shock escapes or transfers by ES and IS mice (individual values for 17 brother-pairs and group means) for Experiment III, Reﬁned conditions, Screening
allocation. (A) ES Screening (Pre-exposure session 1): number of escapes by mice in response to 30  5-s maximum  0.15 mA e-shocks, with 10 trials each at 75%, 50% 30% safe area
in the escape compartment. In each pair, the brother with the higher mean escape latency to the last 10 e-shocks was allocated to the IS group. (B) Pre-exposure session 2: number
of escapes by ES mice and transfers by IS mice in response to 30  5-s maximum  0.15 mA e-shocks, with 30% safe area in the escape compartment. (C) Pre-exposure session 3:
number of escapes by ES mice and transfers by IS mice in response to 24  4-s maximum  0.15 mA e-shocks, with 30% safe area in the escape compartment. (D) Escape test:
number of escapes by ES mice and IS mice in response to 24  4-s maximum  0.15 mA e-shocks. AeD: p values are for paired t-tests. (E) E-shock escapes (mean þ SD) at Escape
test, with data divided into 4 blocks of 6 trials per block to demonstrate the consistent effect of Group (F(1, 16) ¼ 140.75, p < 0.0005) and lack of effect of Block (F(3, 96) < 1, p < 0.67)
in ES and IS mice. (F) Scattergram, regression line and associated probability, and Pearson’s r for Pre-exposure 3 escapes versus Test escape responses in ES mice. (G) Scattergram,
regression line and associated probability, and Pearson’s r for Pre-exposure 3 escapes versus Test escape responses in IS mice.
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of escape responses at test to transfers at Pre-exposure 3 (t ¼ 1.11,
p < 0.29), and number of e-shock transfers at Pre-exposure 3 pre-
dicted number of escape responses at Escape test (r ¼ 0.62, N ¼ 17,
p < 0.009; Fig. 4G).
As given in Table 2, at Pre-exposures 2 and 3, there were
consistent ESeIS differences in ITI distance, with IS mice moving
greater distances than ES mice and ES mice spending more time in
freezing. Using the activity tracking option of the software it was
possible to identify evidence for consistent ESeIS differences in the
distribution of activity on the grid within the arena: as exempliﬁed
in Fig. 5, there was evidence that ES mice focussed their activity to
the four corners of the grid/arena e the safe areas e during ITI’s,
whereas IS mice distributed their high levels of activity more
equably throughout the grid/arena.
Data for pain response latencies in the hot plate test and body
weight are given in Table 1. There was a signiﬁcant interaction
effect of Group  Time on pain response latency (F(1, 32) ¼ 5.03,
p < 0.04). A posteriori analysis of ES-Pre, ES-Post, IS-Pre and IS-Post
did not yield a signiﬁcant effect (F(2, 32) ¼ 3.04, p < 0.07). For body
weight measured on the day of Habituation (Pre) and the day of
Escape test (Post), there were no signiﬁcant effects of Group or
Time.
It was necessary to assess whether differences in behaviour
between ES and IS mice at ES Screening on Day 2 predicted, and
therefore confounded, escape responses at Escape test on Day 6.
The most relevant ES Screening measures were total duration of e-
shock exposure on trials 1e30 and total duration of e-shock
exposure on trials 21e30. Using regression, in neither the ES nor
the IS group did inter-individual differences in Escape-test escape
responses correlate signiﬁcantly with total duration of e-shock
exposure on trials 1e30 (ES: r ¼ 0.02, p < 0.96; IS: r ¼ 0.28,
p < 0.29; Fig. 6) or total duration of e-shock exposure on trials
21e30 (ES: r ¼ 0.35, p < 0.18; IS: r ¼ 0.25, p < 0.34). When total
duration of e-shock exposure on trials 1e30 was included as
a covariate in ANCOVA with the between-subject factor of Group
(ES, IS) and the dependent variable of Escape test escape responses,
the covariate was not signiﬁcantly related to Escape test escapes
(p < 0.44). There was a signiﬁcant main effect of Group after
adjusting for the covariate scores, with Escape test e-shock escapes
signiﬁcantly increased in ES versus IS mice (F(1, 31) ¼ 69.01,
p < 0.0005). When total duration of e-shock exposure on trials
21e30 was included as a covariate in ANCOVA, the covariate was
not signiﬁcantly related to Escape test escapes (p< 0.71). There was
a signiﬁcant main effect of Group after adjusting for the covariate
scores, with Escape test e-shock escapes signiﬁcantly increased in
ES versus IS mice (F(1, 31) ¼ 70.40, p < 0.0005). Therefore, there
was no statistical evidence that total duration of e-shock exposure
(reﬂecting mean escape latency) of ES and/or IS mice at ES
Screening predicted their escape responding at Escape test. This
was in contrast to ES escape responses and IS transfer responses at
Pre-exposure 3, which did correlate with escape responses at
Escape test.
Given the absence of statistical evidence that inter-individual
differences within or between ES and IS groups at ES Screening
accounted for escape responses at Escape test, it would be pre-
dicted that in the validation experiment where brother-pairs were
exposed to ES Screening but then both brothers were exposed to ES
pre-exposure and Escape test, there would not be a consistent
difference in Escape test escapes in mice allocated to “ES” and “IS”
on the basis of their escape behaviour at ES Screening. Retrospec-
tive analysis demonstrated that there were no “ES”e“IS” behav-
ioural differences during Habituation. At ES Screening, across trials
1e30 “ES” mice exhibited signiﬁcantly more e-shock escape
responses than “IS” mice (t ¼ 2.30, df ¼ 9, p < 0.05; Fig. 7A) and
mean escape latency was signiﬁcantly shorter in “ES” (2.3  0.3 s)
than “IS” mice (2.7  0.4 s) (t ¼ 2 to 29, p < 0.05). At PE2, PE3 and
escape test, there was no signiﬁcant “ES”e“IS” difference in escape
responses (p  0.17; Fig. 7BeD) and this was also the case for mean
escape latency (PE1: “ES” 2.3  0.2 s, “IS” 2.6  0.6; PE2:
“ES” 2.5  0.3, “IS” 2.6  0.6; Escape test: “ES” 2.6  0.4,
“IS” 2.8  0.6, p  0.20). Two of the ten “IS” mice exhibited notably
low within-group total escape responses across all sessions (Fig. 7).
At Escape test, the “ES” brothers of these two mice also exhibited
low within-group total escape responses. Thus, the validation
experiment provided further evidence that ES screening does not
separate mice on characteristics that themselves lead to the ESeIS
differences that emerge during pre-exposures and escape test. The
validation experiment also provided further evidence to that
observed in Experiments I and II that one brother in some pairs
does develop a high level of escape failure under ES conditions.
In Experiment III main study, eleven brother-pairs were studied
in tone CS e uncontrollable e-shock conditioning, using 60 pairings
of tone CS that predicted an unavoidable/inescapable e-shock.
During ITI’s (Table 3), ES mice spent signiﬁcantly more % time
freezing than did IS brothers (t ¼ 4.07, df ¼ 10, p < 0.003), whereas
IS mice exhibited signiﬁcantly greater distance moved (t ¼ 3.74,
p < 0.005) and signiﬁcantly more rears/climbs/jumps (t ¼ 2.76,
Fig. 5. Example of activity tracking data from Pre-exposure 3 in Experiment III, for one
brother-pair, (A) ES mouse # 66 and (B) IS mouse # 65. Whereas the ES mouse focussed
its relatively low levels of activity to the four “safe” corners of the grid ﬂoor and most
divider-crossings were escape responses, the IS mouse distributed its relatively high
levels of activity more equably throughout the grid ﬂoor area.
A B
Fig. 6. Scattergram, regression line and associated probability, and Pearson’s r for ES
Screening (Pre-exposure 1) total e-shock exposure on trials 1e30 (proportional to
mean escape latency) versus Escape test escape responses in (A) ES mice and (B) IS
mice. In both groups, there was no predictive relationship between total e-shock
exposure at ES Screen and escape responses at Escape test.
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p < 0.03) than did ES brothers. During CS’s, ES mice spent signiﬁ-
cantly more % time freezing than did IS brothers (t ¼ 5.21,
p < 0.0005), and IS mice exhibited signiﬁcantly greater distance
moved (t ¼ 4.73, p < 0.002) and signiﬁcantly more rears/climbs/
jumps (t ¼ 2.78, p < 0.03) than did ES brothers.
To inform interpretation of these ﬁndings, a group of naive mice
(NS) was given a habituation session only and thenwere also run in
the tone CSe uncontrollable e-shock test. Datawere analysed using
a 1-way ANOVA (Group: ES, IS, NS). Data are presented in Table 3
and Fig. 8. During ITI’s: There was a signiﬁcant effect of Group on
distance moved (F(2, 27) ¼ 7.70, p < 0.003), with IS mice exhibiting
signiﬁcantly greater distance moved than ES mice (p < 0.003).
Therewas a signiﬁcant effect of Group on % time freezing (F¼ 10.36,
p < 0.0005), with ES mice exhibiting increased freezing versus IS
mice (p < 0.0005) and NS mice (p < 0.04). During CS’s: There was
a signiﬁcant effect of Group on distance moved (F ¼ 13.06,
p < 0.0005), with IS mice exhibiting increased distance moved
versus ES mice (p < 0.0005) and NS mice (p < 0.002). There was
a signiﬁcant effect of Group on rears/climbs/jumps (F ¼ 5.72,
p < 0.01), with IS mice exhibiting more versus ES mice (p < 0.03)
and NS mice (p < 0.05). There was a signiﬁcant effect of Group on %
time freezing (F¼ 21.50, p< 0.0005), with ESmice (p< 0.0005) and
NS mice (p < 0.0005) spending more time freezing than IS mice.
Thus, during ITI’s, ES mice maintained the relatively high level of
freezing they developed during the LH procedure and IS and NS
mice exhibited similar, lower levels. During CS’s, ES and NS mice
exhibited comparable levels of behaviour in terms of freezing,
rearing/climbing/jumping and distance moved, and both groups
differed signiﬁcantly and similarly from IS mice. In the validation
experiment, the “ES” and “IS” mice which did not exhibit a signiﬁ-
cant LH effect also did not exhibit signiﬁcant differences in the CSe
uncontrollable e-shock conditioning test. In both groups, behaviour
was similar to that of ES mice in the main Experiment III (Table 3).
For example, ITI % time freezing was 23  6% in “ES” mice and
20  10% in “IS” mice and CS % time freezing was 25  9% in “ES”
mice and 19  10% in “IS” mice. These ﬁndings provide support for
the interpretation that the ESeIS differences observed in main
Experiment III were primarily the result of different respective
ESeIS pre-exposure experiences.
3.4. Experiment IV: 5-HTT knockout mice under Reﬁned conditions,
ES Screening allocation
During Habituation, there were no signiﬁcant effects of Geno-
type (5-HTT HET,WT) or Group (“ES”, “IS”). At ES Screening (Fig. 9A,
D), across trials 1e24, “ES” mice exhibited signiﬁcantly more e-
stimulus escapes than “IS” mice (Groupmain effect: F(1, 28)¼ 9.48,
p < 0.005; Fig. 9A) and mean escape latency was signiﬁcantly
shorter in “ES” mice than in “IS” mice (Group main effect: F(1,
28) ¼ 11.92, p < 0.002; Table 4). ITI rears/climbs/jumps was also
signiﬁcantly increased in “IS” relative to “ES” mice (F(1, 28) ¼ 8.76,
p < 0.006; Table 4). ITI % time spent freezing was signiﬁcantly
increased in HET relative to WT mice (F(1, 28) ¼ 6.50, p < 0.02;
Fig. 9D). At Pre-exposure 2, ES mice exhibited signiﬁcantly more e-
shock escapes (WTeES: 23  1, HETeES: 22  2) than IS mice
exhibited e-shock transfers (WTeIS: 9  6, HETeIS: 7  4) (F(1,
28) ¼ 150.22, p < 0.0005). ES mice moved a greater e-shock
distance than did IS mice (F(1, 28) ¼ 4.63, p < 0.04). WT mice
moved a greater ITI distance than did HET mice (F(1, 28) ¼ 9.20,
A B C D
Fig. 7. Number of e-shock escapes or transfers by “ES” and “IS” mice (individual values for 10 brother-pairs and group means) for the Experiment III validation experiment. (A) ES
Screening (Pre-exposure session 1): number of escapes by mice in response to 30  5-s maximum  0.15 mA e-shocks, with 10 trials each at 75%, 50% 30% safe area in the escape
compartment. In each pair, the brother with the higher mean escape latency to the last 10 e-shocks was treated as the “IS” group but received escapable e-shocks on subsequent
sessions. (B) Pre-exposure session 2: number of escapes by “ES” and “IS” mice in response to 30  5-s maximum  0.15 mA e-shocks, with 30% safe area in the escape compartment.
(C) Pre-exposure session 3: number of escapes by “ES” and “IS” mice in response to 24  4-s maximum  0.15 mA e-shocks, with 30% safe area in the escape compartment. (D)
Escape test: number of escapes by “ES” and “IS” mice in response to 24  4-s maximum  0.15 mA e-shocks. AeD: p values are for paired t-tests.
Table 3
Data summary for tone CS e e-shock conditioning test in brother-pairs allocated to
ES and IS treatment groups following screening and in a groupwith no e-shock prior
to test (NS).
Parameter ES IS NS
ITI Distance/sec (X, Y, Z) X 51 79**/** 60
SD 18 19 11
ITI Rears/Climbs/Jumps (Total) X 132 208*/- 115
SD 92 142 52
ITI Freezing (% Time) X 27 12**/**** 16* vs ES
SD 11 7 3
E-shock Distance/sec (X, Y, Z) X 221 183 229
SD 61 59 58
CS Distance/sec (X, Y, Z) X 51 79***/**** 53*** vs IS
SD 14 14 14
CS Rears/Climbs/Jumps (Total) X 20 43*/* 21* vs IS
SD 16 26 9
CS Freezing (% Time) X 24 7****/**** 22**** vs IS
SD 8 5 6
N ¼ 11, 11, 8 males per group for ES, IS, NS, respectively.
Total trials ¼ 60.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005.
For both ES and IS, signiﬁcance levels are for paired t-test/1-way ANOVA,
respectively.
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p < 0.005). HET mice spent more % time freezing during ITI than
did WT mice (F(1, 28) ¼ 13.36, p < 0.001). At Pre-exposure 3
(Fig. 9B, E), for e-shock escapes/transfers there was a signiﬁcant
Genotype  Group interaction effect (F(1, 28) ¼ 4.66, p < 0.04) and
a signiﬁcant main effect of Group (F(1, 28) ¼ 286.85, p < 0.0005)
(Fig. 9B, Table 4). A posteriori one-way ANOVA and post hoc testing
demonstrated that: HETeIS mice performed signiﬁcantly less
transfers than did WTeIS (p < 0.007); HETeIS mice performed
A
D E F
B C
Fig. 8. Comparison of ES, IS and NS mouse behaviour (mean þ SD, N¼ 11, 11, 8, respectively) in the tone CS-uncontrollable e-shock conditioning readout. During 59  50-s inter-trial
intervals: (A) Mean distance moved/sec, (B) Total number of rears/climbs/jumps, (C) Mean percent time spent freezing. During 60  10-s CS’s: (D) Mean distance moved/sec, (E)
Total number of rears/climbs/jumps, (F) Mean percent time spent freezing.
A
D E F
B C
Fig. 9. Number of e-shock escapes or transfers and % ITI time spent freezing by ES and IS mice of WT or HET genotype in the 5-HTT knockout strain (mean  SD for 8 brother-pairs
per genotype) for Experiment IV, Reﬁned conditions, Screening allocation. (A) ES Screening (Pre-exposure session 1): number of escapes by mice in response to 24  5-s
maximum  0.15 mA e-shocks, with 8 trials each at 75%, 50% 30% safe area in the escape compartment. In each pair, the brother with the higher mean escape latency to the
last 8 e-shocks was allocated to the IS group. (B) Pre-exposure session 3: number of escapes by ES mice and transfers by IS mice in response to 24  4-s maximum  0.15 mA
e-shocks, with 30% safe area in the escape compartment. (C) Escape test: number of escapes by ES mice and IS mice in response to 24  4-s maximum  0.15 mA e-shocks. (D) ES
Screening: % ITI spent freezing. (E) Pre-exposure session 3: % ITI spent freezing. (F) Escape test: % ITI spent freezing. AeF: p values are for factorial ANOVA.
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signiﬁcantly less transfers than HETeES (p < 0.0005) and WTeES
(p < 0.0005) mice performed escapes; and WTeIS mice performed
signiﬁcantly less transfers than WTeES (p < 0.0005) and HETeES
(p < 0.0005) mice performed escapes. For e-shock distance moved
there was a signiﬁcant main effect of Group (F(1, 28) ¼ 8.00,
p < 0.009; Table 4), with IS mice moving a shorter distance than ES
mice. For ITI distance moved there was a signiﬁcant main effect of
Genotype (F(1, 28)¼ 4.39, p< 0.05; Table 4), with HETmicemoving
a shorter distance thanWTmice. For ITI % time spent freezing, there
was a signiﬁcantmain effect of Genotype (F(1, 28)¼ 8.57, p< 0.007;
Fig. 9E), with HETmice spendingmore time freezing thanWTmice.
At Escape test (Fig. 9C, F), for e-shock escapes therewas a signiﬁcant
Genotype  Group interaction effect (F(1, 28) ¼ 6.03, p < 0.03) and
signiﬁcant main effects of Genotype (F(1, 28) ¼ 6.51, p < 0.02) and
Group (F(1, 28) ¼ 80.53, p < 0.0005; Fig. 9C). A posteriori one-way
ANOVA and post hoc testing demonstrated that: HETeIS mice per-
formed signiﬁcantly less escapes than HETeES (p < 0.0005),
WTeES (p< 0.0005) andWTeIS (p< 0.009) mice; andWTeIS mice
performed signiﬁcantly less escapes than WTeES (p < 0.0005) and
HETeES (p < 0.001) mice. For mean e-shock escape latency there
was a signiﬁcant main effect of Group (F(1, 28) ¼ 17.91, p < 0.0005;
Table 4) with IS mice exhibiting a signiﬁcantly longer latency. For
e-shock distance moved there was a signiﬁcant main effect of
Group (F(1, 28) ¼ 15.20, p < 0.001; Table 4) with IS mice moving
a shorter distance. For ITI distance moved there were signiﬁcant
main effects of Genotype (F(1, 28) ¼ 4.49, p < 0.05) and Group (F(1,
28) ¼ 5.16, p < 0.04), with HET moving a shorter distance than WT
mice and ISmoving a shorter distance than ESmice (Table 4). For ITI
% time spent freezing, there was a signiﬁcant main effect of
Genotype (F(1, 28) ¼ 6.60, p < 0.02; Fig. 9F) with HET mice
spending more time freezing than WT mice.
Data for pain response latencies in the hot plate test and body
weight are given in Table 1. For pain response latency (p 0.10) and
body weight (p  0.37) there were no signiﬁcant effects of Geno-
type, Group or Time.
4. Discussion
Objective mouse behaviour analogues of human emotional,
motivational and cognitive processes underlying psychiatric
disorders are essential to valid translational pre-clinical research
into the aetiology and pathophysiology of those disorders and to
predictive neuropsychopharmacological screening of potential
novel treatments. Conductingmouse behavioural studies with tests
of negligible face and construct validity is a major bottle-neck to
progress, as no amount of development of molecular-genetic tools
for the manipulation of the mouse brain and imaging tools for the
visualization of its activity will bring progress unless they can be
combined with psychopathology models of high aetiological, face
and construct validity (Krishnan and Nestler, 2008; Markou et al.,
2009; Willner and Mitchell, 2002). Against this background, the
present development of a robustmouse paradigm of the LH effect is
a signiﬁcant step forward, particularly with respect to objective
face validity.
The starting point of the study (Experiment I) was to use
a standard two-way shuttle box, as has been used previously in
mice to study the LH (ISeES) effect or the aversive US pre-exposure/
interference (ISeNS) effect (Anisman and Merali, 2001; Randich
and LoLordo, 1979). A standard open gate delineating a single,
immediate transfer point from the e-shock- to the safe-
compartment, was used. Also as is typical, mice were allocated
randomly to the ES and IS groups (Anisman and Merali, 2001).
Brother-pairs were used because this: allowed subjects to be caged
socially until 1 week prior to the experiment without the risk of
high aggression; could reduce the extent of any pre-existing indi-
vidual differences ((epi)genetic, early environmental) between
mice allocated randomly to the same ESeIS dyad; and was
consistent with the dependent-pair statistical model used for
analysis. Under these standard conditions, it was possible to
demonstrate a borderline non-signiﬁcant deﬁcit in number of
escape responses by IS relative to ES mice at test. This weak LH
Table 4
Summary table for experiment with 5-HTT HETeHET or WTeWT brother-pairs allocated to ES and IS treatment groups following screening.
Parameter Pre-exposure 1 Pre-exposure 3 Escape test
WT WT HET HET WT WT HET HET WT WT HET HET
ES IS ES IS ES IS ES IS ES IS ES IS
E-shock, ES Escapes/IS Transfers (Total) X 23 20 22 17** 22 8 23 5x, **** 20 11 19 4x, ****, #
SD 1 4 4 6 3 3 1 3 4 5 3 3
E-shock Escape Latency (Mean, sec) X 2.1 2.9 2.3 3.3** 2.7 2.3 2.8 3.6 2.6 3.8****
SD 0.4 0.6 0.8 1.1 1.0 0.6 1.0 0.5 0.7 0.4
E-shock exposure (Total duration, sec) X 50 71 55 80** 68 59 66 86 63 92****
SD 9 13 20 27 23 14 24 11 17 10
E-shock Distance/sec (X, Y, Z) (Mean) X 314 286 319 289 266 204 298 199** 248 187 249 143***
SD 28 54 34 58 81 50 87 95 58 51 81 48
ITI Distance/min (X, Y, Z) (Mean) X 4054 4852 3878 3885 5181 5519 4646 3859# 6047 4914 4985 4026*, #
SD 1049 1501 1150 870 1722 2049 1029 745 1646 1177 1195 1122
ITI Transfers (Total) X 11 18 11 12 25 32 28 23 30 26 26 24
SD 8 14 9 10 18 16 5 7 9 18 7 7
ITI Rears/Climbs/Jumps (Total) X 25 67 28 41** 34 35 20 28# 39 59 38 53
SD 14 40 21 24 15 16 10 14 21 51 24 66
ITI Freezing/% Time X 11 13 17 21# 12 11 16 19## 11 10 14 19#
SD 6 8 8 7 6 7 6 6 9 6 6 5
N ¼ 8, 8, 8, 8 males per group for WTeES, WTeIS, HETeES, HETeIS; * ES vs IS, # HET vs WT, x (ES vs IS)  (HET vs WT); *#x p < 0.05, **## p < 0.01, *** p < 0.001, ****
p < 0.0005.
C.R. Pryce et al. / Neuropharmacology 62 (2012) 358e372368
effect is in broad agreement with previous studies using C57BL/6
mice and standard conditions. For example, one aversive US pre-
exposure effect (ISeNS) study reports that only 30% of mice
exposed to 360 IS e-shocks of 1e3 s  0.15 mA subsequently failed
to escape the majority of 10-s escapable e-shocks at test; the
remaining 70% of IS mice exhibited few escape failures and the
average escape latency of 2.5 s at test was similar to that of the ES
mice in the present experiment (Chourbaji et al., 2005). A study in
Swiss-Webster mice that used a similar design to that used here,
albeit with a closable gate and 6-s delay between e-shock onset and
gate opening, and a 24-s maximum e-shock duration, observed
a robust LH effect (Anisman et al., 1978). In the present experiment
I, IS mice made more escape responses at test than e-stimulus
transfers at ﬁnal IS pre-exposure, and in terms of inter-individual
differences the latter predicted the former. At the ﬁnal pre-
exposure session, there was an average probability of 0.29 (range
0.0e0.67) that an IS mouse would transfer through the gate, even
though this behaviour had not been reinforced across three pre-
exposure sessions. These ﬁndings suggest a superstitious but
nonetheless pre-adaptive association between gate transfer and
e-shock termination, such that the habit of IS gate transferring was
sufﬁcient to support within-session escape learning by approxi-
mately half of the IS mice during the escape test. This development
of spontaneous gate transfer during IS pre-exposure made
a substantial contribution to there being only a marginal LH effect.
The other contributing factor was that two ES mice developed low
levels of escape responding, suggesting that repeated experience of
two-way e-shocks, although escapable, nonetheless induced a state
of uncontrollability in these mice. The brothers of these two mice
exhibited considerably more escape responses at test despite
having experienced only IS e and at relatively long durations e
previously. The marked within-group ES and IS differences suggest
that mice exhibit marked individual differences in both ability to
utilise controllability of an aversive situation (i.e. ES) and in their
vulnerability-resilience to the uncontrollability of an aversive
situation (i.e. IS). That ES mice that were poor escapers had IS
brothers that were relatively good escapers, suggests that within-
litter (intra-familial) differences can contribute substantially to
inter-individual differences.
The aim of experiment II was to investigate whether (i)
replacement of the gate with a divider that allowed movement
between compartments across the depth of the arena, combined
with (ii) gradual separation of the central divider from the border of
the safe area of the opposite compartment, would result in
a reduction in the spontaneous transfers during IS pre-exposure
that appeared to act as a superstitious pre-adaptation to escape
learning, and thereby lead to a robust LH effect. At the ﬁnal pre-
exposure session the average probability that an IS subject would
transfer under the divider to the safe area was halved relative to
experiment I, to 0.17 (range 0.00e0.67) and, probably as a conse-
quence of this low transfer rate, there was no overall increase in
escape responses at test relative to transfers at ﬁnal pre-exposure in
IS mice. This led to a signiﬁcant LH effect being obtained under
these test conditions. Apparently therefore, a threshold rate of pre-
adaptive spontaneous transfer is required to support escape
learning at test In IS mice. These ﬁndings provide an interesting
parallel to the ﬁndings of the rat LH model in which an LH effect is
observed when two crossings of the shuttle arena are required for
escape (ﬁxed ratio 2, FR2) but not at FR1 (e.g. Jackson et al., 1978).
Taken together, the mouse and rat ﬁndings suggest that the escape
response must pose a certain level of cognitive challenge to ES and
IS subjects for a consistent LH effect to be obtained. Although the LH
effect was statistically signiﬁcant, there was marked within-group
variability and therefore some between-group overlap in escape
test escape responses. As in Experiment I, a minority of ESmicee in
this case 3 of 12e developed low levels of escape responding across
repeated ES sessions. Furthermore, the IS brothers of these mice
exhibited high levels of escape at test, in both relative and absolute
terms. This suggests that in some mice, the experience of IS fol-
lowed by ES leads to a highly reinforcing effect of ES that could be
related to the emotion of relief. This phenomenon will be the
subject of future studies in this paradigm.
The aim of experiment III was to investigate whether exposure
of both males of each brother-pair to a session of escapable
e-shocks would (i) allow for screening of individual differences
between brothers in their ability to exhibit behavioural control over
e-shocks in the modiﬁed two-way escape set-up, such that (ii)
assignment of the brother exhibiting the shorter mean escape
latency at the end of the screening session to the ES group would
reduce subsequent within-group variability in both ES and IS mice
and thereby increase the robustness of the LH effect. The differ-
ences within brother-pairs in number of escape responses and
average escape latency across the entire screening session were
typically small. However, they did increase towards the end of the
session, and assigning the brother with the shorter mean escape
latency in the ﬁnal 10 trials of screening to the ES group resulted in
each ES male exhibiting more escapes at test than did its IS brother
and therefore a robust LH effect. Screening results in an IS group
that has experienced more total e-shock exposure prior to the
escape test and this could be a confounding variable. To demon-
strate that the subsequent ESeIS pre-exposure sessions and not the
screening procedure was the primary factor underlying the LH
effect, several validation steps were carried out. These included
statistical demonstrations that duration of e-shock exposure/
latency of escape responses at screening did not predict escape
responses in ES or IS mice whereas e-shock exposure at ﬁnal pre-
exposure did; e-shock exposure at screening was not a signiﬁcant
covariate of escape responses at test and the ESeIS effect on escape
responses at test remained signiﬁcant after adjusting for the
covariate; a separate experiment demonstrating that screening
followed by ES only did not lead to an LH effect. Nonetheless, it is
clear from Experiments I and II that there are brother-pairs within
which there are marked pre-existing differences that contribute to
their relative escape behaviour at escape test, in addition to/inter-
action with the effects of ES and IS. The cause of these pre-existing
within-family differences are of course highly relevant (see
Experiment IV). Indeed, inadequate consideration of individual
differences in vulnerability-resilience to helplessness following
uncontrollable life events has been a major criticism of the LH
theory of human depression (Miller and Norman, 1979). One
possibility is that high differences in social status and agonistic
interactions within brother-pairs were a contributing factor to
development of behavioural differences in the LH effect paradigm.
Certainly, inter-male aggression is more marked in mice than rats,
and this could lead to more marked differences in capacity for
controllability in mice, such that random allocation to ES and IS
groups is more problematic than it is in rats (Amat et al., 2005;
Maier and Seligman, 1976). Finally here, it is important to note
that ES screening could have resulted in immunization of the IS
mice against the effects of subsequent IS. Immunization i.e. expo-
sure of an IS group to ES prior to IS, has been demonstrated to block
the LH effect in rat (e.g. Amat et al., 2006) and mouse (Anisman
et al., 1983). In the mouse study, mice were exposed to escapable
e-shock or no e-shock in a shuttle arena (day 1), inescapable
e-shock or no e-shock in a single compartment arena (day 2), and
escape test in the shuttle arena (day 3). Mice that received escap-
able e-shock on day 1 and inescapable e-shock on day 2 did not
exhibit an escape deﬁcit on day 3 relative to mice that received no
e-shock on day 2, i.e. no LH effect (Anisman et al., 1983). One major
difference of this study to the current study was that in the latter
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mice experienced ES, IS and escape test in the same environment,
and it could be that an immunization effect of ES was blocked by
the subsequent association of IS with the escape test context.
Clearly, however, it cannot be assumed that there was no immu-
nization effect in the present study.
Also in experiment III, evidence was obtained in the ESeIS
pre-exposure sessions, escape test and CS-uncontrollable e-
shock test, that the controllability status of e-shock is associated
with the development of differences in its emotional valence for
ES versus IS mice. Firstly, relative to ES mice, IS mice exhibited
reduced motor responses to e-shock (e-shock distance/sec)
during pre-exposure sessions and escape test. The causality of
the reduced motor response to e-shock and the causal contri-
bution of this reduced motor response per se to the LH effect, are
currently unclear. In earlier studies, which did not accurately
quantify motor responses, the LH effect in mouse was attributed
to a decline in motor response initiation and maintenance
following exposure to IS speciﬁcally (Anisman et al., 1978), and IS
mouse-speciﬁc decreases in central noradrenaline and dopamine
were proposed to underlie this (Anisman et al., 1979, 1980). These
earlier studies did not have the beneﬁt of being able to accurately
quantify motor responses, and the current data may provide the
ﬁrst quantitative evidence for reduced motor response to e-shock
in IS mice. However, the present data also indicate that IS mice
exhibited increased ITI motor activity relative to ES mice, and this
effect cannot be readily reconciled with a motor-deﬁcit expla-
nation for the LH effect. Alternatively, it is possible that the
reduced motor response to e-shock, speciﬁcally, reﬂects reduced
incentive-motivation to attempt to escape in the IS mice, in
accordance with the motivational component of the original
interpretation of the LH effect (Maier and Seligman, 1976). This
explanation would also infer a major role for monoamine
neurotransmission, but in terms of reward/punishment-goal-
action pathways, rather than motor activity per se (Huys and
Dayan, 2009). A further difference in ESeIS behaviour was the
relatively high amount of ITI time spent in freezing by ES relative
to IS mice, both during Pre-exposure session 3 and CS condi-
tioning test. Direct anecdotal observation, combined with
freezing scores and activity tracking images, indicated that ES
mice spent a relatively high proportion of the ITI’s between
escapable e-shocks in freezing in one or other of the corners of
the arena, and facing towards the opposite arena side. As such
this ITI freezing could have reﬂected a state of readiness to escape
the e-shock. ES mice maintained this relatively high level of
freezing behaviour during the CS conditioning test; here the
state-of-readiness explanation would not apply as IS conditions
were applied, so that freezing might have carried over as a habit
from ES sessions. Certainly, NS mice also exhibited a lower level
of ITI freezing than did ES mice during the CS conditioning test,
indicating that high ITI freezing was speciﬁc to the ES mice.
During CS’s that predicted IS’s, freezing behaviour was exhibited
to a similar level in ES and NS mice, and to a relatively high level
in both groups compared to IS mice. The latter exhibited
increased CS distance moved and CS rears/climbs/jumps relative
to both ES and NSmice that again exhibited similar levels of these
behaviours to each other. Integrating these ﬁndings, we propose
that: (i) High ITI freezing in ES mice reﬂects development of
a controlled adaptive anticipatory response to an escapable
aversive stimulus in ES sessions, which is maintained as a habit
when the stimulus becomes inescapable. (ii) High CS-induced
freezing e as typically observed in fear conditioning experi-
ments e by ES and NS mice constitutes a controlled, moderate
response to a signalled uncontrollable aversive stimulus. (iii)
High CS horizontal-vertical motor activity e as rarely observed in
fear conditioning experiments e by IS mice constitutes an
uncontrolled, marked response to a signalled uncontrollable
aversive stimulus. That is, chronic exposure to an uncontrollable
aversive stimulus leads to development of a potentiated uncon-
trolled response (e.g. panic-ﬂight (Blanchard et al., 2001)) to
stimuli that accurately predict the imminence of that uncon-
trollable stimulus. The preceding interpretation is clearly spec-
ulative and requires further investigation. Furthermore, it is
important to note that in rat LH studies it has been demonstrated
that freezing to context is increased in IS relative to ES subjects
(e.g. Grahn et al., 2000), which is the opposite of the current
ﬁndings. One possible explanation is that the amplitude of e-
shock used in the present study was below that required to yield
fear-conditioned freezing to context but does support fear-
conditioned freezing to a discrete, predictive CS. This explana-
tion would ﬁt with the low ITI freezing by IS mice during the LH
procedure, the adaptive state-of-readiness explanation put
forward to account for relatively high ITI freezing by ES mice
during the LH procedure, the controlled response explanation
put forward to account for relatively high CS freezing by ES and
NS mice, and the uncontrolled response explanation put forward
to account for relatively high CS vertical-horizontal motor
activity by IS mice. When ES and IS rats are compared on fear-
conditioned freezing to CS, IS potentiates fear-induced freezing
to the CS (Barratta et al., 2007). According to our proposed
interpretation of the high horizontal-vertical motor activity
induced by the CS in IS mice, IS would potentiate CS fear condi-
tioning in both rats and mice. Finally here, as for the LH effect, the
validation experiment provided evidence that the ESeIS
differences observed in the CS conditioning test were due to
ESeIS pre-exposure and were not confounded by ES screening.
The aim of Experiment IV was to apply the LH effect model to
study the effects of constitutional heterozygote knockout of the
serotonin transporter gene. Genetically-determined reduced 5-HTT
function is an aetiological risk factor for depression in interaction
with aversive life events (Caspi et al., 2003; Murphy and Lesch, 2008).
If the LH effect model has validity for depression-relevant neuro-
biological and epharmacological studies, it would be expected to
demonstrate an increased LH effect in HET relative toWTmice. The ES
screening designwas used as in Experiment III. In this 5-HTT ko strain
on a C57BL/6 background, a robust LH effect was observed similar to
that obtainedwith C57BL/6mice in Experiment III. This demonstrates
that the model has applicability to other strains, although a pilot
study is recommended to optimise parameters for each strain e.g. the
number of trials per session, which was reduced in this 5-HTT ko
strain experiment relative to the C57BL/6 experiments. Furthermore,
the LH effect was more marked in the HET mice relative to WT and
this was exclusively due to the low number of escapes by HETeIS
mice relative to WTeIS mice. This ﬁnding indicates that developing
with only one copy of the 5-HTT gene increases sensitivity to
uncontrollable e-shock in terms of increased escape failure at escape
test. Indeed, the HETeISmice also exhibited reduced transfers relative
to their WTeIS counterparts in the ﬁnal pre-exposure session. It has
recently been demonstrated that 5-HTT HET mice exhibit increased
escape failure relative toWT following IS (Muller et al., 2011), and the
present study replicates thisﬁnding. However, the previous studywas
conducted without an ES comparison group (i.e. the US pre-exposure
effect paradigm), so it was unclear whether the phenotype was at all
related to the uncontrollability of the e-shock. Using the LH model it
has been possible to demonstrate that the 5-HTT HET phenotype is
indeed entirely due to uncontrollability. The neuropsychological
processes underlying this genotype  environment interaction
(G E) require andwarrant detailed investigation, but there are some
interesting co-ﬁndings in the current experiment that could well be
relevant. Particularly interesting is the increased time spent in
freezing behaviour by HET mice relative to WT mice and in both ES
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and IS groups. This increased freezing was already present at ES
screening e but not at habituation e and was maintained up to and
including escape test. This suggests that HET mice exhibit an endo-
phenotype of increased fear conditioning to context associated with
aversive stimuli and that this endophenotype contributes to devel-
opment of LH if uncontrollability is experienced in such environ-
ments. There are interesting parallels with the human situation, given
that healthy individuals with the short variant of the regulatory gene-
linked polymorphic region of the 5-HTT gene (reduced 5-HTT func-
tion, cf. 5-HTT HET mouse) exhibit increased reactivity to fearful
stimuli (Phelps and LeDoux, 2005) and a relatively high prevalence of
depression when exposed to several aversive life events (Caspi et al.,
2003; Karg et al., 2011). The important inference that can be made
from the present experiment is that uncontrollability in these life
events is a key factor in their aetio-pathology.
With respect to the important question of which is the optimal
experimental design for the study of the LH effect, it would appear
that this is dependent on the research question. This situation is
illustrated in Fig. 10. In studies where the aim is to investigate the
neurobiology of the LH effect, then random allocation is superior
because this wouldmaximise the extent towhich ESeIS differences
are attributable to differential experience of the un/controllability
of the aversive stimulus per se. To eliminate brother-pairs where
one or two brothers exhibit an “escape failure trait” i.e. vulnera-
bility to develop escape failure even if exposed to ES, minimum
thresholds can be set for performance at Pre-exposure 1. In studies
where the aim is to investigate the contribution of genetic factors to
the LH effect, as in Experiment IV, then ES screening is superior
because this ensures that the different genotype groups are
balanced with respect to allocation of mice to ES and IS. It also
ensures that mice with an “escape failure trait” are allocated to the
IS group and allows this to be comparedwith the equivalentWTeIS
group. In pharmacological studies, both designs are appropriate.
For example, it would be desirable to include mice with an “escape
failure trait” in a study of a putative anti-depressant com-
pound because such mice would constitute the at-risk-for-LH
population.
Establishment of a mouse model to demonstrate robust effects
of the uncontrollability per se of a speciﬁc, chronically aversive
environment provides a signiﬁcant advance in the methods avail-
able for valid translational study of psychological processes of
major relevance to depression. In accordance with the original LH
effect theory (Maier and Seligman, 1976), there is evidence that the
impact of the aversive uncontrollability was: emotional, evidenced
by uncontrolled responding to CS’s that predicted uncontrollable
e-shocks; incentive-motivational, evidenced by reduced motor
responding to e-shocks; cognitive, evidenced by a consistent low
level of escape responses across escape test without development
of response-outcome association/expectancy. The parsimonious
view is that this constitutes a speciﬁc learned aversive uncontrol-
lability (LAU) effect and not a generalized LH effect. The LAU effect
was achieved with a duration and intensity of e-shocks that were
minimal relative to those typically used e in this respect the model
represents signiﬁcant reﬁnement and reductionwith respect to the
3R’s of animal welfare. Withstanding the qualiﬁcation that the
effect is speciﬁc and does not itself constitute LH, this model is
important given that it will enable the study of: (i) The contribu-
tions of emotional, motivational and cognitive processes, and their
interaction, to the LAU effect. (ii) The generalized LH effect: one of
the major applications will be to investigate whether prior expe-
rience of uncontrollable aversive events other than e-shocks, e.g.
chronic social defeat (Krishnan and Nestler, 2008) induces a spon-
taneous escape deﬁcit in the current escape test, which would
constitute a model of a generalized LH effect, given that such mice
would not have prior experience of e-shocks as uncontrollable. That
is, the current deﬁcit in IS mice provides a comparator with which
two-way escape deﬁcits exhibited by mice exposed to other aver-
sive environments can be interpreted as being underlain by the
Fig. 10. Flow diagram depicting the relationship between appropriate experimental design and research question for the mouse LH effect paradigm.
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psychological state of (generalized) uncontrollability (Fig. 10). (iii)
The neural circuitry and synaptic neurobiology of the LAU and LH
effects. This will include the application of molecular-genetic tools
to study the contribution of speciﬁc genetic and geneeenviron-
ment interaction effects to the LAU effect and LH effect, as con-
ducted here for the 5-HTT gene. (iv) Discovery and validation of
novel therapeutic targets, and the screening of compounds and
biologics, for reversal of the LH effect. As such, this establishment of
a mouse model of the classical translational paradigm of learned
aversive uncontrollability will provide extensive opportunities for
psychopathological research in depression with aetiological, face
and construct validity, with potential for delivery of pre-clinical
evidence that will translate into improved understanding and
treatment of human depression.
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